1,Big,Merck & Co.,Public,North America,California,South San Francisco,Massachusetts,Boston,"$10,124.0m",Actual,Yes,Yes,Yes,No,6%,$558.9m,$450.8m,$598.3m,$664.1m,$0.0m,,9%,10%,5%,3%,0%,28%,,3%,6%,2%,2%,0%,,6%,4%,4%,1%,0%,,,,$207.0m,$270.5m,$187.0m,$369.0m,$0.0m,,$351.9m,$180.3m,$411.4m,$295.2m,$0.0m,$296.2m,$252.4m,$335.1m,$371.9m,,"$11,750.9m","$2,765.4m",$680.3m,$548.6m,$728.2m,$808.3m,,"$1,083.0m","$1,079.6m","$2,765.4m",$425.3m,$652.0m,$276.7m,$105.2m,"$2,600.1m",$409.8m,$446.9m,$639.7m,$578.4m,$497.6m,$0.0m,$89.1m,$102.1m
2,Big,Roche,Public,Europe,Switzerland,Zurich,Germany,Penzberg,"$8,717.8m",Actual,Yes,Yes,Yes,Yes,5%,$413.6m,$445.4m,$915.8m,$665.7m,$0.0m,,7%,11%,9%,3%,1%,32%,,3%,6%,4%,2%,0%,,4%,5%,5%,1%,1%,,,,$173.4m,$261.4m,$433.8m,$428.0m,$0.0m,,$240.1m,$184.0m,$482.0m,$237.8m,$0.0m,$219.2m,$249.4m,$512.8m,$372.8m,,"$8,961.0m",,$509.2m,$548.4m,"$1,127.5m",$819.7m,,$571.8m,"$1,070.1m","$3,004.7m",$602.6m,$654.4m,$195.6m,$172.3m,$699.5m,$226.0m,$408.9m,$478.4m,$390.0m,$343.6m,$99.0m,$0.0m,$43.9m
3,Big,Novartis,Public,Europe,Switzerland,Basel,Massachusetts,Cambridge,"$7,916.0m",Actual,Yes,Yes,Yes,Yes,4%,$287.4m,$335.0m,$818.0m,$527.7m,$0.0m,,6%,10%,10%,3%,0%,29%,,4%,7%,6%,2%,0%,,2%,3%,4%,1%,0%,,,,$174.2m,$233.8m,$503.4m,$310.4m,$0.0m,,$113.2m,$101.1m,$314.6m,$217.3m,$0.0m,$152.3m,$187.6m,$458.1m,$295.5m,,"$11,197.6m",,$469.4m,$547.2m,"$1,336.3m",$862.0m,,$994.8m,"$1,032.9m","$3,214.9m",$641.0m,$754.8m,$198.5m,$249.9m,$816.2m,$361.0m,$413.0m,$724.9m,$533.3m,$789.8m,$230.0m,$51.2m,$191.3m
4,Big,Pfizer,Public,North America,California,La Jolla,California,San Francisco,"$7,872.0m",Actual,Yes,Yes,No,No,4%,$298.8m,$325.3m,$662.5m,$338.9m,$0.0m,,6%,9%,7%,2%,2%,26%,,3%,6%,5%,1%,1%,,3%,2%,2%,1%,1%,,,,$163.0m,$236.6m,$441.6m,$193.7m,$0.0m,,$135.8m,$88.7m,$220.8m,$145.2m,$0.0m,$158.4m,$182.2m,$371.0m,$189.8m,,"$7,745.9m",,$329.0m,$358.2m,$729.3m,$373.1m,,$98.6m,$756.3m,"$1,789.6m",$671.3m,$368.3m,$192.6m,$239.6m,$914.7m,$405.2m,$350.8m,$400.5m,$719.1m,$580.6m,$124.8m,$0.0m,$133.9m
5,Big,Johnson & Johnson,Public,North America,Ontario,Toronto,New Jersey,Raritan,"$6,967.0m",Actual,Yes,Yes,Yes,Yes,4%,$272.5m,$134.8m,$313.2m,$264.9m,$0.0m,,6%,4%,4%,2%,0%,16%,,3%,3%,2%,0%,0%,,3%,1%,2%,2%,0%,,,,$148.6m,$89.9m,$134.2m,$0.0m,$0.0m,,$123.9m,$44.9m,$179.0m,$264.9m,$0.0m,$144.4m,$75.5m,$175.4m,$148.3m,,"$8,014.9m",,$336.4m,$166.5m,$386.7m,$327.0m,,$573.9m,$830.8m,"$1,216.5m",$492.5m,$48.0m,$278.3m,$189.6m,"$1,622.5m",$124.6m,$538.5m,$462.0m,"$1,187.3m",$372.7m,$39.5m,$0.0m,$38.1m
6,Big,AstraZeneca,Public,Europe,United Kingdom,Alderley Park,Massachusetts,Boston,"$5,890.0m",Actual,Yes,Yes,No,No,5%,$323.8m,$341.1m,$641.5m,$372.3m,$0.0m,,8%,12%,9%,3%,0%,31%,,6%,8%,5%,1%,0%,,2%,3%,4%,2%,0%,,,,$229.8m,$242.6m,$339.6m,$148.9m,$0.0m,,$94.0m,$98.6m,$301.9m,$223.4m,$0.0m,$171.6m,$191.0m,$359.2m,$208.5m,,"$6,682.6m",,$400.6m,$422.1m,$793.7m,$460.6m,,"$1,065.3m",$227.7m,"$2,077.0m",$549.8m,$131.7m,$11.4m,$144.7m,$501.4m,$276.9m,$563.6m,$306.3m,$496.8m,$277.2m,$33.5m,$0.0m,$19.5m
7,Big,Sanofi,Public,Europe,France,Paris,,,"$5,722.1m",Actual,Yes,Yes,No,No,3%,$176.8m,$121.6m,$420.3m,$199.0m,$0.0m,,5%,5%,7%,2%,0%,18%,,1%,3%,2%,0%,0%,,4%,2%,4%,2%,0%,,,,$37.2m,$74.3m,$134.5m,$0.0m,$0.0m,,$139.6m,$47.3m,$285.8m,$199.0m,$0.0m,$93.7m,$68.1m,$235.4m,$111.5m,,"$4,430.5m",,$166.7m,$114.6m,$396.2m,$187.6m,,$226.6m,$352.1m,$865.1m,$289.1m,$134.6m,$166.5m,$48.6m,$661.1m,$138.9m,$270.9m,$200.2m,$571.2m,$316.5m,$22.3m,$46.6m,$120.2m
8,Big,Eli Lilly,Public,North America,Massachusetts,Cambridge,New York ,New York,"$5,244.0m",Actual,Yes,Yes,Yes,No,4%,$207.6m,$282.5m,$656.2m,$369.9m,$0.0m,,6%,11%,10%,3%,1%,31%,,3%,9%,7%,1%,0%,,3%,2%,3%,2%,1%,,,,$116.8m,$226.0m,$468.7m,$138.7m,$0.0m,,$90.8m,$56.5m,$187.5m,$231.2m,$0.0m,$110.0m,$158.2m,$367.5m,$207.2m,,"$5,460.7m",,$258.7m,$352.0m,$817.7m,$461.0m,,$34.3m,$974.9m,"$1,889.3m",$473.1m,$17.8m,$131.9m,$187.3m,$124.4m,$114.1m,$239.3m,$342.1m,$755.6m,$121.6m,$55.0m,$0.0m,$0.0m
9,Big,Gilead Sciences,Public,North America,California,Foster City,Washington,Seattle,"$5,098.0m",Actual,Yes,Yes,Yes,Yes,8%,$401.6m,$145.8m,$498.8m,$268.4m,$0.0m,,12%,6%,8%,2%,1%,30%,,8%,5%,6%,2%,1%,,4%,2%,2%,1%,0%,,,,$276.1m,$109.3m,$362.8m,$179.0m,$0.0m,,$125.5m,$36.4m,$136.0m,$89.5m,$0.0m,$212.9m,$81.6m,$279.3m,$150.3m,,"$6,443.3m",,$552.7m,$200.6m,$686.4m,$369.4m,,$425.4m,$90.0m,"$1,809.2m",$976.1m,$104.7m,$133.3m,$0.0m,"$1,776.7m",$0.0m,$262.9m,$155.5m,$697.4m,$12.3m,$0.0m,$0.0m,$0.0m
10,Big,Bristol-Myers Squibb,Public,North America,Massachusetts,Cambridge,New Jersey,New Brunswick,"$4,940.0m",Actual,Yes,Yes,Yes,No,3%,$171.6m,$182.6m,$805.8m,$407.7m,$0.0m,,5%,8%,14%,4%,1%,32%,,2%,3%,8%,1%,0%,,4%,5%,6%,2%,1%,,,,$57.2m,$66.4m,$475.2m,$163.1m,$0.0m,,$114.4m,$116.2m,$330.6m,$244.6m,$0.0m,$90.9m,$102.3m,$451.2m,$228.3m,,"$6,566.9m",,$275.2m,$293.0m,"$1,292.6m",$654.0m,,$163.3m,$485.5m,"$2,514.7m",$793.4m,$0.0m,$104.1m,$47.8m,$580.5m,$257.9m,$364.8m,$451.6m,$401.0m,$402.3m,$0.0m,$0.0m,$0.0m
11,Big,Celgene,Public,North America,Washington,Seattle,,,"$4,470.1m",Actual,Yes,Yes,Yes,Yes,10%,$456.5m,$370.3m,$630.6m,$335.0m,$0.0m,,14%,15%,10%,3%,0%,42%,,6%,9%,5%,1%,0%,,8%,6%,5%,2%,0%,,,,$188.0m,$224.1m,$315.3m,$143.6m,$0.0m,,$268.5m,$146.2m,$315.3m,$191.4m,$0.0m,$242.0m,$207.4m,$353.2m,$187.6m,,"$5,798.3m",,$788.3m,$639.5m,"$1,089.0m",$578.5m,,$112.1m,$354.4m,"$3,095.4m",$409.9m,$19.3m,$149.9m,$76.7m,$0.0m,$87.4m,$86.6m,$392.7m,$500.1m,$479.0m,$0.0m,$0.0m,$34.8m
12,Big,GlaxoSmithKline,Public,Europe,Germany,Heidelberg,Spain,Madrid,"$4,460.3m",Actual,Yes,Yes,Yes,Yes,2%,$104.4m,$81.2m,$242.5m,$132.9m,$0.0m,,4%,4%,5%,1%,0%,14%,,2%,2%,3%,1%,0%,,2%,2%,2%,1%,0%,,,,$52.2m,$48.7m,$148.2m,$79.8m,$0.0m,,$52.2m,$32.5m,$94.3m,$53.2m,$0.0m,$55.3m,$45.5m,$135.8m,$74.4m,,"$3,970.4m",,$106.2m,$82.6m,$246.6m,$135.2m,,$427.2m,$352.2m,$570.6m,$378.1m,$106.6m,$133.8m,$44.7m,$875.9m,$114.0m,$178.1m,$110.1m,$414.2m,$186.8m,$19.6m,$0.0m,$58.5m
13,Big,AbbVie,Public,North America,California,Redwood City,Illinois,Lake County,"$4,366.0m",Actual,Yes,Yes,No,No,5%,$212.9m,$278.2m,$307.7m,$354.2m,$0.0m,,7%,13%,6%,3%,1%,31%,,3%,8%,1%,1%,0%,,4%,5%,4%,2%,1%,,,,$85.2m,$175.2m,$76.9m,$101.2m,$0.0m,,$127.8m,$103.0m,$230.8m,$253.0m,$0.0m,$112.9m,$155.8m,$172.3m,$198.4m,,"$8,384.0m",,$475.8m,$621.6m,$687.6m,$791.4m,,$473.5m,$408.6m,"$2,576.3m","$1,011.4m",$272.2m,$57.7m,$446.8m,$31.3m,$607.9m,$310.7m,$836.4m,"$1,154.4m",$145.9m,$0.0m,$0.0m,$50.7m
14,Big,Amgen,Public,North America,California,Thousand Oaks,Massachusetts,Cambridge,"$3,840.0m",Actual,Yes,Yes,Yes,Yes,5%,$200.6m,$324.8m,$501.8m,$385.1m,$0.0m,,7%,17%,10%,4%,0%,38%,,3%,11%,6%,2%,0%,,5%,6%,5%,2%,0%,,,,$77.2m,$212.8m,$278.8m,$165.0m,$0.0m,,$123.5m,$112.0m,$223.0m,$220.0m,$0.0m,$106.3m,$181.9m,$281.0m,$215.6m,,"$4,816.8m",,$299.4m,$484.8m,$748.9m,$574.7m,,$234.1m,$311.6m,"$2,107.7m",$495.2m,$0.0m,$104.6m,$46.4m,$129.0m,$130.6m,$264.5m,$319.1m,$324.5m,$167.3m,$182.3m,$0.0m,$0.0m
15,Big,Boehringer Ingelheim,Private,Europe,Austria,Vienna,Connecticut,Ridgefield,"$3,443.0m",Actual,Yes,Yes,No,No,8%,$278.4m,$215.5m,$201.2m,$264.6m,$0.0m,,10%,11%,4%,3%,0%,27%,,3%,9%,3%,2%,0%,,7%,2%,1%,1%,0%,,,,$92.8m,$175.1m,$134.1m,$198.5m,$0.0m,,$185.6m,$40.4m,$67.1m,$66.2m,$0.0m,$147.6m,$120.7m,$112.7m,$148.2m,,"$4,599.8m",,$388.9m,$301.1m,$281.0m,$369.6m,,$351.1m,$432.4m,"$1,340.5m",$453.7m,$179.2m,$395.2m,$88.8m,$155.4m,$77.7m,$113.1m,$171.5m,$841.1m,$0.0m,$0.0m,$0.0m,$0.0m
16,Big,Bayer,Public,Europe,Germany,Berlin,Germany,Leverkusen,"$2,906.6m",Actual,Yes,Yes,No,No,4%,$115.8m,$187.5m,$241.4m,$190.5m,$0.0m,,6%,13%,7%,3%,0%,29%,,4%,10%,4%,2%,0%,,2%,3%,3%,1%,0%,,,,$71.3m,$142.3m,$128.7m,$127.0m,$0.0m,,$44.5m,$45.3m,$112.7m,$63.5m,$0.0m,$61.4m,$105.0m,$135.2m,$106.7m,,"$3,239.1m",,$141.9m,$229.8m,$295.9m,$233.5m,,$324.1m,$70.2m,$901.1m,$110.9m,$113.2m,$63.8m,$18.3m,$404.7m,$447.6m,$300.0m,$102.5m,$111.9m,$252.9m,$0.0m,$0.0m,$17.8m
17,Big,Takeda,Public,Asia/Oceania,Japan,Tokyo,,,"$2,871.3m",Actual,Yes,Yes,Yes,Yes,6%,$159.9m,$102.7m,$211.1m,$197.3m,$0.0m,,8%,7%,6%,3%,1%,25%,,4%,4%,4%,1%,0%,,4%,3%,2%,2%,0%,,,,$79.9m,$62.5m,$133.3m,$87.7m,$0.0m,,$79.9m,$40.2m,$77.8m,$109.6m,$0.0m,$84.7m,$57.5m,$118.2m,$110.5m,,"$2,252.4m",,$155.1m,$99.6m,$204.7m,$191.4m,,$58.1m,$320.6m,$650.7m,$133.7m,$52.8m,$58.9m,$6.4m,$137.2m,$88.2m,$163.7m,$98.0m,$352.9m,$93.8m,$0.0m,$0.0m,$37.4m
18,Big,Allergan,Public,Europe,Ireland,Dublin,,,"$2,575.7m",Actual,No,Yes,No,No,1%,$31.0m,$15.0m,$55.9m,$36.8m,$0.0m,,2%,1%,2%,1%,1%,7%,,1%,1%,1%,1%,0%,,1%,1%,1%,0%,1%,,,,$20.6m,$7.5m,$18.6m,$36.8m,$0.0m,,$10.3m,$7.5m,$37.3m,$0.0m,$0.0m,$16.4m,$8.4m,$31.3m,$20.6m,,"$2,780.9m",,$30.5m,$14.8m,$55.2m,$36.3m,,$27.7m,$569.4m,$136.7m,$90.3m,$510.3m,$0.0m,$105.1m,$367.9m,$212.0m,$180.4m,$128.9m,$374.0m,$78.3m,$0.0m,$0.0m,$0.0m
19,Big,Novo Nordisk,Public,Europe,Denmark,Malow,United Kingdom,Oxford,"$2,164.0m",Actual,No,No,No,No,3%,$59.8m,$43.4m,$54.0m,$0.0m,$0.0m,,4%,4%,2%,0%,0%,9%,,2%,2%,0%,0%,0%,,2%,2%,2%,0%,0%,,,,$29.9m,$21.7m,$0.0m,$0.0m,$0.0m,,$29.9m,$21.7m,$54.0m,$0.0m,$0.0m,$31.7m,$24.3m,$30.3m,$0.0m,,"$3,041.6m",,$77.6m,$56.3m,$70.1m,$0.0m,,$160.5m,$165.4m,$204.0m,$78.1m,$31.4m,$148.1m,$0.0m,$479.8m,$58.1m,$30.2m,$26.1m,"$1,254.7m",$216.5m,$188.7m,$0.0m,$0.0m
20,Big,Teva,Public,Middle East/Africa,,,,,"$2,111.0m",Actual,Yes,Yes,No,No,3%,$56.0m,$40.7m,$222.7m,$119.9m,$0.0m,,4%,4%,10%,3%,0%,21%,,0%,1%,0%,0%,0%,,4%,4%,10%,3%,0%,,,,$0.0m,$8.1m,$0.0m,$0.0m,$0.0m,,$56.0m,$32.5m,$222.7m,$119.9m,$0.0m,$29.7m,$22.8m,$124.7m,$67.1m,,"$3,311.7m",,$102.5m,$74.4m,$407.5m,$219.3m,,$273.4m,$700.3m,$803.8m,$248.3m,$131.5m,$33.7m,$61.1m,$62.4m,$222.8m,$179.1m,$180.8m,$181.5m,$161.7m,$0.0m,$71.2m,$0.0m
21,Big,Biogen,Public,Europe,Switzerland,Zug,,,"$1,973.3m",Actual,Yes,Yes,No,No,2%,$35.9m,$32.6m,$81.2m,$64.1m,$0.0m,,3%,4%,4%,1%,0%,12%,,1%,1%,1%,0%,0%,,2%,3%,3%,1%,0%,,,,$9.0m,$6.5m,$16.2m,$0.0m,$0.0m,,$27.0m,$26.1m,$64.9m,$64.1m,$0.0m,$19.1m,$18.3m,$45.5m,$35.9m,,"$2,843.3m",,$60.3m,$54.7m,$136.1m,$107.4m,,$54.6m,"$1,182.3m",$358.4m,$292.3m,$278.8m,$27.4m,$22.7m,$30.4m,$46.5m,$88.3m,$152.8m,$58.9m,$250.0m,$0.0m,$0.0m,$0.0m
22,Big,Daiichi Sankyo,Public,Asia/Oceania,,,,,"$1,970.7m",Actual,Yes,Yes,Yes,Yes,7%,$138.0m,$105.8m,$194.0m,$164.0m,$0.0m,,10%,11%,8%,3%,1%,33%,,6%,9%,6%,2%,0%,,5%,2%,2%,1%,1%,,,,$76.7m,$89.1m,$138.5m,$109.3m,$0.0m,,$61.4m,$16.7m,$55.4m,$54.7m,$0.0m,$73.2m,$59.2m,$108.6m,$91.9m,,"$2,314.7m",,$200.6m,$153.7m,$281.8m,$238.3m,,$91.2m,$209.1m,$874.4m,$58.8m,$10.7m,$45.4m,$53.4m,$139.5m,$0.0m,$143.9m,$274.6m,$208.1m,$163.5m,$28.7m,$0.0m,$13.6m
23,Big,Astellas Pharma,Public,Asia/Oceania,,,,,"$1,913.3m",Actual,Yes,Yes,No,Yes,2%,$35.2m,$70.2m,$158.8m,$156.6m,$0.0m,,3%,7%,6%,3%,1%,21%,,1%,3%,4%,2%,0%,,2%,4%,3%,1%,1%,,,,$8.8m,$31.9m,$95.3m,$94.0m,$0.0m,,$26.4m,$38.3m,$63.5m,$62.7m,$0.0m,$18.6m,$39.3m,$88.9m,$87.7m,,"$2,569.4m",,$56.2m,$112.1m,$253.6m,$250.2m,,$161.6m,$156.3m,$672.1m,$146.9m,$104.9m,$110.2m,$14.6m,$133.9m,$400.3m,$108.1m,$101.5m,$246.9m,$111.5m,$0.0m,$13.1m,$87.5m
24,Big,Merck KGaA,Public,Europe,Germany,Darmstadt,Massachusetts,Boston,"$1,655.1m",Actual,Yes,Yes,Yes,Yes,9%,$147.4m,$135.1m,$196.1m,$82.9m,$0.0m,,12%,15%,9%,2%,0%,38%,,6%,8%,4%,1%,0%,,6%,7%,4%,1%,0%,,,,$69.8m,$73.2m,$98.1m,$27.6m,$0.0m,,$77.6m,$61.9m,$98.1m,$55.3m,$0.0m,$78.1m,$75.7m,$109.8m,$46.4m,,"$2,200.5m",,$235.9m,$216.3m,$314.1m,$132.8m,,$126.6m,$283.6m,$899.1m,$249.2m,$13.7m,$21.9m,$54.8m,$22.2m,$50.3m,$9.5m,$136.4m,$208.8m,$4.3m,$32.3m,$0.0m,$87.8m
25,Big,Regeneron,Public,North America,New York,New York,New Jersey,Basking Ridge,"$1,580.0m",Actual,Yes,Yes,No,Yes,4%,$63.2m,$107.1m,$76.1m,$75.1m,$0.0m,,4%,10%,3%,1%,1%,21%,,4%,7%,3%,1%,1%,,0%,3%,0%,0%,0%,,,,$63.2m,$76.5m,$76.1m,$75.1m,$0.0m,,$0.0m,$30.6m,$0.0m,$0.0m,$0.0m,$33.5m,$60.0m,$42.6m,$42.1m,,"$4,781.5m",,$170.8m,$289.2m,$205.7m,$202.9m,,$873.4m,$276.0m,$868.5m,$259.1m,$775.1m,$48.4m,$48.5m,$122.7m,$0.0m,$622.9m,$572.2m,$294.7m,$19.9m,$0.0m,$0.0m,$0.0m
26,Big,Otsuka Pharmaceutical,Public,Asia/Oceania,,,,,"$1,465.5m",Actual,Yes,Yes,Yes,Yes,4%,$51.8m,$85.4m,$221.1m,$184.6m,$0.0m,,6%,13%,13%,6%,2%,39%,,4%,8%,8%,3%,1%,,2%,5%,5%,3%,1%,,,,$33.0m,$54.7m,$136.1m,$83.9m,$0.0m,,$18.8m,$30.7m,$85.0m,$100.7m,$0.0m,$27.4m,$47.8m,$123.8m,$103.4m,,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
27,Big,Shire,Public,Europe,Switzerland,Zug,Massachusetts,Lexington,"$1,439.8m",Actual,Yes,Yes,Yes,Yes,2%,$30.5m,$44.3m,$88.3m,$108.9m,$0.0m,,4%,7%,6%,4%,1%,21%,,1%,0%,1%,0%,0%,,3%,7%,5%,4%,1%,,,,$6.1m,$0.0m,$11.0m,$0.0m,$0.0m,,$24.4m,$44.3m,$77.2m,$108.9m,$0.0m,$16.2m,$24.8m,$49.4m,$61.0m,,"$2,145.3m",,$54.3m,$78.8m,$157.0m,$193.6m,,$36.6m,$234.2m,$483.7m,$287.8m,$79.1m,$19.4m,$44.7m,$156.9m,$6.1m,$164.4m,$46.4m,$273.6m,$248.9m,$45.2m,$18.2m,$0.0m
28,Big,UCB,Public,Europe,Belgium,Brussels,,,"$1,128.5m",Actual,Yes,Yes,No,No,0%,$0.0m,$8.0m,$20.0m,$39.4m,$0.0m,,0%,2%,2%,2%,0%,5%,,0%,2%,0%,0%,0%,,0%,0%,2%,2%,0%,,,,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$20.0m,$39.4m,$0.0m,$0.0m,$4.5m,$11.2m,$22.0m,,"$1,390.5m",,$0.0m,$11.9m,$29.5m,$58.2m,,$16.3m,$396.5m,$99.6m,$361.9m,$0.0m,$12.8m,$52.3m,$0.0m,$0.0m,$92.1m,$116.5m,$158.9m,$83.5m,$0.0m,$0.0m,$0.0m
29,Big,Servier,Private,Europe,United Kingdom,Slough,,,"$1,106.0m",Actual,Yes,Yes,Yes,Yes,5%,$53.2m,$57.9m,$128.2m,$126.5m,$0.0m,,7%,11%,10%,5%,1%,35%,,1%,2%,1%,0%,0%,,6%,9%,9%,5%,1%,,,,$8.9m,$12.9m,$16.0m,$0.0m,$0.0m,,$44.3m,$45.1m,$112.2m,$126.5m,$0.0m,$28.2m,$32.4m,$71.8m,$70.8m,,"$1,226.4m",,$64.0m,$69.7m,$154.2m,$152.1m,,$0.0m,$204.2m,$439.9m,$85.4m,$0.0m,$9.0m,$26.9m,$0.0m,$0.0m,$195.1m,$84.9m,$82.0m,$99.0m,$0.0m,$0.0m,$0.0m
30,Big,Vertex Pharmaceuticals,Public,North America,Massachusetts,Cambridge,California,San Diego,"$1,047.7m",Actual,Yes,No,No,No,2%,$18.8m,$20.4m,$33.9m,$0.0m,$0.0m,,3%,5%,3%,0%,0%,12%,,3%,5%,3%,0%,0%,,0%,0%,0%,0%,0%,,,,$18.8m,$20.4m,$33.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.9m,$11.4m,$19.0m,$0.0m,,"$1,489.8m",,$33.9m,$36.9m,$61.2m,$0.0m,,$889.6m,$173.1m,$132.0m,$0.0m,$0.0m,$0.0m,$15.5m,$157.5m,$0.0m,$0.0m,$0.0m,$8.6m,$113.6m,$0.0m,$0.0m,$0.0m
31,Big,Eisai,Public,Asia/Oceania,,,,,"$1,034.3m",Actual,Yes,Yes,No,No,7%,$68.8m,$49.9m,$109.7m,$43.3m,$0.0m,,10%,10%,9%,2%,1%,32%,,8%,7%,7%,1%,1%,,2%,3%,2%,1%,0%,,,,$56.7m,$35.2m,$80.4m,$14.4m,$0.0m,,$12.1m,$14.7m,$29.2m,$28.8m,$0.0m,$36.5m,$28.0m,$61.4m,$24.2m,,$856.3m,,$69.2m,$50.2m,$110.3m,$43.5m,,$50.7m,$247.8m,$273.3m,$34.8m,$6.7m,$3.7m,$24.3m,$25.6m,$0.0m,$0.0m,$65.8m,$60.9m,$0.0m,$0.0m,$0.0m,$62.7m
32,Medium,Mylan,Public,Europe,United Kingdom,Hertfordshire,United Kingdom,Kent,$826.8m,Actual,No,Yes,No,No,3%,$24.5m,$8.9m,$22.1m,$0.0m,$0.0m,,3%,2%,2%,0%,2%,8%,,2%,2%,2%,0%,0%,,2%,0%,0%,0%,2%,,,,$12.2m,$8.9m,$22.1m,$0.0m,$0.0m,,$12.2m,$0.0m,$0.0m,$0.0m,$0.0m,$13.0m,$5.0m,$12.4m,$0.0m,,"$1,160.6m",,$30.1m,$10.9m,$27.2m,$0.0m,,$88.6m,$69.4m,$68.2m,$214.9m,$139.8m,$0.0m,$65.9m,$187.1m,$26.9m,$0.0m,$105.7m,$174.4m,$0.0m,$0.0m,$0.0m,$19.8m
33,Medium,Alexion,Public,North America,Massachusetts,Boston,Switzerland,Zurich,$757.0m,Actual,Yes,Yes,No,No,0%,$0.0m,$0.0m,$29.3m,$0.0m,$0.0m,,0%,0%,3%,0%,0%,3%,,0%,0%,3%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$29.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$16.4m,$0.0m,,"$1,243.5m",,$0.0m,$0.0m,$65.5m,$0.0m,,$0.0m,$75.4m,$65.5m,$262.2m,$221.9m,$87.0m,$0.0m,$0.0m,$33.0m,$30.2m,$85.8m,$227.9m,$154.7m,$0.0m,$0.0m,$0.0m
34,Medium,Sumitomo Dainippon Pharma,Public,Asia/Oceania,,,,,$743.1m,Actual,Yes,Yes,Yes,No,4%,$28.4m,$26.5m,$58.7m,$43.4m,$0.0m,,6%,8%,7%,3%,1%,25%,,4%,7%,4%,2%,1%,,2%,1%,3%,1%,0%,,,,$20.3m,$23.6m,$36.7m,$28.9m,$0.0m,,$8.1m,$2.9m,$22.0m,$14.5m,$0.0m,$15.1m,$14.8m,$32.8m,$24.3m,,$772.7m,,$33.9m,$31.7m,$70.1m,$51.8m,,$45.0m,$212.1m,$187.5m,$22.6m,$30.2m,$0.0m,$4.1m,$27.6m,$0.0m,$44.1m,$46.3m,$112.9m,$34.3m,$0.0m,$0.0m,$5.9m
35,Medium,Baxter International,Public,North America,Illinois,Chicago,,,$647.0m,Actual,No,Yes,No,No,3%,$17.1m,$16.6m,$51.6m,$81.5m,$0.0m,,4%,6%,7%,6%,0%,24%,,0%,0%,0%,0%,0%,,4%,6%,7%,6%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$17.1m,$16.6m,$51.6m,$81.5m,$0.0m,$9.1m,$9.3m,$28.9m,$45.6m,,"$1,145.9m",,$37.3m,$36.1m,$112.2m,$177.1m,,$70.7m,$42.7m,$362.6m,$254.8m,$0.0m,$0.0m,$50.5m,$28.2m,$34.3m,$14.7m,$117.8m,$59.4m,$87.6m,$0.0m,$22.6m,$0.0m
36,Medium,CSL Limited,Public,Asia/Oceania,,,,,$614.0m,Actual,Yes,Yes,No,No,1%,$7.7m,$0.0m,$13.8m,$0.0m,$0.0m,,2%,0%,2%,0%,0%,4%,,2%,0%,2%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.7m,$0.0m,$13.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.0m,$7.7m,$0.0m,,$870.1m,,$10.9m,$0.0m,$19.6m,$0.0m,,$124.1m,$76.4m,$30.5m,$204.7m,$0.0m,$0.0m,$10.4m,$189.1m,$0.0m,$77.5m,$28.3m,$15.1m,$113.9m,$0.0m,$0.0m,$0.0m
37,Medium,Shanghai Fosun Pharma,Public,Asia/Oceania,China,Shanghai,,,$600.0m,Actual,No,Yes,No,No,7%,$43.2m,$10.4m,$26.0m,$0.0m,$0.0m,,11%,4%,4%,0%,0%,18%,,7%,4%,4%,0%,0%,,4%,0%,0%,0%,0%,,,,$28.8m,$10.4m,$26.0m,$0.0m,$0.0m,,$14.4m,$0.0m,$0.0m,$0.0m,$0.0m,$22.9m,$5.8m,$14.6m,$0.0m,,$778.3m,,$47.0m,$11.4m,$28.3m,$0.0m,,$0.0m,$0.0m,$86.7m,$0.0m,$0.0m,$0.0m,$0.0m,$125.1m,$134.8m,$74.2m,$0.0m,$272.6m,$84.8m,$0.0m,$0.0m,$0.0m
38,Medium,Mitsubishi Tanabe Pharma,Public,Asia/Oceania,,,,,$594.9m,Actual,Yes,No,No,No,1%,$4.0m,$2.9m,$7.2m,$0.0m,$0.0m,,1%,1%,1%,0%,0%,3%,,1%,1%,1%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$2.9m,$7.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$1.6m,$4.0m,$0.0m,,$292.9m,,$1.9m,$1.4m,$3.4m,$0.0m,,$19.2m,$67.5m,$6.6m,$17.0m,$9.7m,$7.5m,$11.0m,$44.6m,$4.9m,$10.2m,$13.1m,$50.3m,$17.7m,$9.0m,$2.0m,$2.5m
39,Medium,Incyte Corporation,Public,North America,Delaware,Wilmington,Switzerland,Epalinges,$581.9m,Actual,Yes,Yes,No,No,5%,$30.1m,$47.3m,$135.7m,$35.7m,$0.0m,,8%,17%,20%,3%,0%,47%,,0%,8%,13%,1%,0%,,8%,9%,7%,1%,0%,,,,$0.0m,$21.8m,$90.5m,$17.9m,$0.0m,,$30.1m,$25.4m,$45.2m,$17.9m,$0.0m,$15.9m,$26.5m,$76.0m,$20.0m,,$894.5m,,$66.1m,$104.0m,$298.6m,$78.6m,,$0.0m,$0.0m,$547.2m,$119.7m,$0.0m,$0.0m,$64.3m,$0.0m,$0.0m,$0.0m,$0.0m,$8.4m,$154.8m,$0.0m,$0.0m,$0.0m
40,Medium,Ono Pharmaceutical,Public,Asia/Oceania,,,,,$528.7m,Actual,Yes,Yes,Yes,Yes,5%,$28.5m,$29.9m,$103.0m,$79.0m,$0.0m,,8%,12%,16%,6%,2%,45%,,2%,4%,2%,1%,0%,,6%,8%,15%,5%,2%,,,,$6.3m,$9.2m,$11.4m,$11.3m,$0.0m,,$22.2m,$20.7m,$91.6m,$67.7m,$0.0m,$15.1m,$16.7m,$57.7m,$44.3m,,$340.8m,,$22.2m,$23.2m,$80.0m,$61.4m,,$6.5m,$22.8m,$186.8m,$30.4m,$4.8m,$4.4m,$6.2m,$1.5m,$18.3m,$14.3m,$31.0m,$0.0m,$12.8m,$1.0m,$0.0m,$0.0m
41,Medium,Kyowa Hakko Kirin,Public,Asia/Oceania,,,,,$494.8m,Actual,Yes,Yes,No,No,4%,$18.8m,$13.6m,$27.1m,$26.7m,$0.0m,,7%,7%,5%,3%,1%,23%,,0%,5%,3%,0%,0%,,7%,1%,3%,3%,1%,,,,$0.0m,$10.9m,$13.6m,$0.0m,$0.0m,,$18.8m,$2.7m,$13.6m,$26.7m,$0.0m,$9.9m,$7.6m,$15.2m,$15.0m,,$604.7m,,$23.8m,$17.3m,$34.4m,$33.9m,,$45.3m,$12.8m,$109.3m,$54.9m,$0.0m,$8.7m,$8.0m,$31.6m,$87.2m,$35.0m,$40.2m,$70.9m,$47.9m,$53.0m,$0.0m,$0.0m
42,Medium,Shionogi,Public,Asia/Oceania,,,,,$478.1m,Actual,No,Yes,No,No,0%,$0.0m,$0.0m,$27.4m,$18.0m,$0.0m,,0%,0%,5%,2%,0%,7%,,0%,0%,2%,0%,0%,,0%,0%,3%,2%,0%,,,,$0.0m,$0.0m,$9.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$18.3m,$18.0m,$0.0m,$0.0m,$0.0m,$15.4m,$10.1m,,$606.2m,,$0.0m,$0.0m,$37.0m,$24.4m,,$59.3m,$148.7m,$61.4m,$0.0m,$0.0m,$24.8m,$24.6m,$161.2m,$4.9m,$16.7m,$30.2m,$54.4m,$20.0m,$0.0m,$0.0m,$0.0m
43,Medium,Lundbeck,Public,Europe,Denmark,Valby,Illinois,Deerfield,$440.9m,Actual,Yes,No,No,No,0%,$0.0m,$4.1m,$20.2m,$19.9m,$0.0m,,0%,2%,4%,2%,0%,9%,,0%,0%,0%,0%,0%,,0%,2%,4%,2%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.1m,$20.2m,$19.9m,$0.0m,$0.0m,$2.3m,$11.3m,$11.1m,,$930.7m,,$0.0m,$10.8m,$53.6m,$52.9m,,$18.4m,$593.4m,$117.2m,$18.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$84.4m,$42.3m,$0.0m,$56.2m,$0.0m,$0.0m,$0.0m
44,Medium,Bausch Health Companies,Public,North America,Quebec,Laval,New Jersey,Bridgewater,$421.0m,Actual,No,Yes,No,No,1%,$4.9m,$0.0m,$4.4m,$8.7m,$0.0m,,2%,0%,1%,1%,0%,4%,,0%,0%,0%,0%,0%,,2%,0%,1%,1%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.9m,$0.0m,$4.4m,$8.7m,$0.0m,$2.6m,$0.0m,$2.5m,$4.9m,,$511.0m,,$6.2m,$0.0m,$5.6m,$11.1m,,$12.0m,$94.6m,$23.0m,$37.2m,$79.7m,$0.0m,$40.8m,$33.8m,$44.4m,$3.7m,$50.3m,$76.4m,$0.0m,$0.0m,$10.7m,$4.4m
45,Medium,Fresenius,Public,Europe,Germany,Bad Homburg,Massachusetts,Waltham,$391.0m,Actual,No,No,No,No,0%,$0.0m,$0.0m,$92.3m,$0.0m,$0.0m,,0%,0%,11%,0%,0%,11%,,0%,0%,0%,0%,0%,,0%,0%,11%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$92.3m,$0.0m,$0.0m,$0.0m,$0.0m,$51.7m,$0.0m,,$521.1m,,$0.0m,$0.0m,$86.4m,$0.0m,,$0.0m,$0.0m,$86.4m,$341.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$42.2m,$27.8m,$23.2m,$0.0m,$0.0m,$0.0m
46,Medium,Alkermes,Public,Europe,Ireland,Dublin,Massachusetts,Waltham,$387.1m,Actual,No,Yes,No,No,0%,$0.0m,$30.8m,$0.0m,$0.0m,$0.0m,,0%,10%,0%,0%,0%,10%,,0%,10%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$30.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$17.3m,$0.0m,$0.0m,,$502.2m,,$0.0m,$38.6m,$0.0m,$0.0m,,$0.0m,$463.6m,$38.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
47,Medium,Seattle Genetics,Public,North America,Washington,Bothell,Switzerland,Zug,$379.3m,Actual,Yes,Yes,No,No,12%,$44.3m,$38.6m,$80.0m,$78.9m,$0.0m,,18%,21%,18%,9%,0%,66%,,9%,11%,7%,4%,0%,,9%,11%,11%,5%,0%,,,,$22.1m,$19.3m,$32.0m,$31.6m,$0.0m,,$22.1m,$19.3m,$48.0m,$47.4m,$0.0m,$23.5m,$21.6m,$44.8m,$44.2m,,$492.0m,,$87.6m,$76.3m,$158.3m,$156.2m,,$0.0m,$0.0m,$478.4m,$7.1m,$0.0m,$0.0m,$0.0m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
48,Medium,Chiesi,Private,Europe,Italy,Parma,France,Paris,$376.2m,Actual,No,No,No,No,0%,$0.0m,$0.0m,$10.2m,$0.0m,$0.0m,,0%,0%,3%,0%,0%,3%,,0%,0%,0%,0%,0%,,0%,0%,3%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.2m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.0m,,$534.2m,,$0.0m,$0.0m,$16.6m,$0.0m,,$326.3m,$48.6m,$16.6m,$0.0m,$0.0m,$7.9m,$13.0m,$6.9m,$28.9m,$0.0m,$0.0m,$30.6m,$55.5m,$0.0m,$0.0m,$0.0m
49,Medium,Sun Pharma Advanced Research,Public,Asia/Oceania,,,,,$344.5m,Actual,Yes,No,No,No,6%,$20.4m,$9.9m,$12.3m,$0.0m,$0.0m,,8%,5%,3%,0%,0%,16%,,5%,5%,3%,0%,0%,,3%,0%,0%,0%,0%,,,,$13.6m,$9.9m,$12.3m,$0.0m,$0.0m,,$6.8m,$0.0m,$0.0m,$0.0m,$0.0m,$10.8m,$5.5m,$6.9m,$0.0m,,$776.9m,,$44.2m,$21.4m,$26.6m,$0.0m,,$38.5m,$134.6m,$92.1m,$159.1m,$159.7m,$0.0m,$40.2m,$0.0m,$0.0m,$0.0m,$128.3m,$24.3m,$0.0m,$0.0m,$0.0m,$0.0m
50,Medium,Lupin,Public,Asia/Oceania,,,,,$343.9m,Actual,No,Yes,No,No,3%,$9.8m,$0.0m,$0.0m,$0.0m,$0.0m,,4%,0%,0%,0%,0%,4%,,4%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,,$607.2m,,$12.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$28.3m,$12.1m,$66.3m,$25.9m,$0.0m,$21.0m,$86.6m,$21.7m,$89.0m,$12.1m,$158.6m,$51.3m,$34.3m,$0.0m,$0.0m
51,Medium,Ferring,Private,Europe,Denmark,Copenhagen,New Jersey,Parsippany,$304.0m,Actual,No,No,No,No,1%,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,2%,0%,0%,0%,0%,2%,,0%,0%,0%,0%,0%,,2%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$250.7m,,$3.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$23.1m,$3.7m,$0.0m,$0.0m,$7.0m,$11.5m,$28.9m,$70.0m,$23.5m,$32.1m,$39.7m,$11.3m,$0.0m,$0.0m,$0.0m
52,Medium,Dr. Reddy's Laboratories,Public,Asia/Oceania,India,Hyderabad,,,$291.1m,Actual,Yes,Yes,No,No,14%,$40.1m,$11.6m,$29.0m,$28.6m,$0.0m,,20%,8%,8%,4%,0%,39%,,20%,4%,1%,1%,0%,,0%,4%,7%,3%,0%,,,,$40.1m,$5.8m,$4.8m,$9.5m,$0.0m,,$0.0m,$5.8m,$24.2m,$19.1m,$0.0m,$21.3m,$6.5m,$16.2m,$16.0m,,$721.7m,,$106.8m,$31.0m,$77.2m,$76.2m,,$0.0m,$80.0m,$291.2m,$6.1m,$5.8m,$55.0m,$72.1m,$85.9m,$0.0m,$0.0m,$42.9m,$63.9m,$0.0m,$18.9m,$0.0m,$0.0m
98,Medium,NANT,Public,North America,California,Los Angeles,,,$285.0m,Estimate,Yes,Yes,Yes,Yes,15%,$43.9m,$15.9m,$68.5m,$28.5m,$0.0m,,22%,11%,19%,4%,0%,57%,,16%,5%,9%,1%,0%,,6%,6%,10%,3%,0%,,,,31.9347562202443,$7.2m,$32.4m,$7.1m,$0.0m,,$12.0m,$8.7m,$36.1m,$21.3m,$0.0m,$23.3m,$8.9m,$38.4m,$15.9m,,$345.9m,,$90.9m,$33.0m,$141.9m,$58.9m,,$11.6m,$0.0m,$324.8m,$0.0m,$0.0m,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
53,Medium,Mallinckrodt,Public,Europe,United Kingdom,Surrey,Ireland,Dublin,$262.2m,Actual,No,Yes,No,Yes,3%,$6.8m,$0.0m,$0.0m,$12.2m,$0.0m,,5%,0%,0%,2%,0%,7%,,2%,0%,0%,0%,0%,,2%,0%,0%,2%,0%,,,,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.4m,$0.0m,$0.0m,$12.2m,$0.0m,$3.6m,$0.0m,$0.0m,$6.8m,,$492.0m,,$15.7m,$0.0m,$0.0m,$27.9m,,$63.2m,$88.9m,$43.6m,$12.4m,$0.0m,$0.0m,$30.2m,$0.0m,$0.0m,$45.0m,$55.8m,$138.3m,$3.7m,$0.0m,$10.9m,$0.0m
54,Medium,Apotex,Private,North America,Florida,Weston,Ontario,Toronto,$250.0m,Actual,Yes,Yes,No,No,5%,$12.1m,$17.6m,$0.0m,$0.0m,$0.0m,,6%,11%,0%,0%,0%,17%,,6%,11%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$12.1m,$17.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.4m,$9.9m,$0.0m,$0.0m,,$262.9m,,$16.1m,$23.4m,$0.0m,$0.0m,,$0.0m,$108.9m,$39.5m,$20.6m,$0.0m,$0.0m,$0.0m,$12.9m,$0.0m,$5.7m,$0.0m,$0.0m,$75.2m,$0.0m,$0.0m,$0.0m
55,Medium,Portola Pharmaceuticals,Public,North America,California,South San Francisco,,,$246.9m,Actual,Yes,No,No,No,0%,$0.0m,$0.0m,$35.0m,$0.0m,$0.0m,,0%,0%,13%,0%,0%,13%,,0%,0%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$35.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$19.6m,$0.0m,,$320.2m,,$0.0m,$0.0m,$48.7m,$0.0m,,$0.0m,$0.0m,$48.7m,$0.0m,$59.9m,$0.0m,$9.2m,$24.5m,$0.0m,$35.4m,$24.1m,$0.0m,$118.4m,$0.0m,$0.0m,$0.0m
99,Medium,Ionis Pharmaceuticals,Public,North America,California,Carlsbad,,,$241.1m,Estimate,Yes,Yes,No,No,3%,$7.2m,$1.3m,$9.8m,$0.0m,$0.0m,,4%,1%,3%,0%,0%,8%,,3%,0%,2%,0%,0%,,1%,1%,1%,0%,0%,,,,5.42541619441265,$0.0m,$6.5m,$0.0m,$0.0m,,$1.8m,$1.3m,$3.3m,$0.0m,$0.0m,$3.8m,$0.7m,$5.5m,$0.0m,,$292.6m,,$11.2m,$2.0m,$15.2m,$0.0m,,$6.4m,$52.5m,$28.4m,$13.4m,$13.5m,$0.0m,$0.0m,$28.5m,$5.0m,$19.9m,$14.4m,$72.3m,$23.4m,$14.9m,$0.0m,$0.0m
56,Medium,Ipsen,Public,Europe,France,Paris,United Kingdom,Oxford,$231.1m,Actual,Yes,No,No,No,4%,$10.0m,$4.4m,$28.9m,$14.3m,$0.0m,,8%,5%,12%,3%,2%,29%,,3%,0%,3%,2%,0%,,5%,5%,9%,2%,2%,,,,$4.0m,$0.0m,$7.2m,$7.1m,$0.0m,,$6.0m,$4.4m,$21.7m,$7.1m,$0.0m,$5.3m,$2.4m,$16.2m,$8.0m,,$272.9m,,$14.3m,$6.2m,$41.2m,$20.3m,,$0.0m,$53.0m,$82.0m,$0.0m,$2.2m,$5.2m,$5.6m,$6.8m,$19.3m,$20.3m,$14.6m,$29.7m,$0.0m,$24.1m,$10.1m,$0.0m
57,Medium,Agios Pharmaceuticals,Public,North America,Massachusetts,Cambridge,,,$220.2m,Actual,Yes,Yes,No,No,11%,$24.4m,$23.6m,$14.7m,$29.0m,$0.0m,,16%,21%,5%,5%,0%,47%,,11%,21%,5%,5%,0%,,5%,0%,0%,0%,0%,,,,$16.3m,$23.6m,$14.7m,$29.0m,$0.0m,,$8.1m,$0.0m,$0.0m,$0.0m,$0.0m,$12.9m,$13.2m,$8.2m,$16.2m,,$285.6m,,$53.2m,$51.5m,$32.1m,$63.3m,,$0.0m,$0.0m,$200.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$69.9m,$15.6m,$0.0m,$0.0m,$0.0m
58,Medium,Santen,Public,Asia/Oceania,,,,,$209.5m,Actual,No,Yes,No,No,0%,$0.0m,$5.1m,$12.7m,$25.1m,$0.0m,,0%,6%,6%,6%,0%,17%,,0%,0%,0%,0%,0%,,0%,6%,6%,6%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.1m,$12.7m,$25.1m,$0.0m,$0.0m,$2.9m,$7.1m,$14.1m,,$219.3m,,$0.0m,$6.6m,$16.5m,$32.5m,,$0.0m,$9.7m,$55.6m,$0.0m,$144.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m
59,Medium,bluebird bio,Public,North America,Massachusetts,Cambridge,Washington,Seattle,$204.8m,Actual,No,Yes,Yes,Yes,18%,$36.6m,$3.8m,$28.3m,$0.0m,$0.0m,,29%,4%,13%,0%,0%,46%,,8%,4%,8%,0%,0%,,21%,0%,4%,0%,0%,,,,$10.5m,$3.8m,$18.9m,$0.0m,$0.0m,,$26.2m,$0.0m,$9.4m,$0.0m,$0.0m,$19.4m,$2.1m,$15.9m,$0.0m,,$265.6m,,$66.8m,$6.9m,$51.7m,$0.0m,,$0.0m,$36.6m,$125.4m,$0.0m,$0.0m,$8.8m,$0.0m,$20.8m,$0.0m,$0.0m,$0.0m,$0.0m,$74.0m,$0.0m,$0.0m,$0.0m
60,Medium,Nektar Therapeutics,Public,North America,California,South San Francisco,Alabama,Huntsville,$203.8m,Actual,Yes,Yes,No,No,6%,$12.6m,$1.8m,$18.3m,$18.0m,$0.0m,,11%,2%,9%,4%,2%,28%,,7%,0%,7%,2%,2%,,4%,2%,2%,2%,0%,,,,$7.6m,$0.0m,$13.7m,$9.0m,$0.0m,,$5.1m,$1.8m,$4.6m,$9.0m,$0.0m,$6.7m,$1.0m,$10.2m,$10.1m,,$264.4m,,$18.3m,$2.7m,$26.5m,$26.2m,,$40.1m,$12.7m,$73.7m,$24.6m,$21.9m,$0.0m,$3.1m,$55.7m,$0.0m,$0.0m,$0.0m,$15.2m,$17.4m,$0.0m,$0.0m,$0.0m
100,Medium,Evotec,Public,Europe,Germany,Hamburg,United Kingdom,Oxford,$195.5m,Estimate,No,Yes,No,No,14%,$27.3m,$1.3m,$3.3m,$0.0m,$0.0m,,16%,1%,1%,0%,0%,18%,,11%,1%,0%,0%,0%,,5%,0%,1%,0%,0%,,,,18.21955749926,$1.3m,$0.0m,$0.0m,$0.0m,,$9.1m,$0.0m,$3.3m,$0.0m,$0.0m,$14.5m,$0.7m,$1.8m,$0.0m,,$237.3m,,$35.4m,$1.7m,$4.3m,$0.0m,,$13.7m,$33.4m,$41.4m,$19.2m,$12.7m,$0.0m,$4.4m,$27.0m,$15.6m,$0.0m,$16.6m,$44.9m,$0.0m,$8.3m,$0.0m,$0.0m
61,Medium,Leo,Public,Europe,United Kingdom,Berkshire,Ireland,Dublin,$191.7m,Actual,No,Yes,No,No,5%,$10.2m,$0.0m,$9.2m,$0.0m,$0.0m,,8%,0%,4%,0%,0%,12%,,0%,0%,4%,0%,0%,,8%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$9.2m,$0.0m,$0.0m,,$10.2m,$0.0m,$0.0m,$0.0m,$0.0m,$5.4m,$0.0m,$5.2m,$0.0m,,$216.2m,,$10.5m,$0.0m,$9.5m,$0.0m,,$15.0m,$0.0m,$19.9m,$10.8m,$6.0m,$0.0m,$87.2m,$20.5m,$0.0m,$33.0m,$23.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
62,Medium,Fibrogen,Public,North America,California,San Francisco,,,$187.2m,Actual,No,Yes,No,No,0%,$0.0m,$0.0m,$20.3m,$0.0m,$0.0m,,0%,0%,11%,0%,0%,11%,,0%,0%,0%,0%,0%,,0%,0%,11%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$20.3m,$0.0m,$0.0m,$0.0m,$0.0m,$11.3m,$0.0m,,$242.8m,,$0.0m,$0.0m,$23.7m,$0.0m,,$35.4m,$0.0m,$23.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.5m,$0.0m,$39.0m,$44.3m,$90.9m,$0.0m,$0.0m,$0.0m
63,Medium,Perrigo,Public,Europe,Ireland,Dublin,Michigan,Allegan,$184.0m,Actual,No,No,No,No,0%,$0.0m,$0.0m,$17.9m,$11.8m,$0.0m,,0%,0%,11%,4%,0%,15%,,0%,0%,4%,0%,0%,,0%,0%,7%,4%,0%,,,,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.9m,$11.8m,$0.0m,$0.0m,$0.0m,$10.0m,$6.6m,,$307.4m,,$0.0m,$0.0m,$33.6m,$22.1m,,$16.4m,$118.7m,$55.7m,$0.0m,$17.7m,$32.9m,$0.0m,$14.5m,$0.0m,$4.0m,$0.0m,$19.2m,$28.4m,$0.0m,$0.0m,$0.0m
101,Medium,Cancer Research Technology,Private,Europe,United Kingdom,Cambridge,United Kingdom,London,$181.4m,Estimate,Yes,Yes,Yes,Yes,18%,$31.9m,$20.3m,$46.8m,$14.2m,$0.0m,,22%,19%,18%,3%,1%,64%,,14%,3%,4%,0%,0%,,8%,17%,14%,3%,1%,,,,19.9396952365174,$2.9m,$10.8m,$0.0m,$0.0m,,$12.0m,$17.4m,$36.0m,$14.2m,$0.0m,$16.9m,$11.3m,$26.2m,$8.0m,,$220.2m,,$58.3m,$37.0m,$85.6m,$26.0m,,$0.0m,$0.0m,$206.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$5.0m,$0.0m,$5.4m,$0.0m,$0.0m,$0.0m
64,Medium,Asahi Kasei Pharma,Private,Asia/Oceania,,,,,$180.0m,Actual,No,No,No,No,0%,$0.0m,$0.0m,$5.3m,$10.5m,$0.0m,,0%,0%,3%,3%,0%,6%,,0%,0%,3%,0%,0%,,0%,0%,0%,3%,0%,,,,$0.0m,$0.0m,$5.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$10.5m,$0.0m,$0.0m,$0.0m,$3.0m,$5.9m,,$54.2m,,$0.0m,$0.0m,$1.7m,$3.3m,,$5.4m,$4.5m,$5.0m,$8.0m,$2.6m,$0.8m,$3.3m,$0.0m,$3.2m,$6.5m,$13.8m,$1.0m,$0.0m,$0.0m,$0.0m,$0.0m
65,Medium,Jiangsu Hengrui Medicine,Public,Asia/Oceania,,,,,$178.2m,Actual,Yes,Yes,No,No,7%,$12.0m,$16.0m,$25.3m,$35.6m,$0.0m,,10%,19%,12%,9%,0%,50%,,7%,17%,9%,7%,0%,,3%,2%,3%,2%,0%,,,,$8.0m,$14.5m,$18.1m,$28.5m,$0.0m,,$4.0m,$1.5m,$7.2m,$7.1m,$0.0m,$6.4m,$8.9m,$14.2m,$19.9m,,$231.1m,,$21.1m,$28.1m,$44.6m,$62.8m,,$0.0m,$14.7m,$156.7m,$15.4m,$0.0m,$0.0m,$7.8m,$0.0m,$2.9m,$5.2m,$11.1m,$17.4m,$0.0m,$0.0m,$0.0m,$0.0m
66,Medium,Lexicon Pharmaceuticals,Public,North America,Texas,The Woodlands,,,$178.2m,Actual,No,No,No,No,19%,$33.3m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$33.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$17.6m,$0.0m,$0.0m,$0.0m,,$231.1m,,$37.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$28.3m,$37.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$165.6m,$0.0m,$0.0m,$0.0m,$0.0m
67,Medium,Menarini,Private,Europe,Italy,Florence,Spain,Barcelona,$175.0m,Actual,Yes,Yes,No,No,5%,$8.7m,$6.3m,$10.4m,$0.0m,$0.0m,,9%,9%,6%,0%,0%,23%,,0%,3%,0%,0%,0%,,9%,6%,6%,0%,0%,,,,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$8.7m,$4.2m,$10.4m,$0.0m,$0.0m,$4.6m,$3.5m,$5.8m,$0.0m,,$291.9m,,$14.7m,$10.7m,$17.7m,$0.0m,,$41.4m,$0.0m,$43.1m,$0.0m,$28.8m,$0.0m,$0.0m,$70.8m,$0.0m,$36.6m,$14.6m,$32.9m,$23.8m,$0.0m,$0.0m,$0.0m
68,Medium,Teijin Pharma,Public,Asia/Oceania,,,,,$168.3m,Actual,No,No,No,No,0%,$0.0m,$0.0m,$4.3m,$8.5m,$0.0m,,0%,0%,3%,3%,0%,6%,,0%,0%,0%,0%,0%,,0%,0%,3%,3%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.3m,$8.5m,$0.0m,$0.0m,$0.0m,$2.4m,$4.7m,,$224.5m,,$0.0m,$0.0m,$6.3m,$12.4m,,$8.9m,$25.7m,$18.7m,$16.5m,$21.7m,$6.1m,$0.0m,$0.0m,$15.1m,$28.3m,$18.2m,$26.4m,$0.0m,$38.9m,$0.0m,$0.0m
69,Medium,Jazz Pharmaceuticals,Public,Europe,Ireland,Dublin,California,Palo Alto,$162.3m,Actual,Yes,No,No,No,9%,$15.0m,$0.0m,$4.5m,$0.0m,$0.0m,,14%,0%,2%,0%,0%,16%,,9%,0%,2%,0%,0%,,5%,0%,0%,0%,0%,,,,$10.0m,$0.0m,$4.5m,$0.0m,$0.0m,,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.9m,$0.0m,$2.5m,$0.0m,,$325.4m,,$36.2m,$0.0m,$10.9m,$0.0m,,$0.0m,$137.1m,$47.1m,$42.4m,$5.4m,$0.0m,$0.0m,$5.1m,$0.0m,$0.0m,$63.0m,$0.0m,$25.2m,$0.0m,$0.0m,$0.0m
70,Medium,Merrimack,Public,North America,Massachusetts,Cambridge,,,$160.9m,Actual,No,Yes,No,No,24%,$38.7m,$14.0m,$23.3m,$23.0m,$0.0m,,29%,14%,10%,5%,0%,57%,,29%,14%,5%,5%,0%,,0%,0%,5%,0%,0%,,,,$38.7m,$14.0m,$11.7m,$23.0m,$0.0m,,$0.0m,$0.0m,$11.7m,$0.0m,$0.0m,$20.5m,$7.9m,$13.0m,$12.9m,,$208.7m,,$67.9m,$24.7m,$40.9m,$40.4m,,$0.0m,$7.4m,$173.8m,$14.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.8m,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m
71,Medium,Array BioPharma,Public,North America,Colorado,Boulder,Massachusetts,Cambridge,$160.7m,Actual,Yes,Yes,No,No,3%,$5.5m,$10.6m,$39.6m,$39.1m,$0.0m,,6%,16%,24%,12%,2%,61%,,4%,14%,20%,8%,2%,,2%,2%,4%,4%,0%,,,,$3.7m,$9.3m,$33.0m,$26.1m,$0.0m,,$1.8m,$1.3m,$6.6m,$13.0m,$0.0m,$2.9m,$5.9m,$22.2m,$21.9m,,$208.4m,,$10.5m,$20.3m,$76.0m,$74.9m,,$0.0m,$9.2m,$181.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$15.2m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
72,Medium,Ziopharm Oncology,Public,North America,Massachusetts,Boston,,,$157.8m,Actual,Yes,Yes,Yes,Yes,20%,$32.2m,$23.4m,$23.2m,$0.0m,$0.0m,,21%,21%,8%,0%,0%,50%,,21%,17%,4%,0%,0%,,0%,4%,4%,0%,0%,,,,$32.2m,$18.7m,$11.6m,$0.0m,$0.0m,,$0.0m,$4.7m,$11.6m,$0.0m,$0.0m,$17.1m,$13.1m,$13.0m,$0.0m,,$204.7m,,$54.3m,$39.4m,$39.2m,$0.0m,,$0.0m,$0.0m,$132.9m,$41.0m,$0.0m,$30.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
102,Medium,Lee's Pharmaceutical,Public,Asia/Oceania,,,,,$157.4m,Estimate,Yes,Yes,Yes,No,3%,$4.5m,$3.3m,$10.8m,$10.7m,$0.0m,,5%,5%,7%,3%,2%,21%,,2%,0%,3%,0%,0%,,3%,5%,3%,3%,2%,,,,1.49980417966133,$0.0m,$5.4m,$0.0m,$0.0m,,$3.0m,$3.3m,$5.4m,$10.7m,$0.0m,$2.4m,$1.8m,$6.1m,$6.0m,,$191.0m,,$5.8m,$4.2m,$13.9m,$13.8m,,$16.4m,$9.4m,$37.7m,$0.0m,$32.3m,$0.0m,$9.9m,$1.9m,$6.0m,$27.3m,$0.0m,$0.0m,$43.3m,$0.0m,$6.8m,$0.0m
73,Medium,Halozyme,Public,North America,California,San Diego,,,$150.8m,Actual,No,Yes,No,No,12%,$18.5m,$6.7m,$8.3m,$16.5m,$0.0m,,22%,11%,6%,6%,0%,44%,,11%,6%,6%,6%,0%,,11%,6%,0%,0%,0%,,,,$9.2m,$3.4m,$8.3m,$16.5m,$0.0m,,$9.2m,$3.4m,$0.0m,$0.0m,$0.0m,$9.8m,$3.8m,$4.7m,$9.2m,,$195.7m,,$36.5m,$13.2m,$16.5m,$32.5m,,$0.0m,$34.7m,$98.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$30.6m,$31.6m,$0.0m,$0.0m,$0.0m
238,Substantial,Leadiant Biosciences,Private,North America,Maryland,Gaithersburg,, ,$140.6m,Estimate,No,Yes,No,No,4%,$5.0m,$3.6m,$15.0m,$5.9m,$0.0m,,6%,6%,11%,2%,2%,28%,,2%,6%,2%,0%,2%,,4%,0%,9%,2%,0%,,,,$1.7m,$3.6m,$3.0m,$0.0m,$0.0m,,$3.3m,$0.0m,$12.0m,$5.9m,$0.0m,$2.6m,$2.0m,$8.4m,$3.3m,,$170.7m,,$8.1m,$5.9m,$24.5m,$9.7m,,$3.5m,$0.0m,$48.1m,$11.0m,$15.9m,$0.0m,$4.2m,$0.0m,$0.0m,$6.4m,$21.8m,$24.1m,$25.8m,$0.0m,$9.7m,$0.0m
74,Substantial,Hanmi Pharmaceutical,Public,Asia/Oceania,South Korea,Seoul,,,$140.1m,Actual,Yes,Yes,No,Yes,11%,$15.5m,$6.6m,$7.0m,$9.2m,$0.0m,,16%,9%,4%,3%,0%,31%,,14%,8%,3%,1%,0%,,1%,1%,1%,1%,0%,,,,$14.2m,$5.6m,$4.7m,$4.6m,$0.0m,,$1.3m,$0.9m,$2.3m,$4.6m,$0.0m,$8.2m,$3.7m,$3.9m,$5.2m,,$308.5m,,$38.2m,$16.2m,$17.2m,$22.7m,,$0.0m,$18.9m,$94.3m,$17.7m,$13.4m,$5.8m,$11.8m,$2.2m,$9.3m,$53.0m,$12.2m,$49.8m,$11.2m,$9.1m,$0.0m,$0.0m
75,Substantial,Pierre Fabre,Private,Europe,France,Toulouse,France,Saint-Julien-en-Genevois,$139.5m,Actual,Yes,Yes,No,No,11%,$14.7m,$4.0m,$23.3m,$19.7m,$0.0m,,17%,6%,15%,6%,2%,46%,,6%,4%,4%,2%,2%,,10%,2%,10%,4%,0%,,,,$5.5m,$2.7m,$6.7m,$6.6m,$0.0m,,$9.2m,$1.3m,$16.7m,$13.1m,$0.0m,$7.8m,$2.2m,$13.1m,$11.0m,,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
239,Substantial,Fortress Biotech,Public,North America,New York,New York,Massachusetts,Waltham,$136.4m,Estimate,Yes,Yes,Yes,Yes,13%,$17.5m,$11.3m,$14.1m,$0.0m,$0.0m,,16%,14%,7%,0%,0%,37%,,12%,9%,4%,0%,0%,,4%,5%,4%,0%,0%,,,,$13.6m,$7.1m,$7.0m,$0.0m,$0.0m,,$3.9m,$4.2m,$7.0m,$0.0m,$0.0m,$9.3m,$6.3m,$7.9m,$0.0m,,$165.6m,,$28.6m,$18.4m,$22.9m,$0.0m,,$0.0m,$24.0m,$69.9m,$15.2m,$0.0m,$0.0m,$3.6m,$12.0m,$7.5m,$0.0m,$13.0m,$15.9m,$3.0m,$0.0m,$1.5m,$0.0m
103,Substantial,SK Holdings,Public,Asia/Oceania,,,,,$136.3m,Estimate,No,No,No,No,1%,$1.6m,$1.2m,$2.9m,$0.0m,$0.0m,,2%,2%,2%,0%,0%,5%,,2%,2%,2%,0%,0%,,0%,0%,0%,0%,0%,,,,1.61116499656489,$1.2m,$2.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.7m,$1.6m,$0.0m,,$165.4m,,$1.8m,$1.3m,$3.2m,$0.0m,,$16.5m,$37.0m,$6.3m,$0.0m,$0.0m,$5.0m,$0.0m,$17.9m,$10.0m,$20.3m,$23.1m,$20.0m,$9.3m,$0.0m,$0.0m,$0.0m
76,Substantial,Orion Pharma,Public,Europe,United Kingdom,Nottingham,Finland,Espoo,$131.0m,Actual,No,No,No,No,7%,$8.9m,$2.2m,$26.8m,$21.1m,$0.0m,,11%,4%,18%,7%,0%,39%,,4%,0%,11%,4%,0%,,7%,4%,7%,4%,0%,,,,$3.0m,$0.0m,$16.1m,$10.6m,$0.0m,,$5.9m,$2.2m,$10.7m,$10.6m,$0.0m,$4.7m,$1.2m,$15.0m,$11.8m,,$142.0m,,$11.9m,$2.9m,$35.9m,$28.4m,,$9.3m,$47.1m,$79.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
77,Substantial,GW Pharmaceuticals,Public,Europe,United Kingdom,Cambridge,United Kingdom,London,$128.9m,Actual,No,No,No,No,0%,$0.0m,$0.0m,$28.6m,$0.0m,$0.0m,,0%,0%,21%,0%,0%,21%,,0%,0%,21%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$28.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$16.0m,$0.0m,,$167.2m,,$0.0m,$0.0m,$43.9m,$0.0m,,$0.0m,$123.2m,$43.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
240,Substantial,Roivant Sciences,Private,North America,New York,New York,North Carolina,Durham,$127.7m,Estimate,Yes,No,No,No,0%,$0.0m,$1.1m,$5.7m,$11.3m,$0.0m,,0%,2%,3%,3%,0%,8%,,0%,0%,0%,0%,0%,,0%,2%,3%,3%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.1m,$5.7m,$11.3m,$0.0m,$0.0m,$0.6m,$3.2m,$6.3m,,$155.0m,,$0.0m,$1.5m,$7.6m,$15.1m,,$0.0m,$21.9m,$24.3m,$6.5m,$2.2m,$1.7m,$12.1m,$26.5m,$23.8m,$0.7m,$7.9m,$24.6m,$2.9m,$0.0m,$0.0m,$0.0m
78,Substantial,Kissei,Public,Asia/Oceania,,,,,$127.6m,Actual,Yes,Yes,No,No,0%,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,,0%,0%,5%,0%,0%,5%,,0%,0%,0%,0%,0%,,0%,0%,5%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,,$154.5m,,$0.0m,$0.0m,$8.0m,$0.0m,,$7.6m,$32.1m,$8.0m,$7.2m,$1.7m,$0.0m,$11.8m,$0.0m,$48.6m,$0.0m,$0.0m,$19.5m,$18.0m,$0.0m,$0.0m,$0.0m
79,Substantial,Meiji,Public,Asia/Oceania,,,,,$126.0m,Actual,Yes,Yes,No,No,3%,$4.3m,$3.1m,$3.9m,$0.0m,$0.0m,,5%,5%,3%,0%,0%,14%,,3%,0%,0%,0%,0%,,3%,5%,3%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$3.1m,$3.9m,$0.0m,$0.0m,$2.3m,$1.7m,$2.2m,$0.0m,,$82.2m,,$3.0m,$2.1m,$2.7m,$0.0m,,$7.0m,$10.3m,$7.8m,$5.0m,$10.6m,$0.0m,$1.6m,$10.7m,$7.0m,$11.4m,$6.6m,$1.7m,$2.7m,$0.0m,$0.0m,$0.0m
80,Substantial,Gedeon Richter,Public,Europe,United Kingdom,London,,,$124.9m,Actual,No,Yes,No,No,0%,$0.0m,$10.8m,$0.0m,$0.0m,$0.0m,,0%,15%,0%,0%,0%,15%,,0%,8%,0%,0%,0%,,0%,8%,0%,0%,0%,,,,$0.0m,$5.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.4m,$0.0m,$0.0m,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,,$222.5m,,$0.0m,$17.8m,$0.0m,$0.0m,,$0.0m,$99.6m,$17.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$90.3m,$14.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
81,Substantial,Mochida,Public,Asia/Oceania,,,,,$123.7m,Actual,No,Yes,No,No,0%,$0.0m,$6.3m,$0.0m,$0.0m,$0.0m,,0%,9%,0%,0%,0%,9%,,0%,0%,0%,0%,0%,,0%,9%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$124.6m,,$0.0m,$4.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.9m,$34.0m,$0.0m,$0.0m,$2.1m,$0.0m,$24.0m,$0.0m,$34.0m,$25.5m,$0.0m,$0.0m,$0.0m,$0.0m
82,Substantial,Nippon Kayaku,Public,Asia/Oceania,,,,,$123.2m,Actual,No,Yes,No,No,3%,$3.1m,$4.5m,$22.4m,$33.1m,$0.0m,,5%,10%,19%,14%,5%,52%,,0%,0%,5%,0%,0%,,5%,10%,14%,14%,5%,,,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,,$3.1m,$4.5m,$16.8m,$33.1m,$0.0m,$1.6m,$2.5m,$12.5m,$18.5m,,$145.2m,,$5.5m,$8.0m,$39.6m,$58.6m,,$0.0m,$19.8m,$111.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.6m,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
83,Substantial,MacroGenics,Public,North America,Maryland,Rockville, , ,$122.1m,Actual,Yes,Yes,No,No,16%,$19.5m,$14.2m,$28.2m,$13.9m,$0.0m,,21%,21%,17%,4%,0%,63%,,21%,21%,17%,4%,0%,,0%,0%,0%,0%,0%,,,,$19.5m,$14.2m,$28.2m,$13.9m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$10.4m,$7.9m,$15.8m,$7.8m,,$158.4m,,$30.7m,$22.3m,$44.3m,$21.9m,,$0.0m,$0.0m,$119.1m,$7.7m,$0.0m,$5.6m,$0.0m,$5.4m,$0.0m,$0.0m,$0.0m,$20.5m,$0.0m,$0.0m,$0.0m,$0.0m
84,Substantial,Infinity Pharmaceuticals,Public,North America,Massachusetts,Cambridge,,,$119.6m,Actual,Yes,Yes,No,No,0%,$0.0m,$13.2m,$16.4m,$32.3m,$0.0m,,0%,22%,11%,11%,11%,56%,,0%,11%,0%,0%,0%,,0%,11%,11%,11%,11%,,,,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$6.6m,$16.4m,$32.3m,$0.0m,$0.0m,$7.4m,$9.2m,$18.1m,,$155.2m,,$0.0m,$33.0m,$41.1m,$81.1m,,$0.0m,$0.0m,$155.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
85,Substantial,BTG,Public,Europe,United Kingdom,Camberley,United Kingdom,London,$118.6m,Actual,Yes,No,No,No,0%,$0.0m,$3.0m,$7.4m,$14.7m,$0.0m,,0%,7%,7%,7%,0%,21%,,0%,7%,0%,7%,0%,,0%,0%,7%,0%,0%,,,,$0.0m,$3.0m,$0.0m,$14.7m,$0.0m,,$0.0m,$0.0m,$7.4m,$0.0m,$0.0m,$0.0m,$1.7m,$4.2m,$8.2m,,$153.8m,,$0.0m,$5.3m,$13.1m,$25.8m,,$0.0m,$24.3m,$44.1m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$0.0m,$40.1m,$0.0m,$38.7m,$2.3m,$0.0m,$0.0m,$0.0m
86,Substantial,PTC Therapeutics,Public,North America,New Jersey,South Plainfield,Ireland,Dublin,$117.6m,Actual,No,No,No,No,8%,$9.0m,$2.2m,$0.0m,$0.0m,$0.0m,,13%,4%,0%,0%,0%,17%,,13%,4%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.8m,$1.2m,$0.0m,$0.0m,,$152.6m,,$14.4m,$3.5m,$0.0m,$0.0m,,$0.0m,$40.4m,$17.8m,$0.0m,$11.3m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$23.9m,$54.3m,$0.0m,$0.0m,$0.0m,$0.0m
87,Substantial,Akebia Therapeutics,Public,North America,Massachusetts,Cambridge,, ,$115.8m,Actual,No,No,No,No,7%,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.0m,$0.0m,$0.0m,,$150.2m,,$7.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.9m,$0.0m,$54.0m,$8.4m,$8.1m,$0.0m,$0.0m,$0.0m,$0.0m,$30.0m,$41.9m,$0.0m,$0.0m,$0.0m
88,Substantial,Glenmark,Public,Asia/Oceania,,,,,$114.0m,Actual,No,Yes,No,No,5%,$5.3m,$3.8m,$0.0m,$9.5m,$0.0m,,7%,7%,0%,3%,0%,17%,,7%,7%,0%,3%,0%,,0%,0%,0%,0%,0%,,,,$5.3m,$3.8m,$0.0m,$9.5m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$2.2m,$0.0m,$5.3m,,$113.1m,,$5.1m,$3.7m,$0.0m,$9.2m,,$47.1m,$19.6m,$18.0m,$5.1m,$0.0m,$0.0m,$4.4m,$0.0m,$0.0m,$0.0m,$6.0m,$12.8m,$0.0m,$0.0m,$0.0m,$0.0m
104,Substantial,Debiopharm,Private,Europe,Switzerland,Martigny,,,$112.7m,Estimate,Yes,Yes,No,No,10%,$11.4m,$8.2m,$17.1m,$13.5m,$0.0m,,15%,15%,12%,5%,0%,46%,,2%,0%,0%,2%,0%,,12%,15%,12%,2%,0%,,,,1.89330904654397,$0.0m,$0.0m,$6.7m,$0.0m,,$9.5m,$8.2m,$17.1m,$6.7m,$0.0m,$6.0m,$4.6m,$9.6m,$7.6m,,$136.8m,,$21.0m,$15.2m,$31.6m,$24.9m,,$0.0m,$8.0m,$92.7m,$0.0m,$0.0m,$0.0m,$3.6m,$20.7m,$0.0m,$5.1m,$2.8m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m
89,Substantial,Opko Health,Public,North America,Florida,Miami,, ,$111.2m,Actual,No,No,No,No,2%,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,,4%,0%,0%,0%,0%,4%,,4%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$144.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$21.0m,$3.2m,$0.0m,$0.0m,$0.0m,$4.2m,$3.3m,$15.7m,$3.0m,$11.9m,$46.5m,$15.8m,$19.7m,$0.0m,$0.0m
90,Substantial,OncoMed,Public,North America,California,Redwood City,,,$109.7m,Actual,Yes,Yes,No,No,27%,$29.9m,$54.3m,$0.0m,$0.0m,$0.0m,,20%,50%,0%,0%,0%,70%,,20%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$29.9m,$54.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$15.9m,$30.4m,$0.0m,$0.0m,,$142.3m,,$50.6m,$91.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$142.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
91,Substantial,Almirall,Public,Europe,Spain,Barcelona,,,$108.8m,Actual,Yes,No,No,No,0%,$0.0m,$1.1m,$8.4m,$0.0m,$0.0m,,0%,3%,8%,0%,0%,10%,,0%,0%,3%,0%,0%,,0%,3%,5%,0%,0%,,,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,,$0.0m,$1.1m,$5.6m,$0.0m,$0.0m,$0.0m,$0.6m,$4.7m,$0.0m,,$94.8m,,$0.0m,$0.9m,$6.9m,$0.0m,,$6.2m,$4.9m,$7.8m,$12.0m,$0.0m,$0.0m,$16.4m,$12.5m,$0.0m,$0.0m,$21.8m,$13.1m,$0.0m,$0.0m,$0.0m,$0.0m
92,Substantial,Radius Health,Public,North America,Massachusetts,Waltham,Massachusetts,Boston,$107.4m,Actual,Yes,No,No,No,9%,$10.0m,$14.5m,$36.0m,$0.0m,$0.0m,,11%,22%,22%,0%,0%,56%,,0%,11%,0%,0%,0%,,11%,11%,22%,0%,0%,,,,$0.0m,$7.2m,$0.0m,$0.0m,$0.0m,,$10.0m,$7.2m,$36.0m,$0.0m,$0.0m,$5.3m,$8.1m,$20.2m,$0.0m,,$139.3m,,$14.3m,$20.7m,$51.6m,$0.0m,,$0.0m,$0.0m,$86.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$52.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
93,Substantial,MorphoSys,Public,Europe,Germany,Planegg,,,$105.9m,Actual,Yes,Yes,No,No,5%,$4.9m,$6.4m,$12.4m,$3.5m,$0.0m,,7%,12%,9%,1%,0%,29%,,7%,3%,5%,0%,0%,,0%,9%,4%,1%,0%,,,,$4.9m,$1.4m,$7.1m,$0.0m,$0.0m,,$0.0m,$5.0m,$5.3m,$3.5m,$0.0m,$2.6m,$3.6m,$6.9m,$2.0m,,$137.4m,,$6.7m,$8.7m,$16.9m,$4.8m,,$12.0m,$6.1m,$37.1m,$22.1m,$2.3m,$1.2m,$6.9m,$0.0m,$0.0m,$5.9m,$7.2m,$16.4m,$20.1m,$0.0m,$0.0m,$0.0m
94,Substantial,Celldex Therapeutics,Public,North America,New Jersey,Hampton,Connecticut,New Haven,$102.7m,Actual,Yes,Yes,No,No,7%,$7.5m,$13.7m,$34.1m,$0.0m,$0.0m,,9%,23%,23%,0%,0%,55%,,5%,14%,5%,0%,0%,,5%,9%,18%,0%,0%,,,,$3.8m,$8.2m,$6.8m,$0.0m,$0.0m,,$3.8m,$5.5m,$27.3m,$0.0m,$0.0m,$4.0m,$7.7m,$19.1m,$0.0m,,$133.2m,,$15.6m,$28.3m,$70.4m,$0.0m,,$0.0m,$0.0m,$114.3m,$0.0m,$0.0m,$0.0m,$0.0m,$18.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
241,Substantial,Sorrento Therapeutics,Public,North America,California,San Diego,,,$102.0m,Estimate,Yes,Yes,Yes,Yes,42%,$42.9m,$10.9m,$11.6m,$0.0m,$0.0m,,45%,16%,7%,0%,0%,68%,,41%,11%,5%,0%,0%,,5%,5%,2%,0%,0%,,,,$38.6m,$7.8m,$7.8m,$0.0m,$0.0m,,$4.3m,$3.1m,$3.9m,$0.0m,$0.0m,$22.8m,$6.1m,$6.5m,$0.0m,,$123.8m,,$68.9m,$17.5m,$18.7m,$0.0m,,$0.0m,$15.5m,$105.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
95,Substantial,Shanghai Pharmaceuticals Holding,Public,Asia/Oceania,China,Shanghai,,,$100.9m,Actual,Yes,Yes,No,No,0%,$0.0m,$49.9m,$0.0m,$0.0m,$0.0m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$49.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$27.9m,$0.0m,$0.0m,,$171.5m,,$0.0m,$76.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$76.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$95.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
96,Substantial,GC Pharma,Public,Asia/Oceania,,,,,$100.8m,Actual,Yes,Yes,Yes,Yes,6%,$6.3m,$2.9m,$10.0m,$11.2m,$0.0m,,10%,6%,9%,5%,0%,30%,,6%,4%,4%,1%,0%,,4%,3%,5%,4%,0%,,,,$3.9m,$1.7m,$4.3m,$2.8m,$0.0m,,$2.4m,$1.1m,$5.7m,$8.4m,$0.0m,$3.3m,$1.6m,$5.6m,$6.3m,,$122.4m,,$9.4m,$4.2m,$14.8m,$16.7m,,$0.0m,$0.0m,$45.1m,$3.4m,$0.0m,$5.0m,$1.0m,$31.5m,$0.0m,$8.7m,$2.8m,$4.1m,$20.0m,$0.8m,$0.0m,$0.0m
97,Substantial,Kyorin,Public,Asia/Oceania,,,,,$100.0m,Actual,Yes,Yes,Yes,No,2%,$2.3m,$1.7m,$4.1m,$0.0m,$0.0m,,4%,4%,4%,0%,0%,12%,,4%,4%,4%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$1.7m,$4.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$2.3m,$0.0m,,$51.6m,,$1.3m,$0.9m,$2.3m,$0.0m,,$13.0m,$8.7m,$4.4m,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,$13.3m,$2.1m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m
105,Substantial,Suzhou Alphamab,Private,Asia/Oceania,China,Suzhou,,,$99.6m,Estimate,Yes,Yes,No,No,28%,$27.7m,$2.9m,$3.6m,$0.0m,$0.0m,,29%,4%,2%,0%,0%,35%,,29%,4%,2%,0%,0%,,0%,0%,0%,0%,0%,,,,27.6675646319509,$2.9m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$14.7m,$1.6m,$2.0m,$0.0m,,$120.9m,,$39.1m,$4.1m,$5.0m,$0.0m,,$0.0m,$0.0m,$48.2m,$16.1m,$7.8m,$0.0m,$2.8m,$5.5m,$8.5m,$0.0m,$5.4m,$5.0m,$21.6m,$0.0m,$0.0m,$0.0m
124,Substantial,Cadila Pharmaceuticals,Public,Asia/Oceania,,,,,$99.0m,Actual,No,No,No,No,5%,$4.5m,$0.0m,$16.3m,$0.0m,$0.0m,,9%,0%,18%,0%,0%,27%,,0%,0%,0%,0%,0%,,9%,0%,18%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.5m,$0.0m,$16.3m,$0.0m,$0.0m,$2.4m,$0.0m,$9.1m,$0.0m,,$128.5m,,$6.7m,$0.0m,$24.4m,$0.0m,,$0.0m,$15.9m,$31.1m,$0.0m,$0.0m,$0.0m,$10.3m,$45.5m,$0.0m,$0.0m,$0.0m,$15.9m,$9.7m,$0.0m,$0.0m,$0.0m
106,Substantial,Zydus Cadila,Public,Asia/Oceania,,,,,$98.8m,Estimate,No,Yes,No,No,8%,$7.5m,$1.4m,$0.0m,$0.0m,$0.0m,,11%,3%,0%,0%,0%,14%,,9%,3%,0%,0%,0%,,3%,0%,0%,0%,0%,,,,5.59833227558445,$1.4m,$0.0m,$0.0m,$0.0m,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$4.0m,$0.8m,$0.0m,$0.0m,,$120.0m,,$10.3m,$1.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$12.1m,$8.5m,$0.0m,$0.0m,$0.0m,$38.1m,$17.6m,$3.5m,$2.4m,$18.3m,$15.2m,$0.0m,$0.0m,$4.3m
125,Substantial,Genmab,Public,Europe,Denmark,Copenhagen,New Jersey,Princeton,$98.2m,Actual,Yes,Yes,No,Yes,16%,$15.3m,$2.8m,$16.2m,$4.6m,$0.0m,,24%,6%,14%,2%,0%,46%,,14%,2%,12%,2%,0%,,10%,4%,2%,0%,0%,,,,$8.9m,$0.9m,$13.9m,$4.6m,$0.0m,,$6.4m,$1.9m,$2.3m,$0.0m,$0.0m,$8.1m,$1.6m,$9.1m,$2.6m,,$127.4m,,$26.7m,$4.8m,$28.1m,$7.9m,,$0.0m,$19.1m,$67.6m,$4.6m,$17.8m,$4.1m,$0.0m,$2.0m,$0.0m,$0.0m,$3.2m,$5.6m,$3.4m,$0.0m,$0.0m,$0.0m
126,Substantial,BeiGene,Public,North America,Massachusetts,Cambridge,California,Emeryville,$98.0m,Actual,Yes,Yes,No,No,7%,$7.1m,$6.9m,$19.3m,$21.1m,$0.0m,,11%,15%,16%,9%,4%,55%,,5%,7%,7%,5%,4%,,5%,7%,9%,4%,0%,,,,$3.6m,$3.4m,$8.6m,$12.7m,$0.0m,,$3.6m,$3.4m,$10.7m,$8.4m,$0.0m,$3.8m,$3.9m,$10.8m,$11.8m,,$127.2m,,$16.5m,$15.9m,$44.6m,$48.9m,,$0.0m,$0.0m,$125.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m
242,Substantial,Intrexon,Public,North America,Maryland,Germantown,,,$97.5m,Estimate,Yes,Yes,Yes,Yes,9%,$8.8m,$3.8m,$3.2m,$0.0m,$0.0m,,10%,6%,2%,0%,0%,19%,,4%,2%,2%,0%,0%,,6%,4%,0%,0%,0%,,,,$3.5m,$1.3m,$3.2m,$0.0m,$0.0m,,$5.3m,$2.6m,$0.0m,$0.0m,$0.0m,$4.7m,$2.1m,$1.8m,$0.0m,,$118.3m,,$12.7m,$5.5m,$4.6m,$0.0m,,$4.3m,$5.1m,$22.8m,$19.0m,$8.4m,$2.3m,$4.1m,$14.6m,$0.0m,$0.9m,$7.2m,$14.7m,$3.9m,$0.0m,$0.0m,$11.1m
107,Substantial,Innovent Biologics,Private,Asia/Oceania,China,Suzhou,China,Shanghai,$96.9m,Estimate,Yes,Yes,No,No,19%,$18.3m,$4.4m,$3.7m,$21.7m,$0.0m,,23%,8%,3%,8%,3%,43%,,15%,5%,0%,8%,3%,,8%,3%,3%,0%,0%,,,,12.1992412539223,$3.0m,$0.0m,$21.7m,$0.0m,,$6.1m,$1.5m,$3.7m,$0.0m,$0.0m,$9.7m,$2.5m,$2.1m,$12.2m,,$117.7m,,$29.0m,$7.0m,$5.8m,$34.4m,,$0.0m,$0.0m,$76.2m,$6.4m,$5.5m,$2.8m,$1.0m,$2.6m,$0.0m,$3.5m,$18.2m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m
108,Substantial,Omeros,Public,North America,Washington,Seattle,,,$96.3m,Estimate,No,No,No,No,5%,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,,7%,0%,0%,0%,0%,7%,,7%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,5.15345740460791,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,,$116.9m,,$6.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$26.0m,$6.7m,$12.1m,$2.6m,$0.0m,$2.3m,$2.2m,$14.0m,$9.1m,$4.4m,$10.3m,$23.8m,$1.8m,$1.6m,$0.0m
127,Substantial,Exelixis,Public,North America,California,South San Francisco,,,$96.0m,Actual,Yes,Yes,No,No,5%,$5.2m,$7.6m,$28.2m,$9.3m,$0.0m,,7%,14%,21%,4%,4%,50%,,4%,14%,21%,4%,4%,,4%,0%,0%,0%,0%,,,,$2.6m,$7.6m,$28.2m,$9.3m,$0.0m,,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$4.2m,$15.8m,$5.2m,,$124.5m,,$8.6m,$12.5m,$46.5m,$15.3m,,$0.0m,$0.0m,$82.8m,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,$10.5m,$4.8m,$6.5m,$16.1m,$0.0m,$0.0m,$0.0m,$0.0m
128,Substantial,Five Prime Therapeutics,Public,North America,California,South San Francisco,,,$94.1m,Actual,Yes,Yes,Yes,Yes,28%,$26.3m,$8.5m,$10.6m,$10.4m,$0.0m,,35%,15%,8%,4%,0%,62%,,23%,15%,8%,4%,0%,,12%,0%,0%,0%,0%,,,,$17.5m,$8.5m,$10.6m,$10.4m,$0.0m,,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m,$13.9m,$4.8m,$5.9m,$5.8m,,$122.0m,,$44.0m,$14.2m,$17.7m,$17.4m,,$0.0m,$3.9m,$93.3m,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$20.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
129,Substantial,Recordati,Public,Europe,Italy,Milan,,,$92.6m,Actual,Yes,No,No,No,2%,$1.5m,$0.0m,$5.6m,$5.5m,$0.0m,,3%,0%,6%,3%,0%,13%,,0%,0%,0%,0%,0%,,3%,0%,6%,3%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.5m,$0.0m,$5.6m,$5.5m,$0.0m,$0.8m,$0.0m,$3.1m,$3.1m,,$121.5m,,$2.5m,$0.0m,$9.0m,$8.9m,,$17.5m,$14.7m,$20.4m,$0.0m,$7.4m,$0.0m,$2.5m,$23.1m,$19.6m,$7.3m,$7.2m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m
130,Substantial,Swedish Orphan Biovitrum,Public,Europe,Sweden,Stockholm,,,$92.2m,Actual,Yes,No,No,No,0%,$0.0m,$1.8m,$9.1m,$4.5m,$0.0m,,0%,4%,9%,2%,2%,17%,,0%,0%,0%,0%,0%,,0%,4%,9%,2%,2%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.8m,$9.1m,$4.5m,$0.0m,$0.0m,$1.0m,$5.1m,$2.5m,,$119.6m,,$0.0m,$2.8m,$14.0m,$6.9m,,$0.0m,$12.1m,$23.7m,$6.5m,$0.0m,$0.0m,$6.9m,$1.4m,$4.1m,$2.3m,$17.7m,$24.6m,$9.7m,$10.6m,$0.0m,$0.0m
243,Substantial,Zhejiang Hisun Pharmaceutical,Public,Asia/Oceania,China,Taizhou,,,$91.9m,Estimate,Yes,Yes,No,No,12%,$10.8m,$0.0m,$9.8m,$6.4m,$0.0m,,16%,0%,8%,3%,0%,27%,,11%,0%,3%,0%,0%,,5%,0%,5%,3%,0%,,,,$7.2m,$0.0m,$3.3m,$0.0m,$0.0m,,$3.6m,$0.0m,$6.5m,$6.4m,$0.0m,$5.7m,$0.0m,$5.5m,$3.6m,,$111.5m,,$14.6m,$0.0m,$13.2m,$8.7m,,$0.0m,$1.6m,$36.5m,$12.6m,$0.0m,$0.0m,$2.9m,$2.6m,$0.0m,$14.1m,$14.5m,$13.6m,$13.1m,$0.0m,$0.0m,$0.0m
244,Substantial,Akeso Biopharma,Private,Asia/Oceania,China,Guangdong,California,Fremont,$91.7m,Estimate,Yes,Yes,No,No,35%,$32.1m,$7.3m,$3.6m,$0.0m,$0.0m,,34%,11%,2%,0%,0%,47%,,34%,11%,2%,0%,0%,,0%,0%,0%,0%,0%,,,,$32.1m,$7.3m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$17.0m,$4.1m,$2.0m,$0.0m,,$111.3m,,$41.4m,$9.4m,$4.7m,$0.0m,,$2.4m,$2.3m,$55.5m,$23.4m,$4.8m,$0.0m,$8.5m,$0.0m,$0.0m,$3.3m,$4.9m,$3.7m,$2.7m,$0.0m,$0.0m,$0.0m
131,Substantial,Epizyme,Public,North America,Massachusetts,Cambridge,,,$91.5m,Actual,Yes,No,No,No,13%,$12.0m,$13.0m,$10.8m,$0.0m,$0.0m,,13%,20%,7%,0%,0%,40%,,13%,20%,7%,0%,0%,,0%,0%,0%,0%,0%,,,,$12.0m,$13.0m,$10.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.4m,$7.3m,$6.1m,$0.0m,,$118.6m,,$30.0m,$32.7m,$27.1m,$0.0m,,$0.0m,$0.0m,$89.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$28.8m,$0.0m,$0.0m,$0.0m
245,Substantial,Walvax Biotechnology,Public,Asia/Oceania,,,,,$90.6m,Estimate,Yes,Yes,No,No,9%,$7.8m,$5.7m,$7.1m,$13.9m,$0.0m,,11%,11%,5%,5%,0%,32%,,11%,8%,5%,5%,0%,,0%,3%,0%,0%,0%,,,,$7.8m,$4.2m,$7.1m,$13.9m,$0.0m,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$4.1m,$3.2m,$3.9m,$7.8m,,$109.9m,,$10.7m,$7.8m,$9.7m,$19.1m,,$0.0m,$0.0m,$47.3m,$16.1m,$0.0m,$0.0m,$3.1m,$32.2m,$0.0m,$2.0m,$3.9m,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m
132,Substantial,Nippon Shinyaku,Public,Asia/Oceania,,,,,$89.5m,Actual,Yes,Yes,No,No,2%,$1.9m,$1.4m,$8.6m,$3.4m,$0.0m,,4%,4%,11%,2%,0%,22%,,2%,0%,2%,0%,0%,,2%,4%,9%,2%,0%,,,,$0.9m,$0.0m,$1.7m,$0.0m,$0.0m,,$0.9m,$1.4m,$6.8m,$3.4m,$0.0m,$1.0m,$0.8m,$4.8m,$1.9m,,$108.9m,,$2.9m,$2.1m,$13.2m,$5.2m,,$12.7m,$6.4m,$23.4m,$11.5m,$0.0m,$0.0m,$3.1m,$0.0m,$3.4m,$16.8m,$9.7m,$8.3m,$13.6m,$0.0m,$0.0m,$0.0m
133,Substantial,Inovio,Public,North America,Pennsylvania,Plymouth Meeting,California,San Diego,$88.7m,Actual,Yes,Yes,Yes,No,3%,$2.7m,$4.9m,$12.3m,$0.0m,$0.0m,,4%,9%,9%,0%,0%,23%,,2%,8%,8%,0%,0%,,2%,2%,2%,0%,0%,,,,$1.4m,$3.9m,$9.8m,$0.0m,$0.0m,,$1.4m,$1.0m,$2.5m,$0.0m,$0.0m,$1.4m,$2.8m,$6.9m,$0.0m,,$115.1m,,$4.4m,$7.9m,$19.6m,$0.0m,,$0.0m,$0.0m,$31.9m,$0.0m,$0.0m,$0.0m,$0.0m,$63.2m,$11.8m,$0.0m,$0.0m,$5.4m,$0.0m,$0.0m,$0.0m,$2.8m
134,Substantial,Aduro BioTech,Public,North America,California,Berkley,,,$87.7m,Actual,Yes,Yes,No,No,28%,$24.6m,$14.9m,$14.8m,$0.0m,$0.0m,,30%,25%,10%,0%,0%,65%,,30%,25%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$24.6m,$14.9m,$14.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$13.0m,$8.3m,$8.3m,$0.0m,,$113.8m,,$38.2m,$23.1m,$23.0m,$0.0m,,$0.0m,$0.0m,$84.2m,$5.8m,$0.0m,$6.2m,$0.0m,$11.7m,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
135,Substantial,Karyopharm Therapeutics,Public,North America,Massachusetts,Newton,,,$86.9m,Actual,Yes,No,No,No,13%,$11.3m,$4.1m,$10.2m,$10.1m,$0.0m,,15%,8%,8%,4%,4%,38%,,15%,8%,8%,4%,4%,,0%,0%,0%,0%,0%,,,,$11.3m,$4.1m,$10.2m,$10.1m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.0m,$2.3m,$5.7m,$5.6m,,$112.8m,,$25.7m,$9.3m,$23.2m,$22.9m,,$0.0m,$5.1m,$81.2m,$5.5m,$0.0m,$0.0m,$5.6m,$9.9m,$0.0m,$0.0m,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
136,Substantial,LFB,Private,Europe,France,Paris,,,$86.0m,Actual,Yes,Yes,No,No,0%,$0.0m,$1.1m,$2.7m,$5.3m,$0.0m,,0%,3%,3%,3%,0%,9%,,0%,3%,3%,3%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.1m,$2.7m,$5.3m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$1.5m,$3.0m,,$143.4m,,$0.0m,$2.3m,$5.7m,$11.3m,,$2.4m,$24.4m,$19.4m,$24.2m,$2.4m,$0.0m,$0.0m,$7.2m,$9.5m,$13.3m,$15.7m,$1.8m,$23.2m,$0.0m,$0.0m,$0.0m
246,Substantial,Serum Institute of India,Private,Asia/Oceania,,,,,$85.8m,Estimate,No,Yes,No,No,4%,$3.4m,$1.2m,$3.1m,$0.0m,$0.0m,,7%,3%,3%,0%,0%,13%,,0%,3%,0%,0%,0%,,7%,0%,3%,0%,0%,,,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$3.4m,$0.0m,$3.1m,$0.0m,$0.0m,$1.8m,$0.7m,$1.7m,$0.0m,,$104.2m,,$5.3m,$1.9m,$4.8m,$0.0m,,$0.0m,$0.0m,$12.0m,$7.0m,$0.0m,$0.0m,$2.8m,$69.6m,$0.0m,$0.0m,$3.5m,$0.0m,$9.1m,$0.0m,$0.0m,$0.0m
109,Substantial,HitGen,Private,Asia/Oceania,China,Chengdu,,,$85.4m,Estimate,No,Yes,No,No,43%,$36.9m,$0.0m,$0.0m,$0.0m,$0.0m,,43%,0%,0%,0%,0%,43%,,41%,0%,0%,0%,0%,,2%,0%,0%,0%,0%,,,,34.9229458219966,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$19.5m,$0.0m,$0.0m,$0.0m,,$103.6m,,$49.4m,$0.0m,$0.0m,$0.0m,,$2.5m,$0.0m,$49.4m,$5.2m,$2.5m,$22.2m,$2.6m,$0.0m,$0.0m,$7.1m,$2.6m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m
110,Substantial,Luye Pharma,Public,Asia/Oceania,China,Shanghai,Hong Kong,Hong Kong,$84.8m,Estimate,No,Yes,Yes,Yes,15%,$12.7m,$2.6m,$3.3m,$19.4m,$0.0m,,20%,6%,3%,9%,0%,37%,,11%,3%,0%,6%,0%,,9%,3%,3%,3%,0%,,,,7.25781492977013,$1.3m,$0.0m,$12.9m,$0.0m,,$5.4m,$1.3m,$3.3m,$6.5m,$0.0m,$6.7m,$1.5m,$1.8m,$10.9m,,$38.9m,,$6.3m,$1.3m,$1.6m,$9.7m,,$0.0m,$14.2m,$19.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$1.5m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m
137,Substantial,Dynavax Technologies,Public,North America,California,Berkley,,,$84.5m,Actual,No,Yes,No,No,10%,$8.8m,$3.2m,$15.8m,$0.0m,$0.0m,,15%,8%,15%,0%,0%,38%,,15%,8%,8%,0%,0%,,0%,0%,8%,0%,0%,,,,$8.8m,$3.2m,$7.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.9m,$0.0m,$0.0m,$4.6m,$1.8m,$8.9m,$0.0m,,$109.6m,,$10.6m,$3.8m,$19.1m,$0.0m,,$23.2m,$0.0m,$33.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$15.9m,$17.3m,$19.6m,$0.0m,$0.0m,$0.0m,$0.0m
138,Substantial,Esteve,Private,Europe,Spain,Barcelona,,,$82.9m,Actual,No,Yes,No,No,1%,$1.0m,$0.0m,$1.8m,$3.6m,$0.0m,,2%,0%,2%,2%,0%,7%,,0%,0%,0%,0%,0%,,2%,0%,2%,2%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.0m,$0.0m,$1.8m,$3.6m,$0.0m,$0.5m,$0.0m,$1.0m,$2.0m,,$85.7m,,$1.3m,$0.0m,$2.4m,$4.7m,,$6.8m,$25.0m,$8.4m,$5.7m,$0.0m,$0.0m,$0.0m,$17.5m,$6.4m,$9.9m,$0.0m,$4.2m,$1.8m,$0.0m,$0.0m,$0.0m
139,Substantial,Seres Therapeutics,Public,North America,Massachusetts,Cambridge,,,$82.0m,Actual,No,Yes,No,No,9%,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,,12%,0%,0%,0%,0%,12%,,12%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,,$106.4m,,$11.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.8m,$5.9m,$0.0m,$0.0m,$0.0m,$57.3m,$6.0m,$0.0m,$0.0m,$25.3m,$0.0m,$0.0m,$0.0m,$0.0m
247,Substantial,GENESIS Pharma,Private,Europe,Spain,Madrid,,,$81.9m,Estimate,Yes,Yes,No,No,4%,$3.3m,$1.2m,$12.0m,$17.7m,$0.0m,,8%,4%,16%,12%,0%,40%,,0%,0%,0%,0%,0%,,8%,4%,16%,12%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.3m,$1.2m,$12.0m,$17.7m,$0.0m,$1.8m,$0.7m,$6.7m,$9.9m,,$99.4m,,$5.5m,$2.0m,$19.8m,$29.3m,,$0.0m,$16.0m,$56.5m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.8m,$1.5m,$0.0m,$14.7m,$0.0m,$0.0m
248,Substantial,Ferrer,Private,Europe,Spain,Barcelona,,,$81.7m,Estimate,Yes,Yes,No,No,0%,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,,0%,0%,7%,0%,3%,10%,,0%,0%,0%,0%,0%,,0%,0%,7%,0%,3%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,,$99.2m,,$0.0m,$0.0m,$8.4m,$0.0m,,$13.7m,$38.3m,$8.4m,$0.0m,$3.6m,$4.3m,$0.0m,$12.0m,$0.0m,$2.9m,$10.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m
140,Substantial,Daewoong Pharmaceutical,Public,Asia/Oceania,,,,,$81.2m,Actual,No,Yes,No,No,2%,$1.3m,$1.4m,$0.0m,$2.3m,$0.0m,,2%,3%,0%,1%,0%,6%,,2%,3%,0%,0%,0%,,0%,0%,0%,1%,0%,,,,$1.3m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.7m,$0.8m,$0.0m,$1.3m,,$199.8m,,$3.5m,$3.8m,$0.0m,$6.2m,,$6.4m,$24.9m,$13.4m,$6.3m,$20.8m,$10.4m,$14.1m,$0.0m,$13.6m,$13.4m,$22.3m,$43.1m,$9.9m,$1.1m,$0.0m,$0.0m
141,Substantial,Blueprint Medicines,Public,North America,Massachusetts,Cambridge,,,$81.1m,Actual,Yes,Yes,No,No,14%,$11.4m,$12.4m,$0.0m,$20.3m,$0.0m,,17%,25%,0%,8%,0%,50%,,17%,25%,0%,8%,0%,,0%,0%,0%,0%,0%,,,,$11.4m,$12.4m,$0.0m,$20.3m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.0m,$6.9m,$0.0m,$11.4m,,$105.2m,,$23.8m,$25.9m,$0.0m,$42.4m,,$0.0m,$0.0m,$92.1m,$0.0m,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
249,Substantial,RedHill Biopharma,Public,Middle East/Africa,,,,,$80.9m,Estimate,Yes,No,No,No,4%,$3.3m,$1.2m,$6.0m,$0.0m,$0.0m,,7%,3%,7%,0%,0%,17%,,0%,0%,0%,0%,0%,,7%,3%,7%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.3m,$1.2m,$6.0m,$0.0m,$0.0m,$1.8m,$0.7m,$3.4m,$0.0m,,$32.7m,,$1.6m,$0.6m,$2.8m,$0.0m,,$0.0m,$1.8m,$5.0m,$1.0m,$0.0m,$0.0m,$0.0m,$10.6m,$0.0m,$0.0m,$1.0m,$10.5m,$0.0m,$0.0m,$2.8m,$0.0m
111,Substantial,Aphios,Private,North America,Massachusetts,Woburn,,,$80.4m,Estimate,Yes,No,No,No,19%,$15.3m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,15.3056936398462,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.1m,$0.0m,$0.0m,$0.0m,,$97.6m,,$22.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$24.3m,$22.0m,$0.0m,$2.7m,$2.9m,$2.8m,$18.9m,$2.8m,$0.0m,$2.7m,$18.4m,$0.0m,$0.0m,$0.0m,$0.0m
142,Substantial,CSPC Pharmaceutical,Public,Asia/Oceania,,,,,$80.0m,Actual,Yes,Yes,No,No,9%,$7.0m,$2.5m,$12.6m,$12.5m,$0.0m,,14%,7%,14%,7%,0%,43%,,14%,7%,7%,0%,0%,,0%,0%,7%,7%,0%,,,,$7.0m,$2.5m,$6.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.3m,$12.5m,$0.0m,$3.7m,$1.4m,$7.1m,$7.0m,,$103.8m,,$12.5m,$4.5m,$22.6m,$22.3m,,$5.0m,$8.8m,$62.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$27.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
250,Substantial,China Medical System,Public,Middle East/Africa,,,,,$79.8m,Estimate,No,No,No,No,2%,$1.7m,$0.0m,$6.1m,$6.0m,$0.0m,,4%,0%,7%,4%,0%,15%,,0%,0%,0%,4%,0%,,4%,0%,7%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$6.0m,$0.0m,,$1.7m,$0.0m,$6.1m,$0.0m,$0.0m,$0.9m,$0.0m,$3.4m,$3.4m,,$96.9m,,$2.6m,$0.0m,$9.5m,$9.4m,,$11.4m,$2.8m,$21.5m,$14.7m,$7.2m,$0.0m,$5.3m,$18.8m,$0.0m,$5.4m,$0.0m,$8.5m,$1.2m,$0.0m,$0.0m,$0.0m
251,Substantial,Nerviano Medical Sciences,Private,Europe,Italy,Milan,,,$79.5m,Estimate,Yes,Yes,No,No,31%,$24.8m,$6.0m,$18.7m,$14.7m,$0.0m,,44%,15%,19%,7%,0%,85%,,41%,15%,15%,4%,0%,,4%,0%,4%,4%,0%,,,,$22.7m,$6.0m,$14.9m,$7.4m,$0.0m,,$2.1m,$0.0m,$3.7m,$7.4m,$0.0m,$13.1m,$3.4m,$10.4m,$8.2m,,$96.5m,,$37.3m,$9.0m,$28.1m,$22.1m,,$0.0m,$0.0m,$96.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
112,Substantial,Biocad,Private,Europe,Russia,Moscow,Russia,Saint-Petersburg,$78.8m,Estimate,Yes,Yes,No,No,2%,$1.7m,$4.9m,$0.0m,$6.0m,$0.0m,,3%,11%,0%,3%,0%,17%,,3%,11%,0%,3%,0%,,0%,0%,0%,0%,0%,,,,1.67395055290903,$4.9m,$0.0m,$6.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$2.7m,$0.0m,$3.3m,,$95.6m,,$2.1m,$6.2m,$0.0m,$7.6m,,$0.0m,$10.0m,$15.9m,$20.6m,$1.6m,$0.0m,$8.8m,$0.0m,$0.0m,$1.5m,$10.1m,$6.7m,$20.4m,$0.0m,$0.0m,$0.0m
252,Substantial,HEC Pharm,Public,Asia/Oceania,China,Dongguan,Japan,Tokyo,$78.5m,Estimate,Yes,No,No,No,12%,$9.4m,$4.1m,$0.0m,$0.0m,$0.0m,,14%,8%,0%,0%,0%,22%,,14%,8%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.4m,$4.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.0m,$2.3m,$0.0m,$0.0m,,$95.3m,,$11.5m,$5.0m,$0.0m,$0.0m,,$9.8m,$1.6m,$16.5m,$4.3m,$0.0m,$0.0m,$0.0m,$31.0m,$0.0m,$0.0m,$0.0m,$29.8m,$2.3m,$0.0m,$0.0m,$0.0m
143,Substantial,Cellectis,Public,Europe,France,Paris,New York,New York,$78.4m,Actual,Yes,Yes,Yes,Yes,50%,$39.2m,$8.1m,$0.0m,$0.0m,$0.0m,,47%,13%,0%,0%,0%,60%,,40%,13%,0%,0%,0%,,7%,0%,0%,0%,0%,,,,$33.6m,$8.1m,$0.0m,$0.0m,$0.0m,,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$20.8m,$4.5m,$0.0m,$0.0m,,$101.7m,,$75.7m,$15.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$91.4m,$0.0m,$0.0m,$0.0m,$10.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
253,Substantial,Sihuan Pharmaceutical,Public,Asia/Oceania,,,,,$78.4m,Estimate,No,No,No,No,2%,$1.9m,$2.7m,$3.4m,$0.0m,$0.0m,,2%,5%,2%,0%,0%,10%,,2%,5%,2%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$2.7m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$1.5m,$1.9m,$0.0m,,$49.6m,,$1.2m,$1.8m,$2.2m,$0.0m,,$2.5m,$5.8m,$5.2m,$1.1m,$0.0m,$0.0m,$0.0m,$10.4m,$3.9m,$4.6m,$3.0m,$11.9m,$1.2m,$0.0m,$0.0m,$0.0m
254,Substantial,Handok,Public,Asia/Oceania,,,,,$77.6m,Estimate,No,No,No,No,5%,$4.2m,$1.0m,$2.6m,$0.0m,$0.0m,,10%,3%,3%,0%,3%,20%,,3%,0%,0%,0%,0%,,7%,3%,3%,0%,3%,,,,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.8m,$1.0m,$2.6m,$0.0m,$0.0m,$2.2m,$0.6m,$1.4m,$0.0m,,$94.2m,,$5.7m,$1.4m,$3.4m,$0.0m,,$0.0m,$14.2m,$10.5m,$15.4m,$13.0m,$0.0m,$0.0m,$0.0m,$2.8m,$4.4m,$16.9m,$2.9m,$9.1m,$5.0m,$0.0m,$0.0m
113,Substantial,Grupo Biotoscana,Public,Latin America,Uruguay ,Montevideo,,,$77.5m,Estimate,Yes,Yes,No,No,2%,$1.7m,$3.6m,$9.0m,$17.7m,$0.0m,,3%,10%,10%,10%,6%,39%,,0%,0%,0%,0%,0%,,3%,10%,10%,10%,6%,,,,0,$0.0m,$0.0m,$0.0m,$0.0m,,$1.7m,$3.6m,$9.0m,$17.7m,$0.0m,$0.9m,$2.0m,$5.0m,$9.9m,,$94.1m,,$2.5m,$5.3m,$13.3m,$26.2m,,$0.0m,$8.8m,$47.3m,$7.6m,$2.5m,$0.0m,$5.0m,$16.7m,$0.0m,$2.9m,$2.1m,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m
114,Substantial,Betta Pharmaceuticals,Public,Asia/Oceania,China,Beijing,China,Hangzhou,$76.3m,Estimate,No,No,No,No,23%,$17.9m,$5.2m,$9.7m,$12.8m,$0.0m,,32%,13%,10%,6%,0%,61%,,29%,10%,6%,0%,0%,,3%,3%,3%,6%,0%,,,,16.096827587025,$3.9m,$6.5m,$0.0m,$0.0m,,$1.8m,$1.3m,$3.2m,$12.8m,$0.0m,$9.5m,$2.9m,$5.4m,$7.1m,,$92.6m,,$27.9m,$8.1m,$15.1m,$19.9m,,$0.0m,$0.0m,$71.0m,$0.0m,$8.5m,$0.0m,$8.3m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$2.6m,$0.0m,$0.0m,$0.0m
144,Substantial,Humanwell Healthcare,Public,Asia/Oceania,,,,,$75.6m,Actual,No,No,No,No,9%,$6.5m,$9.4m,$0.0m,$0.0m,$0.0m,,9%,18%,0%,0%,0%,27%,,9%,18%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.5m,$9.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$5.3m,$0.0m,$0.0m,,$98.1m,,$7.8m,$11.3m,$0.0m,$0.0m,,$0.0m,$43.7m,$19.1m,$9.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$19.9m,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
255,Substantial,Medigene,Public,Europe,Germany,Martinsried,,,$75.4m,Estimate,Yes,Yes,Yes,Yes,17%,$12.9m,$0.0m,$10.0m,$6.6m,$0.0m,,27%,0%,12%,4%,0%,42%,,23%,0%,12%,4%,0%,,4%,0%,0%,0%,0%,,,,$11.1m,$0.0m,$10.0m,$6.6m,$0.0m,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$6.8m,$0.0m,$5.6m,$3.7m,,$91.5m,,$22.4m,$0.0m,$17.3m,$11.4m,,$4.5m,$3.9m,$51.0m,$2.8m,$0.0m,$0.0m,$5.3m,$6.3m,$17.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
256,Substantial,Ildong,Public,Asia/Oceania,,,,,$75.4m,Estimate,Yes,Yes,No,No,7%,$5.2m,$3.8m,$3.1m,$6.2m,$0.0m,,10%,10%,3%,3%,0%,26%,,10%,6%,0%,0%,0%,,0%,3%,3%,3%,0%,,,,$5.2m,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.3m,$3.1m,$6.2m,$0.0m,$2.8m,$2.1m,$1.8m,$3.5m,,$91.5m,,$6.7m,$4.9m,$4.0m,$7.9m,,$0.0m,$33.6m,$23.5m,$3.0m,$8.5m,$0.0m,$0.0m,$2.3m,$0.0m,$2.2m,$0.0m,$17.3m,$1.1m,$0.0m,$0.0m,$0.0m
145,Substantial,YuHan,Public,Asia/Oceania,South Korea,Seoul,,,$74.5m,Actual,No,Yes,No,No,27%,$20.4m,$0.6m,$1.5m,$0.0m,$0.0m,,38%,2%,2%,0%,0%,42%,,31%,0%,0%,0%,0%,,8%,2%,2%,0%,0%,,,,$16.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.1m,$0.6m,$1.5m,$0.0m,$0.0m,$10.8m,$0.3m,$0.8m,$0.0m,,$96.6m,,$24.1m,$0.7m,$1.7m,$0.0m,,$11.1m,$4.7m,$26.6m,$0.0m,$11.1m,$0.0m,$2.8m,$2.7m,$0.0m,$15.5m,$7.5m,$13.7m,$1.0m,$0.0m,$0.0m,$0.0m
146,Substantial,Insys Therapeutics,Public,North America,Arizona,Chandler,Arizona,Chandler,$73.9m,Actual,No,No,No,No,4%,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,,6%,0%,0%,0%,0%,6%,,6%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$204.1m,,$8.7m,$0.0m,$0.0m,$0.0m,,$11.4m,$145.6m,$8.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$38.4m,$0.0m,$0.0m,$0.0m,$0.0m
257,Substantial,Philogen,Private,Europe,Italy,Sienna,,,$73.8m,Estimate,Yes,Yes,No,No,10%,$7.6m,$5.5m,$6.9m,$13.6m,$0.0m,,15%,15%,7%,7%,0%,44%,,15%,11%,7%,7%,0%,,0%,4%,0%,0%,0%,,,,$7.6m,$4.2m,$6.9m,$13.6m,$0.0m,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$4.0m,$3.1m,$3.9m,$7.6m,,$89.6m,,$11.4m,$8.2m,$10.3m,$20.2m,,$0.0m,$0.0m,$50.1m,$12.7m,$0.0m,$10.2m,$0.0m,$0.0m,$2.4m,$0.0m,$6.1m,$8.1m,$0.0m,$0.0m,$0.0m,$0.0m
258,Substantial,Galderma,Private,Europe,Switzerland,Lausanne,,,$73.7m,Estimate,Yes,No,No,No,2%,$1.5m,$0.0m,$2.7m,$0.0m,$0.0m,,3%,0%,3%,0%,0%,6%,,3%,0%,0%,0%,0%,,0%,0%,3%,0%,0%,,,,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.8m,$0.0m,$1.5m,$0.0m,,$89.5m,,$1.7m,$0.0m,$3.0m,$0.0m,,$0.0m,$17.1m,$4.7m,$0.0m,$1.9m,$0.0m,$29.8m,$12.7m,$10.4m,$0.0m,$11.6m,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m
147,Substantial,Pharmstandard,Private,Europe,Russia,Moscow,,,$72.7m,Actual,No,Yes,No,Yes,12%,$9.0m,$6.6m,$32.6m,$0.0m,$0.0m,,17%,17%,33%,0%,0%,67%,,0%,0%,0%,0%,0%,,17%,17%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$9.0m,$6.6m,$32.6m,$0.0m,$0.0m,$4.8m,$3.7m,$18.3m,$0.0m,,$314.3m,,$58.9m,$42.7m,$212.7m,$0.0m,,$0.0m,$0.0m,$314.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
259,Substantial,Arbutus Biopharma,Public,North America,Pennsylvania,Warminster,,,$71.9m,Estimate,Yes,No,No,No,6%,$4.0m,$1.4m,$10.7m,$7.1m,$0.0m,,7%,3%,10%,3%,0%,24%,,3%,0%,7%,3%,0%,,3%,3%,3%,0%,0%,,,,$2.0m,$0.0m,$7.2m,$7.1m,$0.0m,,$2.0m,$1.4m,$3.6m,$0.0m,$0.0m,$2.1m,$0.8m,$6.0m,$4.0m,,$87.2m,,$6.4m,$2.3m,$17.4m,$11.4m,,$0.0m,$3.6m,$37.6m,$0.0m,$0.0m,$0.0m,$0.0m,$42.4m,$0.0m,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m
260,Substantial,Senju,Private,Asia/Oceania,,,,,$71.5m,Estimate,No,No,No,No,2%,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,,5%,0%,0%,0%,0%,5%,,0%,0%,0%,0%,0%,,5%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,$0.0m,,$86.8m,,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$11.5m,$1.6m,$0.0m,$69.6m,$0.0m,$2.4m,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
261,Substantial,NanoCarrier,Public,Asia/Oceania,,,,,$71.1m,Estimate,Yes,No,Yes,No,2%,$1.7m,$5.0m,$12.5m,$18.4m,$0.0m,,5%,19%,19%,14%,0%,57%,,0%,14%,14%,10%,0%,,5%,5%,5%,5%,0%,,,,$0.0m,$3.8m,$9.3m,$12.3m,$0.0m,,$1.7m,$1.3m,$3.1m,$6.1m,$0.0m,$0.9m,$2.8m,$7.0m,$10.3m,,$86.4m,,$3.5m,$10.1m,$25.2m,$37.3m,,$0.0m,$0.0m,$76.1m,$0.0m,$0.0m,$10.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
262,Substantial,Bukwang Pharmaceutical,Public,Asia/Oceania,,,,,$70.6m,Estimate,Yes,Yes,No,No,5%,$3.3m,$1.2m,$3.0m,$5.9m,$0.0m,,8%,4%,4%,4%,0%,20%,,0%,0%,0%,0%,0%,,8%,4%,4%,4%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.3m,$1.2m,$3.0m,$5.9m,$0.0m,$1.8m,$0.7m,$1.7m,$3.3m,,$85.7m,,$5.5m,$2.0m,$5.0m,$9.8m,,$0.0m,$18.0m,$22.3m,$2.2m,$0.0m,$0.0m,$16.4m,$0.0m,$0.0m,$0.0m,$8.4m,$18.4m,$0.0m,$0.0m,$0.0m,$0.0m
263,Substantial,Moderna Therapeutics,Private,North America,Massachusetts,Cambridge,Massachusetts,Cambridge,$70.3m,Estimate,No,Yes,Yes,No,8%,$5.7m,$2.8m,$0.0m,$0.0m,$0.0m,,8%,5%,0%,0%,0%,13%,,8%,5%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.7m,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$1.6m,$0.0m,$0.0m,,$85.4m,,$10.4m,$5.0m,$0.0m,$0.0m,,$3.1m,$0.0m,$15.5m,$0.0m,$0.0m,$3.4m,$3.3m,$35.7m,$0.0m,$10.7m,$0.0m,$13.8m,$0.0m,$0.0m,$0.0m,$0.0m
148,Substantial,Zeria,Public,Asia/Oceania,,,,,$70.0m,Actual,No,No,No,No,5%,$3.5m,$0.0m,$6.4m,$12.6m,$0.0m,,8%,0%,8%,8%,0%,25%,,0%,0%,4%,4%,0%,,8%,0%,4%,4%,0%,,,,$0.0m,$0.0m,$3.2m,$6.3m,$0.0m,,$3.5m,$0.0m,$3.2m,$6.3m,$0.0m,$1.9m,$0.0m,$3.6m,$7.0m,,$77.6m,,$4.3m,$0.0m,$7.7m,$15.2m,,$0.0m,$7.7m,$27.2m,$0.0m,$0.0m,$0.0m,$0.0m,$1.5m,$0.0m,$0.0m,$7.7m,$33.4m,$0.0m,$0.0m,$0.0m,$0.0m
149,Substantial,TG Therapeutics,Public,North America,New York,New York,,,$69.2m,Actual,Yes,Yes,No,No,10%,$6.9m,$3.3m,$4.1m,$8.2m,$0.0m,,16%,11%,5%,5%,0%,38%,,3%,3%,0%,0%,0%,,14%,8%,5%,5%,0%,,,,$1.1m,$0.8m,$0.0m,$0.0m,$0.0m,,$5.7m,$2.5m,$4.1m,$8.2m,$0.0m,$3.7m,$1.9m,$2.3m,$4.6m,,$89.8m,,$11.0m,$5.3m,$6.6m,$13.0m,,$7.1m,$8.7m,$35.9m,$18.7m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$15.4m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m
150,Substantial,Bavarian Nordic,Public,Europe,Denmark,Germany,Martinsried,,$68.8m,Actual,Yes,Yes,Yes,No,5%,$3.5m,$3.9m,$6.4m,$0.0m,$0.0m,,8%,12%,8%,0%,0%,27%,,0%,8%,4%,0%,0%,,8%,4%,4%,0%,0%,,,,$0.0m,$2.6m,$3.2m,$0.0m,$0.0m,,$3.5m,$1.3m,$3.2m,$0.0m,$0.0m,$1.9m,$2.2m,$3.6m,$0.0m,,$89.3m,,$6.4m,$7.0m,$11.6m,$0.0m,,$0.0m,$0.0m,$25.0m,$0.0m,$0.0m,$0.0m,$0.0m,$64.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
151,Substantial,Acceleron Pharma,Public,North America,Massachusetts,Cambridge,,,$68.6m,Actual,Yes,Yes,No,No,0%,$0.0m,$0.0m,$2.9m,$5.7m,$0.0m,,0%,0%,5%,5%,0%,9%,,0%,0%,5%,5%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$2.9m,$5.7m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$3.2m,,$89.0m,,$0.0m,$0.0m,$5.0m,$9.9m,,$2.1m,$7.0m,$14.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.2m,$3.1m,$16.4m,$8.2m,$31.1m,$0.0m,$0.0m,$0.0m
115,Substantial,Vernalis,Public,Europe,United Kingdom,Cambridge,,,$68.5m,Estimate,Yes,Yes,No,No,8%,$5.5m,$2.6m,$13.2m,$0.0m,$0.0m,,8%,6%,11%,0%,0%,25%,,8%,6%,8%,0%,0%,,0%,0%,3%,0%,0%,,,,5.475695717765,$2.6m,$9.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$2.9m,$1.5m,$7.4m,$0.0m,,$83.2m,,$7.8m,$3.8m,$18.8m,$0.0m,,$18.9m,$7.2m,$30.4m,$0.0m,$0.0m,$0.0m,$0.0m,$9.0m,$0.0m,$4.3m,$0.0m,$0.0m,$13.4m,$0.0m,$0.0m,$0.0m
264,Substantial,Knight Therapeutics,Public,North America,Quebec,Montreal,,,$68.5m,Estimate,Yes,Yes,No,No,4%,$2.9m,$0.0m,$7.8m,$0.0m,$0.0m,,6%,0%,10%,0%,3%,19%,,0%,0%,0%,0%,0%,,6%,0%,10%,0%,3%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.9m,$0.0m,$7.8m,$0.0m,$0.0m,$1.5m,$0.0m,$4.4m,$0.0m,,$83.1m,,$3.8m,$0.0m,$10.2m,$0.0m,,$0.0m,$5.3m,$13.9m,$0.0m,$7.5m,$0.0m,$0.0m,$18.1m,$5.9m,$14.1m,$5.6m,$6.3m,$3.6m,$0.0m,$0.0m,$2.8m
116,Substantial,Antengene,Private,Asia/Oceania,China,Shanghai,,,$67.8m,Estimate,Yes,No,No,No,8%,$5.2m,$5.0m,$9.4m,$12.4m,$0.0m,,10%,14%,10%,7%,3%,45%,,0%,0%,0%,0%,0%,,10%,14%,10%,7%,3%,,,,0,$0.0m,$0.0m,$0.0m,$0.0m,,$5.2m,$5.0m,$9.4m,$12.4m,$0.0m,$2.8m,$2.8m,$5.3m,$6.9m,,$82.4m,,$11.7m,$11.3m,$21.1m,$27.8m,,$0.0m,$0.0m,$71.8m,$0.0m,$0.0m,$0.0m,$4.0m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
265,Substantial,Immunocore,Private,Europe,United Kingdom,Oxford,Pennsylvania,Conshohocken,$67.6m,Estimate,Yes,Yes,No,Yes,18%,$12.2m,$3.0m,$7.4m,$14.6m,$0.0m,,26%,9%,9%,9%,0%,52%,,26%,9%,9%,9%,0%,,0%,0%,0%,0%,0%,,,,$12.2m,$3.0m,$7.4m,$14.6m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.5m,$1.7m,$4.1m,$8.1m,,$82.1m,,$23.8m,$5.7m,$14.3m,$28.2m,,$0.0m,$0.0m,$72.1m,$3.3m,$0.0m,$0.0m,$0.0m,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
266,Substantial,XL-protein,Private,Europe,Germany,Freising,,,$67.6m,Estimate,Yes,Yes,No,No,14%,$9.4m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,8%,0%,0%,0%,0%,,6%,0%,0%,0%,0%,,,,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,,$82.0m,,$13.2m,$0.0m,$0.0m,$0.0m,,$3.9m,$7.9m,$13.2m,$7.3m,$6.5m,$5.2m,$0.0m,$4.9m,$0.0m,$0.0m,$7.3m,$16.9m,$6.9m,$1.9m,$0.0m,$0.0m
267,Substantial,CJ HealthCare,Private,Asia/Oceania,,,,,$67.4m,Estimate,No,Yes,No,No,2%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,3%,0%,0%,0%,0%,3%,,3%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$81.8m,,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.1m,$1.5m,$3.1m,$5.3m,$0.0m,$8.0m,$9.8m,$12.4m,$11.7m,$2.5m,$14.9m,$5.6m,$4.8m,$0.0m,$0.0m
268,Substantial,Fogangren Bio-Pharma,Private,Asia/Oceania,,,,,$67.1m,Estimate,No,No,No,No,3%,$1.8m,$1.3m,$6.4m,$0.0m,$0.0m,,5%,5%,11%,0%,0%,21%,,5%,5%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$1.3m,$6.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.7m,$3.6m,$0.0m,,$81.4m,,$2.0m,$1.5m,$7.3m,$0.0m,,$1.8m,$0.0m,$10.8m,$8.2m,$0.0m,$0.0m,$4.4m,$30.7m,$16.8m,$0.0m,$0.0m,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m
152,Substantial,Hutchison China MediTech,Public,Asia/Oceania,,,,,$66.9m,Actual,Yes,Yes,No,No,2%,$1.5m,$7.5m,$15.9m,$15.7m,$0.0m,,3%,23%,20%,10%,3%,60%,,3%,23%,20%,10%,3%,,0%,0%,0%,0%,0%,,,,$1.5m,$7.5m,$15.9m,$15.7m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$4.2m,$8.9m,$8.8m,,$86.7m,,$2.8m,$14.4m,$30.7m,$30.2m,,$0.0m,$1.7m,$78.1m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m
269,Substantial,Kwang Dong,Public,Asia/Oceania,,,,,$66.8m,Estimate,No,Yes,No,No,5%,$3.5m,$0.0m,$6.4m,$0.0m,$0.0m,,7%,0%,7%,0%,0%,15%,,0%,0%,0%,0%,0%,,7%,0%,7%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.5m,$0.0m,$6.4m,$0.0m,$0.0m,$1.9m,$0.0m,$3.6m,$0.0m,,$81.1m,,$4.3m,$0.0m,$7.7m,$0.0m,,$0.0m,$9.2m,$11.9m,$9.8m,$6.2m,$0.0m,$4.6m,$0.0m,$8.5m,$4.3m,$8.1m,$12.1m,$1.0m,$5.4m,$0.0m,$0.0m
153,Substantial,Nichi-Iko,Public,Asia/Oceania,Japan,Toyama,,,$66.8m,Actual,Yes,Yes,No,No,33%,$22.3m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,0%,0%,0%,0%,0%,,14%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$22.3m,$0.0m,$0.0m,$0.0m,$0.0m,$11.8m,$0.0m,$0.0m,$0.0m,,$129.5m,,$55.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$55.3m,$74.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
154,Substantial,ImmunoGen,Public,North America,Massachusetts,Waltham,Massachusetts,Norwood,$66.6m,Actual,Yes,Yes,No,No,12%,$8.0m,$6.6m,$14.5m,$8.2m,$0.0m,,18%,20%,18%,5%,0%,60%,,10%,13%,10%,5%,0%,,8%,8%,8%,0%,0%,,,,$4.6m,$4.2m,$8.3m,$8.2m,$0.0m,,$3.4m,$2.5m,$6.2m,$0.0m,$0.0m,$4.2m,$3.7m,$8.1m,$4.6m,,$86.3m,,$18.1m,$15.0m,$32.6m,$18.4m,,$0.0m,$0.0m,$84.1m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
270,Substantial,Southern Research Institute,Private,North America,Alabama,Birmingham,Maryland,Frederick,$66.4m,Estimate,Yes,Yes,No,No,37%,$24.7m,$1.5m,$0.0m,$0.0m,$0.0m,,36%,3%,0%,0%,0%,39%,,33%,3%,0%,0%,0%,,3%,0%,0%,0%,0%,,,,$22.6m,$1.5m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$13.1m,$0.8m,$0.0m,$0.0m,,$80.6m,,$38.4m,$2.3m,$0.0m,$0.0m,,$0.0m,$11.5m,$40.7m,$0.0m,$0.0m,$0.0m,$0.0m,$13.3m,$3.1m,$0.0m,$6.2m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m
271,Substantial,I-Mab Biopharma,Private,Asia/Oceania,,,,,$65.8m,Estimate,Yes,Yes,No,No,5%,$3.4m,$1.2m,$6.1m,$0.0m,$0.0m,,6%,3%,6%,0%,0%,15%,,3%,0%,0%,0%,0%,,3%,3%,6%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.7m,$1.2m,$6.1m,$0.0m,$0.0m,$1.8m,$0.7m,$3.4m,$0.0m,,$79.8m,,$4.1m,$1.5m,$7.5m,$0.0m,,$0.0m,$0.0m,$13.1m,$4.5m,$0.0m,$29.9m,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,$11.3m,$14.0m,$5.4m,$0.0m,$0.0m
155,Substantial,Sangamo Therapeutics,Public,North America,California,Richmond,,,$65.6m,Actual,No,Yes,No,Yes,5%,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,4%,0%,0%,0%,0%,,4%,0%,0%,0%,0%,,,,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$85.1m,,$5.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$6.9m,$5.4m,$2.5m,$0.0m,$0.0m,$0.0m,$12.4m,$0.0m,$0.0m,$0.0m,$16.6m,$41.4m,$0.0m,$0.0m,$0.0m
156,Substantial,CTI BioPharma,Public,North America,Washington,Seattle,,,$65.0m,Actual,Yes,Yes,No,No,4%,$2.4m,$3.5m,$13.0m,$17.1m,$0.0m,,6%,13%,19%,13%,0%,50%,,0%,6%,6%,13%,0%,,6%,6%,13%,0%,0%,,,,$0.0m,$1.7m,$4.3m,$17.1m,$0.0m,,$2.4m,$1.7m,$8.7m,$0.0m,$0.0m,$1.3m,$2.0m,$7.3m,$9.6m,,$84.3m,,$5.6m,$8.2m,$30.4m,$40.0m,,$0.0m,$0.0m,$84.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
157,Substantial,Torrent Pharmaceuticals,Public,Asia/Oceania,,,,,$64.9m,Actual,Yes,Yes,No,No,5%,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,,7%,0%,0%,0%,0%,7%,,0%,0%,0%,0%,0%,,7%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,,$72.7m,,$3.8m,$0.0m,$0.0m,$0.0m,,$3.0m,$2.9m,$3.8m,$5.1m,$3.0m,$0.0m,$3.2m,$0.0m,$0.0m,$26.0m,$0.0m,$25.7m,$0.0m,$0.0m,$0.0m,$0.0m
272,Substantial,Tianjin Tasly Pharmaceutical,Private,Asia/Oceania,,,,,$64.5m,Estimate,No,Yes,No,No,9%,$6.0m,$0.0m,$5.4m,$0.0m,$0.0m,,18%,0%,9%,0%,0%,27%,,9%,0%,5%,0%,0%,,9%,0%,5%,0%,0%,,,,$3.0m,$0.0m,$2.7m,$0.0m,$0.0m,,$3.0m,$0.0m,$2.7m,$0.0m,$0.0m,$3.2m,$0.0m,$3.0m,$0.0m,,$78.3m,,$6.6m,$0.0m,$6.0m,$0.0m,,$4.3m,$8.8m,$12.6m,$0.0m,$9.9m,$0.0m,$5.4m,$1.3m,$0.0m,$24.0m,$0.0m,$2.0m,$5.3m,$4.6m,$0.0m,$0.0m
158,Substantial,Adaptimmune,Public,Europe,United Kingdom,Oxford,Pennsylvania,Philadelphia,$63.8m,Actual,Yes,Yes,Yes,Yes,10%,$6.6m,$4.8m,$15.8m,$7.8m,$0.0m,,15%,15%,20%,5%,0%,55%,,10%,10%,15%,0%,0%,,5%,5%,5%,5%,0%,,,,$4.4m,$3.2m,$11.8m,$0.0m,$0.0m,,$2.2m,$1.6m,$3.9m,$7.8m,$0.0m,$3.5m,$2.7m,$8.8m,$4.4m,,$82.7m,,$13.9m,$10.1m,$33.4m,$16.5m,,$0.0m,$0.0m,$73.9m,$0.0m,$0.0m,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
159,Substantial,Rigel,Public,North America,California,South San Francisco,,,$63.4m,Actual,Yes,Yes,No,No,7%,$4.1m,$3.0m,$3.7m,$0.0m,$0.0m,,9%,9%,5%,0%,0%,23%,,9%,9%,5%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$3.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$1.7m,$2.1m,$0.0m,,$82.3m,,$6.1m,$4.4m,$5.5m,$0.0m,,$2.7m,$2.1m,$16.0m,$16.3m,$6.8m,$0.0m,$14.8m,$0.0m,$8.0m,$0.0m,$2.2m,$0.0m,$13.4m,$0.0m,$0.0m,$0.0m
117,Substantial,Advenchen,Private,North America,California,Moonpark,,,$63.4m,Estimate,Yes,No,No,No,12%,$7.7m,$5.6m,$10.4m,$13.7m,$0.0m,,19%,19%,14%,10%,0%,62%,,14%,19%,10%,5%,0%,,5%,0%,5%,5%,0%,,,,5.75487397479292,$5.6m,$6.9m,$6.8m,$0.0m,,$1.9m,$0.0m,$3.5m,$6.8m,$0.0m,$4.1m,$3.1m,$5.8m,$7.7m,,$77.0m,,$15.8m,$11.5m,$21.5m,$28.2m,,$0.0m,$0.0m,$77.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
118,Substantial,Melinta Therapeutics,Public,North America,Connecticut,New Haven,,,$63.3m,Estimate,No,No,No,No,2%,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,,4%,0%,0%,0%,0%,4%,,4%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,1.44033265729784,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$76.9m,,$1.3m,$0.0m,$0.0m,$0.0m,,$1.8m,$0.0m,$1.3m,$0.0m,$10.9m,$0.0m,$2.2m,$51.7m,$3.6m,$0.0m,$0.0m,$0.0m,$5.4m,$0.0m,$0.0m,$0.0m
273,Substantial,argenx,Public,Europe,Netherlands,Breda,Belgium,Zwjnaarde,$63.3m,Estimate,Yes,Yes,No,No,6%,$4.0m,$2.9m,$3.6m,$0.0m,$0.0m,,9%,9%,5%,0%,0%,23%,,9%,9%,5%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$2.9m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$1.6m,$2.0m,$0.0m,,$45.3m,,$3.0m,$2.2m,$2.7m,$0.0m,,$0.0m,$1.9m,$7.8m,$16.5m,$0.0m,$1.4m,$0.5m,$0.0m,$0.0m,$1.2m,$7.0m,$0.0m,$8.9m,$0.0m,$0.0m,$0.0m
160,Substantial,La Jolla Pharmaceutical,Public,North America,California,San Diego,,,$62.3m,Actual,Yes,No,No,No,0%,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,,0%,8%,0%,0%,0%,8%,,0%,8%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,,$80.8m,,$0.0m,$4.9m,$0.0m,$0.0m,,$5.2m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$5.5m,$15.6m,$0.0m,$5.4m,$15.6m,$28.6m,$0.0m,$0.0m,$0.0m
274,Substantial,Celprogen,Private,North America,California,Torrance,,,$62.0m,Estimate,No,Yes,No,Yes,75%,$46.5m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$46.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$24.7m,$0.0m,$0.0m,$0.0m,,$75.3m,,$72.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$72.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m
275,Substantial,Heidelberg Pharma,Public,Europe,Germany,Ladenburg,,,$61.9m,Estimate,Yes,Yes,No,No,42%,$26.1m,$0.0m,$7.9m,$7.8m,$0.0m,,55%,0%,9%,5%,0%,68%,,36%,0%,5%,0%,0%,,18%,0%,5%,5%,0%,,,,$17.4m,$0.0m,$3.9m,$0.0m,$0.0m,,$8.7m,$0.0m,$3.9m,$7.8m,$0.0m,$13.8m,$0.0m,$4.4m,$4.3m,,$75.1m,,$42.1m,$0.0m,$12.7m,$12.5m,,$0.0m,$0.0m,$67.3m,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m
276,Substantial,Quark Pharmaceuticals,Private,North America,California,Newark,Israel,International,$61.5m,Estimate,No,No,No,No,5%,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$74.7m,,$3.7m,$0.0m,$0.0m,$0.0m,,$11.4m,$1.7m,$3.7m,$8.4m,$25.1m,$0.0m,$3.7m,$0.0m,$6.2m,$1.7m,$3.8m,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m
277,Substantial,Zai Lab,Public,Asia/Oceania,,,,,$61.2m,Estimate,Yes,Yes,No,No,2%,$1.5m,$2.2m,$5.5m,$10.8m,$0.0m,,4%,8%,8%,8%,0%,27%,,4%,0%,0%,0%,0%,,0%,8%,8%,8%,0%,,,,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.2m,$5.5m,$10.8m,$0.0m,$0.8m,$1.2m,$3.1m,$6.0m,,$74.3m,,$2.4m,$3.5m,$8.6m,$17.0m,,$5.6m,$0.0m,$31.5m,$3.0m,$0.0m,$0.0m,$2.4m,$25.9m,$3.3m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m
278,Substantial,MolMed,Public,Europe,Italy,Milan,,,$61.0m,Estimate,Yes,Yes,Yes,Yes,18%,$11.1m,$1.3m,$3.4m,$6.6m,$0.0m,,32%,5%,5%,5%,0%,47%,,21%,5%,5%,5%,0%,,11%,0%,0%,0%,0%,,,,$7.4m,$1.3m,$3.4m,$6.6m,$0.0m,,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.8m,$1.9m,$3.7m,,$74.0m,,$20.4m,$2.5m,$6.1m,$12.1m,,$0.0m,$13.4m,$41.1m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$16.5m,$0.0m,$0.0m,$0.0m
279,Substantial,Aldeyra Therapeutics,Public,North America,Massachusetts,Lexington,,,$60.9m,Estimate,Yes,No,No,No,3%,$1.6m,$0.0m,$3.0m,$0.0m,$0.0m,,4%,0%,4%,0%,0%,7%,,4%,0%,0%,0%,0%,,0%,0%,4%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.9m,$0.0m,$1.7m,$0.0m,,$73.9m,,$2.5m,$0.0m,$4.6m,$0.0m,,$0.0m,$2.0m,$7.1m,$15.1m,$24.6m,$0.0m,$6.2m,$0.0m,$0.0m,$0.0m,$4.4m,$14.6m,$0.0m,$0.0m,$0.0m,$0.0m
161,Substantial,Horizon Pharma,Public,North America,Illinois,Lake Forest,California,Brisbane,$60.7m,Actual,No,Yes,No,No,4%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,6%,0%,0%,0%,0%,6%,,6%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$192.3m,,$6.7m,$0.0m,$0.0m,$0.0m,,$32.9m,$52.0m,$6.7m,$0.0m,$55.0m,$0.0m,$0.0m,$8.2m,$0.0m,$0.0m,$28.4m,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m
280,Substantial,ABL Bio,Private,Asia/Oceania,South Korea,Seongnam,,,$60.7m,Estimate,Yes,Yes,No,No,60%,$36.4m,$1.6m,$0.0m,$0.0m,$0.0m,,59%,3%,0%,0%,0%,62%,,52%,3%,0%,0%,0%,,7%,0%,0%,0%,0%,,,,$32.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$19.3m,$0.9m,$0.0m,$0.0m,,$73.6m,,$54.4m,$2.3m,$0.0m,$0.0m,,$0.0m,$2.9m,$56.7m,$0.0m,$0.0m,$14.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
281,Substantial,Reata Pharmaceuticals,Public,North America,Texas,Irving,,,$60.4m,Estimate,No,No,No,No,3%,$1.7m,$0.0m,$3.0m,$0.0m,$0.0m,,6%,0%,6%,0%,0%,11%,,6%,0%,6%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$3.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$1.7m,$0.0m,,$51.2m,,$1.5m,$0.0m,$2.7m,$0.0m,,$0.0m,$4.4m,$4.2m,$2.1m,$3.5m,$0.0m,$2.4m,$0.0m,$8.9m,$7.6m,$8.5m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m
282,Substantial,UAB Research Foundation,Private,North America,Alabama,Birmingham,,,$60.3m,Estimate,Yes,Yes,No,No,33%,$19.9m,$1.4m,$0.0m,$0.0m,$0.0m,,32%,3%,0%,0%,0%,35%,,0%,0%,0%,0%,0%,,32%,3%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$19.9m,$1.4m,$0.0m,$0.0m,$0.0m,$10.6m,$0.8m,$0.0m,$0.0m,,$73.2m,,$29.6m,$2.1m,$0.0m,$0.0m,,$0.0m,$13.5m,$31.7m,$0.0m,$0.0m,$0.0m,$0.0m,$9.0m,$4.3m,$0.0m,$8.0m,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m
283,Substantial,LegoChem Biosciences,Public,Asia/Oceania,South Korea,Daejeon,,,$60.2m,Estimate,Yes,Yes,No,No,42%,$25.4m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,38%,0%,0%,0%,0%,,13%,0%,0%,0%,0%,,,,$19.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,$13.5m,$0.0m,$0.0m,$0.0m,,$73.0m,,$35.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$35.0m,$0.0m,$0.0m,$2.9m,$0.0m,$14.8m,$0.0m,$4.0m,$0.0m,$0.0m,$13.6m,$0.0m,$0.0m,$0.0m
162,Substantial,Northwest Biotherapeutics,Public,North America,Maryland,Bethesda,,,$60.1m,Actual,No,Yes,No,Yes,18%,$10.6m,$0.0m,$19.2m,$18.9m,$0.0m,,33%,0%,33%,17%,0%,83%,,33%,0%,33%,17%,0%,,0%,0%,0%,0%,0%,,,,$10.6m,$0.0m,$19.2m,$18.9m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.6m,$0.0m,$10.7m,$10.6m,,$77.9m,,$17.0m,$0.0m,$30.7m,$30.3m,,$0.0m,$0.0m,$77.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
284,Substantial,PharmaEssentia,Public,Asia/Oceania,,,,,$60.0m,Estimate,Yes,Yes,No,No,6%,$3.6m,$4.0m,$9.9m,$6.5m,$0.0m,,9%,13%,13%,4%,0%,39%,,4%,0%,4%,0%,0%,,4%,13%,9%,4%,0%,,,,$1.8m,$0.0m,$3.3m,$0.0m,$0.0m,,$1.8m,$4.0m,$6.6m,$6.5m,$0.0m,$1.9m,$2.2m,$5.5m,$3.6m,,$72.8m,,$5.3m,$5.7m,$14.2m,$9.4m,,$0.0m,$0.0m,$34.6m,$0.0m,$0.0m,$0.0m,$6.4m,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,$18.2m,$0.0m,$0.0m,$0.0m
163,Substantial,Dong-A ST,Public,Asia/Oceania,,,,,$59.9m,Actual,No,Yes,No,No,8%,$4.7m,$2.0m,$1.7m,$0.0m,$0.0m,,11%,6%,2%,0%,0%,19%,,6%,4%,0%,0%,0%,,4%,2%,2%,0%,0%,,,,$2.8m,$1.4m,$0.0m,$0.0m,$0.0m,,$1.9m,$0.7m,$1.7m,$0.0m,$0.0m,$2.5m,$1.1m,$0.9m,$0.0m,,$76.1m,,$5.7m,$2.5m,$2.1m,$0.0m,,$1.3m,$10.7m,$10.3m,$10.6m,$4.4m,$0.0m,$2.4m,$11.6m,$2.9m,$0.0m,$1.0m,$16.3m,$4.7m,$0.0m,$0.0m,$0.0m
285,Substantial,NewLink Genetics,Public,North America,Texas,Austin,Iowa,Austin,$59.8m,Estimate,Yes,Yes,No,No,0%,$0.0m,$4.3m,$10.8m,$14.2m,$0.0m,,0%,20%,20%,13%,0%,53%,,0%,13%,7%,13%,0%,,0%,7%,13%,0%,0%,,,,$0.0m,$2.9m,$3.6m,$14.2m,$0.0m,,$0.0m,$1.4m,$7.2m,$0.0m,$0.0m,$0.0m,$2.4m,$6.0m,$8.0m,,$72.6m,,$0.0m,$8.4m,$20.9m,$27.4m,,$0.0m,$0.0m,$56.7m,$0.0m,$0.0m,$0.0m,$0.0m,$15.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
119,Substantial,Forty Seven,Public,North America,California,Menlo Park,,,$59.8m,Estimate,Yes,Yes,No,No,9%,$5.3m,$3.8m,$9.5m,$12.5m,$0.0m,,14%,14%,14%,10%,0%,52%,,5%,5%,5%,0%,0%,,10%,10%,10%,10%,0%,,,,1.75517655539702,$1.3m,$3.2m,$0.0m,$0.0m,,$3.5m,$2.5m,$6.3m,$12.5m,$0.0m,$2.8m,$2.1m,$5.3m,$7.0m,,$72.5m,,$12.3m,$8.9m,$22.2m,$29.2m,,$0.0m,$0.0m,$72.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
164,Substantial,Kaken Pharmaceutical,Public,Asia/Oceania,,,,,$59.3m,Actual,No,Yes,No,No,6%,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,,7%,0%,0%,0%,0%,7%,,0%,0%,0%,0%,0%,,7%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,,$64.0m,,$3.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.7m,$13.0m,$0.0m,$0.0m,$16.9m,$2.4m,$0.0m,$0.0m,$19.2m,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m
286,Substantial,Specialised Therapeutics,Private,Asia/Oceania,,,,,$59.3m,Estimate,Yes,No,No,No,0%,$0.0m,$3.6m,$12.1m,$11.9m,$0.0m,,0%,12%,15%,8%,4%,38%,,0%,0%,0%,0%,0%,,0%,12%,15%,8%,4%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.6m,$12.1m,$11.9m,$0.0m,$0.0m,$2.0m,$6.8m,$6.7m,,$71.9m,,$0.0m,$6.9m,$23.0m,$22.7m,,$0.0m,$0.0m,$52.6m,$0.0m,$12.1m,$0.0m,$0.0m,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
287,Substantial,Kymab,Private,Europe,United Kingdom,Cambridge,,,$59.0m,Estimate,No,Yes,No,No,31%,$18.1m,$0.0m,$0.0m,$0.0m,$0.0m,,30%,0%,0%,0%,0%,30%,,20%,0%,0%,0%,0%,,10%,0%,0%,0%,0%,,,,$12.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,,$71.6m,,$25.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$25.9m,$6.6m,$0.0m,$0.0m,$3.8m,$10.9m,$0.0m,$2.5m,$2.7m,$2.5m,$8.7m,$0.0m,$0.0m,$8.0m
288,Substantial,JW Pharmaceutical,Public,Asia/Oceania,South Korea,Seoul,,,$58.9m,Estimate,Yes,Yes,No,No,12%,$7.0m,$2.5m,$6.3m,$0.0m,$0.0m,,14%,7%,7%,0%,0%,28%,,10%,3%,0%,0%,0%,,3%,3%,7%,0%,0%,,,,$5.2m,$1.3m,$0.0m,$0.0m,$0.0m,,$1.7m,$1.3m,$6.3m,$0.0m,$0.0m,$3.7m,$1.4m,$3.5m,$0.0m,,$35.3m,,$5.4m,$2.0m,$4.9m,$0.0m,,$0.0m,$1.2m,$12.2m,$4.7m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$4.2m,$1.2m,$0.0m,$5.4m,$3.6m,$0.0m,$0.0m
165,Substantial,Spectrum Pharmaceuticals,Public,North America,California,Irvine,Nevada,Henderson,$58.9m,Actual,Yes,No,No,No,5%,$3.0m,$2.2m,$10.9m,$10.8m,$0.0m,,9%,9%,17%,9%,4%,48%,,0%,0%,0%,4%,4%,,9%,9%,17%,4%,0%,,,,$0.0m,$0.0m,$0.0m,$5.4m,$0.0m,,$3.0m,$2.2m,$10.9m,$5.4m,$0.0m,$1.6m,$1.2m,$6.1m,$6.0m,,$76.4m,,$5.2m,$3.8m,$18.8m,$18.6m,,$0.0m,$5.9m,$46.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.6m,$3.8m,$0.0m,$8.3m,$8.5m,$0.0m,$0.0m,$0.0m
166,Substantial,Mesoblast,Public,Asia/Oceania,,,,,$58.9m,Actual,No,Yes,Yes,Yes,4%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$76.4m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$9.9m,$2.2m,$9.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$18.5m,$20.4m,$15.6m,$0.0m,$0.0m,$0.0m,$0.0m
289,Substantial,LG Chem,Public,Asia/Oceania,,,,,$58.8m,Estimate,No,Yes,No,No,3%,$1.8m,$1.3m,$0.0m,$0.0m,$0.0m,,4%,4%,0%,0%,0%,8%,,0%,4%,0%,0%,0%,,4%,0%,0%,0%,0%,,,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.7m,$0.0m,$0.0m,,$71.4m,,$2.4m,$1.7m,$0.0m,$0.0m,,$6.5m,$0.0m,$4.1m,$9.9m,$0.0m,$4.4m,$0.7m,$22.4m,$0.0m,$4.7m,$6.3m,$12.3m,$0.0m,$0.0m,$0.0m,$0.0m
290,Substantial,Helsinn,Private,Europe,Switzerland,Lugano,,,$58.1m,Estimate,Yes,No,No,No,6%,$3.2m,$1.2m,$5.9m,$5.8m,$0.0m,,9%,4%,9%,4%,0%,26%,,4%,0%,4%,0%,0%,,4%,4%,4%,4%,0%,,,,$1.6m,$0.0m,$2.9m,$0.0m,$0.0m,,$1.6m,$1.2m,$2.9m,$5.8m,$0.0m,$1.7m,$0.7m,$3.3m,$3.2m,,$70.6m,,$4.2m,$1.5m,$7.5m,$7.4m,,$0.0m,$1.3m,$20.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$30.1m,$16.9m,$0.0m,$0.0m,$0.0m
291,Substantial,Shenzhen Chipscreen Biosciences,Private,Asia/Oceania,China,Shenzhen,China,Shanghai,$58.1m,Estimate,Yes,Yes,No,No,20%,$11.7m,$2.8m,$7.0m,$6.9m,$0.0m,,26%,9%,9%,4%,0%,48%,,26%,9%,9%,4%,0%,,0%,0%,0%,0%,0%,,,,$11.7m,$2.8m,$7.0m,$6.9m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.2m,$1.6m,$3.9m,$3.9m,,$70.5m,,$17.7m,$4.3m,$10.6m,$10.5m,,$0.0m,$2.4m,$43.1m,$7.7m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$2.4m,$0.0m,$12.4m,$0.0m,$0.0m,$0.0m,$0.0m
167,Substantial,Chong Kun Dang Pharmaceutical,Public,Asia/Oceania,,,,,$57.9m,Actual,No,Yes,No,No,2%,$1.2m,$1.3m,$2.2m,$0.0m,$0.0m,,4%,5%,4%,0%,0%,13%,,4%,4%,2%,0%,0%,,0%,2%,2%,0%,0%,,,,$1.2m,$0.9m,$1.1m,$0.0m,$0.0m,,$0.0m,$0.4m,$1.1m,$0.0m,$0.0m,$0.6m,$0.7m,$1.2m,$0.0m,,$138.9m,,$2.7m,$3.0m,$5.0m,$0.0m,,$9.9m,$16.6m,$10.7m,$14.5m,$12.2m,$1.3m,$3.1m,$9.9m,$5.4m,$29.0m,$15.1m,$6.5m,$1.0m,$3.7m,$0.0m,$0.0m
292,Substantial,Midatech,Public,Europe,United Kingdom,Lugano,,,$57.8m,Estimate,Yes,Yes,No,No,18%,$10.2m,$1.2m,$6.1m,$6.1m,$0.0m,,22%,4%,7%,4%,0%,37%,,19%,0%,4%,0%,0%,,4%,4%,4%,4%,0%,,,,$8.5m,$0.0m,$3.1m,$0.0m,$0.0m,,$1.7m,$1.2m,$3.1m,$6.1m,$0.0m,$5.4m,$0.7m,$3.4m,$3.4m,,$70.1m,,$15.4m,$1.9m,$9.3m,$9.1m,,$0.0m,$9.4m,$35.6m,$0.0m,$2.1m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.5m,$14.0m,$1.1m,$0.0m,$0.0m
293,Substantial,Immunitor,Private,Asia/Oceania,,,,,$57.7m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$17.1m,$6.7m,$0.0m,,0%,0%,36%,7%,0%,43%,,0%,0%,36%,7%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$17.1m,$6.7m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.6m,$3.8m,,$70.1m,,$0.0m,$0.0m,$31.0m,$12.2m,,$0.0m,$0.0m,$43.3m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$8.4m,$15.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
294,Substantial,BridgeBio,Private,North America,California,Palo Alto,,,$57.6m,Estimate,No,No,No,No,10%,$5.5m,$1.3m,$3.3m,$0.0m,$0.0m,,13%,4%,4%,0%,0%,22%,,13%,0%,0%,0%,0%,,0%,4%,4%,0%,0%,,,,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.3m,$3.3m,$0.0m,$0.0m,$2.9m,$0.7m,$1.9m,$0.0m,,$69.9m,,$8.9m,$2.1m,$5.3m,$0.0m,,$0.0m,$8.6m,$16.3m,$11.8m,$3.5m,$0.0m,$10.0m,$0.0m,$0.0m,$4.0m,$9.7m,$3.6m,$0.0m,$2.1m,$0.0m,$0.0m
295,Small,ChemoCentryx,Public,North America,California,Mountain View,,,$57.3m,Estimate,No,Yes,No,No,10%,$5.5m,$1.3m,$3.3m,$0.0m,$4.7m,,14%,5%,5%,0%,0%,24%,,14%,5%,5%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.5m,$1.3m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.7m,$1.9m,$0.0m,,$69.5m,,$6.7m,$1.6m,$4.0m,$0.0m,,$0.0m,$1.9m,$12.4m,$9.3m,$0.0m,$0.0m,$4.3m,$0.0m,$12.1m,$1.9m,$0.0m,$17.3m,$10.2m,$0.0m,$0.0m,$0.0m
296,Small,Shanghai Henlius Biotech,Private,Asia/Oceania,China,Shanghai,,,$57.3m,Estimate,No,Yes,No,No,17%,$9.6m,$4.2m,$3.5m,$13.6m,$21.3m,,20%,12%,4%,8%,4%,48%,,16%,12%,4%,8%,4%,,4%,0%,0%,0%,0%,,,,$7.7m,$4.2m,$3.5m,$13.6m,$0.0m,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$5.1m,$2.3m,$1.9m,$7.6m,,$69.5m,,$12.9m,$5.6m,$4.7m,$18.4m,,$0.0m,$0.0m,$41.5m,$12.7m,$4.1m,$0.0m,$7.2m,$0.0m,$0.0m,$0.0m,$2.1m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m
297,Small,CStone Pharmaceuticals,Private,Asia/Oceania,China,Beijing,,,$57.0m,Estimate,Yes,Yes,No,No,21%,$11.9m,$9.9m,$3.1m,$12.1m,$25.1m,,27%,31%,4%,8%,0%,69%,,27%,15%,4%,0%,0%,,0%,15%,0%,8%,0%,,,,$11.9m,$4.9m,$3.1m,$0.0m,$0.0m,,$0.0m,$4.9m,$0.0m,$12.1m,$0.0m,$6.3m,$5.5m,$1.7m,$6.8m,,$69.2m,,$21.1m,$17.5m,$5.4m,$21.5m,,$0.0m,$0.0m,$65.5m,$0.0m,$0.0m,$2.7m,$1.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
298,Small,Medac,Private,Europe,Germany,Wedel,,,$57.0m,Estimate,Yes,Yes,Yes,No,7%,$3.9m,$0.0m,$7.0m,$6.9m,$14.0m,,15%,0%,15%,8%,0%,38%,,0%,0%,15%,8%,0%,,15%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$7.0m,$6.9m,$0.0m,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$3.9m,$3.9m,,$69.2m,,$6.0m,$0.0m,$10.9m,$10.7m,,$0.0m,$0.0m,$27.6m,$0.0m,$0.0m,$0.0m,$0.0m,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m,$35.5m,$0.0m,$0.0m,$0.0m
168,Small,Editas,Public,North America,Massachusetts,Cambridge,,,$57.0m,Actual,No,Yes,Yes,Yes,7%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,7%,0%,0%,0%,0%,7%,,7%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$73.9m,,$8.0m,$0.0m,$0.0m,$0.0m,,$7.8m,$0.0m,$8.0m,$0.0m,$26.1m,$0.0m,$0.0m,$8.1m,$0.0m,$0.0m,$7.9m,$7.4m,$8.6m,$0.0m,$0.0m,$0.0m
120,Small,Bio-Thera Solutions,Private,Asia/Oceania,China,Suzhou,,,$56.9m,Estimate,No,Yes,No,No,29%,$16.7m,$2.7m,$0.0m,$6.6m,$9.3m,,29%,6%,0%,3%,0%,39%,,29%,6%,0%,3%,0%,,0%,0%,0%,0%,0%,,,,16.6933888739694,$2.7m,$0.0m,$6.6m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.8m,$1.5m,$0.0m,$3.7m,,$69.1m,,$25.4m,$4.1m,$0.0m,$10.0m,,$0.0m,$0.0m,$39.5m,$13.7m,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m
169,Small,Atara Biotherapeutics,Public,North America,California,Thousand Oaks,Colorado,Aurora,$56.5m,Actual,Yes,Yes,No,Yes,30%,$17.0m,$1.5m,$0.0m,$0.0m,$1.5m,,38%,5%,0%,0%,0%,43%,,38%,5%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$17.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.0m,$0.9m,$0.0m,$0.0m,,$73.3m,,$23.1m,$2.1m,$0.0m,$0.0m,,$0.0m,$4.3m,$25.2m,$13.0m,$0.0m,$0.0m,$0.0m,$30.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
299,Small,BioElectron,Private,North America,California,Mountain View,,,$56.3m,Estimate,No,No,No,No,3%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,5%,0%,0%,0%,0%,5%,,5%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$68.4m,,$2.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$32.5m,$2.7m,$0.0m,$6.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.4m,$20.9m,$0.0m,$0.0m,$0.0m,$0.0m
170,Small,Celltrion,Public,Asia/Oceania,South Korea,Incheon City,,,$56.3m,Actual,No,Yes,No,No,14%,$8.1m,$2.0m,$0.0m,$0.0m,$2.0m,,16%,5%,0%,0%,0%,21%,,16%,5%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.1m,$2.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$1.1m,$0.0m,$0.0m,,$14.4m,,$2.2m,$0.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$3.9m,$0.0m,$0.0m,$0.7m,$4.5m,$0.0m,$1.3m,$0.7m,$0.6m,$0.0m,$0.0m,$0.0m,$0.0m
300,Small,CRISPR Therapeutics,Public,Europe,Switzerland,Zug,,,$56.3m,Estimate,No,Yes,Yes,Yes,14%,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m,,15%,0%,0%,0%,0%,15%,,12%,0%,0%,0%,0%,,4%,0%,0%,0%,0%,,,,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.0m,$0.0m,$0.0m,,$54.8m,,$11.9m,$0.0m,$0.0m,$0.0m,,$2.8m,$5.3m,$11.9m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$9.2m,$20.0m,$0.0m,$0.0m,$0.0m
301,Small,Ambrx,Private,North America,California,La Jolla,,,$56.0m,Estimate,Yes,Yes,No,No,15%,$8.4m,$3.7m,$3.0m,$6.0m,$12.7m,,20%,12%,4%,4%,0%,40%,,20%,8%,0%,0%,0%,,0%,4%,4%,4%,0%,,,,$8.4m,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$3.0m,$6.0m,$0.0m,$4.4m,$2.0m,$1.7m,$3.3m,,$68.0m,,$13.9m,$6.1m,$5.0m,$9.9m,,$0.0m,$3.3m,$34.9m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$4.4m,$6.9m,$10.1m,$0.0m,$0.0m,$0.0m,$0.0m
302,Small,Hualan Biological Engineering,Public,Asia/Oceania,China,Xinxiang,,,$55.9m,Estimate,Yes,Yes,No,No,14%,$7.9m,$1.4m,$0.0m,$0.0m,$1.4m,,27%,7%,0%,0%,0%,33%,,27%,7%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.9m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.2m,$0.8m,$0.0m,$0.0m,,$67.9m,,$11.1m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.1m,$2.7m,$0.0m,$0.0m,$0.0m,$49.7m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
121,Small,Jiangsu Chia-tai Tianqing,Private,Asia/Oceania,China,Lianyungang,China,Nanjing,$55.7m,Estimate,Yes,No,No,No,10%,$5.6m,$13.6m,$6.8m,$6.7m,$27.0m,,14%,45%,9%,5%,0%,73%,,14%,41%,9%,5%,0%,,0%,5%,0%,0%,0%,,,,5.61216086923133,$12.2m,$6.8m,$6.7m,$0.0m,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$3.0m,$7.6m,$3.8m,$3.7m,,$67.6m,,$9.7m,$23.4m,$11.7m,$11.5m,,$0.0m,$0.0m,$56.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$11.3m,$0.0m,$0.0m,$0.0m
303,Small,Cyclacel,Public,North America,New Jersey,Berkeley Heights,United Kingdom,Dundee,$55.6m,Estimate,Yes,No,No,No,10%,$5.4m,$3.9m,$6.5m,$6.4m,$16.8m,,14%,14%,10%,5%,0%,43%,,14%,10%,5%,0%,0%,,0%,5%,5%,5%,0%,,,,$5.4m,$2.6m,$3.2m,$0.0m,$0.0m,,$0.0m,$1.3m,$3.2m,$6.4m,$0.0m,$2.9m,$2.2m,$3.6m,$3.6m,,$67.5m,,$9.7m,$7.0m,$11.7m,$11.5m,,$7.9m,$0.0m,$39.9m,$12.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.6m,$0.0m,$0.0m
304,Small,Genexine,Public,Asia/Oceania,,,,,$55.6m,Estimate,Yes,Yes,No,No,3%,$1.8m,$1.3m,$6.7m,$0.0m,$8.0m,,5%,5%,9%,0%,0%,18%,,5%,5%,9%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$1.3m,$6.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$3.7m,$0.0m,,$67.5m,,$2.2m,$1.6m,$8.1m,$0.0m,,$0.0m,$0.0m,$12.0m,$0.0m,$0.0m,$4.3m,$2.1m,$6.7m,$5.9m,$0.0m,$0.0m,$7.9m,$22.9m,$5.7m,$0.0m,$0.0m
305,Small,Portage Biotech,Public,North America,Ontario,Toronto,,,$55.3m,Estimate,No,No,No,No,3%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,6%,0%,0%,0%,0%,6%,,6%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$67.1m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$62.4m,$2.4m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
306,Small,Agenus,Public,North America,Massachusetts,Lexington,New York,New York,$55.1m,Estimate,Yes,Yes,No,No,21%,$11.4m,$6.9m,$20.6m,$0.0m,$27.5m,,27%,23%,27%,0%,0%,77%,,27%,23%,23%,0%,0%,,0%,0%,5%,0%,0%,,,,$11.4m,$6.9m,$17.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$6.0m,$3.9m,$11.5m,$0.0m,,$66.9m,,$17.6m,$10.6m,$31.7m,$0.0m,,$0.0m,$0.0m,$59.9m,$0.0m,$0.0m,$7.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
307,Small,NovImmune,Private,Europe,Switzerland,Geneva,,,$54.9m,Estimate,Yes,Yes,No,No,14%,$7.5m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.0m,$0.0m,$0.0m,$0.0m,,$66.7m,,$9.6m,$0.0m,$0.0m,$0.0m,,$5.8m,$2.2m,$9.6m,$22.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$8.6m,$10.5m,$5.2m,$0.0m,$0.0m,$0.0m
308,Small,Simcere Pharmaceutical Group,Public,Asia/Oceania,,,,,$54.9m,Estimate,Yes,Yes,No,No,9%,$5.1m,$3.7m,$9.2m,$0.0m,$12.9m,,12%,12%,12%,0%,0%,36%,,0%,0%,8%,0%,0%,,12%,12%,4%,0%,0%,,,,$0.0m,$0.0m,$6.1m,$0.0m,$0.0m,,$5.1m,$3.7m,$3.1m,$0.0m,$0.0m,$2.7m,$2.1m,$5.1m,$0.0m,,$45.4m,,$4.9m,$3.5m,$8.8m,$0.0m,,$0.0m,$1.4m,$17.2m,$8.7m,$1.4m,$0.0m,$0.5m,$0.0m,$5.3m,$3.6m,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
171,Small,Zhejiang Huahai Pharmaceutical,Public,Asia/Oceania,China,Zheijiang,,,$54.8m,Actual,No,No,No,No,48%,$26.0m,$9.4m,$0.0m,$0.0m,$9.4m,,40%,20%,0%,0%,0%,60%,,20%,20%,0%,0%,0%,,20%,0%,0%,0%,0%,,,,$13.0m,$9.4m,$0.0m,$0.0m,$0.0m,,$13.0m,$0.0m,$0.0m,$0.0m,$0.0m,$13.8m,$5.3m,$0.0m,$0.0m,,$71.1m,,$32.2m,$11.7m,$0.0m,$0.0m,,$0.0m,$10.7m,$43.9m,$0.0m,$16.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
172,Small,CytomX Therapeutics,Public,North America,California,South San Francisco,,,$54.8m,Actual,Yes,Yes,No,No,28%,$15.6m,$2.3m,$16.9m,$0.0m,$19.1m,,42%,8%,25%,0%,0%,75%,,42%,8%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$15.6m,$2.3m,$16.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.3m,$1.3m,$9.5m,$0.0m,,$71.0m,,$31.9m,$4.6m,$34.5m,$0.0m,,$0.0m,$0.0m,$71.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
309,Small,Prestige BioPharma,Private,Asia/Oceania,,,,,$54.2m,Estimate,Yes,Yes,No,No,10%,$5.3m,$1.3m,$0.0m,$6.2m,$7.5m,,11%,4%,0%,4%,0%,19%,,7%,0%,0%,0%,0%,,4%,4%,0%,4%,0%,,,,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$1.3m,$0.0m,$6.2m,$0.0m,$2.8m,$0.7m,$0.0m,$3.5m,,$65.8m,,$10.2m,$2.5m,$0.0m,$12.1m,,$0.0m,$0.0m,$24.8m,$11.1m,$2.7m,$0.0m,$8.5m,$0.0m,$0.0m,$2.6m,$11.0m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m
123,Small,PharmaMar,Public,Europe,Spain,Madrid,,,$53.9m,Estimate,Yes,No,No,No,7%,$4.0m,$4.3m,$10.8m,$14.2m,$29.4m,,11%,17%,17%,11%,6%,61%,,11%,17%,17%,11%,6%,,0%,0%,0%,0%,0%,,,,$4.0m,$4.3m,$10.8m,$14.2m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$2.4m,$6.1m,$8.0m,,$65.4m,,$7.6m,$8.3m,$20.6m,$27.1m,,$0.0m,$0.0m,$63.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m
173,Small,Concordia Healthcare Corp,Public,Europe,United Kingdom,London,,,$53.8m,Actual,Yes,No,No,No,0%,$0.0m,$0.0m,$24.6m,$0.0m,$24.6m,,0%,0%,25%,0%,25%,50%,,0%,0%,0%,0%,0%,,0%,0%,25%,0%,25%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$24.6m,$0.0m,$0.0m,$0.0m,$0.0m,$13.8m,$0.0m,,$160.0m,,$0.0m,$0.0m,$160.0m,$0.0m,,$0.0m,$0.0m,$160.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
174,Small,Innate Pharma,Public,Europe,France,Marseille,,,$53.8m,Actual,Yes,Yes,No,No,30%,$16.4m,$6.8m,$8.4m,$0.0m,$15.2m,,33%,19%,10%,0%,0%,62%,,24%,14%,10%,0%,0%,,10%,5%,0%,0%,0%,,,,$11.7m,$5.1m,$8.4m,$0.0m,$0.0m,,$4.7m,$1.7m,$0.0m,$0.0m,$0.0m,$8.7m,$3.8m,$4.7m,$0.0m,,$69.8m,,$28.0m,$11.6m,$14.5m,$0.0m,,$3.5m,$0.0m,$54.1m,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m
310,Small,NovaMedica,Private,Europe,Russia,Moscow,,,$53.7m,Estimate,Yes,Yes,No,No,0%,$0.0m,$1.0m,$2.5m,$4.9m,$8.4m,,0%,6%,6%,6%,0%,19%,,0%,0%,0%,0%,0%,,0%,6%,6%,6%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.0m,$2.5m,$4.9m,$0.0m,$0.0m,$0.6m,$1.4m,$2.7m,,$65.2m,,$0.0m,$1.5m,$3.8m,$7.6m,,$0.0m,$14.5m,$12.9m,$0.0m,$31.5m,$0.0m,$0.0m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
175,Small,Biotest,Public,Europe,Germany,Dreieich,,,$53.7m,Actual,No,Yes,No,No,2%,$1.0m,$0.0m,$5.2m,$0.0m,$5.2m,,3%,0%,9%,0%,0%,13%,,3%,0%,6%,0%,0%,,0%,0%,3%,0%,0%,,,,$1.0m,$0.0m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.7m,$0.0m,$0.0m,$0.5m,$0.0m,$2.9m,$0.0m,,$122.2m,,$2.3m,$0.0m,$12.4m,$0.0m,,$0.0m,$9.0m,$14.7m,$28.4m,$0.0m,$6.8m,$6.9m,$18.0m,$2.0m,$3.1m,$3.3m,$0.0m,$30.0m,$0.0m,$0.0m,$0.0m
311,Small,Cell Medica,Private,Europe,United Kingdom,London,,,$53.6m,Estimate,Yes,Yes,No,Yes,21%,$11.2m,$4.1m,$3.4m,$0.0m,$7.5m,,27%,14%,5%,0%,0%,45%,,27%,14%,5%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.2m,$4.1m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$2.3m,$1.9m,$0.0m,,$65.1m,,$16.8m,$6.1m,$5.1m,$0.0m,,$0.0m,$0.0m,$27.9m,$11.6m,$18.9m,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
176,Small,Immunomedics,Public,North America,New Jersey,Morris Plains,Germany,Rodermark,$53.5m,Actual,Yes,Yes,No,No,5%,$2.8m,$2.1m,$15.4m,$5.1m,$22.5m,,9%,9%,26%,4%,4%,52%,,9%,4%,26%,4%,4%,,0%,4%,0%,0%,0%,,,,$2.8m,$1.0m,$15.4m,$5.1m,$0.0m,,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,$1.5m,$1.2m,$8.6m,$2.8m,,$69.4m,,$5.0m,$3.6m,$26.9m,$8.8m,,$0.0m,$0.0m,$44.3m,$14.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$10.4m,$0.0m,$0.0m,$0.0m
312,Small,Geron,Public,North America,California,Menlo Park,,,$53.3m,Estimate,Yes,No,No,No,7%,$3.8m,$0.0m,$6.9m,$6.8m,$13.6m,,13%,0%,13%,7%,0%,33%,,13%,0%,7%,7%,0%,,0%,0%,7%,0%,0%,,,,$3.8m,$0.0m,$3.4m,$6.8m,$0.0m,,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$2.0m,$0.0m,$3.8m,$3.8m,,$64.7m,,$7.8m,$0.0m,$14.1m,$13.9m,,$0.0m,$10.4m,$35.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$15.6m,$0.0m,$0.0m,$0.0m
313,Small,Takara Bio,Public,Asia/Oceania,Japan,Shiga,Japan,Tokyo,$53.2m,Estimate,Yes,Yes,Yes,Yes,11%,$6.1m,$8.9m,$14.7m,$7.3m,$30.8m,,14%,29%,19%,5%,0%,67%,,5%,24%,10%,0%,0%,,10%,5%,10%,5%,0%,,,,$2.0m,$7.4m,$7.4m,$0.0m,$0.0m,,$4.1m,$1.5m,$7.4m,$7.3m,$0.0m,$3.2m,$5.0m,$8.2m,$4.1m,,$64.6m,,$10.7m,$15.5m,$25.7m,$12.7m,,$0.0m,$0.0m,$64.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
314,Small,Ergomed,Public,North America,Texas,San Antonio,United Kingdom,Surrey,$53.1m,Estimate,No,Yes,No,No,3%,$1.4m,$0.0m,$5.1m,$5.1m,$10.2m,,5%,0%,10%,5%,0%,19%,,0%,0%,0%,0%,0%,,5%,0%,10%,5%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.4m,$0.0m,$5.1m,$5.1m,$0.0m,$0.8m,$0.0m,$2.9m,$2.8m,,$64.4m,,$1.9m,$0.0m,$6.8m,$6.7m,,$14.7m,$8.5m,$15.4m,$3.5m,$0.0m,$0.0m,$0.0m,$1.4m,$2.6m,$0.0m,$0.0m,$1.1m,$8.5m,$0.0m,$3.1m,$5.6m
315,Small,4SC,Public,Europe,Germany,Planegg,,,$52.7m,Estimate,Yes,No,No,No,11%,$5.9m,$4.3m,$7.1m,$0.0m,$11.3m,,13%,13%,9%,0%,0%,35%,,9%,0%,0%,0%,0%,,4%,13%,9%,0%,0%,,,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$4.3m,$7.1m,$0.0m,$0.0m,$3.1m,$2.4m,$4.0m,$0.0m,,$64.0m,,$10.2m,$7.4m,$12.3m,$0.0m,,$0.0m,$0.0m,$29.8m,$2.9m,$9.8m,$0.0m,$2.9m,$5.8m,$0.0m,$0.0m,$2.8m,$9.9m,$0.0m,$0.0m,$0.0m,$0.0m
316,Small,Eurofarma,Private,Asia/Oceania,,,,,$52.1m,Estimate,No,Yes,No,No,6%,$3.2m,$2.3m,$5.7m,$5.7m,$13.7m,,9%,9%,9%,5%,0%,32%,,5%,0%,0%,0%,0%,,5%,9%,9%,5%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.6m,$2.3m,$5.7m,$5.7m,$0.0m,$1.7m,$1.3m,$3.2m,$3.2m,,$63.3m,,$5.1m,$3.7m,$9.1m,$9.0m,,$3.2m,$0.0m,$26.9m,$0.0m,$0.0m,$0.0m,$0.0m,$28.1m,$0.0m,$0.0m,$0.0m,$4.2m,$0.8m,$0.0m,$0.0m,$0.0m
177,Small,Xencor,Public,North America,California,San Diego,California,Monrovia,$51.9m,Actual,Yes,Yes,No,No,15%,$7.8m,$5.7m,$7.1m,$4.7m,$17.4m,,19%,19%,10%,3%,0%,52%,,19%,16%,3%,3%,0%,,0%,3%,6%,0%,0%,,,,$7.8m,$4.7m,$2.4m,$4.7m,$0.0m,,$0.0m,$0.9m,$4.7m,$0.0m,$0.0m,$4.2m,$3.2m,$4.0m,$2.6m,,$67.3m,,$14.3m,$10.4m,$12.9m,$8.5m,,$2.6m,$0.0m,$46.2m,$14.0m,$0.0m,$2.1m,$0.8m,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
317,Small,R-Pharm,Private,Europe,Russia,Moscow,,,$51.7m,Estimate,No,Yes,No,No,3%,$1.4m,$0.0m,$2.6m,$5.0m,$7.6m,,5%,0%,5%,5%,0%,15%,,5%,0%,5%,0%,0%,,0%,0%,0%,5%,0%,,,,$1.4m,$0.0m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$5.0m,$0.0m,$0.7m,$0.0m,$1.4m,$2.8m,,$62.8m,,$1.6m,$0.0m,$2.8m,$5.6m,,$4.3m,$6.0m,$10.0m,$5.1m,$0.0m,$0.0m,$0.0m,$29.1m,$5.8m,$0.0m,$1.0m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m
178,Small,Bellicum Pharmaceuticals,Public,North America,Texas,Houston,California,Brisbane,$51.3m,Actual,Yes,Yes,Yes,Yes,36%,$18.4m,$3.3m,$4.2m,$0.0m,$7.5m,,42%,11%,5%,0%,0%,58%,,37%,11%,5%,0%,0%,,5%,0%,0%,0%,0%,,,,$16.1m,$3.3m,$4.2m,$0.0m,$0.0m,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$9.8m,$1.9m,$2.3m,$0.0m,,$66.5m,,$28.6m,$5.2m,$6.5m,$0.0m,,$0.0m,$0.0m,$40.2m,$14.9m,$0.0m,$11.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
318,Small,GeoVax,Public,North America,Georgia,Atlanta,,,$50.7m,Estimate,No,Yes,No,No,8%,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,9%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$61.5m,,$6.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,$51.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m
319,Small,LTT Bio-Pharma,Private,Asia/Oceania,,,,,$50.7m,Estimate,No,No,No,No,0%,$0.0m,$1.4m,$0.0m,$0.0m,$1.4m,,0%,4%,0%,0%,0%,4%,,0%,4%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,,$61.5m,,$0.0m,$2.0m,$0.0m,$0.0m,,$23.9m,$1.7m,$2.0m,$0.0m,$8.1m,$2.3m,$0.0m,$0.0m,$0.0m,$12.4m,$2.2m,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m
320,Small,Rhizen Pharmaceuticals,Private,Europe,Switzerland,La Chaux-de-Fonds,,,$50.5m,Estimate,Yes,No,No,No,8%,$3.9m,$4.3m,$7.1m,$7.0m,$18.3m,,11%,17%,11%,6%,0%,44%,,11%,17%,11%,6%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$4.3m,$7.1m,$7.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$2.4m,$4.0m,$3.9m,,$61.3m,,$7.6m,$8.2m,$13.7m,$13.5m,,$12.3m,$2.9m,$43.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
321,Small,Link Health Group,Private,Asia/Oceania,,,,,$50.2m,Estimate,No,Yes,No,No,8%,$3.8m,$2.8m,$10.3m,$0.0m,$13.0m,,10%,10%,14%,0%,0%,33%,,5%,5%,10%,0%,0%,,5%,5%,5%,0%,0%,,,,$1.9m,$1.4m,$6.8m,$0.0m,$0.0m,,$1.9m,$1.4m,$3.4m,$0.0m,$0.0m,$2.0m,$1.5m,$5.7m,$0.0m,,$60.9m,,$5.4m,$3.9m,$14.6m,$0.0m,,$6.8m,$0.0m,$23.9m,$0.0m,$0.0m,$0.0m,$2.4m,$1.8m,$0.0m,$0.0m,$11.4m,$12.1m,$2.5m,$0.0m,$0.0m,$0.0m
322,Small,Albumedix,Private,Europe,United Kingdom,Nottingham,,,$50.1m,Estimate,No,Yes,No,No,15%,$7.6m,$1.4m,$3.4m,$0.0m,$4.8m,,24%,6%,6%,0%,0%,35%,,24%,6%,6%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.6m,$1.4m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.0m,$0.8m,$1.9m,$0.0m,,$60.8m,,$10.6m,$1.9m,$4.8m,$0.0m,,$0.0m,$0.0m,$17.3m,$0.0m,$0.0m,$0.0m,$0.0m,$21.5m,$15.8m,$0.0m,$2.5m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m
323,Small,BioLineRx,Public,Middle East/Africa,,,,,$50.1m,Estimate,Yes,Yes,No,No,3%,$1.6m,$0.0m,$5.6m,$5.6m,$11.2m,,6%,0%,12%,6%,0%,24%,,0%,0%,6%,0%,0%,,6%,0%,6%,6%,0%,,,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,,$1.6m,$0.0m,$2.8m,$5.6m,$0.0m,$0.8m,$0.0m,$3.2m,$3.1m,,$60.8m,,$2.1m,$0.0m,$7.7m,$7.6m,,$0.0m,$0.0m,$17.5m,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,$5.8m,$0.0m,$18.8m,$17.0m,$0.0m,$0.0m,$0.0m
324,Small,MabVax Therapeutics,Public,North America,California,San Diego,,,$50.0m,Estimate,Yes,Yes,Yes,Yes,49%,$24.3m,$6.4m,$0.0m,$0.0m,$6.4m,,44%,16%,0%,0%,0%,60%,,40%,16%,0%,0%,0%,,4%,0%,0%,0%,0%,,,,$22.1m,$6.4m,$0.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$12.9m,$3.6m,$0.0m,$0.0m,,$60.7m,,$48.0m,$12.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$60.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
179,Small,Curis,Public,North America,Massachusetts,Lexington,,,$49.6m,Actual,Yes,Yes,No,No,10%,$4.7m,$8.0m,$11.4m,$0.0m,$19.3m,,11%,25%,14%,0%,0%,50%,,4%,11%,7%,0%,0%,,7%,14%,7%,0%,0%,,,,$1.6m,$3.4m,$5.7m,$0.0m,$0.0m,,$3.1m,$4.6m,$5.7m,$0.0m,$0.0m,$2.5m,$4.5m,$6.4m,$0.0m,,$64.3m,,$7.8m,$13.3m,$18.8m,$0.0m,,$7.3m,$0.0m,$39.9m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$3.9m,$0.0m,$8.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m
325,Small,SRI International,Private,North America,California,Menlo Park,New Jersey,Princeton,$49.5m,Estimate,Yes,Yes,No,No,25%,$12.2m,$0.0m,$3.7m,$0.0m,$3.7m,,29%,0%,5%,0%,0%,33%,,24%,0%,5%,0%,0%,,5%,0%,0%,0%,0%,,,,$10.2m,$0.0m,$3.7m,$0.0m,$0.0m,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.5m,$0.0m,$2.1m,$0.0m,,$60.1m,,$18.5m,$0.0m,$5.6m,$0.0m,,$0.0m,$6.8m,$24.1m,$4.8m,$0.0m,$0.0m,$3.8m,$5.9m,$8.5m,$0.0m,$0.0m,$4.0m,$0.0m,$0.0m,$2.1m,$0.0m
326,Small,Auven Therapeutics,Private,North America,Florida,Delray Beach,,,$49.3m,Estimate,Yes,Yes,No,No,28%,$13.9m,$4.3m,$7.2m,$0.0m,$11.5m,,33%,14%,10%,0%,0%,57%,,19%,14%,10%,0%,0%,,14%,0%,0%,0%,0%,,,,$7.9m,$4.3m,$7.2m,$0.0m,$0.0m,,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.4m,$2.4m,$4.0m,$0.0m,,$59.8m,,$21.4m,$6.7m,$11.1m,$0.0m,,$0.0m,$7.9m,$39.2m,$0.0m,$9.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
327,Small,Inventiva,Public,Europe,France,Dijon,,,$49.2m,Estimate,Yes,Yes,No,No,12%,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,,16%,0%,0%,0%,0%,16%,,16%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,,$59.8m,,$8.8m,$0.0m,$0.0m,$0.0m,,$10.4m,$0.0m,$8.8m,$13.1m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$2.7m,$4.8m,$17.0m,$0.0m,$0.0m,$0.0m,$0.0m
328,Small,SBIO,Private,Asia/Oceania,,,,,$49.2m,Estimate,Yes,No,No,No,8%,$4.0m,$4.4m,$7.2m,$7.1m,$18.7m,,11%,17%,11%,6%,0%,44%,,11%,17%,11%,6%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$4.4m,$7.2m,$7.1m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$2.4m,$4.0m,$4.0m,,$59.7m,,$7.7m,$8.4m,$14.0m,$13.8m,,$0.0m,$0.0m,$44.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$15.7m,$0.0m,$0.0m,$0.0m
180,Small,Basilea Pharmaceutica,Public,Europe,Switzerland,Basel,,,$49.2m,Actual,No,No,No,No,0%,$0.0m,$3.4m,$8.5m,$8.4m,$20.4m,,0%,18%,18%,9%,0%,45%,,0%,0%,9%,0%,0%,,0%,18%,9%,9%,0%,,,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,,$0.0m,$3.4m,$4.3m,$8.4m,$0.0m,$0.0m,$1.9m,$4.8m,$4.7m,,$63.8m,,$0.0m,$5.8m,$14.5m,$14.3m,,$0.0m,$0.0m,$34.7m,$0.0m,$0.0m,$0.0m,$0.0m,$29.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
329,Small,Y-mAbs Therapeutics,Public,North America,New York,New York,Denmark,Hoersholm,$49.1m,Estimate,Yes,Yes,No,No,16%,$7.9m,$2.9m,$3.6m,$14.1m,$20.6m,,25%,13%,6%,13%,0%,56%,,25%,6%,6%,13%,0%,,0%,6%,0%,0%,0%,,,,$7.9m,$1.4m,$3.6m,$14.1m,$0.0m,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$4.2m,$1.6m,$2.0m,$7.9m,,$59.5m,,$16.6m,$6.0m,$7.5m,$29.5m,,$0.0m,$0.0m,$59.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
330,Small,Selvita,Public,Europe,Poland,Krakow,,,$48.9m,Estimate,Yes,Yes,No,No,52%,$25.6m,$0.0m,$3.8m,$0.0m,$3.8m,,57%,0%,5%,0%,0%,62%,,52%,0%,5%,0%,0%,,5%,0%,0%,0%,0%,,,,$23.4m,$0.0m,$3.8m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$13.5m,$0.0m,$2.2m,$0.0m,,$59.3m,,$40.6m,$0.0m,$6.1m,$0.0m,,$0.0m,$3.1m,$46.7m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m
331,Small,Ascentage Pharma,Private,Asia/Oceania,China,Suzhou,China,Shanghai,$48.8m,Estimate,Yes,No,No,No,12%,$6.0m,$5.9m,$14.6m,$0.0m,$20.4m,,14%,19%,19%,0%,0%,52%,,14%,14%,10%,0%,0%,,0%,5%,10%,0%,0%,,,,$6.0m,$4.4m,$7.3m,$0.0m,$0.0m,,$0.0m,$1.5m,$7.3m,$0.0m,$0.0m,$3.2m,$3.3m,$8.2m,$0.0m,,$59.3m,,$9.0m,$8.7m,$21.7m,$0.0m,,$4.2m,$0.0m,$39.5m,$0.0m,$6.0m,$0.0m,$0.0m,$2.1m,$4.7m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
181,Small,Advaxis,Public,North America,New Jersey,Princeton,,,$48.8m,Actual,Yes,Yes,Yes,Yes,35%,$17.1m,$2.5m,$18.5m,$0.0m,$21.0m,,42%,8%,25%,0%,8%,83%,,33%,8%,25%,0%,8%,,8%,0%,0%,0%,0%,,,,$13.7m,$2.5m,$18.5m,$0.0m,$0.0m,,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$9.0m,$1.4m,$10.4m,$0.0m,,$63.3m,,$28.4m,$4.1m,$30.8m,$0.0m,,$0.0m,$0.0m,$63.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
332,Small,AOP Orphan Pharmaceuticals,Private,Europe,Austria,Vienna,,,$48.7m,Estimate,Yes,No,No,No,3%,$1.6m,$0.0m,$2.8m,$0.0m,$2.8m,,6%,0%,6%,0%,0%,11%,,0%,0%,0%,0%,0%,,6%,0%,6%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.6m,$0.0m,$2.8m,$0.0m,$0.0m,$0.8m,$0.0m,$1.6m,$0.0m,,$59.1m,,$2.2m,$0.0m,$3.9m,$0.0m,,$0.0m,$19.1m,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m,$10.5m,$0.0m,$0.0m,$0.0m,$0.0m,$17.8m,$5.6m,$0.0m,$0.0m
333,Small,Molecular Templates,Public,North America,Texas,Austin,,,$48.7m,Estimate,Yes,Yes,No,No,23%,$11.4m,$2.8m,$6.9m,$6.8m,$16.4m,,33%,11%,11%,6%,0%,61%,,22%,11%,11%,0%,0%,,11%,0%,0%,6%,0%,,,,$7.6m,$2.8m,$6.9m,$0.0m,$0.0m,,$3.8m,$0.0m,$0.0m,$6.8m,$0.0m,$6.1m,$1.5m,$3.9m,$3.8m,,$59.1m,,$22.8m,$5.5m,$13.7m,$13.5m,,$0.0m,$0.0m,$55.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m
334,Small,Avacta,Public,Europe,United Kingdom,Cambridge,,,$48.6m,Estimate,No,Yes,Yes,No,86%,$42.0m,$0.0m,$0.0m,$0.0m,$0.0m,,86%,0%,0%,0%,0%,86%,,86%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$42.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$22.3m,$0.0m,$0.0m,$0.0m,,$59.0m,,$50.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$50.5m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m
335,Small,Druggability Technologies,Private,Europe,Malta,Msida,,,$48.5m,Estimate,No,No,No,No,7%,$3.6m,$0.0m,$6.4m,$0.0m,$6.4m,,10%,0%,10%,0%,0%,20%,,10%,0%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.6m,$0.0m,$6.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$3.6m,$0.0m,,$58.9m,,$4.6m,$0.0m,$8.4m,$0.0m,,$6.3m,$13.1m,$13.0m,$9.6m,$2.1m,$0.0m,$0.0m,$0.0m,$6.3m,$0.0m,$0.0m,$6.3m,$2.3m,$0.0m,$0.0m,$0.0m
336,Small,Cellectar Biosciences,Public,North America,Wisconsin,Middleton,,,$48.5m,Estimate,Yes,No,No,No,63%,$30.8m,$1.6m,$7.9m,$0.0m,$9.5m,,70%,5%,10%,0%,0%,85%,,70%,5%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$30.8m,$1.6m,$7.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$16.3m,$0.9m,$4.4m,$0.0m,,$58.8m,,$44.9m,$2.3m,$11.6m,$0.0m,,$0.0m,$0.0m,$58.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
337,Small,Gamida Cell,Private,Middle East/Africa,,,,,$48.4m,Estimate,Yes,Yes,No,Yes,4%,$1.8m,$0.0m,$3.3m,$6.4m,$9.7m,,8%,0%,8%,8%,0%,25%,,8%,0%,8%,8%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$3.3m,$6.4m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$1.8m,$3.6m,,$58.7m,,$2.8m,$0.0m,$5.0m,$9.9m,,$0.0m,$0.0m,$17.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.6m,$32.4m,$0.0m,$0.0m,$0.0m
338,Small,Jeil Pharmaceutical,Public,Asia/Oceania,,,,,$48.4m,Estimate,No,No,No,No,3%,$1.6m,$2.3m,$2.9m,$5.8m,$11.0m,,6%,11%,6%,6%,6%,33%,,6%,11%,0%,0%,0%,,0%,0%,6%,6%,6%,,,,$1.6m,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.9m,$5.8m,$0.0m,$0.9m,$1.3m,$1.6m,$3.2m,,$58.7m,,$2.3m,$3.3m,$4.1m,$8.2m,,$0.0m,$0.0m,$17.9m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$6.2m,$22.2m,$0.0m,$9.8m,$0.0m,$0.0m,$0.0m,$0.0m
339,Small,Toyama Chemical,Private,Asia/Oceania,,,,,$48.0m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$2.8m,$0.0m,$2.8m,,0%,0%,6%,0%,0%,6%,,0%,0%,6%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,,$58.3m,,$0.0m,$0.0m,$3.3m,$0.0m,,$2.3m,$3.8m,$3.3m,$0.0m,$13.9m,$0.0m,$0.0m,$30.6m,$2.9m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
340,Small,GlycoMimetics,Public,North America,Maryland,Rockville,,,$48.0m,Estimate,Yes,No,No,No,20%,$9.7m,$2.8m,$3.5m,$0.0m,$6.3m,,28%,11%,6%,0%,0%,44%,,28%,11%,6%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.7m,$2.8m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.2m,$1.6m,$2.0m,$0.0m,,$30.2m,,$8.3m,$2.4m,$3.0m,$0.0m,,$0.0m,$0.0m,$13.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$13.3m,$0.0m,$0.0m,$0.0m
341,Small,BioNTech,Private,Europe,Germany,Mainz,,,$47.8m,Estimate,No,Yes,Yes,Yes,32%,$15.1m,$7.8m,$11.7m,$0.0m,$19.5m,,35%,25%,15%,0%,0%,75%,,20%,25%,10%,0%,0%,,15%,0%,5%,0%,0%,,,,$8.6m,$7.8m,$7.8m,$0.0m,$0.0m,,$6.5m,$0.0m,$3.9m,$0.0m,$0.0m,$8.0m,$4.4m,$6.5m,$0.0m,,$58.0m,,$20.3m,$10.5m,$15.7m,$0.0m,,$0.0m,$0.0m,$46.6m,$0.0m,$0.0m,$5.8m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
342,Small,Biosion,Private,Asia/Oceania,China,Nanjing,,,$47.6m,Estimate,No,Yes,No,No,82%,$38.9m,$0.0m,$0.0m,$0.0m,$0.0m,,82%,0%,0%,0%,0%,82%,,82%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$38.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$20.6m,$0.0m,$0.0m,$0.0m,,$57.8m,,$47.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$47.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
343,Small,Pharmaxis,Public,Asia/Oceania,Australia,Sydney,,,$47.2m,Estimate,No,No,No,No,11%,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,,$57.3m,,$6.1m,$0.0m,$0.0m,$0.0m,,$21.7m,$1.9m,$6.1m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,$2.9m,$5.6m,$2.0m,$10.0m,$2.2m,$0.0m,$0.0m,$0.0m
344,Small,Biocidium,Private,North America,California,Chatsworth,Quebec,Pointe-Claire,$47.1m,Estimate,No,No,No,No,9%,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,9%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$57.2m,,$5.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,$12.7m,$39.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
345,Small,Cellular Biomedicine Group,Public,North America,New York,New York,,,$47.1m,Estimate,Yes,Yes,Yes,Yes,29%,$13.7m,$1.4m,$7.1m,$0.0m,$8.5m,,35%,5%,10%,0%,0%,50%,,35%,5%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$13.7m,$1.4m,$7.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.3m,$0.8m,$4.0m,$0.0m,,$57.2m,,$21.1m,$2.2m,$10.9m,$0.0m,,$5.6m,$6.7m,$34.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$10.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
346,Small,EpiVax,Private,North America,New York,New York,Rhode Island,Providence,$46.9m,Estimate,No,Yes,No,No,4%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,4%,0%,0%,0%,0%,4%,,4%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$56.9m,,$2.9m,$0.0m,$0.0m,$0.0m,,$2.8m,$2.7m,$2.9m,$2.9m,$0.0m,$0.0m,$0.0m,$28.9m,$0.0m,$0.0m,$2.9m,$5.3m,$6.2m,$2.3m,$0.0m,$0.0m
347,Small,MediciNova,Public,Asia/Oceania,,,,,$46.8m,Estimate,No,No,No,No,4%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,6%,0%,0%,0%,0%,6%,,0%,0%,0%,0%,0%,,6%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$56.8m,,$2.1m,$0.0m,$0.0m,$0.0m,,$14.0m,$15.5m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.7m,$3.2m,$1.9m,$7.2m,$6.1m,$0.0m,$0.0m,$0.0m
348,Small,VBL Therapeutics,Public,Middle East/Africa,Israel,Modi'in,,,$46.7m,Estimate,No,Yes,Yes,No,17%,$7.8m,$1.4m,$3.5m,$6.9m,$11.9m,,22%,6%,6%,6%,0%,39%,,22%,6%,6%,6%,0%,,0%,0%,0%,0%,0%,,,,$7.8m,$1.4m,$3.5m,$6.9m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.8m,$2.0m,$3.9m,,$56.7m,,$13.3m,$2.4m,$6.0m,$11.9m,,$0.0m,$0.0m,$33.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$9.4m,$2.8m,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m
349,Small,Akari Therapeutics,Public,Europe,United Kingdom,London,,,$46.7m,Estimate,No,No,No,No,7%,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$56.7m,,$3.9m,$0.0m,$0.0m,$0.0m,,$6.5m,$5.6m,$3.9m,$4.6m,$3.8m,$0.0m,$5.6m,$0.0m,$0.0m,$1.6m,$3.8m,$0.0m,$21.3m,$0.0m,$0.0m,$0.0m
350,Small,Protheragen,Private,North America,New York,Ronkonkoma,,,$46.7m,Estimate,Yes,Yes,Yes,Yes,44%,$20.6m,$1.5m,$0.0m,$0.0m,$1.5m,,43%,4%,0%,0%,0%,48%,,43%,4%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$20.6m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$10.9m,$0.8m,$0.0m,$0.0m,,$56.7m,,$32.5m,$2.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$34.9m,$12.8m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m
351,Small,Cloud Pharmaceuticals,Private,North America,North Carolina,Research Triangle Park,,,$46.6m,Estimate,No,No,No,No,35%,$16.2m,$0.0m,$0.0m,$0.0m,$0.0m,,35%,0%,0%,0%,0%,35%,,30%,0%,0%,0%,0%,,4%,0%,0%,0%,0%,,,,$14.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.6m,$0.0m,$0.0m,$0.0m,,$56.6m,,$25.3m,$0.0m,$0.0m,$0.0m,,$3.0m,$4.3m,$25.3m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$6.1m,$11.4m,$3.3m,$0.0m,$0.0m,$0.0m
352,Small,Microbio Group,Public,Asia/Oceania,Taiwan,Taipei,,,$46.3m,Estimate,No,Yes,No,No,19%,$8.9m,$3.9m,$0.0m,$0.0m,$3.9m,,20%,12%,0%,0%,0%,32%,,20%,8%,0%,0%,0%,,0%,4%,0%,0%,0%,,,,$8.9m,$2.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,$4.7m,$2.2m,$0.0m,$0.0m,,$56.2m,,$10.5m,$4.6m,$0.0m,$0.0m,,$8.3m,$0.0m,$15.1m,$19.1m,$0.0m,$0.0m,$8.1m,$3.5m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m
353,Small,RaQualia,Public,Asia/Oceania,,,,,$46.3m,Estimate,No,No,No,No,3%,$1.6m,$1.1m,$0.0m,$0.0m,$1.1m,,4%,4%,0%,0%,0%,8%,,4%,4%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$1.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.6m,$0.0m,$0.0m,,$56.2m,,$1.7m,$1.3m,$0.0m,$0.0m,,$2.1m,$15.9m,$3.0m,$3.9m,$1.5m,$0.0m,$0.0m,$15.9m,$0.0m,$0.0m,$1.6m,$12.3m,$0.0m,$0.0m,$0.0m,$0.0m
354,Small,GlobeImmune,Public,North America,Colorado,Louisville,,,$46.1m,Estimate,Yes,Yes,No,No,9%,$4.1m,$3.0m,$11.1m,$0.0m,$14.0m,,13%,13%,19%,0%,0%,44%,,13%,13%,19%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$3.0m,$11.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$1.7m,$6.2m,$0.0m,,$56.0m,,$8.1m,$5.9m,$21.8m,$0.0m,,$0.0m,$0.0m,$35.8m,$0.0m,$0.0m,$0.0m,$0.0m,$20.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
355,Small,Neurimmune,Private,Europe,Switzerland,Schlieren,,,$45.8m,Estimate,No,Yes,No,No,8%,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,9%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,,$55.6m,,$5.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$38.6m,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$6.5m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m
182,Small,vTv Therapeutics,Public,North America,North Carolina,High Point,,,$45.7m,Actual,No,No,No,No,8%,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,,$59.3m,,$3.4m,$0.0m,$0.0m,$0.0m,,$4.5m,$17.9m,$3.4m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$3.7m,$26.3m,$0.0m,$0.0m,$0.0m,$0.0m
356,Small,Dompe,Private,Europe,Italy,Milan,,,$45.7m,Estimate,No,No,No,No,3%,$1.6m,$0.0m,$5.6m,$5.6m,$11.2m,,7%,0%,13%,7%,0%,27%,,0%,0%,7%,0%,0%,,7%,0%,7%,7%,0%,,,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,,$1.6m,$0.0m,$2.8m,$5.6m,$0.0m,$0.8m,$0.0m,$3.2m,$3.1m,,$55.5m,,$2.4m,$0.0m,$8.5m,$8.4m,,$6.3m,$0.0m,$19.3m,$6.7m,$15.4m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m
183,Small,ASKA Pharmaceutical,Public,Asia/Oceania,Japan,Tokyo,Japan,Kanagawa,$45.7m,Actual,No,No,No,No,3%,$1.4m,$1.0m,$2.5m,$14.7m,$18.1m,,6%,6%,6%,19%,0%,38%,,0%,0%,0%,0%,0%,,6%,6%,6%,19%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.4m,$1.0m,$2.5m,$14.7m,$0.0m,$0.7m,$0.6m,$1.4m,$8.2m,,$26.0m,,$0.8m,$0.6m,$1.4m,$8.4m,,$2.8m,$0.0m,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m
357,Small,Can-Fite BioPharma,Public,Middle East/Africa,,,,,$45.5m,Estimate,No,No,No,No,4%,$1.8m,$0.0m,$6.4m,$0.0m,$6.4m,,6%,0%,11%,0%,0%,17%,,6%,0%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$6.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$3.6m,$0.0m,,$55.3m,,$2.8m,$0.0m,$10.0m,$0.0m,,$0.0m,$2.4m,$12.7m,$16.7m,$6.3m,$0.0m,$6.2m,$0.0m,$2.6m,$0.0m,$0.0m,$7.4m,$1.1m,$0.0m,$0.0m,$0.0m
358,Small,MEI Pharma,Public,North America,California,San Diego,,,$45.5m,Estimate,Yes,No,No,No,11%,$5.2m,$5.0m,$6.2m,$6.2m,$17.4m,,17%,22%,11%,6%,0%,56%,,0%,6%,6%,0%,0%,,17%,17%,6%,6%,0%,,,,$0.0m,$1.3m,$3.1m,$0.0m,$0.0m,,$5.2m,$3.8m,$3.1m,$6.2m,$0.0m,$2.7m,$2.8m,$3.5m,$3.5m,,$55.2m,,$9.4m,$9.1m,$11.3m,$11.1m,,$0.0m,$0.0m,$40.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$14.4m,$0.0m,$0.0m,$0.0m
359,Small,Nanjing Sanhome Pharmaceutical,Private,Asia/Oceania,China,Nanjing,,,$45.4m,Estimate,Yes,No,No,No,62%,$28.0m,$3.1m,$0.0m,$0.0m,$3.1m,,59%,9%,0%,0%,0%,68%,,59%,9%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$28.0m,$3.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$14.8m,$1.7m,$0.0m,$0.0m,,$55.1m,,$34.4m,$3.8m,$0.0m,$0.0m,,$0.0m,$4.8m,$38.3m,$0.0m,$0.0m,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m
360,Small,OSE Immunotherapeutics,Public,Europe,France,Nantes,,,$45.4m,Estimate,Yes,Yes,No,No,26%,$11.9m,$0.0m,$3.6m,$7.0m,$10.6m,,32%,0%,5%,5%,0%,42%,,21%,0%,0%,0%,0%,,11%,0%,5%,5%,0%,,,,$7.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.0m,$0.0m,$3.6m,$7.0m,$0.0m,$6.3m,$0.0m,$2.0m,$3.9m,,$55.1m,,$19.4m,$0.0m,$5.9m,$11.6m,,$3.6m,$0.0m,$36.9m,$9.5m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m
361,Small,Shanghai Junshi Biosciences,Private,Asia/Oceania,China,Shanghai,,,$45.4m,Estimate,No,Yes,No,No,26%,$11.7m,$1.4m,$3.5m,$0.0m,$4.9m,,23%,4%,4%,0%,4%,35%,,23%,4%,4%,0%,4%,,0%,0%,0%,0%,0%,,,,$11.7m,$1.4m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.2m,$0.8m,$2.0m,$0.0m,,$55.1m,,$14.4m,$1.7m,$4.3m,$0.0m,,$0.0m,$2.1m,$20.5m,$11.5m,$2.3m,$0.0m,$0.9m,$0.0m,$0.0m,$3.1m,$10.8m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m
184,Small,Immune Design,Public,North America,Washington,Seattle,California,South San Francisco,$45.1m,Actual,Yes,Yes,Yes,No,19%,$8.6m,$3.7m,$6.2m,$6.1m,$16.1m,,25%,15%,10%,5%,0%,55%,,15%,15%,10%,5%,0%,,10%,0%,0%,0%,0%,,,,$5.2m,$3.7m,$6.2m,$6.1m,$0.0m,,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$2.1m,$3.5m,$3.4m,,$58.5m,,$16.5m,$7.2m,$12.0m,$11.8m,,$3.6m,$0.0m,$47.5m,$0.0m,$0.0m,$4.6m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
362,Small,Bionomics,Public,Asia/Oceania,Australia,Adelaide,,,$44.8m,Estimate,Yes,Yes,No,No,22%,$9.8m,$2.8m,$3.5m,$0.0m,$6.4m,,24%,10%,5%,0%,0%,38%,,19%,5%,5%,0%,0%,,5%,5%,0%,0%,0%,,,,$7.8m,$1.4m,$3.5m,$0.0m,$0.0m,,$2.0m,$1.4m,$0.0m,$0.0m,$0.0m,$5.2m,$1.6m,$2.0m,$0.0m,,$54.4m,,$16.0m,$4.6m,$5.8m,$0.0m,,$0.0m,$22.1m,$26.4m,$0.0m,$2.8m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
363,Small,Onxeo,Public,Europe,France,Paris,,,$44.7m,Estimate,Yes,Yes,No,No,9%,$3.9m,$4.3m,$10.6m,$0.0m,$14.9m,,13%,19%,19%,0%,0%,50%,,13%,19%,19%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$4.3m,$10.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$2.4m,$6.0m,$0.0m,,$54.3m,,$6.2m,$6.8m,$16.9m,$0.0m,,$0.0m,$0.0m,$30.0m,$0.0m,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$19.5m,$0.0m,$0.0m,$0.0m,$0.0m
364,Small,Beike Biotechnology Co.,Private,Asia/Oceania,China,Shenzhen,,,$44.6m,Estimate,Yes,Yes,Yes,Yes,38%,$17.0m,$3.1m,$7.7m,$7.6m,$18.3m,,47%,12%,12%,6%,0%,76%,,0%,0%,0%,0%,0%,,47%,12%,12%,6%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$17.0m,$3.1m,$7.7m,$7.6m,$0.0m,$9.0m,$1.7m,$4.3m,$4.2m,,$54.1m,,$24.9m,$4.5m,$11.3m,$11.1m,,$0.0m,$0.0m,$51.8m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
365,Small,L.E.A.F. Pharmaceuticals,Private,North America,Massachusetts,Woburn,,,$44.4m,Estimate,No,No,No,No,67%,$29.6m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$29.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$15.7m,$0.0m,$0.0m,$0.0m,,$53.8m,,$35.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$35.9m,$18.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
366,Small,AIMM Therapeutics,Private,Europe,Netherlands,Amsterdam,,,$44.3m,Estimate,Yes,Yes,No,No,42%,$18.5m,$0.0m,$0.0m,$0.0m,$0.0m,,47%,0%,0%,0%,0%,47%,,47%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$18.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.8m,$0.0m,$0.0m,$0.0m,,$53.8m,,$26.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$26.6m,$0.0m,$0.0m,$6.3m,$0.0m,$20.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
367,Small,Gene Techno Science,Public,Asia/Oceania,Japan,Sapporo,Japan,Tokyo,$44.3m,Estimate,No,Yes,No,No,11%,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,,$53.8m,,$6.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$0.0m,$6.0m,$8.1m,$17.6m,$0.0m,$2.1m,$2.0m,$0.0m,$0.8m,$2.0m,$3.7m,$9.5m,$0.0m,$0.0m,$0.0m
368,Small,Immune Pharmaceuticals,Public,North America,California,Emeryville,,,$44.3m,Estimate,Yes,Yes,No,No,16%,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,,21%,0%,0%,0%,0%,21%,,21%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,,$53.8m,,$8.4m,$0.0m,$0.0m,$0.0m,,$3.4m,$11.8m,$8.4m,$0.0m,$2.8m,$0.0m,$9.5m,$2.1m,$0.0m,$0.0m,$2.1m,$13.7m,$0.0m,$0.0m,$0.0m,$0.0m
185,Small,Xoma,Public,North America,Maryland,Rockville,,,$44.2m,Actual,Yes,Yes,No,No,15%,$6.8m,$1.7m,$2.1m,$0.0m,$3.7m,,20%,7%,3%,0%,0%,30%,,7%,3%,0%,0%,0%,,13%,3%,3%,0%,0%,,,,$2.3m,$0.8m,$0.0m,$0.0m,$0.0m,,$4.6m,$0.8m,$2.1m,$0.0m,$0.0m,$3.6m,$0.9m,$1.2m,$0.0m,,$57.4m,,$8.6m,$2.1m,$2.6m,$0.0m,,$0.0m,$0.0m,$13.2m,$14.7m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$15.2m,$1.1m,$0.0m,$12.0m,$0.0m,$0.0m
369,Small,Fujifilm,Public,Asia/Oceania,,,,,$44.2m,Estimate,Yes,Yes,Yes,Yes,4%,$1.7m,$5.1m,$9.5m,$12.5m,$27.0m,,6%,24%,18%,12%,0%,59%,,6%,18%,18%,0%,0%,,0%,6%,0%,12%,0%,,,,$1.7m,$3.8m,$9.5m,$0.0m,$0.0m,,$0.0m,$1.3m,$0.0m,$12.5m,$0.0m,$0.9m,$2.8m,$5.3m,$7.0m,,$53.7m,,$2.5m,$7.4m,$13.8m,$18.1m,,$0.0m,$0.0m,$41.8m,$2.1m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
370,Small,SymBio Pharmaceuticals,Public,Asia/Oceania,,,,,$44.2m,Estimate,Yes,No,No,No,4%,$1.6m,$2.4m,$5.9m,$11.6m,$19.8m,,7%,14%,14%,14%,0%,50%,,7%,0%,0%,0%,0%,,0%,14%,14%,14%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.4m,$5.9m,$11.6m,$0.0m,$0.9m,$1.3m,$3.3m,$6.5m,,$53.6m,,$3.1m,$4.4m,$11.0m,$21.8m,,$0.0m,$0.0m,$40.3m,$13.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
371,Small,LifeArc,Private,Europe,United Kingdom,London,,,$44.0m,Estimate,Yes,Yes,No,No,21%,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,,23%,0%,0%,0%,0%,23%,,23%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,,$53.5m,,$13.3m,$0.0m,$0.0m,$0.0m,,$2.6m,$4.9m,$13.3m,$0.0m,$0.0m,$0.0m,$0.0m,$10.5m,$0.0m,$0.0m,$13.2m,$4.9m,$0.0m,$0.0m,$0.0m,$4.0m
372,Small,Eddingpharm,Private,Asia/Oceania,China,Shanghai,,,$44.0m,Estimate,No,Yes,No,No,7%,$3.1m,$3.3m,$5.6m,$5.5m,$14.4m,,12%,18%,12%,6%,0%,47%,,0%,0%,0%,0%,0%,,12%,18%,12%,6%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.1m,$3.3m,$5.6m,$5.5m,$0.0m,$1.6m,$1.9m,$3.1m,$3.1m,,$53.4m,,$3.6m,$3.9m,$6.5m,$6.4m,,$0.0m,$0.0m,$20.5m,$8.0m,$10.3m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$1.5m,$5.8m,$6.0m,$0.0m,$0.0m,$0.0m
373,Small,Rexahn,Public,North America,Maryland,Rockville,,,$44.0m,Estimate,No,No,No,No,23%,$10.3m,$1.5m,$11.1m,$0.0m,$12.6m,,29%,6%,18%,0%,0%,53%,,29%,6%,18%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.3m,$1.5m,$11.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.4m,$0.8m,$6.2m,$0.0m,,$53.3m,,$22.0m,$3.2m,$23.8m,$0.0m,,$0.0m,$0.0m,$49.0m,$0.0m,$0.0m,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
374,Small,Palobiofarma,Private,Europe,Spain,Barcelona,,,$43.9m,Estimate,Yes,No,No,No,14%,$6.2m,$3.0m,$3.7m,$0.0m,$6.8m,,14%,10%,5%,0%,0%,29%,,10%,10%,5%,0%,0%,,5%,0%,0%,0%,0%,,,,$4.1m,$3.0m,$3.7m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$1.7m,$2.1m,$0.0m,,$53.2m,,$7.9m,$3.8m,$4.7m,$0.0m,,$12.9m,$3.2m,$16.4m,$0.0m,$2.7m,$0.0m,$0.9m,$0.0m,$1.7m,$0.0m,$3.8m,$11.6m,$0.0m,$0.0m,$0.0m,$0.0m
375,Small,Eutilex,Private,Asia/Oceania,South Korea,Seoul,,,$43.9m,Estimate,Yes,Yes,Yes,Yes,50%,$21.8m,$4.7m,$11.8m,$0.0m,$16.5m,,53%,16%,16%,0%,0%,84%,,53%,16%,16%,0%,0%,,0%,0%,0%,0%,0%,,,,$21.8m,$4.7m,$11.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$11.5m,$2.7m,$6.6m,$0.0m,,$53.2m,,$30.3m,$6.6m,$16.4m,$0.0m,,$0.0m,$0.0m,$53.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
376,Small,Redx Pharma,Public,Europe,United Kingdom,Macclesfield,,,$43.7m,Estimate,No,No,No,No,23%,$10.0m,$0.0m,$3.6m,$0.0m,$3.6m,,25%,0%,5%,0%,0%,30%,,25%,0%,5%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.3m,$0.0m,$2.0m,$0.0m,,$53.1m,,$16.3m,$0.0m,$5.9m,$0.0m,,$6.2m,$0.0m,$22.2m,$3.2m,$0.0m,$0.0m,$0.0m,$3.2m,$3.2m,$0.0m,$6.3m,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m
377,Small,SynCore Biotechnology,Public,Asia/Oceania,Taiwan,Taipei,,,$43.4m,Estimate,No,No,No,No,12%,$5.1m,$1.2m,$6.1m,$6.1m,$13.4m,,21%,7%,14%,7%,0%,50%,,14%,7%,7%,0%,0%,,7%,0%,7%,7%,0%,,,,$3.4m,$1.2m,$3.1m,$0.0m,$0.0m,,$1.7m,$0.0m,$3.1m,$6.1m,$0.0m,$2.7m,$0.7m,$3.4m,$3.4m,,$52.7m,,$8.6m,$2.1m,$10.3m,$10.2m,,$0.0m,$0.0m,$31.1m,$0.0m,$17.1m,$0.0m,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
378,Small,SELLAS Life Sciences Group,Public,Europe,United Kingdom,Altrincham,,,$43.4m,Estimate,Yes,Yes,No,No,14%,$6.0m,$0.0m,$14.4m,$0.0m,$14.4m,,23%,0%,31%,0%,0%,54%,,15%,0%,31%,0%,0%,,8%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$14.4m,$0.0m,$0.0m,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$8.0m,$0.0m,,$52.6m,,$9.9m,$0.0m,$23.9m,$0.0m,,$0.0m,$0.0m,$33.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$14.7m,$0.0m,$0.0m,$0.0m
379,Small,Eiger BioPharmaceuticals,Public,North America,California,Palo Alto,,,$43.4m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$6.1m,$0.0m,$6.1m,,0%,0%,17%,0%,0%,17%,,0%,0%,8%,0%,0%,,0%,0%,8%,0%,0%,,,,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,,$52.6m,,$0.0m,$0.0m,$8.3m,$0.0m,,$0.0m,$0.0m,$8.3m,$0.0m,$0.0m,$0.0m,$0.0m,$28.0m,$0.0m,$3.6m,$7.2m,$0.0m,$0.0m,$5.5m,$0.0m,$0.0m
380,Small,Taiwan Liposome Company,Public,Asia/Oceania,,,,,$43.3m,Estimate,Yes,No,No,No,4%,$1.8m,$0.0m,$6.5m,$6.4m,$12.9m,,8%,0%,17%,8%,0%,33%,,8%,0%,17%,8%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$6.5m,$6.4m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$3.6m,$3.6m,,$29.6m,,$1.9m,$0.0m,$7.0m,$6.9m,,$0.0m,$3.7m,$15.8m,$0.0m,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
381,Small,Camurus,Public,Europe,Sweden,Lund,,,$42.9m,Estimate,Yes,No,Yes,No,0%,$0.0m,$0.0m,$6.1m,$0.0m,$6.1m,,0%,0%,13%,0%,0%,13%,,0%,0%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$6.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,,$26.1m,,$0.0m,$0.0m,$4.2m,$0.0m,,$0.0m,$9.6m,$4.2m,$0.0m,$0.0m,$1.7m,$0.0m,$0.0m,$1.1m,$0.4m,$0.0m,$6.1m,$0.0m,$3.0m,$0.0m,$0.0m
186,Small,Japan Tobacco,Public,Asia/Oceania,Japan,Tokyo,,,$42.8m,Actual,Yes,No,No,No,0%,$0.0m,$0.6m,$1.5m,$3.0m,$5.1m,,0%,3%,3%,3%,0%,10%,,0%,3%,3%,0%,0%,,0%,0%,0%,3%,0%,,,,$0.0m,$0.6m,$1.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.3m,$0.8m,$1.7m,,$1.6m,,$0.0m,$0.0m,$0.1m,$0.1m,,$0.3m,$0.1m,$0.2m,$0.2m,$0.0m,$0.0m,$0.3m,$0.2m,$0.0m,$0.2m,$0.0m,$0.0m,$0.2m,$0.0m,$0.0m,$0.0m
382,Small,Athenex,Public,North America,New York,Buffalo,Hong Kong,Hong Kong,$42.6m,Estimate,Yes,No,No,No,22%,$9.4m,$6.8m,$6.8m,$6.7m,$20.4m,,25%,25%,10%,5%,0%,65%,,15%,10%,5%,0%,0%,,10%,15%,5%,5%,0%,,,,$5.7m,$2.7m,$3.4m,$0.0m,$0.0m,,$3.8m,$4.1m,$3.4m,$6.7m,$0.0m,$5.0m,$3.8m,$3.8m,$3.8m,,$51.7m,,$13.9m,$10.1m,$10.0m,$9.9m,,$0.0m,$0.0m,$43.9m,$0.0m,$0.0m,$0.0m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m
383,Small,GP Pharm,Private,Europe,Spain,Barcelona,,,$42.6m,Estimate,No,Yes,No,No,7%,$3.2m,$0.0m,$5.7m,$11.3m,$17.0m,,13%,0%,13%,13%,0%,40%,,0%,0%,0%,0%,0%,,13%,0%,13%,13%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.2m,$0.0m,$5.7m,$11.3m,$0.0m,$1.7m,$0.0m,$3.2m,$6.3m,,$51.7m,,$5.8m,$0.0m,$10.4m,$20.6m,,$0.0m,$0.0m,$36.8m,$0.0m,$0.0m,$0.0m,$0.0m,$11.3m,$2.0m,$0.0m,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m
384,Small,Pint Pharma,Private,Europe,Austria,Vienna,,,$42.6m,Estimate,Yes,No,No,No,4%,$1.8m,$2.7m,$10.0m,$6.6m,$19.2m,,6%,13%,19%,6%,6%,50%,,0%,0%,0%,0%,0%,,6%,13%,19%,6%,6%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$2.7m,$10.0m,$6.6m,$0.0m,$1.0m,$1.5m,$5.6m,$3.7m,,$51.7m,,$4.5m,$6.6m,$24.5m,$16.1m,,$0.0m,$0.0m,$51.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
187,Small,XBiotech,Public,North America,Texas,Austin,,,$42.5m,Actual,No,Yes,No,No,0%,$0.0m,$2.0m,$0.0m,$0.0m,$2.0m,,0%,8%,0%,0%,8%,15%,,0%,8%,0%,0%,8%,,0%,0%,0%,0%,0%,,,,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,,$55.1m,,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,$7.1m,$22.9m,$0.0m,$6.0m,$3.3m,$12.0m,$0.0m,$0.0m,$0.0m,$0.0m
188,Small,3SBio,Public,Asia/Oceania,China,Shanghai,China,Shenzhen,$42.5m,Actual,Yes,Yes,Yes,Yes,13%,$5.4m,$3.5m,$5.4m,$0.0m,$8.8m,,14%,12%,8%,0%,5%,38%,,5%,5%,0%,0%,3%,,9%,8%,8%,0%,2%,,,,$1.8m,$1.3m,$0.0m,$0.0m,$0.0m,,$3.6m,$2.2m,$5.4m,$0.0m,$0.0m,$2.8m,$1.9m,$3.0m,$0.0m,,$55.1m,,$8.2m,$5.3m,$8.2m,$0.0m,,$0.0m,$0.0m,$21.7m,$8.3m,$4.3m,$0.0m,$2.9m,$0.7m,$4.3m,$0.7m,$5.7m,$0.7m,$5.8m,$0.0m,$0.0m,$0.0m
385,Small,JHL Biotech,Private,Asia/Oceania,Taiwan,Zhubei City,,,$42.4m,Estimate,Yes,Yes,No,No,28%,$11.7m,$1.4m,$0.0m,$0.0m,$1.4m,,26%,4%,0%,0%,0%,30%,,17%,4%,0%,0%,0%,,9%,0%,0%,0%,0%,,,,$7.8m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$6.2m,$0.8m,$0.0m,$0.0m,,$51.5m,,$17.1m,$2.1m,$0.0m,$0.0m,,$10.1m,$0.0m,$19.1m,$9.1m,$0.0m,$0.0m,$6.1m,$0.0m,$0.0m,$2.4m,$2.6m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m
386,Small,Kowa,Public,Asia/Oceania,,,,,$41.9m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$2.9m,$0.0m,$2.9m,,0%,0%,7%,0%,7%,13%,,0%,0%,0%,0%,7%,,0%,0%,7%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,,$50.8m,,$0.0m,$0.0m,$4.0m,$0.0m,,$0.0m,$12.3m,$4.0m,$0.0m,$6.5m,$1.9m,$0.0m,$0.0m,$0.0m,$13.2m,$6.7m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m
387,Small,Actinium Pharmaceuticals,Public,North America,New York,New York,,,$41.7m,Estimate,Yes,Yes,No,No,23%,$9.8m,$1.4m,$3.5m,$7.0m,$11.9m,,36%,7%,7%,7%,0%,57%,,36%,7%,7%,7%,0%,,0%,0%,0%,0%,0%,,,,$9.8m,$1.4m,$3.5m,$7.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.2m,$0.8m,$2.0m,$3.9m,,$50.6m,,$17.7m,$2.6m,$6.4m,$12.7m,,$0.0m,$0.0m,$39.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$11.2m,$0.0m,$0.0m,$0.0m
388,Small,IBC Generium,Private,Europe,Russia,Moscow,,,$41.3m,Estimate,Yes,Yes,No,No,4%,$1.6m,$1.2m,$0.0m,$5.8m,$6.9m,,6%,6%,0%,6%,0%,18%,,6%,0%,0%,6%,0%,,0%,6%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$5.8m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.9m,$0.7m,$0.0m,$3.2m,,$50.2m,,$2.3m,$1.6m,$0.0m,$8.1m,,$15.1m,$0.0m,$12.0m,$1.8m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,$9.4m,$0.0m,$1.0m,$10.2m,$0.0m,$0.0m,$0.0m
389,Small,Megapharm,Private,Middle East/Africa,Israel,Tel Aviv,,,$41.3m,Estimate,No,Yes,No,No,0%,$0.0m,$1.3m,$0.0m,$6.4m,$7.7m,,0%,5%,0%,5%,10%,19%,,0%,0%,0%,0%,0%,,0%,5%,0%,5%,10%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.3m,$0.0m,$6.4m,$0.0m,$0.0m,$0.7m,$0.0m,$3.6m,,$50.1m,,$0.0m,$1.9m,$0.0m,$9.4m,,$0.0m,$8.5m,$11.3m,$3.2m,$0.0m,$0.0m,$3.7m,$0.0m,$3.5m,$6.7m,$2.2m,$11.0m,$0.0m,$0.0m,$0.0m,$0.0m
390,Small,CHA Biotech,Public,Asia/Oceania,,,,,$41.2m,Estimate,No,Yes,No,Yes,4%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,5%,0%,0%,0%,0%,5%,,5%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$50.0m,,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.8m,$1.5m,$4.5m,$6.7m,$0.0m,$1.5m,$0.0m,$0.0m,$19.2m,$11.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
391,Small,Suzhou Zelgen Biopharmaceuticals,Private,Asia/Oceania,China,Kunshua,China ,Shanghai,$41.2m,Estimate,No,No,No,No,14%,$5.7m,$1.4m,$0.0m,$6.8m,$8.2m,,19%,6%,0%,6%,0%,31%,,19%,6%,0%,6%,0%,,0%,0%,0%,0%,0%,,,,$5.7m,$1.4m,$0.0m,$6.8m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.8m,$0.0m,$3.8m,,$50.0m,,$8.9m,$2.2m,$0.0m,$10.6m,,$2.4m,$0.0m,$21.6m,$0.0m,$0.0m,$2.5m,$2.5m,$0.0m,$2.5m,$0.0m,$0.0m,$2.3m,$14.6m,$0.0m,$1.8m,$0.0m
392,Small,Vaxart,Public,North America,California,South San Francisco,,,$41.1m,Estimate,No,No,No,No,5%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,7%,0%,0%,0%,0%,7%,,7%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$49.9m,,$2.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$13.3m,$0.0m,$32.6m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
393,Small,SciClone Pharmaceuticals,Private,North America,California,Foster City,,,$41.1m,Estimate,Yes,Yes,No,No,4%,$1.7m,$2.4m,$9.1m,$0.0m,$11.5m,,6%,12%,18%,0%,0%,35%,,0%,0%,0%,0%,0%,,6%,12%,18%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.7m,$2.4m,$9.1m,$0.0m,$0.0m,$0.9m,$1.4m,$5.1m,$0.0m,,$49.8m,,$2.1m,$3.1m,$11.5m,$0.0m,,$0.0m,$0.0m,$16.7m,$0.0m,$0.0m,$1.7m,$0.0m,$2.1m,$0.0m,$15.1m,$0.0m,$7.0m,$7.2m,$0.0m,$0.0m,$0.0m
394,Small,CBT Pharmaceuticals,Private,North America,California,Santa Clara,,,$41.0m,Estimate,Yes,Yes,No,No,21%,$8.4m,$3.1m,$11.4m,$0.0m,$14.5m,,27%,13%,20%,0%,0%,60%,,27%,7%,7%,0%,0%,,0%,7%,13%,0%,0%,,,,$8.4m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$1.5m,$7.6m,$0.0m,$0.0m,$4.5m,$1.7m,$6.4m,$0.0m,,$49.8m,,$18.3m,$6.7m,$24.8m,$0.0m,,$0.0m,$0.0m,$49.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
395,Small,Telix Pharmaceuticals,Public,Asia/Oceania,Australia,Melbourne,,,$40.9m,Estimate,No,Yes,No,No,15%,$6.3m,$1.5m,$19.0m,$7.5m,$28.0m,,25%,8%,42%,8%,0%,83%,,8%,8%,33%,8%,0%,,17%,0%,8%,0%,0%,,,,$2.1m,$1.5m,$15.2m,$7.5m,$0.0m,,$4.2m,$0.0m,$3.8m,$0.0m,$0.0m,$3.3m,$0.9m,$10.6m,$4.2m,,$49.6m,,$9.1m,$2.2m,$27.5m,$10.8m,,$0.0m,$0.0m,$49.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
396,Small,Idorsia Pharmaceuticals,Public,Europe,Switzerland,Allschwil,,,$40.4m,Estimate,No,Yes,No,No,3%,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,,6%,0%,0%,0%,0%,6%,,6%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,$0.0m,,$49.0m,,$1.1m,$0.0m,$0.0m,$0.0m,,$3.5m,$11.8m,$1.1m,$6.5m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$12.6m,$0.0m,$4.7m,$6.6m,$0.0m,$0.0m,$0.0m
397,Small,OncoTherapy Science,Public,Asia/Oceania,Japan,Kawasaki,,,$40.3m,Estimate,Yes,Yes,No,No,10%,$4.1m,$2.9m,$11.0m,$7.2m,$21.2m,,15%,15%,23%,8%,0%,62%,,15%,15%,23%,8%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$2.9m,$11.0m,$7.2m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$1.6m,$6.2m,$4.1m,,$49.0m,,$7.5m,$5.4m,$20.3m,$13.3m,,$0.0m,$2.4m,$46.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
398,Small,Orient Europharma,Public,Asia/Oceania,Taiwan,Taipei,,,$40.2m,Estimate,No,Yes,No,No,4%,$1.6m,$1.1m,$5.7m,$11.3m,$18.1m,,7%,7%,13%,13%,0%,40%,,0%,0%,0%,0%,0%,,7%,7%,13%,13%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.6m,$1.1m,$5.7m,$11.3m,$0.0m,$0.8m,$0.6m,$3.2m,$6.3m,,$48.8m,,$2.7m,$2.0m,$9.8m,$19.4m,,$0.0m,$9.7m,$33.8m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$1.9m,$0.0m,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m
399,Small,Synlogic,Public,North America,Massachusetts,Cambridge,,,$40.0m,Estimate,No,Yes,No,No,5%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,6%,0%,0%,0%,0%,6%,,6%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$48.6m,,$3.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.2m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$39.4m,$0.0m,$0.0m,$0.0m,$0.0m
189,Small,Intas Pharmaceuticals,Private,Asia/Oceania,,,,,$40.0m,Actual,No,Yes,No,No,5%,$1.8m,$1.3m,$6.7m,$13.2m,$21.2m,,8%,8%,15%,15%,0%,46%,,8%,8%,15%,15%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$1.3m,$6.7m,$13.2m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$3.7m,$7.4m,,$123.1m,,$6.1m,$4.4m,$22.1m,$43.7m,,$0.0m,$0.0m,$76.4m,$22.1m,$0.0m,$0.0m,$0.0m,$20.1m,$0.0m,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
190,Small,Zealand Pharma,Public,Europe,Denmark,Copenhagen,,,$39.9m,Actual,Yes,No,No,No,5%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,5%,0%,0%,0%,0%,5%,,0%,0%,0%,0%,0%,,5%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$51.7m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.2m,$0.0m,$27.3m,$5.4m,$12.0m,$0.0m,$0.0m
191,Small,Idera Pharmaceuticals,Public,North America,Pennsylvania,Exton,,,$39.8m,Actual,No,Yes,No,No,5%,$2.0m,$1.4m,$0.0m,$7.1m,$8.5m,,6%,6%,0%,6%,0%,19%,,6%,6%,0%,6%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.4m,$0.0m,$7.1m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$0.0m,$4.0m,,$51.7m,,$3.8m,$2.7m,$0.0m,$13.5m,,$0.0m,$0.0m,$20.0m,$7.2m,$2.8m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$11.4m,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m
192,Small,Biocon,Public,Asia/Oceania,,,,,$39.8m,Actual,Yes,Yes,No,No,7%,$2.9m,$1.0m,$3.9m,$5.1m,$10.1m,,11%,5%,8%,5%,3%,32%,,5%,0%,0%,0%,0%,,5%,5%,8%,5%,3%,,,,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.4m,$1.0m,$3.9m,$5.1m,$0.0m,$1.5m,$0.6m,$2.2m,$2.9m,,$64.0m,,$5.4m,$2.0m,$7.3m,$9.6m,,$0.0m,$3.8m,$24.2m,$6.0m,$11.6m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,$3.9m,$10.9m,$0.0m,$0.0m,$0.0m,$0.0m
400,Small,Livzon Pharmaceutical,Public,Asia/Oceania,,,,,$39.7m,Estimate,No,Yes,No,No,4%,$1.5m,$2.2m,$0.0m,$0.0m,$2.2m,,7%,13%,0%,0%,0%,20%,,7%,13%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.5m,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$1.2m,$0.0m,$0.0m,,$48.2m,,$1.5m,$2.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.7m,$12.0m,$9.1m,$1.4m,$3.2m,$0.0m,$1.2m,$0.0m,$7.0m,$10.6m,$0.0m,$0.0m,$0.0m,$0.0m
401,Small,Onconova,Public,North America,Pennsylvania,Newtown,,,$39.6m,Estimate,Yes,No,No,No,27%,$10.7m,$1.6m,$3.9m,$7.7m,$13.1m,,38%,8%,8%,8%,0%,62%,,15%,8%,8%,8%,0%,,23%,0%,0%,0%,0%,,,,$4.3m,$1.6m,$3.9m,$7.7m,$0.0m,,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.9m,$2.2m,$4.3m,,$26.0m,,$11.3m,$1.6m,$4.1m,$8.0m,,$0.0m,$0.0m,$25.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m
402,Small,Xcovery,Private,North America,Florida,Palm Beach Gardens,,,$39.4m,Estimate,No,No,No,No,5%,$1.9m,$2.8m,$3.5m,$13.8m,$20.1m,,9%,18%,9%,18%,0%,55%,,9%,18%,9%,18%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$2.8m,$3.5m,$13.8m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$1.6m,$2.0m,$7.7m,,$47.9m,,$3.6m,$5.2m,$6.5m,$25.6m,,$0.0m,$0.0m,$41.0m,$0.0m,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
403,Small,Profectus BioSciences,Private,North America,Maryland,Baltimore,New York ,New York,$39.3m,Estimate,No,Yes,No,No,5%,$1.9m,$1.4m,$0.0m,$0.0m,$1.4m,,4%,4%,0%,0%,0%,9%,,4%,0%,0%,0%,0%,,0%,4%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$0.0m,$0.0m,,$47.7m,,$3.2m,$2.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$42.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
404,Small,ERYtech Pharma,Public,Europe,France,Lyon,,,$39.2m,Estimate,Yes,Yes,No,No,20%,$8.0m,$0.0m,$3.6m,$7.1m,$10.7m,,31%,0%,8%,8%,0%,46%,,31%,0%,8%,8%,0%,,0%,0%,0%,0%,0%,,,,$8.0m,$0.0m,$3.6m,$7.1m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.2m,$0.0m,$2.0m,$4.0m,,$47.6m,,$16.1m,$0.0m,$7.3m,$14.4m,,$0.0m,$0.0m,$37.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m
405,Small,Kadmon Holdings,Public,North America,New York,New York,Massachusetts,Cambridge,$39.2m,Estimate,No,No,No,No,9%,$3.5m,$0.0m,$3.2m,$0.0m,$3.2m,,12%,0%,6%,0%,0%,18%,,12%,0%,0%,0%,0%,,0%,0%,6%,0%,0%,,,,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$1.9m,$0.0m,$1.8m,$0.0m,,$46.5m,,$3.8m,$0.0m,$3.5m,$0.0m,,$5.8m,$0.0m,$7.3m,$17.4m,$3.3m,$0.0m,$3.3m,$0.0m,$6.7m,$0.0m,$1.7m,$1.0m,$0.0m,$0.0m,$0.0m,$0.0m
406,Small,Isarna Therapeutics,Private,Europe,Germany,Munich,,,$39.1m,Estimate,No,No,No,No,22%,$8.5m,$0.0m,$3.9m,$7.6m,$11.5m,,31%,0%,8%,8%,0%,46%,,23%,0%,8%,8%,0%,,8%,0%,0%,0%,0%,,,,$6.4m,$0.0m,$3.9m,$7.6m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$2.2m,$4.3m,,$47.5m,,$13.1m,$0.0m,$5.9m,$11.7m,,$0.0m,$0.0m,$30.7m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
407,Small,Sareum,Public,Europe,United Kingdom,Cambridge,,,$39.1m,Estimate,Yes,No,No,No,20%,$7.8m,$0.0m,$3.5m,$0.0m,$3.5m,,22%,0%,6%,0%,0%,28%,,22%,0%,6%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.8m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.2m,$0.0m,$2.0m,$0.0m,,$47.5m,,$14.3m,$0.0m,$6.4m,$0.0m,,$0.0m,$6.4m,$20.7m,$6.9m,$0.0m,$0.0m,$7.1m,$0.0m,$0.0m,$0.0m,$0.0m,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m
408,Small,Verastem Oncology,Public,Asia/Oceania,,,,,$39.1m,Estimate,Yes,No,No,No,9%,$3.7m,$4.0m,$6.6m,$6.5m,$17.2m,,13%,20%,13%,7%,7%,60%,,0%,0%,0%,0%,0%,,13%,20%,13%,7%,7%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.7m,$4.0m,$6.6m,$6.5m,$0.0m,$1.9m,$2.2m,$3.7m,$3.7m,,$47.4m,,$8.4m,$9.1m,$15.1m,$14.9m,,$0.0m,$0.0m,$47.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
409,Small,Amunix,Private,North America,California,Mountain View,,,$39.1m,Estimate,No,Yes,No,No,21%,$8.2m,$0.0m,$0.0m,$0.0m,$0.0m,,26%,0%,0%,0%,0%,26%,,26%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.4m,$0.0m,$0.0m,$0.0m,,$47.4m,,$11.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.0m,$0.0m,$0.0m,$17.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.3m,$13.1m,$0.0m,$0.0m,$0.0m
410,Small,Immatics Biotechnologies,Private,Europe,Germany,Munich,,,$39.1m,Estimate,Yes,Yes,Yes,Yes,58%,$22.5m,$4.9m,$8.1m,$0.0m,$13.0m,,59%,18%,12%,0%,0%,88%,,47%,18%,12%,0%,0%,,12%,0%,0%,0%,0%,,,,$18.0m,$4.9m,$8.1m,$0.0m,$0.0m,,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m,$11.9m,$2.7m,$4.6m,$0.0m,,$47.4m,,$30.0m,$6.5m,$10.8m,$0.0m,,$0.0m,$0.0m,$47.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
411,Small,InnoPharmax,Public,Asia/Oceania,,,,,$39.0m,Estimate,Yes,No,No,No,0%,$0.0m,$2.6m,$6.4m,$6.3m,$15.2m,,0%,18%,18%,9%,0%,45%,,0%,9%,9%,0%,0%,,0%,9%,9%,9%,0%,,,,$0.0m,$1.3m,$3.2m,$0.0m,$0.0m,,$0.0m,$1.3m,$3.2m,$6.3m,$0.0m,$0.0m,$1.4m,$3.6m,$3.5m,,$47.3m,,$0.0m,$4.6m,$11.5m,$11.3m,,$0.0m,$0.0m,$27.4m,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$13.5m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m
412,Small,Active Biotech,Public,Europe,Sweden,Lund,,,$39.0m,Estimate,No,Yes,No,No,14%,$5.6m,$0.0m,$0.0m,$6.7m,$6.7m,,27%,0%,0%,9%,0%,36%,,27%,0%,0%,9%,0%,,0%,0%,0%,0%,0%,,,,$5.6m,$0.0m,$0.0m,$6.7m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$3.7m,,$47.3m,,$10.9m,$0.0m,$0.0m,$13.0m,,$0.0m,$7.0m,$23.9m,$16.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
413,Small,Kuhnil Pharmaceutical,Private,Latin America,,,,,$39.0m,Estimate,No,Yes,No,No,4%,$1.7m,$1.2m,$3.0m,$5.9m,$10.1m,,7%,7%,7%,7%,0%,29%,,0%,0%,0%,0%,0%,,7%,7%,7%,7%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.7m,$1.2m,$3.0m,$5.9m,$0.0m,$0.9m,$0.7m,$1.7m,$3.3m,,$47.3m,,$2.7m,$1.9m,$4.8m,$9.6m,,$0.0m,$24.5m,$19.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
414,Small,CureVac,Private,Europe,Germany,Tubingen,,,$38.9m,Estimate,No,Yes,Yes,No,5%,$1.9m,$1.4m,$3.5m,$0.0m,$4.9m,,5%,5%,5%,0%,0%,14%,,5%,5%,5%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$1.4m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$2.0m,$0.0m,,$47.2m,,$3.2m,$2.3m,$5.7m,$0.0m,,$0.0m,$0.0m,$11.1m,$0.0m,$0.0m,$0.0m,$0.0m,$25.3m,$0.0m,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,$4.2m
415,Small,Apexigen,Private,North America,California,San Carlos,,,$38.8m,Estimate,Yes,Yes,No,No,20%,$7.6m,$4.1m,$6.8m,$0.0m,$10.9m,,24%,18%,12%,0%,0%,53%,,24%,6%,6%,0%,0%,,0%,12%,6%,0%,0%,,,,$7.6m,$1.4m,$3.4m,$0.0m,$0.0m,,$0.0m,$2.7m,$3.4m,$0.0m,$0.0m,$4.0m,$2.3m,$3.8m,$0.0m,,$47.1m,,$11.6m,$6.3m,$10.4m,$0.0m,,$0.0m,$0.0m,$28.3m,$8.8m,$9.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
416,Small,Hemispherx Biopharma,Public,North America,New Jersey,New Brunswick,Florida,Ocala,$38.7m,Estimate,No,Yes,No,No,5%,$1.9m,$0.0m,$3.5m,$6.9m,$10.5m,,9%,0%,9%,9%,0%,27%,,9%,0%,9%,9%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$3.5m,$6.9m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$2.0m,$3.9m,,$47.0m,,$3.7m,$0.0m,$6.7m,$13.2m,,$0.0m,$0.0m,$23.6m,$0.0m,$0.0m,$0.0m,$0.0m,$23.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
193,Small,Jubilant Life Sciences,Public,Asia/Oceania,India,Uttar Pradesh,China,Shanghai,$38.7m,Actual,No,Yes,No,No,43%,$16.7m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$16.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.8m,$0.0m,$0.0m,$0.0m,,$65.5m,,$21.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$7.5m,$21.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$36.3m,$0.0m,$0.0m,$0.0m,$0.0m
417,Small,Shanghai HaiHe Biopharma,Private,Asia/Oceania,China,Shanghai,,,$38.3m,Estimate,No,No,No,No,25%,$9.5m,$4.1m,$3.4m,$6.8m,$14.3m,,31%,19%,6%,6%,0%,63%,,31%,19%,0%,0%,0%,,0%,0%,6%,6%,0%,,,,$9.5m,$4.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.4m,$6.8m,$0.0m,$5.0m,$2.3m,$1.9m,$3.8m,,$46.5m,,$14.0m,$6.1m,$5.1m,$10.0m,,$0.0m,$0.0m,$35.1m,$0.0m,$0.0m,$0.0m,$0.0m,$9.2m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m
418,Small,Arrowhead Pharmaceuticals,Public,North America,Wisconsin,Madison,California,Pasadena,$38.3m,Estimate,No,No,No,No,5%,$2.0m,$2.9m,$3.6m,$0.0m,$6.4m,,5%,11%,5%,0%,0%,21%,,5%,11%,5%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$2.9m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$1.6m,$2.0m,$0.0m,,$46.5m,,$3.2m,$4.6m,$5.7m,$0.0m,,$2.7m,$0.0m,$13.5m,$4.5m,$0.0m,$0.0m,$0.0m,$7.1m,$0.0m,$10.6m,$0.0m,$3.2m,$4.9m,$0.0m,$0.0m,$0.0m
419,Small,Dong Wha,Public,Asia/Oceania,,,,,$38.1m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.0m,$0.0m,$3.0m,,0%,0%,8%,0%,0%,8%,,0%,0%,8%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,,$46.2m,,$0.0m,$0.0m,$3.6m,$0.0m,,$6.9m,$1.3m,$3.6m,$7.1m,$0.0m,$0.0m,$0.0m,$15.8m,$0.0m,$1.6m,$0.0m,$6.8m,$3.1m,$0.0m,$0.0m,$0.0m
420,Small,Benitec Biopharma,Public,Asia/Oceania,,,,,$38.0m,Estimate,No,No,No,No,5%,$1.8m,$0.0m,$3.3m,$0.0m,$3.3m,,5%,0%,5%,0%,0%,10%,,5%,0%,0%,0%,0%,,0%,0%,5%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$1.0m,$0.0m,$1.8m,$0.0m,,$46.1m,,$2.6m,$0.0m,$4.7m,$0.0m,,$0.0m,$24.8m,$7.2m,$0.0m,$7.3m,$0.0m,$0.0m,$4.5m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
194,Small,Mithra Pharmaceuticals,Public,Europe,Belgium,Liege,,,$38.0m,Actual,No,No,No,No,0%,$0.0m,$0.0m,$5.8m,$0.0m,$5.8m,,0%,0%,13%,0%,0%,13%,,0%,0%,0%,0%,0%,,0%,0%,13%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,,$49.2m,,$0.0m,$0.0m,$6.4m,$0.0m,,$0.0m,$6.9m,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$25.4m,$0.0m,$10.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
421,Small,Castle Creek Pharmaceuticals,Private,North America,New Jersey,Parsippany,,,$37.8m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,6%,0%,0%,0%,6%,,0%,6%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$45.8m,,$0.0m,$2.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$6.4m,$0.0m,$0.0m,$27.7m,$0.0m,$0.0m,$0.0m,$0.0m,$9.3m,$0.0m,$0.0m,$0.0m,$0.0m
422,Small,Tesaro,Public,North America,Massachusetts,Waltham,France,Paris,$37.6m,Estimate,Yes,Yes,No,No,35%,$13.2m,$5.5m,$3.4m,$6.7m,$15.6m,,44%,25%,6%,6%,0%,81%,,13%,0%,0%,0%,0%,,31%,25%,6%,6%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$9.4m,$5.5m,$3.4m,$6.7m,$0.0m,$7.0m,$3.1m,$1.9m,$3.8m,,$45.7m,,$20.9m,$8.7m,$5.4m,$10.7m,,$0.0m,$0.0m,$45.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
423,Small,Aslan Pharmaceuticals,Public,Asia/Oceania,Singapore,Singapore,Taiwan,Taipei,$37.6m,Estimate,Yes,Yes,No,No,14%,$5.4m,$1.3m,$6.5m,$6.4m,$14.2m,,23%,8%,15%,8%,0%,54%,,15%,0%,0%,0%,0%,,8%,8%,15%,8%,0%,,,,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$1.3m,$6.5m,$6.4m,$0.0m,$2.9m,$0.7m,$3.6m,$3.6m,,$45.6m,,$10.3m,$2.5m,$12.4m,$12.3m,,$4.5m,$0.0m,$37.5m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
195,Small,Progenics Pharmaceuticals,Public,North America,New York,New York,,,$37.6m,Actual,Yes,Yes,No,No,8%,$2.8m,$2.1m,$2.6m,$10.1m,$14.7m,,15%,15%,8%,15%,0%,54%,,8%,15%,8%,15%,0%,,8%,0%,0%,0%,0%,,,,$1.4m,$2.1m,$2.6m,$10.1m,$0.0m,,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.5m,$1.1m,$1.4m,$5.6m,,$48.7m,,$3.9m,$2.8m,$3.5m,$13.8m,,$0.0m,$0.0m,$23.9m,$6.7m,$0.0m,$10.0m,$0.0m,$8.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
424,Small,TTY Biopharm,Public,Asia/Oceania,,,,,$37.4m,Estimate,No,No,No,No,9%,$3.2m,$0.0m,$5.8m,$5.8m,$11.6m,,11%,0%,11%,6%,11%,39%,,11%,0%,0%,0%,0%,,0%,0%,11%,6%,11%,,,,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.8m,$5.8m,$0.0m,$1.7m,$0.0m,$3.3m,$3.2m,,$45.4m,,$5.1m,$0.0m,$9.2m,$9.0m,,$0.0m,$6.0m,$23.2m,$0.0m,$2.1m,$0.0m,$0.0m,$12.2m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m
425,Small,Autolus,Public,Europe,United Kingdom,London,,,$37.4m,Estimate,Yes,Yes,Yes,Yes,22%,$8.4m,$3.0m,$11.3m,$0.0m,$14.4m,,31%,15%,23%,0%,0%,69%,,31%,15%,23%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.4m,$3.0m,$11.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.4m,$1.7m,$6.3m,$0.0m,,$45.4m,,$16.7m,$6.1m,$22.6m,$0.0m,,$0.0m,$0.0m,$45.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
426,Small,Wuxi AppTec,Public,Asia/Oceania,China,Shanghai,,,$37.3m,Estimate,Yes,Yes,No,No,11%,$4.2m,$3.0m,$7.5m,$0.0m,$10.6m,,12%,12%,12%,0%,0%,35%,,6%,0%,0%,0%,0%,,6%,12%,12%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$3.0m,$7.5m,$0.0m,$0.0m,$2.2m,$1.7m,$4.2m,$0.0m,,$45.3m,,$7.1m,$5.1m,$12.8m,$0.0m,,$4.2m,$2.7m,$25.0m,$4.8m,$0.0m,$0.0m,$0.0m,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
427,Small,Syros Pharmaceuticals,Public,North America,Massachusetts,Cambridge,,,$37.0m,Estimate,Yes,No,No,No,35%,$12.9m,$1.6m,$3.9m,$0.0m,$5.4m,,38%,6%,6%,0%,0%,50%,,31%,6%,0%,0%,0%,,6%,0%,6%,0%,0%,,,,$10.7m,$1.6m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$3.9m,$0.0m,$0.0m,$6.8m,$0.9m,$2.2m,$0.0m,,$44.9m,,$24.2m,$2.9m,$7.3m,$0.0m,,$0.0m,$0.0m,$34.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$10.5m,$0.0m,$0.0m,$0.0m
428,Small,Ribomic,Public,Asia/Oceania,,,,,$36.8m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$44.7m,,$0.0m,$0.0m,$0.0m,$0.0m,,$7.1m,$4.5m,$0.0m,$2.4m,$10.8m,$2.6m,$2.5m,$0.0m,$0.0m,$0.0m,$7.3m,$2.3m,$5.3m,$0.0m,$0.0m,$0.0m
429,Small,Pieris Pharmaceuticals,Public,North America,Massachusetts,Boston,,,$36.7m,Estimate,No,Yes,No,No,48%,$17.6m,$1.6m,$0.0m,$0.0m,$1.6m,,53%,7%,0%,0%,0%,60%,,47%,7%,0%,0%,0%,,7%,0%,0%,0%,0%,,,,$15.4m,$1.6m,$0.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$9.3m,$0.9m,$0.0m,$0.0m,,$44.5m,,$18.1m,$1.6m,$0.0m,$0.0m,,$4.9m,$0.0m,$19.8m,$3.5m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$3.5m,$0.0m,$10.6m,$0.0m,$0.0m,$0.0m
430,Small,Constant Pharmaceuticals,Private,North America,Massachusetts,Boston,,,$36.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$5.7m,$0.0m,$5.7m,,0%,0%,12%,0%,0%,12%,,0%,0%,6%,0%,0%,,0%,0%,6%,0%,0%,,,,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,,$44.3m,,$0.0m,$0.0m,$6.3m,$0.0m,,$0.0m,$0.0m,$6.3m,$5.7m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$7.2m,$3.9m,$2.0m,$15.7m,$0.0m,$0.0m,$0.0m
431,Small,EyePoint Pharmaceuticals,Public,North America,Massachusetts,Watertown,,,$36.3m,Estimate,No,No,No,No,5%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,5%,0%,0%,0%,0%,5%,,5%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$44.1m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.3m,$0.0m,$33.0m,$2.5m,$4.4m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
432,Small,NEOMED Institute,Private,North America,Quebec,Montreal,,,$36.2m,Estimate,Yes,Yes,No,No,34%,$12.1m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,28%,0%,0%,0%,0%,,6%,0%,0%,0%,0%,,,,$10.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.4m,$0.0m,$0.0m,$0.0m,,$44.0m,,$15.5m,$0.0m,$0.0m,$0.0m,,$5.7m,$12.6m,$15.5m,$0.0m,$0.0m,$0.0m,$0.0m,$5.1m,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
433,Small,Celsion,Public,North America,New Jersey,Lawrenceville,,,$36.1m,Estimate,No,Yes,Yes,No,16%,$5.9m,$0.0m,$7.1m,$7.0m,$14.1m,,27%,0%,18%,9%,0%,55%,,27%,0%,18%,9%,0%,,0%,0%,0%,0%,0%,,,,$5.9m,$0.0m,$7.1m,$7.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$4.0m,$3.9m,,$43.9m,,$12.0m,$0.0m,$14.5m,$14.3m,,$0.0m,$0.0m,$40.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
196,Small,BioTime,Public,North America,California,Alameda,,,$36.1m,Actual,Yes,Yes,Yes,Yes,5%,$2.0m,$0.0m,$3.5m,$0.0m,$3.5m,,7%,0%,7%,0%,0%,14%,,0%,0%,0%,0%,0%,,7%,0%,7%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$0.0m,$3.5m,$0.0m,$0.0m,$1.0m,$0.0m,$2.0m,$0.0m,,$46.8m,,$3.3m,$0.0m,$5.9m,$0.0m,,$0.0m,$11.5m,$9.2m,$0.0m,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,$9.1m,$5.3m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m
197,Small,CytRx,Public,North America,California,Los Angeles,,,$35.9m,Actual,Yes,No,No,No,19%,$6.7m,$0.7m,$3.5m,$3.4m,$7.6m,,35%,5%,10%,5%,0%,55%,,30%,5%,5%,5%,0%,,5%,0%,5%,0%,0%,,,,$5.8m,$0.7m,$1.7m,$3.4m,$0.0m,,$1.0m,$0.0m,$1.7m,$0.0m,$0.0m,$3.6m,$0.4m,$2.0m,$1.9m,,$46.6m,,$12.7m,$1.3m,$6.5m,$6.5m,,$0.0m,$6.9m,$27.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.2m,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m
198,Small,Medivir,Public,Europe,Sweden,Stockholm,,,$35.9m,Actual,Yes,No,No,No,12%,$4.3m,$0.8m,$3.9m,$0.0m,$4.6m,,19%,5%,10%,0%,0%,33%,,14%,0%,0%,0%,0%,,5%,5%,10%,0%,0%,,,,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.1m,$0.8m,$3.9m,$0.0m,$0.0m,$2.3m,$0.4m,$2.2m,$0.0m,,$46.6m,,$6.7m,$1.2m,$6.1m,$0.0m,,$8.2m,$0.0m,$14.0m,$0.0m,$0.0m,$0.0m,$1.9m,$11.9m,$0.0m,$0.0m,$4.3m,$0.0m,$6.2m,$0.0m,$0.0m,$0.0m
199,Small,Strongbridge Biopharma,Public,Asia/Oceania,,,,,$35.9m,Actual,No,No,No,No,8%,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,0%,0%,0%,0%,0%,,13%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$46.5m,,$5.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.1m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.7m,$2.9m,$0.0m,$26.0m,$0.0m,$0.0m
434,Small,Cytori Therapeutics,Public,North America,California,San Diego,Texas,Austin,$35.8m,Estimate,Yes,No,No,No,5%,$1.8m,$1.3m,$0.0m,$0.0m,$1.3m,,6%,6%,0%,0%,0%,13%,,6%,6%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.7m,$0.0m,$0.0m,,$43.5m,,$2.6m,$1.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.5m,$8.4m,$0.0m,$0.0m,$2.4m,$0.0m,$10.3m,$5.6m,$8.8m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m
200,Small,Molecular Partners,Public,Europe,Switzerland,Zurich,,,$35.7m,Actual,No,Yes,No,No,13%,$4.5m,$1.6m,$4.1m,$0.0m,$5.7m,,22%,11%,11%,0%,0%,44%,,22%,11%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.5m,$1.6m,$4.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.9m,$2.3m,$0.0m,,$46.3m,,$6.2m,$2.3m,$5.6m,$0.0m,,$0.0m,$0.0m,$14.1m,$0.0m,$32.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
435,Small,Abivax,Public,Europe,France,Paris,,,$35.7m,Estimate,No,Yes,No,No,5%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,7%,0%,0%,0%,0%,7%,,7%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$43.4m,,$2.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$4.8m,$0.0m,$24.7m,$0.0m,$0.0m,$0.0m,$11.0m,$0.0m,$0.0m,$0.0m,$0.0m
436,Small,Center of Molecular Immunology,Private,Latin America,,,,,$35.6m,Estimate,Yes,Yes,No,No,0%,$0.0m,$2.9m,$7.2m,$7.1m,$17.1m,,0%,18%,18%,9%,0%,45%,,0%,18%,18%,9%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$2.9m,$7.2m,$7.1m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$4.0m,$4.0m,,$43.2m,,$0.0m,$5.5m,$13.6m,$13.4m,,$0.0m,$3.1m,$32.5m,$0.0m,$0.0m,$0.0m,$0.0m,$7.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
437,Small,Immunovaccine,Public,North America,Nova Scotia,Dartmouth,Quebec,Quebec City,$35.5m,Estimate,Yes,Yes,No,No,23%,$8.3m,$3.0m,$7.5m,$0.0m,$10.5m,,27%,13%,13%,0%,0%,53%,,20%,7%,7%,0%,0%,,7%,7%,7%,0%,0%,,,,$6.2m,$1.5m,$3.7m,$0.0m,$0.0m,,$2.1m,$1.5m,$3.7m,$0.0m,$0.0m,$4.4m,$1.7m,$4.2m,$0.0m,,$43.1m,,$15.6m,$5.6m,$14.1m,$0.0m,,$0.0m,$0.0m,$35.3m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.1m
438,Small,Polaris Group,Private,North America,Florida,Tampa,,,$35.4m,Estimate,Yes,Yes,No,No,20%,$7.1m,$1.3m,$3.2m,$6.3m,$10.8m,,31%,8%,8%,8%,0%,54%,,23%,0%,0%,0%,0%,,8%,8%,8%,8%,0%,,,,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$1.3m,$3.2m,$6.3m,$0.0m,$3.7m,$0.7m,$1.8m,$3.5m,,$43.0m,,$12.1m,$2.2m,$5.5m,$10.8m,,$0.0m,$0.0m,$30.7m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$9.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
439,Small,Bial,Private,Europe,Portugal,Trofa,,,$35.4m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.0m,$0.0m,$3.0m,,0%,0%,6%,0%,0%,6%,,0%,0%,0%,0%,0%,,0%,0%,6%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,,$45.8m,,$0.0m,$0.0m,$4.0m,$0.0m,,$13.6m,$13.8m,$4.0m,$0.0m,$1.7m,$0.0m,$3.4m,$0.0m,$0.0m,$2.4m,$5.2m,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m
440,Small,Vault Pharma,Private,North America,California,Los Angeles,,,$35.3m,Estimate,No,Yes,No,No,35%,$12.5m,$0.0m,$0.0m,$0.0m,$0.0m,,35%,0%,0%,0%,0%,35%,,35%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$12.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,,$42.9m,,$17.0m,$0.0m,$0.0m,$0.0m,,$2.8m,$0.0m,$17.0m,$2.8m,$0.0m,$3.0m,$0.0m,$17.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
441,Small,Regenacy Pharmaceuticals,Private,North America,Massachusetts,Waltham,,,$35.2m,Estimate,Yes,No,No,No,17%,$6.0m,$1.4m,$3.6m,$0.0m,$5.0m,,18%,6%,6%,0%,0%,29%,,6%,0%,0%,0%,0%,,12%,6%,6%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.0m,$1.4m,$3.6m,$0.0m,$0.0m,$3.2m,$0.8m,$2.0m,$0.0m,,$42.8m,,$10.9m,$2.6m,$6.6m,$0.0m,,$0.0m,$7.1m,$20.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$4.2m,$8.7m,$0.0m,$0.0m,$0.0m
442,Small,Samjin,Public,Asia/Oceania,South Korea,Seoul,,,$35.1m,Estimate,No,No,No,No,25%,$8.9m,$0.0m,$0.0m,$0.0m,$0.0m,,28%,0%,0%,0%,0%,28%,,28%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,,$42.6m,,$10.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$6.0m,$10.8m,$3.2m,$10.7m,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$4.0m,$2.3m,$1.7m,$0.0m,$0.0m
443,Small,Oncodesign Biotechnology,Public,Europe,France,Dijon,Quebec,Montreal,$35.0m,Estimate,No,No,No,No,34%,$11.8m,$1.4m,$0.0m,$0.0m,$1.4m,,33%,6%,0%,0%,0%,39%,,33%,6%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.8m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.3m,$0.8m,$0.0m,$0.0m,,$42.5m,,$15.8m,$1.9m,$0.0m,$0.0m,,$2.5m,$7.1m,$17.7m,$2.6m,$2.5m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$5.1m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m
444,Small,Oasmia,Public,Europe,Sweden,Uppsala,,,$34.9m,Estimate,Yes,No,No,No,23%,$8.2m,$0.0m,$3.7m,$14.6m,$18.3m,,44%,0%,11%,22%,0%,78%,,33%,0%,11%,22%,0%,,11%,0%,0%,0%,0%,,,,$6.1m,$0.0m,$3.7m,$14.6m,$0.0m,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$0.0m,$2.1m,$8.2m,,$42.4m,,$13.1m,$0.0m,$5.9m,$23.3m,,$0.0m,$0.0m,$42.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
445,Small,Mirati Therapeutics,Public,North America,California,San Diego,,,$34.8m,Estimate,Yes,No,No,No,12%,$4.1m,$3.0m,$11.2m,$0.0m,$14.2m,,17%,17%,25%,0%,0%,58%,,17%,17%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$3.0m,$11.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$1.7m,$6.3m,$0.0m,,$42.2m,,$9.5m,$6.9m,$25.8m,$0.0m,,$0.0m,$0.0m,$42.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
446,Small,Everest Medicines,Private,North America,New York,New York,Massachusetts,Boston,$34.7m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$2.7m,$0.0m,$2.7m,,0%,0%,9%,0%,0%,9%,,0%,0%,0%,0%,0%,,0%,0%,9%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.5m,$0.0m,,$42.1m,,$0.0m,$0.0m,$3.7m,$0.0m,,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,$3.2m,$13.6m,$0.0m,$12.3m,$0.0m,$9.3m,$0.0m,$0.0m,$0.0m,$0.0m
447,Small,Genocea Biosciences,Public,North America,Massachusetts,Cambridge,,,$34.6m,Estimate,Yes,Yes,No,No,24%,$8.2m,$0.0m,$7.4m,$0.0m,$7.4m,,31%,0%,15%,0%,0%,46%,,31%,0%,8%,0%,0%,,0%,0%,8%,0%,0%,,,,$8.2m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$4.3m,$0.0m,$4.1m,$0.0m,,$44.9m,,$15.2m,$0.0m,$13.7m,$0.0m,,$0.0m,$0.0m,$28.9m,$0.0m,$0.0m,$3.7m,$0.0m,$7.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.2m
448,Small,Celularity,Private,North America,New Jersey,Warren,,,$34.5m,Estimate,Yes,Yes,Yes,Yes,29%,$10.1m,$2.9m,$0.0m,$0.0m,$2.9m,,29%,12%,0%,0%,0%,41%,,18%,0%,0%,0%,0%,,12%,12%,0%,0%,0%,,,,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.0m,$2.9m,$0.0m,$0.0m,$0.0m,$5.3m,$1.6m,$0.0m,$0.0m,,$41.9m,,$15.3m,$4.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$19.7m,$2.7m,$0.0m,$0.0m,$5.5m,$0.0m,$0.0m,$0.0m,$2.7m,$11.3m,$0.0m,$0.0m,$0.0m,$0.0m
449,Small,Medytox,Public,Asia/Oceania,South Korea,Gwanggyo,,,$34.5m,Estimate,No,No,No,No,10%,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,,$41.8m,,$4.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.9m,$4.1m,$4.1m,$5.9m,$0.0m,$2.1m,$0.0m,$3.5m,$0.0m,$16.4m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m
450,Small,GT Biopharma,Public,North America,California,Westlake Village,,,$34.4m,Estimate,Yes,Yes,No,Yes,30%,$10.4m,$0.0m,$3.8m,$0.0m,$3.8m,,33%,0%,7%,0%,0%,40%,,20%,0%,7%,0%,0%,,13%,0%,0%,0%,0%,,,,$6.3m,$0.0m,$3.8m,$0.0m,$0.0m,,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,$5.5m,$0.0m,$2.1m,$0.0m,,$41.7m,,$16.6m,$0.0m,$6.0m,$0.0m,,$0.0m,$2.8m,$22.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.4m,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m
451,Small,Nimbus Therapeutics,Private,North America,Massachusetts,Cambridge,,,$34.3m,Estimate,Yes,Yes,No,No,34%,$11.7m,$0.0m,$0.0m,$0.0m,$0.0m,,38%,0%,0%,0%,0%,38%,,38%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.2m,$0.0m,$0.0m,$0.0m,,$41.6m,,$15.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$15.9m,$10.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$12.6m,$0.0m,$0.0m,$0.0m,$0.0m
452,Small,Sotio,Private,Europe,Czech Republic,Prague,,,$34.2m,Estimate,Yes,Yes,No,Yes,25%,$8.4m,$0.0m,$7.6m,$7.5m,$15.0m,,36%,0%,18%,9%,0%,64%,,18%,0%,18%,9%,0%,,18%,0%,0%,0%,0%,,,,$4.2m,$0.0m,$7.6m,$7.5m,$0.0m,,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,$4.4m,$0.0m,$4.2m,$4.2m,,$41.5m,,$13.9m,$0.0m,$12.5m,$12.4m,,$0.0m,$0.0m,$38.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m
453,Small,Deciphera Pharmaceuticals,Public,North America,Kansas City,Lawrence,Massachusetts,Waltham,$34.2m,Estimate,Yes,Yes,No,No,18%,$6.2m,$4.5m,$3.7m,$7.3m,$15.5m,,21%,21%,7%,7%,0%,57%,,21%,21%,7%,7%,0%,,0%,0%,0%,0%,0%,,,,$6.2m,$4.5m,$3.7m,$7.3m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$2.5m,$2.1m,$4.1m,,$41.5m,,$11.5m,$8.3m,$6.9m,$13.6m,,$0.0m,$0.0m,$40.3m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
454,Small,NicOx,Public,Europe,France,Valbonne,,,$34.1m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$2.9m,$0.0m,$2.9m,,0%,0%,7%,0%,0%,7%,,0%,0%,0%,0%,0%,,0%,0%,7%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,,$41.4m,,$0.0m,$0.0m,$3.9m,$0.0m,,$0.0m,$1.6m,$3.9m,$0.0m,$27.7m,$0.0m,$0.7m,$2.2m,$0.0m,$2.5m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
455,Small,BioAtla,Private,North America,California,San Diego,,,$34.1m,Estimate,No,Yes,Yes,Yes,18%,$6.1m,$0.0m,$14.8m,$0.0m,$14.8m,,30%,0%,40%,0%,0%,70%,,30%,0%,40%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.1m,$0.0m,$14.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$8.3m,$0.0m,,$41.4m,,$12.1m,$0.0m,$29.2m,$0.0m,,$0.0m,$0.0m,$41.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
456,Small,Olipass,Private,Asia/Oceania,South Korea,Yongin,,,$34.1m,Estimate,No,Yes,No,No,22%,$7.6m,$0.0m,$0.0m,$0.0m,$0.0m,,22%,0%,0%,0%,0%,22%,,22%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.0m,$0.0m,$0.0m,$0.0m,,$41.3m,,$11.3m,$0.0m,$0.0m,$0.0m,,$2.7m,$5.2m,$11.3m,$5.7m,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$2.6m,$2.8m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m
457,Small,Sutro Biopharma,Public,North America,California,South San Francisco,,,$33.9m,Estimate,Yes,Yes,No,No,65%,$22.2m,$1.6m,$0.0m,$0.0m,$1.6m,,63%,6%,0%,0%,0%,69%,,56%,6%,0%,0%,0%,,6%,0%,0%,0%,0%,,,,$20.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$11.8m,$0.9m,$0.0m,$0.0m,,$41.2m,,$35.2m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$37.8m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
458,Small,Novelion Therapeutics,Public,North America,British Columbia,Vancouver,Massachusetts,Cambridge,$33.9m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$2.8m,$0.0m,$2.8m,,0%,0%,9%,0%,9%,18%,,0%,0%,9%,0%,9%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,,$41.2m,,$0.0m,$0.0m,$4.7m,$0.0m,,$0.0m,$0.0m,$4.7m,$0.0m,$16.0m,$0.0m,$5.7m,$0.0m,$10.4m,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
201,Small,Sierra Oncology,Public,North America,British Columbia,Vancouver,,,$33.9m,Actual,Yes,No,No,No,20%,$6.8m,$0.0m,$12.4m,$0.0m,$12.4m,,33%,0%,33%,0%,0%,67%,,0%,0%,0%,0%,0%,,33%,0%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$6.8m,$0.0m,$12.4m,$0.0m,$0.0m,$3.6m,$0.0m,$6.9m,$0.0m,,$44.0m,,$15.7m,$0.0m,$28.3m,$0.0m,,$0.0m,$0.0m,$44.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
459,Small,ViroMed,Public,Asia/Oceania,,,,,$33.8m,Estimate,No,Yes,Yes,Yes,5%,$1.5m,$1.1m,$0.0m,$0.0m,$1.1m,,8%,8%,0%,0%,0%,15%,,8%,8%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.5m,$1.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.6m,$0.0m,$0.0m,,$41.1m,,$1.5m,$1.1m,$0.0m,$0.0m,,$0.0m,$11.7m,$2.6m,$0.0m,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,$15.9m,$1.4m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m
460,Small,Viamet,Private,North America,North Carolina,Durham,,,$33.8m,Estimate,No,No,No,No,12%,$3.9m,$0.0m,$3.6m,$0.0m,$3.6m,,17%,0%,8%,0%,0%,25%,,17%,0%,8%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$2.0m,$0.0m,,$41.0m,,$5.9m,$0.0m,$5.3m,$0.0m,,$0.0m,$0.0m,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,$27.2m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
461,Small,Enteris BioPharma,Private,North America,New Jersey,Boonton,,,$33.7m,Estimate,No,No,Yes,No,11%,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,,$41.0m,,$3.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$15.8m,$3.7m,$0.0m,$0.0m,$2.0m,$4.8m,$1.4m,$9.1m,$0.0m,$0.0m,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m
462,Small,NGM Biopharmaceuticals,Private,North America,California,South San Francisco,,,$33.6m,Estimate,No,Yes,No,No,5%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,6%,0%,0%,0%,0%,6%,,6%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$40.8m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.2m,$9.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$1.8m,$25.1m,$0.0m,$0.0m,$0.0m,$0.0m
463,Small,Vaccinex,Public,North America,New York,Rochester,,,$33.6m,Estimate,No,Yes,No,No,23%,$7.7m,$1.4m,$3.5m,$0.0m,$4.8m,,27%,7%,7%,0%,0%,40%,,27%,7%,7%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.7m,$1.4m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.8m,$1.9m,$0.0m,,$40.8m,,$10.8m,$2.0m,$4.9m,$0.0m,,$0.0m,$12.7m,$17.7m,$2.6m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
202,Small,Aclaris Therapeutics,Public,North America,Missouri,St. Louis,Pennsylvania,Wayne,$33.5m,Actual,No,Yes,No,No,5%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$43.4m,,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.7m,$9.9m,$0.0m,$0.0m,$14.6m,$13.8m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
464,Small,Hyundai Pharm,Public,Asia/Oceania,,,,,$33.5m,Estimate,No,No,No,No,0%,$0.0m,$1.0m,$2.5m,$5.0m,$8.5m,,0%,6%,6%,6%,0%,19%,,0%,0%,0%,0%,0%,,0%,6%,6%,6%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.0m,$2.5m,$5.0m,$0.0m,$0.0m,$0.6m,$1.4m,$2.8m,,$40.6m,,$0.0m,$1.5m,$3.7m,$7.3m,,$11.6m,$2.9m,$12.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.5m,$1.5m,$1.3m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m
465,Small,Rubius Therapeutics,Public,North America,Massachusetts,Cambridge,Rhode Island,Smithfield,$33.4m,Estimate,Yes,Yes,No,Yes,18%,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m,,18%,0%,0%,0%,0%,18%,,18%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,,$40.6m,,$12.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$12.4m,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.2m,$11.5m,$4.4m,$0.0m,$0.0m,$0.0m
203,Small,Affimed,Public,Europe,Germany,Heidelberg,,,$33.4m,Actual,Yes,Yes,No,No,44%,$14.7m,$1.8m,$4.4m,$0.0m,$6.2m,,50%,8%,8%,0%,0%,67%,,50%,8%,8%,0%,0%,,0%,0%,0%,0%,0%,,,,$14.7m,$1.8m,$4.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.8m,$1.0m,$2.5m,$0.0m,,$43.3m,,$30.5m,$3.7m,$9.2m,$0.0m,,$0.0m,$0.0m,$43.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
466,Small,Biokine Therapeutics,Public,Middle East/Africa,,,,,$33.3m,Estimate,Yes,Yes,No,No,5%,$1.8m,$0.0m,$3.3m,$6.5m,$9.8m,,13%,0%,13%,13%,0%,38%,,13%,0%,13%,13%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$3.3m,$6.5m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$1.9m,$3.7m,,$40.4m,,$3.1m,$0.0m,$5.5m,$10.9m,,$0.0m,$0.0m,$19.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$20.9m,$0.0m,$0.0m,$0.0m
204,Small,Recro Pharma,Public,North America,Pennsylvania,Malvern,Ireland,Dublin,$33.3m,Actual,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$43.2m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$37.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.0m,$0.0m
467,Small,Aptevo Therapeutics,Public,North America,Washington,Seattle,United Kingdom,Surrey,$33.3m,Estimate,Yes,Yes,No,No,26%,$8.5m,$1.5m,$3.8m,$0.0m,$5.4m,,29%,7%,7%,0%,0%,43%,,21%,0%,0%,0%,0%,,7%,7%,7%,0%,0%,,,,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$1.5m,$3.8m,$0.0m,$0.0m,$4.5m,$0.9m,$2.1m,$0.0m,,$40.4m,,$13.9m,$2.5m,$6.3m,$0.0m,,$0.0m,$4.3m,$22.8m,$5.0m,$0.0m,$0.0m,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m
468,Small,BioInvent,Public,Europe,Sweden,Lund,,,$33.3m,Estimate,Yes,Yes,No,No,29%,$9.5m,$1.4m,$6.9m,$0.0m,$8.3m,,38%,8%,15%,0%,0%,62%,,31%,0%,0%,0%,0%,,8%,8%,15%,0%,0%,,,,$7.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$1.4m,$6.9m,$0.0m,$0.0m,$5.1m,$0.8m,$3.9m,$0.0m,,$40.4m,,$14.1m,$2.0m,$10.2m,$0.0m,,$0.0m,$0.0m,$26.3m,$0.0m,$8.9m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
469,Small,Prescient Therapeutics,Public,Asia/Oceania,Australia,Melbourne,,,$33.2m,Estimate,Yes,Yes,Yes,No,6%,$2.0m,$1.4m,$14.3m,$0.0m,$15.8m,,10%,10%,40%,0%,0%,60%,,0%,0%,0%,0%,0%,,10%,10%,40%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$1.4m,$14.3m,$0.0m,$0.0m,$1.1m,$0.8m,$8.0m,$0.0m,,$40.3m,,$2.8m,$2.0m,$20.2m,$0.0m,,$0.0m,$0.0m,$25.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.6m,$8.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
470,Small,Genkyotex,Public,Europe,France,Saint-Julien-en-Genevois,,,$33.2m,Estimate,No,No,No,No,6%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,7%,0%,0%,0%,0%,7%,,7%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$40.3m,,$3.0m,$0.0m,$0.0m,$0.0m,,$2.9m,$5.5m,$3.0m,$3.0m,$5.7m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$5.9m,$11.3m,$0.0m,$0.0m,$0.0m,$0.0m
471,Small,Tiziana Life Sciences,Public,Europe,United Kingdom,London,,,$33.1m,Estimate,Yes,Yes,No,No,12%,$4.1m,$1.5m,$3.7m,$0.0m,$5.2m,,14%,7%,7%,0%,0%,29%,,0%,0%,0%,0%,0%,,14%,7%,7%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.1m,$1.5m,$3.7m,$0.0m,$0.0m,$2.2m,$0.8m,$2.1m,$0.0m,,$40.1m,,$6.0m,$2.2m,$5.4m,$0.0m,,$0.0m,$3.4m,$13.6m,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.0m,$15.2m,$0.0m,$0.0m,$0.0m,$0.0m
472,Small,Nuevolution,Public,Europe,Denmark,Copenhagen,,,$33.0m,Estimate,No,No,No,No,38%,$12.4m,$0.0m,$0.0m,$0.0m,$0.0m,,38%,0%,0%,0%,0%,38%,,31%,0%,0%,0%,0%,,6%,0%,0%,0%,0%,,,,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,,$40.1m,,$15.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.3m,$15.4m,$5.0m,$0.0m,$0.0m,$5.1m,$2.5m,$0.0m,$0.0m,$9.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
473,Small,Zymeworks,Public,North America,Washington,Seattle,British Columbia,Vancouver,$33.0m,Estimate,No,Yes,No,No,55%,$18.2m,$1.5m,$0.0m,$0.0m,$1.5m,,53%,6%,0%,0%,0%,59%,,53%,6%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$18.2m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.7m,$0.8m,$0.0m,$0.0m,,$40.1m,,$24.1m,$1.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$26.1m,$0.0m,$0.0m,$14.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
474,Small,Yungjin Pharm.,Public,Asia/Oceania,,,,,$33.0m,Estimate,Yes,No,No,No,5%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,7%,0%,0%,0%,0%,7%,,7%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$40.0m,,$1.9m,$0.0m,$0.0m,$0.0m,,$7.4m,$5.0m,$1.9m,$8.5m,$0.0m,$0.0m,$0.0m,$1.9m,$6.4m,$0.0m,$7.1m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m
475,Small,Triphase Accelerator,Private,North America,Ontario,Toronto,California,La Jolla,$33.0m,Estimate,Yes,Yes,No,No,18%,$5.9m,$0.0m,$7.1m,$7.0m,$14.1m,,30%,0%,20%,10%,0%,60%,,10%,0%,20%,10%,0%,,20%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$7.1m,$7.0m,$0.0m,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$4.0m,$3.9m,,$40.0m,,$9.1m,$0.0m,$11.0m,$10.8m,,$0.0m,$0.0m,$30.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.1m,$0.0m,$0.0m,$0.0m
205,Small,Oxford BioMedica,Public,Europe,United Kingdom,Oxford,,,$32.8m,Actual,Yes,Yes,Yes,Yes,7%,$2.2m,$0.0m,$4.0m,$4.0m,$8.0m,,11%,0%,11%,5%,0%,26%,,11%,0%,11%,5%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$0.0m,$4.0m,$4.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$2.3m,$2.2m,,$42.6m,,$4.5m,$0.0m,$8.2m,$8.1m,,$4.9m,$1.4m,$20.8m,$1.9m,$11.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m
476,Small,Apollo Therapeutics,Private,Europe,United Kingdom,Stevenage,,,$32.8m,Estimate,No,Yes,No,No,17%,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,,$39.8m,,$8.2m,$0.0m,$0.0m,$0.0m,,$5.3m,$2.5m,$8.2m,$0.0m,$2.6m,$0.0m,$0.0m,$5.5m,$0.0m,$7.6m,$5.4m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m
477,Small,Innovative Cellular Therapeutics,Private,Asia/Oceania,China,Shanghai,,,$32.8m,Estimate,Yes,Yes,Yes,Yes,32%,$10.4m,$3.0m,$11.3m,$0.0m,$14.3m,,38%,15%,23%,0%,0%,77%,,38%,15%,23%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.4m,$3.0m,$11.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.5m,$1.7m,$6.3m,$0.0m,,$39.8m,,$14.6m,$4.2m,$15.9m,$0.0m,,$0.0m,$0.0m,$34.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
478,Small,Central Drug Research Institute,Private,Asia/Oceania,,,,,$32.7m,Estimate,Yes,No,No,No,5%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,5%,0%,0%,0%,0%,5%,,5%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$39.7m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.1m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.6m,$6.9m,$2.1m,$5.0m,$0.0m,$0.0m,$12.7m
479,Small,RXi Pharmaceuticals,Public,North America,Massachusetts,Marlborough,,,$32.6m,Estimate,No,Yes,No,Yes,29%,$9.5m,$0.0m,$3.4m,$0.0m,$3.4m,,38%,0%,8%,0%,0%,46%,,23%,0%,0%,0%,0%,,15%,0%,8%,0%,0%,,,,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.8m,$0.0m,$3.4m,$0.0m,$0.0m,$5.0m,$0.0m,$1.9m,$0.0m,,$39.6m,,$11.7m,$0.0m,$4.2m,$0.0m,,$0.0m,$2.9m,$15.9m,$0.0m,$7.2m,$0.0m,$7.5m,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
206,Small,Norgine,Private,Europe,United Kingdom,Harefield,Netherlands,Amsterdam,$32.6m,Actual,Yes,Yes,No,No,24%,$7.8m,$2.3m,$2.8m,$0.0m,$5.1m,,28%,11%,6%,0%,0%,44%,,28%,11%,6%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.8m,$2.3m,$2.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.2m,$1.3m,$1.6m,$0.0m,,$29.4m,,$6.6m,$1.9m,$2.4m,$0.0m,,$0.0m,$0.0m,$11.0m,$1.2m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$1.0m,$1.4m,$12.0m,$0.0m,$0.0m,$0.0m,$0.0m
480,Small,AnaptysBio,Public,North America,California,San Diego,,,$32.6m,Estimate,No,Yes,No,No,17%,$5.7m,$4.1m,$0.0m,$0.0m,$4.1m,,18%,18%,0%,0%,0%,35%,,18%,18%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.7m,$4.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$2.3m,$0.0m,$0.0m,,$39.5m,,$6.8m,$4.9m,$0.0m,$0.0m,,$10.7m,$0.0m,$11.7m,$3.0m,$0.0m,$0.0m,$7.9m,$0.0m,$0.0m,$0.0m,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
481,Small,Jacobio Pharmaceuticals,Private,Asia/Oceania,China,Beijing,,,$32.6m,Estimate,No,No,No,No,84%,$27.3m,$1.7m,$0.0m,$0.0m,$1.7m,,80%,7%,0%,0%,0%,87%,,80%,7%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$27.3m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$14.5m,$0.9m,$0.0m,$0.0m,,$39.5m,,$34.6m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$36.6m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
482,Small,Mologen,Public,Europe,Germany,Berlin,,,$32.5m,Estimate,No,Yes,Yes,No,12%,$4.0m,$2.9m,$3.6m,$7.1m,$13.6m,,18%,18%,9%,9%,0%,55%,,18%,18%,9%,9%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$2.9m,$3.6m,$7.1m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$1.6m,$2.0m,$4.0m,,$39.4m,,$6.1m,$4.4m,$5.5m,$10.9m,,$0.0m,$0.0m,$26.9m,$0.0m,$0.0m,$0.0m,$0.0m,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m
483,Small,PharmaEngine,Public,Asia/Oceania,Taiwan,Taipei,France,Paris,$32.5m,Estimate,Yes,No,No,No,11%,$3.6m,$1.3m,$6.6m,$6.5m,$14.4m,,17%,8%,17%,8%,8%,58%,,0%,0%,0%,0%,0%,,17%,8%,17%,8%,8%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.6m,$1.3m,$6.6m,$6.5m,$0.0m,$1.9m,$0.7m,$3.7m,$3.6m,,$39.4m,,$8.0m,$2.9m,$14.4m,$14.2m,,$0.0m,$0.0m,$39.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
484,Small,Navidea,Public,North America,Ohio,Dublin,,,$32.4m,Estimate,Yes,Yes,No,No,12%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$39.4m,,$4.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$11.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$4.8m,$0.0m,$1.0m,$4.3m,$6.6m,$0.0m,$0.0m,$0.0m,$7.0m
207,Small,Pfenex,Public,North America,California,San Diego,,,$32.4m,Actual,Yes,No,No,No,15%,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,,15%,0%,0%,0%,0%,15%,,10%,0%,0%,0%,0%,,5%,0%,0%,0%,0%,,,,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,,$42.1m,,$6.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.6m,$2.1m,$0.0m,$0.0m,$0.0m,$7.0m,$2.1m,$0.0m,$14.9m,$1.9m,$5.9m,$1.6m,$0.0m,$0.0m
485,Small,Humanigen,Public,North America,California,Burlingame,,,$32.4m,Estimate,Yes,Yes,Yes,Yes,19%,$6.0m,$2.9m,$3.6m,$0.0m,$6.5m,,23%,15%,8%,0%,0%,46%,,23%,15%,8%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.0m,$2.9m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$1.6m,$2.0m,$0.0m,,$39.3m,,$9.4m,$4.6m,$5.7m,$0.0m,,$0.0m,$0.0m,$19.7m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$14.1m,$0.0m,$0.0m,$0.0m
486,Small,Mycenax,Public,Asia/Oceania,Taiwan,Zhunan,,,$32.2m,Estimate,No,Yes,No,No,19%,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,,18%,0%,0%,0%,0%,18%,,18%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,,$39.1m,,$9.5m,$0.0m,$0.0m,$0.0m,,$3.1m,$0.0m,$9.5m,$7.8m,$0.0m,$0.0m,$6.5m,$0.0m,$0.0m,$0.0m,$5.7m,$2.9m,$3.4m,$0.0m,$0.0m,$0.0m
487,Small,Navigen,Private,North America,Utah,Salt Lake City,,,$32.1m,Estimate,No,No,No,No,12%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,12%,0%,0%,0%,0%,12%,,12%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$39.0m,,$5.4m,$0.0m,$0.0m,$0.0m,,$7.9m,$0.0m,$5.4m,$5.5m,$2.6m,$0.0m,$0.0m,$8.3m,$0.0m,$0.0m,$2.7m,$2.5m,$0.0m,$0.0m,$0.0m,$4.0m
488,Small,Madrigal Pharmaceuticals,Public,North America,Pennsylvania,West Conshohocken,,,$32.0m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$6.6m,$0.0m,$6.6m,,0%,0%,15%,0%,0%,15%,,0%,0%,15%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,,$38.9m,,$0.0m,$0.0m,$10.2m,$0.0m,,$0.0m,$0.0m,$10.2m,$3.7m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$11.0m,$0.0m,$13.0m,$0.0m,$0.0m,$0.0m,$0.0m
489,Small,Oncology Venture,Public,Europe,Denmark,Horsholm,,,$32.0m,Estimate,No,Yes,No,No,21%,$6.7m,$1.6m,$12.1m,$0.0m,$13.8m,,27%,9%,27%,0%,0%,64%,,0%,0%,0%,0%,0%,,27%,9%,27%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$6.7m,$1.6m,$12.1m,$0.0m,$0.0m,$3.6m,$0.9m,$6.8m,$0.0m,,$38.8m,,$12.7m,$3.1m,$23.0m,$0.0m,,$0.0m,$0.0m,$38.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
490,Small,Innovation Pharmaceuticals,Public,North America,Massachusetts,Beverly,,,$32.0m,Estimate,Yes,No,No,No,6%,$1.9m,$1.4m,$3.5m,$0.0m,$4.9m,,8%,8%,8%,0%,0%,25%,,8%,8%,8%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$1.4m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$1.9m,$0.0m,,$38.8m,,$2.9m,$2.1m,$5.2m,$0.0m,,$0.0m,$0.0m,$10.2m,$0.0m,$0.0m,$0.0m,$7.2m,$11.3m,$0.0m,$0.0m,$0.0m,$10.0m,$0.0m,$0.0m,$0.0m,$0.0m
491,Small,1Globe Biomedical,Private,Asia/Oceania,,,,,$32.0m,Estimate,Yes,No,No,No,6%,$1.8m,$1.3m,$6.5m,$6.4m,$14.1m,,10%,10%,20%,10%,0%,50%,,0%,0%,0%,0%,0%,,10%,10%,20%,10%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$1.3m,$6.5m,$6.4m,$0.0m,$0.9m,$0.7m,$3.6m,$3.6m,,$38.8m,,$4.4m,$3.2m,$15.7m,$15.5m,,$0.0m,$0.0m,$38.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
492,Small,Glycotope,Private,Europe,Germany,Berlin,,,$31.7m,Estimate,No,Yes,No,No,19%,$6.2m,$4.5m,$7.4m,$0.0m,$11.9m,,23%,23%,15%,0%,0%,62%,,23%,23%,15%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.2m,$4.5m,$7.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$2.5m,$4.2m,$0.0m,,$38.5m,,$9.0m,$6.5m,$10.8m,$0.0m,,$4.3m,$0.0m,$26.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
493,Small,Kancera,Public,Europe,Sweden,Stockholm,,,$31.7m,Estimate,Yes,Yes,No,No,42%,$13.4m,$0.0m,$0.0m,$0.0m,$0.0m,,40%,0%,0%,0%,0%,40%,,27%,0%,0%,0%,0%,,13%,0%,0%,0%,0%,,,,$8.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m,$7.1m,$0.0m,$0.0m,$0.0m,,$38.5m,,$17.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.3m,$17.5m,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.2m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m
494,Small,TaiGen Biotechnology,Public,Asia/Oceania,,,,,$31.6m,Estimate,Yes,No,No,No,0%,$0.0m,$1.3m,$3.3m,$0.0m,$4.7m,,0%,9%,9%,0%,0%,18%,,0%,9%,9%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.3m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$1.9m,$0.0m,,$38.4m,,$0.0m,$1.8m,$4.4m,$0.0m,,$0.0m,$0.0m,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,$18.6m,$0.0m,$3.1m,$0.0m,$0.0m,$10.4m,$0.0m,$0.0m,$0.0m
495,Small,Patrys,Public,Asia/Oceania,Australia,Melbourne,,,$31.5m,Estimate,No,Yes,No,No,40%,$12.7m,$0.0m,$7.7m,$0.0m,$7.7m,,55%,0%,18%,0%,0%,73%,,55%,0%,18%,0%,0%,,0%,0%,0%,0%,0%,,,,$12.7m,$0.0m,$7.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.7m,$0.0m,$4.3m,$0.0m,,$38.3m,,$23.9m,$0.0m,$14.4m,$0.0m,,$0.0m,$0.0m,$38.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
496,Small,PersonGen Biomedicine,Private,Asia/Oceania,,,,,$31.5m,Estimate,Yes,Yes,Yes,Yes,0%,$0.0m,$0.0m,$14.4m,$0.0m,$14.4m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$14.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.1m,$0.0m,,$38.2m,,$0.0m,$0.0m,$38.2m,$0.0m,,$0.0m,$0.0m,$38.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
497,Small,Medicenna Therapeutics,Public,North America,Texas,Houston,Ontario,Toronto,$31.5m,Estimate,No,Yes,No,No,47%,$14.9m,$0.0m,$3.8m,$0.0m,$3.8m,,50%,0%,7%,0%,0%,57%,,43%,0%,0%,0%,0%,,7%,0%,7%,0%,0%,,,,$12.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$3.8m,$0.0m,$0.0m,$7.9m,$0.0m,$2.2m,$0.0m,,$38.2m,,$21.4m,$0.0m,$5.5m,$0.0m,,$5.5m,$0.0m,$26.9m,$2.9m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
208,Small,Yakult Honsha,Public,Asia/Oceania,Japan,Tokyo,,,$31.3m,Actual,Yes,No,No,No,11%,$3.3m,$1.8m,$4.5m,$8.8m,$15.1m,,17%,13%,13%,13%,4%,61%,,9%,0%,0%,0%,0%,,9%,13%,13%,13%,4%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.7m,$1.8m,$4.5m,$8.8m,$0.0m,$1.8m,$1.0m,$2.5m,$4.9m,,$40.5m,,$7.1m,$3.9m,$9.7m,$19.0m,,$0.0m,$0.0m,$39.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m
498,Small,Eureka Therapeutics,Private,North America,California,Emeryville,,,$31.3m,Estimate,Yes,Yes,Yes,Yes,49%,$15.3m,$4.8m,$4.0m,$0.0m,$8.7m,,50%,21%,7%,0%,0%,79%,,50%,14%,0%,0%,0%,,0%,7%,7%,0%,0%,,,,$15.3m,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.6m,$4.0m,$0.0m,$0.0m,$8.1m,$2.7m,$2.2m,$0.0m,,$37.9m,,$24.2m,$7.5m,$6.2m,$0.0m,,$0.0m,$0.0m,$37.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
499,Small,Bolder BioTechnology,Private,North America,Colorado,Boulder,,,$31.1m,Estimate,No,No,No,No,17%,$5.4m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,,$37.8m,,$7.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.4m,$7.1m,$2.4m,$0.0m,$0.0m,$2.4m,$4.8m,$0.0m,$2.2m,$0.0m,$2.2m,$8.7m,$1.9m,$1.7m,$0.0m
500,Small,Neuralstem,Public,North America,Maryland,Germantown,,,$31.1m,Estimate,No,No,No,Yes,6%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,7%,0%,0%,0%,0%,7%,,7%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$37.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$20.4m,$2.8m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$6.7m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m
501,Small,Noxopharm,Public,Asia/Oceania,Australia,Sydney,,,$31.0m,Estimate,No,No,No,No,11%,$3.5m,$0.0m,$3.1m,$0.0m,$3.1m,,13%,0%,6%,0%,0%,19%,,13%,0%,6%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.5m,$0.0m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$1.7m,$0.0m,,$37.7m,,$4.6m,$0.0m,$4.2m,$0.0m,,$0.0m,$12.1m,$8.8m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.4m,$2.2m,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m
502,Small,Moleculin,Public,North America,Texas,Houston,,,$31.0m,Estimate,Yes,No,No,No,34%,$10.6m,$1.5m,$3.8m,$0.0m,$5.4m,,38%,8%,8%,0%,0%,54%,,38%,8%,8%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.6m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.6m,$0.9m,$2.1m,$0.0m,,$37.7m,,$25.0m,$3.6m,$9.0m,$0.0m,,$0.0m,$0.0m,$37.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
503,Small,Adlai Nortye,Private,Asia/Oceania,China,Hangzhou,,,$31.0m,Estimate,No,Yes,No,No,17%,$5.3m,$2.6m,$6.4m,$6.3m,$15.3m,,27%,18%,18%,9%,0%,73%,,18%,0%,0%,0%,0%,,9%,18%,18%,9%,0%,,,,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$2.6m,$6.4m,$6.3m,$0.0m,$2.8m,$1.4m,$3.6m,$3.5m,,$37.6m,,$9.7m,$4.7m,$11.7m,$11.5m,,$0.0m,$0.0m,$37.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
504,Small,Iovance Biotherapeutics,Public,North America,California,Redwood City,,,$31.0m,Estimate,Yes,Yes,No,Yes,27%,$8.3m,$1.5m,$11.3m,$0.0m,$12.8m,,33%,8%,25%,0%,0%,67%,,33%,8%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.3m,$1.5m,$11.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.4m,$0.8m,$6.3m,$0.0m,,$37.6m,,$14.8m,$2.7m,$20.1m,$0.0m,,$0.0m,$0.0m,$37.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
505,Small,Apeiron Biologics,Private,Europe,Austria,Vienna,,,$31.0m,Estimate,No,Yes,No,No,31%,$9.5m,$1.4m,$0.0m,$0.0m,$1.4m,,38%,8%,0%,0%,0%,46%,,31%,8%,0%,0%,0%,,8%,0%,0%,0%,0%,,,,$7.6m,$1.4m,$0.0m,$0.0m,$0.0m,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$5.0m,$0.8m,$0.0m,$0.0m,,$37.6m,,$11.1m,$1.6m,$0.0m,$0.0m,,$6.1m,$0.0m,$12.8m,$0.0m,$0.0m,$0.0m,$3.9m,$0.0m,$9.4m,$3.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
209,Small,AB Science,Public,Europe,France,Paris,,,$30.8m,Actual,Yes,No,No,No,10%,$3.2m,$0.0m,$1.9m,$3.8m,$5.8m,,15%,0%,5%,5%,5%,30%,,15%,0%,5%,5%,5%,,0%,0%,0%,0%,0%,,,,$3.2m,$0.0m,$1.9m,$3.8m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,$1.1m,$2.1m,,$40.0m,,$5.1m,$0.0m,$3.1m,$6.0m,,$11.8m,$9.6m,$14.2m,$1.4m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
506,Small,KAEL-GemVax,Public,Asia/Oceania,South Korea,Seongnam,,,$30.8m,Estimate,No,Yes,No,No,12%,$3.8m,$1.4m,$6.8m,$0.0m,$8.2m,,20%,10%,20%,0%,0%,50%,,20%,10%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$1.4m,$6.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.8m,$3.8m,$0.0m,,$37.3m,,$6.2m,$2.3m,$11.2m,$0.0m,,$0.0m,$6.6m,$19.7m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$8.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
507,Small,SOM Biotech,Private,Europe,Spain,Barcelona,,,$30.7m,Estimate,No,No,No,No,6%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$37.3m,,$4.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$29.2m,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
210,Small,Celyad,Public,Europe,Belgium,Mont-Saint-Guibert,,,$30.6m,Actual,Yes,Yes,Yes,Yes,59%,$17.9m,$0.0m,$4.6m,$0.0m,$4.6m,,70%,0%,10%,0%,0%,80%,,70%,0%,0%,0%,0%,,0%,0%,10%,0%,0%,,,,$17.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.6m,$0.0m,$0.0m,$9.5m,$0.0m,$2.6m,$0.0m,,$39.7m,,$31.6m,$0.0m,$8.1m,$0.0m,,$0.0m,$0.0m,$39.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
508,Small,Lipopharma,Private,Europe,Spain,Mallorca,,,$30.6m,Estimate,Yes,No,No,No,12%,$3.7m,$0.0m,$6.6m,$0.0m,$6.6m,,14%,0%,14%,0%,0%,29%,,14%,0%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.7m,$0.0m,$6.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$3.7m,$0.0m,,$37.1m,,$5.9m,$0.0m,$10.6m,$0.0m,,$0.0m,$7.7m,$16.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.1m,$2.7m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m
509,Small,Siam Bioscience,Private,Asia/Oceania,Thailand,Bangkok,,,$30.6m,Estimate,No,Yes,No,No,12%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,6%,17%,,11%,0%,0%,0%,6%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$37.1m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$9.7m,$5.4m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,$5.6m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m
510,Small,Antisense Therapeutics,Public,Asia/Oceania,,,,,$30.6m,Estimate,No,No,No,No,6%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,9%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$37.1m,,$2.9m,$0.0m,$0.0m,$0.0m,,$2.8m,$6.7m,$2.9m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$10.7m,$2.7m,$0.0m,$8.1m,$0.0m,$0.0m
511,Small,Peloton Therapeutics,Private,North America,Texas,Dallas,California,San Francisco,$30.5m,Estimate,No,No,No,No,13%,$3.9m,$1.4m,$7.1m,$0.0m,$8.5m,,17%,8%,17%,0%,0%,42%,,17%,8%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$1.4m,$7.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.8m,$4.0m,$0.0m,,$37.1m,,$8.3m,$3.0m,$15.1m,$0.0m,,$0.0m,$3.5m,$26.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m
512,Small,EOC Pharma,Private,Asia/Oceania,China,Shanghai,China,Taizhou,$30.5m,Estimate,Yes,Yes,No,No,13%,$3.9m,$4.2m,$7.0m,$6.9m,$18.1m,,17%,25%,17%,8%,0%,67%,,0%,8%,0%,0%,0%,,17%,17%,17%,8%,0%,,,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.9m,$2.8m,$7.0m,$6.9m,$0.0m,$2.1m,$2.4m,$3.9m,$3.9m,,$37.0m,,$6.1m,$6.7m,$11.1m,$10.9m,,$0.0m,$0.0m,$34.8m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
513,Small,Intellia Therapeutics,Public,North America,Massachusetts,Cambridge,,,$30.4m,Estimate,Yes,Yes,Yes,Yes,13%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$36.9m,,$6.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.8m,$6.3m,$3.1m,$3.0m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$6.2m,$5.8m,$3.4m,$0.0m,$0.0m,$0.0m
514,Small,Oncologie,Private,North America,Massachusetts,Waltham,,,$30.2m,Estimate,No,Yes,No,No,12%,$3.7m,$1.3m,$6.7m,$6.6m,$14.6m,,20%,10%,20%,10%,0%,60%,,0%,0%,0%,0%,0%,,20%,10%,20%,10%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.7m,$1.3m,$6.7m,$6.6m,$0.0m,$2.0m,$0.8m,$3.7m,$3.7m,,$36.7m,,$5.6m,$2.0m,$10.1m,$9.9m,,$0.0m,$0.0m,$27.6m,$0.0m,$0.0m,$0.0m,$0.0m,$9.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
515,Small,AVEO,Public,North America,Massachusetts,Cambridge,,,$30.1m,Estimate,Yes,Yes,No,No,13%,$4.0m,$4.4m,$7.2m,$0.0m,$11.6m,,14%,21%,14%,0%,0%,50%,,14%,14%,7%,0%,0%,,0%,7%,7%,0%,0%,,,,$4.0m,$2.9m,$3.6m,$0.0m,$0.0m,,$0.0m,$1.5m,$3.6m,$0.0m,$0.0m,$2.1m,$2.4m,$4.0m,$0.0m,,$36.6m,,$7.7m,$8.4m,$14.0m,$0.0m,,$0.0m,$0.0m,$30.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
516,Small,SignalRx,Private,North America,California,San Diego,,,$30.1m,Estimate,Yes,No,No,No,90%,$27.1m,$1.6m,$0.0m,$0.0m,$1.6m,,86%,7%,0%,0%,0%,93%,,79%,0%,0%,0%,0%,,7%,7%,0%,0%,0%,,,,$24.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$1.6m,$0.0m,$0.0m,$0.0m,$14.4m,$0.9m,$0.0m,$0.0m,,$36.5m,,$34.4m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$36.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
517,Small,Cyclenium,Private,North America,Quebec,Montreal,,,$30.1m,Estimate,No,No,No,No,33%,$10.0m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.3m,$0.0m,$0.0m,$0.0m,,$36.5m,,$14.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$2.6m,$14.0m,$5.6m,$0.0m,$3.0m,$0.0m,$8.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
518,Small,Ligand,Public,North America,California,San Diego,,,$30.0m,Estimate,Yes,Yes,No,No,4%,$1.1m,$1.4m,$3.2m,$1.5m,$6.0m,,5%,9%,8%,2%,0%,24%,,1%,1%,1%,0%,0%,,4%,8%,7%,2%,0%,,,,$0.3m,$0.1m,$0.5m,$0.0m,$0.0m,,$0.8m,$1.3m,$2.7m,$1.5m,$0.0m,$0.6m,$0.8m,$1.8m,$0.8m,,$27.5m,,$1.2m,$1.5m,$3.4m,$1.6m,,$0.2m,$2.5m,$7.6m,$3.3m,$1.7m,$0.3m,$0.7m,$1.9m,$1.1m,$0.7m,$2.0m,$3.0m,$2.0m,$0.0m,$0.1m,$0.4m
519,Small,HPA Porton Down,Private,Europe,United Kingdom,Salisbury,,,$29.9m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$2.7m,$0.0m,$2.7m,,0%,0%,11%,0%,0%,11%,,0%,0%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.5m,$0.0m,,$36.3m,,$0.0m,$0.0m,$3.1m,$0.0m,,$0.0m,$14.7m,$3.1m,$0.0m,$0.0m,$0.0m,$4.0m,$0.0m,$5.2m,$0.0m,$9.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
520,Small,NuvOx Pharma,Private,North America,Arizona,Tuscon,,,$29.9m,Estimate,No,No,No,No,19%,$5.6m,$0.0m,$3.4m,$0.0m,$3.4m,,20%,0%,7%,0%,0%,27%,,20%,0%,7%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.6m,$0.0m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$1.9m,$0.0m,,$36.3m,,$8.5m,$0.0m,$5.1m,$0.0m,,$0.0m,$2.5m,$13.6m,$0.0m,$2.6m,$0.0m,$0.0m,$2.7m,$0.0m,$9.0m,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m
521,Small,f-star,Private,Europe,United Kingdom,Cambridge,,,$29.8m,Estimate,No,Yes,No,No,84%,$25.2m,$3.3m,$0.0m,$0.0m,$3.3m,,79%,14%,0%,0%,0%,93%,,79%,14%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$25.2m,$3.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$13.4m,$1.9m,$0.0m,$0.0m,,$36.2m,,$32.0m,$4.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$36.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
522,Small,Ascenta Therapeutics,Private,North America,Pennsylvania,Malvern,,,$29.8m,Estimate,Yes,No,No,No,7%,$2.1m,$1.5m,$11.4m,$0.0m,$12.9m,,11%,11%,33%,0%,0%,56%,,0%,11%,22%,0%,0%,,11%,0%,11%,0%,0%,,,,$0.0m,$1.5m,$7.6m,$0.0m,$0.0m,,$2.1m,$0.0m,$3.8m,$0.0m,$0.0m,$1.1m,$0.9m,$6.4m,$0.0m,,$36.1m,,$5.1m,$3.7m,$27.4m,$0.0m,,$0.0m,$0.0m,$36.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
523,Small,Constellation Pharmaceuticals,Public,North America,Massachusetts,Cambridge,,,$29.8m,Estimate,Yes,Yes,No,No,28%,$8.4m,$3.1m,$3.8m,$0.0m,$6.9m,,36%,18%,9%,0%,0%,64%,,27%,18%,9%,0%,0%,,9%,0%,0%,0%,0%,,,,$6.3m,$3.1m,$3.8m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$1.7m,$2.1m,$0.0m,,$36.1m,,$12.4m,$4.5m,$5.6m,$0.0m,,$0.0m,$0.0m,$22.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$13.7m,$0.0m,$0.0m,$0.0m
211,Small,Selecta Biosciences,Public,North America,Massachusetts,Watertown,,,$29.7m,Actual,Yes,Yes,No,No,0%,$0.0m,$1.1m,$0.0m,$0.0m,$1.1m,,0%,6%,0%,0%,0%,6%,,0%,6%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$38.5m,,$0.0m,$1.7m,$0.0m,$0.0m,,$1.9m,$1.5m,$1.7m,$1.9m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$19.6m,$7.9m,$2.1m,$0.0m,$0.0m,$0.0m
524,Small,Angelini,Private,Asia/Oceania,,,,,$29.6m,Estimate,Yes,No,No,No,0%,$0.0m,$1.1m,$2.7m,$0.0m,$3.8m,,0%,8%,8%,0%,0%,17%,,0%,0%,0%,0%,0%,,0%,8%,8%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.1m,$2.7m,$0.0m,$0.0m,$0.0m,$0.6m,$1.5m,$0.0m,,$36.0m,,$0.0m,$1.2m,$2.9m,$0.0m,,$7.2m,$11.9m,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,$12.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
212,Small,Sosei,Public,Asia/Oceania,,,,,$29.6m,Actual,No,Yes,No,No,7%,$2.0m,$0.5m,$1.2m,$0.0m,$1.7m,,8%,3%,3%,0%,0%,14%,,8%,3%,3%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.5m,$1.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.3m,$0.7m,$0.0m,,$38.4m,,$2.7m,$0.7m,$1.6m,$0.0m,,$7.0m,$9.4m,$5.0m,$0.0m,$0.0m,$3.7m,$1.7m,$0.0m,$5.3m,$0.8m,$1.7m,$2.4m,$0.0m,$1.4m,$0.0m,$0.0m
525,Small,IGEM Therapeutics,Private,Europe,United Kingdom,London,,,$29.6m,Estimate,No,Yes,No,No,43%,$12.8m,$0.0m,$7.7m,$0.0m,$7.7m,,60%,0%,20%,0%,0%,80%,,60%,0%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$12.8m,$0.0m,$7.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.8m,$0.0m,$4.3m,$0.0m,,$35.9m,,$22.4m,$0.0m,$13.5m,$0.0m,,$0.0m,$0.0m,$35.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
526,Small,Oryzon,Public,Europe,Spain,Barcelona,,,$29.5m,Estimate,Yes,No,No,No,6%,$1.9m,$1.4m,$3.4m,$0.0m,$4.8m,,7%,7%,7%,0%,0%,21%,,7%,7%,7%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$1.4m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$1.9m,$0.0m,,$35.8m,,$3.6m,$2.6m,$6.6m,$0.0m,,$0.0m,$16.2m,$12.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m
527,Small,LSK BioPharma,Private,North America,California,South San Francisco,Utah,Salt Lake City,$29.5m,Estimate,Yes,No,No,No,12%,$3.5m,$1.3m,$3.2m,$6.2m,$10.6m,,18%,9%,9%,9%,0%,45%,,9%,0%,0%,0%,0%,,9%,9%,9%,9%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.7m,$1.3m,$3.2m,$6.2m,$0.0m,$1.8m,$0.7m,$1.8m,$3.5m,,$35.8m,,$8.0m,$2.9m,$7.3m,$14.3m,,$0.0m,$0.0m,$32.6m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
213,Small,Corvus Pharmaceuticals,Public,North America,California,San Mateo,,,$29.4m,Actual,No,Yes,No,No,29%,$8.6m,$4.2m,$5.2m,$0.0m,$9.3m,,30%,20%,10%,0%,0%,60%,,30%,10%,0%,0%,0%,,0%,10%,10%,0%,0%,,,,$8.6m,$2.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.1m,$5.2m,$0.0m,$0.0m,$4.5m,$2.3m,$2.9m,$0.0m,,$38.1m,,$11.7m,$5.7m,$7.1m,$0.0m,,$0.0m,$13.6m,$24.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
528,Small,Celon Pharma,Public,Europe,Poland,Warsaw,,,$29.4m,Estimate,No,No,No,No,25%,$7.4m,$0.0m,$0.0m,$0.0m,$0.0m,,27%,0%,0%,0%,0%,27%,,27%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,,$35.6m,,$9.7m,$0.0m,$0.0m,$0.0m,,$4.7m,$14.3m,$9.7m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m
529,Small,Genisphere,Private,North America,Pennsylvania,Hatfield,,,$29.3m,Estimate,No,No,No,No,50%,$14.7m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$14.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.8m,$0.0m,$0.0m,$0.0m,,$35.6m,,$28.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.7m,$28.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
530,Small,CrystalGenomics,Public,Asia/Oceania,South Korea,Seongnam,,,$29.3m,Estimate,Yes,Yes,No,No,14%,$4.0m,$1.5m,$7.3m,$0.0m,$8.8m,,20%,10%,20%,0%,0%,50%,,20%,0%,10%,0%,0%,,0%,10%,10%,0%,0%,,,,$4.0m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,$2.1m,$0.8m,$4.1m,$0.0m,,$35.6m,,$8.3m,$3.0m,$15.0m,$0.0m,,$0.0m,$0.0m,$26.3m,$0.0m,$0.0m,$0.0m,$0.0m,$9.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
531,Small,Viela Bio,Private,North America,Maryland,Gaithersburg,,,$29.2m,Estimate,Yes,Yes,No,No,0%,$0.0m,$0.0m,$2.6m,$0.0m,$2.6m,,0%,0%,7%,0%,0%,7%,,0%,0%,0%,0%,0%,,0%,0%,7%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,,$35.5m,,$0.0m,$0.0m,$3.7m,$0.0m,,$0.0m,$1.7m,$3.7m,$15.4m,$12.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
214,Small,Transgene,Public,Europe,France,Illkirch,,,$29.2m,Actual,Yes,Yes,Yes,No,16%,$4.6m,$0.7m,$10.0m,$3.3m,$14.0m,,26%,5%,32%,5%,0%,68%,,21%,0%,26%,0%,0%,,5%,5%,5%,5%,0%,,,,$3.7m,$0.0m,$8.3m,$0.0m,$0.0m,,$0.9m,$0.7m,$1.7m,$3.3m,$0.0m,$2.4m,$0.4m,$5.6m,$1.8m,,$37.9m,,$7.4m,$1.1m,$16.1m,$5.3m,,$0.0m,$0.0m,$29.9m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
532,Small,Cipher Pharmaceuticals,Public,North America,Ontario,Oakville,,,$29.2m,Estimate,No,No,No,No,4%,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,,7%,0%,0%,0%,0%,7%,,0%,0%,0%,0%,0%,,7%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,$0.0m,,$35.4m,,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.5m,$7.1m,$0.0m,$0.0m,$0.0m,$25.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m
533,Small,BioNumerik,Private,North America,Texas,San Antonio,,,$29.2m,Estimate,No,No,No,No,7%,$2.0m,$1.4m,$3.6m,$14.1m,$19.1m,,14%,14%,14%,29%,0%,71%,,14%,14%,14%,29%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.4m,$3.6m,$14.1m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$2.0m,$7.9m,,$35.4m,,$3.3m,$2.4m,$6.0m,$23.7m,,$0.0m,$0.0m,$35.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
215,Small,Vanda Pharmaceuticals,Public,North America,"Washington, DC","Washington, DC",,,$29.2m,Actual,No,No,No,No,4%,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,,5%,0%,0%,0%,0%,5%,,5%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,$0.0m,,$37.8m,,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$12.5m,$1.4m,$0.0m,$2.7m,$0.0m,$8.1m,$0.0m,$2.8m,$0.0m,$0.0m,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m
534,Small,Hebei Senlang Biotechnology,Private,Asia/Oceania,China,Shijiazhuang,,,$29.1m,Estimate,Yes,Yes,Yes,Yes,44%,$12.8m,$1.5m,$3.8m,$0.0m,$5.4m,,50%,8%,8%,0%,0%,67%,,50%,8%,8%,0%,0%,,0%,0%,0%,0%,0%,,,,$12.8m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.8m,$0.9m,$2.2m,$0.0m,,$35.3m,,$22.1m,$2.7m,$6.7m,$0.0m,,$0.0m,$0.0m,$31.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m
535,Small,Ohara Pharmaceutical,Private,Asia/Oceania,,,,,$29.1m,Estimate,Yes,No,No,No,7%,$2.0m,$2.9m,$7.3m,$0.0m,$10.2m,,10%,20%,20%,0%,0%,50%,,10%,10%,10%,0%,0%,,0%,10%,10%,0%,0%,,,,$2.0m,$1.5m,$3.6m,$0.0m,$0.0m,,$0.0m,$1.5m,$3.6m,$0.0m,$0.0m,$1.1m,$1.6m,$4.1m,$0.0m,,$35.3m,,$3.7m,$5.3m,$13.2m,$0.0m,,$0.0m,$0.0m,$22.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$13.1m,$0.0m,$0.0m,$0.0m,$0.0m
536,Small,United BioPharma,Public,Asia/Oceania,Taiwan,Zhubei City,Taiwan,Taipei,$29.0m,Estimate,Yes,Yes,No,No,20%,$5.7m,$1.4m,$0.0m,$0.0m,$1.4m,,20%,7%,0%,0%,0%,27%,,20%,7%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.7m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.8m,$0.0m,$0.0m,,$35.2m,,$8.1m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.1m,$5.2m,$0.0m,$0.0m,$5.3m,$9.6m,$0.0m,$0.0m,$2.6m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m
537,Small,Prolong Pharmaceuticals,Private,North America,New Jersey,South Plainfield,,,$28.9m,Estimate,No,Yes,No,No,6%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$35.1m,,$1.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.8m,$6.6m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$2.7m,$0.0m,$1.0m,$19.8m,$0.0m,$0.0m,$0.0m
538,Small,Oxford BioTherapeutics,Private,Europe,United Kingdom,Oxford,,,$28.9m,Estimate,Yes,Yes,No,No,69%,$19.9m,$3.2m,$0.0m,$0.0m,$3.2m,,64%,14%,0%,0%,0%,79%,,57%,7%,0%,0%,0%,,7%,7%,0%,0%,0%,,,,$17.7m,$1.6m,$0.0m,$0.0m,$0.0m,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,$10.6m,$1.8m,$0.0m,$0.0m,,$35.0m,,$30.2m,$4.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$35.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
539,Small,X4 Pharmaceuticals,Private,North America,Massachusetts,Cambridge,,,$28.8m,Estimate,No,Yes,No,No,12%,$3.3m,$1.2m,$3.0m,$0.0m,$4.2m,,20%,10%,10%,0%,0%,40%,,20%,0%,0%,0%,0%,,0%,10%,10%,0%,0%,,,,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$3.0m,$0.0m,$0.0m,$1.8m,$0.7m,$1.7m,$0.0m,,$35.0m,,$6.3m,$2.3m,$5.6m,$0.0m,,$0.0m,$0.0m,$14.2m,$20.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
540,Small,Numab,Private,Europe,Switzerland,Zurich,,,$28.8m,Estimate,No,Yes,No,No,21%,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,,21%,0%,0%,0%,0%,21%,,14%,0%,0%,0%,0%,,7%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,,$35.0m,,$7.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.2m,$7.5m,$6.2m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$7.0m,$9.7m,$0.0m,$0.0m,$0.0m,$0.0m
541,Small,NeuroVive Pharmaceutical,Public,Europe,Sweden,Lund,,,$28.7m,Estimate,No,No,No,No,6%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,6%,0%,0%,0%,0%,6%,,6%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$34.9m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$13.8m,$2.5m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$13.8m,$0.0m,$0.0m,$0.0m,$0.0m
542,Small,Arcus Biosciences,Public,North America,California,Hayward,,,$28.6m,Estimate,Yes,Yes,No,No,38%,$10.8m,$4.7m,$3.9m,$0.0m,$8.6m,,38%,23%,8%,0%,0%,69%,,38%,15%,0%,0%,0%,,0%,8%,8%,0%,0%,,,,$10.8m,$3.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.6m,$3.9m,$0.0m,$0.0m,$5.7m,$2.6m,$2.2m,$0.0m,,$34.8m,,$19.4m,$8.4m,$7.0m,$0.0m,,$0.0m,$0.0m,$34.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
543,Small,Qu Biologics,Private,North America,British Columbia,Burnaby,,,$28.6m,Estimate,No,Yes,No,No,22%,$6.2m,$3.0m,$3.7m,$0.0m,$6.7m,,25%,17%,8%,0%,0%,50%,,25%,17%,8%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.2m,$3.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$1.7m,$2.1m,$0.0m,,$34.7m,,$8.6m,$4.2m,$5.2m,$0.0m,,$0.0m,$0.0m,$17.9m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$2.6m,$7.6m,$0.0m,$0.0m,$0.0m,$0.0m
544,Small,Oncolys BioPharma,Public,Asia/Oceania,Japan,Tokyo,,,$28.6m,Estimate,No,No,No,No,29%,$8.2m,$1.5m,$3.7m,$0.0m,$5.2m,,36%,9%,9%,0%,0%,55%,,36%,0%,9%,0%,0%,,0%,9%,0%,0%,0%,,,,$8.2m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,$4.3m,$0.8m,$2.1m,$0.0m,,$34.7m,,$11.5m,$2.1m,$5.2m,$0.0m,,$0.0m,$0.0m,$18.8m,$0.0m,$3.6m,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
216,Small,Aquinox Pharmaceuticals,Public,North America,British Columbia,Canada,,,$28.4m,Actual,No,No,No,No,7%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$36.8m,,$2.1m,$0.0m,$0.0m,$0.0m,,$8.9m,$9.3m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$13.2m,$0.0m,$2.1m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m
545,Small,NBE Therapeutics,Private,Europe,Switzerland,Basel,,,$28.4m,Estimate,Yes,Yes,No,No,62%,$17.5m,$0.0m,$0.0m,$0.0m,$0.0m,,62%,0%,0%,0%,0%,62%,,62%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$17.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.3m,$0.0m,$0.0m,$0.0m,,$34.4m,,$34.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$34.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
546,Small,Qilu,Public,Asia/Oceania,,,,,$28.2m,Estimate,No,Yes,No,No,0%,$0.0m,$4.6m,$3.8m,$7.5m,$15.9m,,0%,23%,8%,8%,0%,38%,,0%,15%,8%,8%,0%,,0%,8%,0%,0%,0%,,,,$0.0m,$3.1m,$3.8m,$7.5m,$0.0m,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$2.1m,$4.2m,,$34.2m,,$0.0m,$5.8m,$4.8m,$9.4m,,$0.0m,$0.0m,$20.0m,$3.0m,$4.4m,$2.1m,$0.0m,$1.6m,$1.5m,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
547,Small,Cellmid,Public,Asia/Oceania,Australia,Sydney,,,$28.2m,Estimate,No,Yes,No,No,20%,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,,$34.2m,,$7.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.6m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$7.7m,$2.3m,$5.0m,$7.0m,$0.0m,$0.0m,$1.8m,$0.0m
548,Small,Mediolanum farmaceutici,Private,Europe,Italy,Milan,,,$28.2m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.0m,$0.0m,$3.0m,,0%,0%,8%,0%,0%,8%,,0%,0%,0%,0%,0%,,0%,0%,8%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,,$34.2m,,$0.0m,$0.0m,$4.4m,$0.0m,,$6.5m,$0.0m,$4.4m,$0.0m,$9.7m,$0.0m,$0.0m,$2.4m,$0.0m,$5.2m,$3.2m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m
549,Small,Mabspace Biosciences,Private,Asia/Oceania,China,Suzhou,,,$28.0m,Estimate,No,Yes,No,No,55%,$15.4m,$1.6m,$0.0m,$0.0m,$1.6m,,54%,8%,0%,0%,0%,62%,,46%,8%,0%,0%,0%,,8%,0%,0%,0%,0%,,,,$13.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$8.2m,$0.9m,$0.0m,$0.0m,,$34.0m,,$20.6m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$22.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
550,Small,Yisheng Biopharma,Private,Asia/Oceania,,,,,$27.9m,Estimate,No,Yes,No,No,7%,$2.0m,$1.5m,$0.0m,$0.0m,$1.5m,,8%,8%,0%,0%,0%,17%,,8%,8%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$0.0m,$0.0m,,$33.9m,,$3.7m,$2.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m,$24.5m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m
551,Small,Foresee Pharmaceuticals,Public,North America,Delaware,Newark,,,$27.9m,Estimate,Yes,No,No,No,6%,$1.7m,$0.0m,$0.0m,$5.9m,$5.9m,,7%,0%,0%,7%,0%,13%,,7%,0%,0%,0%,0%,,0%,0%,0%,7%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.9m,$0.0m,$0.0m,$3.3m,,$33.9m,,$2.8m,$0.0m,$0.0m,$10.1m,,$2.9m,$2.1m,$12.9m,$0.0m,$4.3m,$2.4m,$2.3m,$0.0m,$0.0m,$0.9m,$0.0m,$2.1m,$2.4m,$1.8m,$0.0m,$0.0m
217,Small,Stemline Therapeutics,Public,North America,New York,New York,,,$27.9m,Actual,Yes,Yes,No,No,31%,$8.8m,$1.1m,$5.3m,$0.0m,$6.3m,,38%,6%,13%,0%,6%,63%,,38%,6%,13%,0%,6%,,0%,0%,0%,0%,0%,,,,$8.8m,$1.1m,$5.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.6m,$3.0m,$0.0m,,$36.2m,,$12.4m,$1.5m,$7.4m,$0.0m,,$0.0m,$0.0m,$21.3m,$2.0m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m
552,Small,Opsona,Private,Europe,Ireland,Dublin,,,$27.8m,Estimate,Yes,Yes,No,No,6%,$1.8m,$0.0m,$3.2m,$0.0m,$3.2m,,8%,0%,8%,0%,0%,17%,,8%,0%,8%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$3.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$1.8m,$0.0m,,$33.8m,,$2.5m,$0.0m,$4.6m,$0.0m,,$2.3m,$2.2m,$7.1m,$15.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$2.4m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m
553,Small,Medigen Biotechnology,Public,Asia/Oceania,,,,,$27.8m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$2.9m,$0.0m,$2.9m,,0%,0%,13%,0%,0%,13%,,0%,0%,0%,0%,0%,,0%,0%,13%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,,$33.7m,,$0.0m,$0.0m,$5.3m,$0.0m,,$0.0m,$0.0m,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,$28.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
554,Small,Assembly Biosciences,Public,North America,California,San Francisco,Indiana,Carpel,$27.8m,Estimate,No,Yes,No,No,7%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$33.7m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$19.3m,$0.0m,$0.0m,$0.0m,$11.8m,$0.0m,$0.0m,$0.0m,$0.0m
555,Small,Adienne,Private,Europe,Switzerland,Lugano,,,$27.8m,Estimate,Yes,No,No,No,7%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$33.7m,,$3.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$17.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.6m,$8.4m,$0.0m,$0.0m,$0.0m
218,Small,Calithera Biosciences,Public,North America,California,South San Francisco,,,$27.7m,Actual,Yes,Yes,No,No,14%,$3.8m,$2.8m,$6.9m,$0.0m,$9.7m,,17%,17%,17%,0%,0%,50%,,8%,8%,8%,0%,0%,,8%,8%,8%,0%,0%,,,,$1.9m,$1.4m,$3.5m,$0.0m,$0.0m,,$1.9m,$1.4m,$3.5m,$0.0m,$0.0m,$2.0m,$1.6m,$3.9m,$0.0m,,$36.0m,,$9.1m,$6.6m,$16.5m,$0.0m,,$3.8m,$0.0m,$32.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
556,Small,Bicycle Therapeutics,Private,Europe,United Kingdom,Cambridge,,,$27.7m,Estimate,No,Yes,No,No,32%,$8.8m,$0.0m,$4.0m,$0.0m,$4.0m,,33%,0%,8%,0%,0%,42%,,33%,0%,8%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.8m,$0.0m,$4.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m,$2.2m,$0.0m,,$33.7m,,$10.1m,$0.0m,$4.6m,$0.0m,,$3.9m,$0.0m,$14.7m,$0.0m,$2.8m,$0.0m,$0.0m,$2.5m,$0.0m,$3.7m,$0.0m,$3.4m,$2.6m,$0.0m,$0.0m,$0.0m
557,Small,Philips Healthcare,Public,Middle East/Africa,Israel,Haifa,,,$27.7m,Estimate,No,No,No,No,5%,$1.4m,$0.0m,$2.5m,$4.9m,$7.4m,,14%,0%,14%,14%,0%,43%,,0%,0%,0%,0%,0%,,14%,0%,14%,14%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.4m,$0.0m,$2.5m,$4.9m,$0.0m,$0.7m,$0.0m,$1.4m,$2.8m,,$33.6m,,$2.0m,$0.0m,$3.7m,$7.3m,,$20.6m,$0.0m,$13.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
558,Small,CASI Pharmaceuticals,Public,North America,Maryland,Rockville,China,Beijing,$27.7m,Estimate,Yes,Yes,No,No,14%,$3.8m,$0.0m,$6.9m,$6.8m,$13.7m,,25%,0%,25%,13%,0%,63%,,25%,0%,13%,0%,0%,,0%,0%,13%,13%,0%,,,,$3.8m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$6.8m,$0.0m,$2.0m,$0.0m,$3.9m,$3.8m,,$33.6m,,$7.3m,$0.0m,$13.2m,$13.0m,,$0.0m,$0.0m,$33.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
559,Small,Principia BioPharma,Public,North America,California,South San Francisco,,,$27.6m,Estimate,No,No,No,No,0%,$0.0m,$1.5m,$0.0m,$0.0m,$1.5m,,0%,10%,0%,0%,0%,10%,,0%,10%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,,$33.5m,,$0.0m,$1.8m,$0.0m,$0.0m,,$0.0m,$1.5m,$1.8m,$13.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.7m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m
560,Small,Marina Biotech,Public,North America,North Carolina,Durham,,,$27.5m,Estimate,No,No,No,No,26%,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,,24%,0%,0%,0%,0%,24%,,24%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,,$33.4m,,$9.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.3m,$9.4m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,$4.3m,$4.7m,$7.0m,$0.0m,$0.0m,$0.0m,$0.0m
561,Small,ApolloBio,Private,Asia/Oceania,China,Beijing,,,$27.5m,Estimate,No,Yes,Yes,No,5%,$1.4m,$1.0m,$2.6m,$5.1m,$8.8m,,11%,11%,11%,11%,0%,44%,,0%,0%,0%,0%,0%,,11%,11%,11%,11%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.4m,$1.0m,$2.6m,$5.1m,$0.0m,$0.8m,$0.6m,$1.5m,$2.9m,,$33.4m,,$1.6m,$1.1m,$2.8m,$5.6m,,$0.0m,$0.0m,$11.1m,$0.0m,$0.0m,$0.0m,$0.0m,$7.1m,$10.1m,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m
219,Small,Endocyte,Public,North America,Indiana,West Lafayette,Indiana,Indianapolis,$27.5m,Actual,Yes,Yes,Yes,Yes,18%,$5.0m,$0.0m,$0.0m,$12.0m,$12.0m,,38%,0%,0%,25%,0%,63%,,38%,0%,0%,13%,0%,,0%,0%,0%,13%,0%,,,,$5.0m,$0.0m,$0.0m,$6.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$6.0m,$0.0m,$2.7m,$0.0m,$0.0m,$6.7m,,$35.7m,,$6.3m,$0.0m,$0.0m,$15.0m,,$0.0m,$0.0m,$21.3m,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,$8.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
562,Small,HSRx Biopharmaceutical,Private,North America,Arizona,Tuscon,,,$27.5m,Estimate,No,No,No,No,0%,$0.0m,$1.3m,$0.0m,$0.0m,$1.3m,,0%,7%,0%,0%,0%,7%,,0%,7%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$33.3m,,$0.0m,$1.7m,$0.0m,$0.0m,,$0.0m,$5.9m,$1.7m,$8.5m,$0.0m,$0.0m,$0.0m,$9.8m,$0.0m,$0.8m,$5.6m,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m
563,Small,CANbridge Life Sciences,Private,North America,Massachusetts,Cambridge,China,Beijing,$27.4m,Estimate,Yes,Yes,No,No,15%,$4.2m,$4.6m,$7.6m,$0.0m,$12.2m,,17%,25%,17%,0%,0%,58%,,0%,0%,0%,0%,0%,,17%,25%,17%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.2m,$4.6m,$7.6m,$0.0m,$0.0m,$2.2m,$2.6m,$4.2m,$0.0m,,$33.3m,,$8.5m,$9.3m,$15.4m,$0.0m,,$0.0m,$0.0m,$33.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
564,Small,Suzhou Ribo Life Science,Private,Asia/Oceania,China,Jiangsu,China,Beijing,$27.4m,Estimate,No,No,No,No,36%,$9.8m,$0.0m,$0.0m,$0.0m,$0.0m,,36%,0%,0%,0%,0%,36%,,29%,0%,0%,0%,0%,,7%,0%,0%,0%,0%,,,,$7.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,,$33.3m,,$13.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.1m,$2.5m,$2.4m,$0.0m,$2.6m,$5.7m,$0.0m,$2.3m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m
565,Small,SillaJen,Public,Asia/Oceania,,,,,$27.4m,Estimate,Yes,Yes,Yes,No,7%,$2.0m,$2.9m,$3.6m,$7.2m,$13.7m,,13%,25%,13%,13%,0%,63%,,13%,25%,13%,13%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$2.9m,$3.6m,$7.2m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$1.6m,$2.0m,$4.0m,,$33.3m,,$4.3m,$6.2m,$7.7m,$15.2m,,$0.0m,$0.0m,$33.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
566,Small,Loxo Oncology,Public,North America,Connecticut,Stamford,California,South San Francisco,$27.4m,Estimate,Yes,No,No,No,17%,$4.7m,$1.7m,$8.5m,$0.0m,$10.2m,,22%,11%,22%,0%,11%,67%,,0%,0%,0%,0%,0%,,22%,11%,22%,0%,11%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.7m,$1.7m,$8.5m,$0.0m,$0.0m,$2.5m,$1.0m,$4.8m,$0.0m,,$33.2m,,$8.7m,$3.1m,$15.7m,$0.0m,,$0.0m,$0.0m,$27.5m,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
567,Small,ANP Technologies,Private,North America,Delaware,Newark,,,$27.3m,Estimate,No,Yes,No,No,54%,$14.7m,$1.5m,$0.0m,$0.0m,$1.5m,,50%,7%,0%,0%,0%,57%,,50%,7%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$14.7m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.8m,$0.9m,$0.0m,$0.0m,,$33.1m,,$22.8m,$2.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$25.1m,$0.0m,$0.0m,$0.0m,$5.5m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
568,Small,On Target Laboratories,Private,North America,Indiana,West Lafayette,,,$27.3m,Estimate,No,No,No,No,64%,$17.4m,$0.0m,$0.0m,$7.7m,$7.7m,,80%,0%,0%,10%,0%,90%,,80%,0%,0%,10%,0%,,0%,0%,0%,0%,0%,,,,$17.4m,$0.0m,$0.0m,$7.7m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.2m,$0.0m,$0.0m,$4.3m,,$33.1m,,$21.3m,$0.0m,$0.0m,$9.5m,,$0.0m,$0.0m,$30.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
569,Small,Harbour Biomed,Private,Asia/Oceania,,,,,$27.3m,Estimate,Yes,Yes,No,No,6%,$1.8m,$1.3m,$3.2m,$0.0m,$4.4m,,8%,8%,8%,0%,0%,23%,,8%,0%,0%,0%,0%,,0%,8%,8%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.3m,$3.2m,$0.0m,$0.0m,$0.9m,$0.7m,$1.8m,$0.0m,,$33.1m,,$2.1m,$1.5m,$3.7m,$0.0m,,$0.0m,$0.0m,$7.3m,$7.1m,$8.7m,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m
570,Small,Cel-Sci,Public,North America,Virginia,Vienna,,,$27.2m,Estimate,No,Yes,No,No,7%,$1.9m,$0.0m,$3.5m,$6.9m,$10.4m,,10%,0%,10%,10%,0%,30%,,10%,0%,10%,10%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$3.5m,$6.9m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$2.0m,$3.9m,,$33.1m,,$3.2m,$0.0m,$5.7m,$11.3m,,$0.0m,$0.0m,$20.2m,$5.1m,$0.0m,$0.0m,$0.0m,$4.6m,$1.8m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m
220,Small,Tocagen,Public,North America,California,San Diego,,,$27.2m,Actual,No,Yes,Yes,No,29%,$7.9m,$2.9m,$0.0m,$14.1m,$17.0m,,40%,20%,0%,20%,0%,80%,,40%,20%,0%,20%,0%,,0%,0%,0%,0%,0%,,,,$7.9m,$2.9m,$0.0m,$14.1m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.2m,$1.6m,$0.0m,$7.9m,,$35.3m,,$11.2m,$4.1m,$0.0m,$20.0m,,$0.0m,$0.0m,$35.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
571,Small,Sinocelltech,Private,Asia/Oceania,China,Beijing,,,$27.2m,Estimate,Yes,Yes,No,No,14%,$3.9m,$0.0m,$3.5m,$0.0m,$3.5m,,17%,0%,8%,0%,0%,25%,,17%,0%,8%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$2.0m,$0.0m,,$33.0m,,$7.0m,$0.0m,$6.3m,$0.0m,,$0.0m,$0.0m,$13.2m,$3.3m,$3.2m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,$3.3m,$3.1m,$3.6m,$0.0m,$0.0m,$0.0m
221,Small,Valneva,Public,Europe,France,Saint-Herblain,,,$27.2m,Actual,Yes,Yes,No,No,0%,$0.0m,$0.6m,$0.0m,$0.0m,$0.6m,,0%,5%,0%,0%,0%,5%,,0%,0%,0%,0%,0%,,0%,5%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.3m,$0.0m,$0.0m,,$35.3m,,$0.0m,$1.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,$29.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m
572,Small,Arrien Pharmaceuticals,Private,North America,Utah,Salt Lake City,,,$27.2m,Estimate,Yes,Yes,No,No,24%,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,,21%,0%,0%,0%,0%,21%,,21%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$33.0m,,$10.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$9.4m,$10.8m,$3.6m,$4.2m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
573,Small,NeuClone,Private,Asia/Oceania,,,,,$27.1m,Estimate,No,Yes,No,No,14%,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$32.9m,,$5.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.5m,$8.3m,$2.7m,$0.0m,$5.6m,$2.8m,$0.0m,$0.0m,$5.5m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m
574,Small,Oscotec,Public,Asia/Oceania,South Korea,Seongnam,,,$27.0m,Estimate,Yes,Yes,No,No,40%,$10.7m,$1.6m,$3.9m,$0.0m,$5.4m,,36%,7%,7%,0%,0%,50%,,36%,7%,7%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.7m,$1.6m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.9m,$2.2m,$0.0m,,$32.8m,,$16.3m,$2.4m,$5.9m,$0.0m,,$0.0m,$0.0m,$24.5m,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m
575,Small,Sirnaomics,Private,North America,Maryland,Gaithersburg,,,$27.0m,Estimate,No,No,No,No,22%,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,,23%,0%,0%,0%,0%,23%,,23%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,,$32.8m,,$9.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$9.1m,$3.0m,$0.0m,$0.0m,$5.3m,$12.3m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
576,Small,Stendhal Internacional,Private,Latin America,Mexico,Mexico City,Panama,Panama,$27.0m,Estimate,No,Yes,No,No,7%,$1.8m,$0.0m,$6.4m,$0.0m,$6.4m,,10%,0%,20%,0%,10%,40%,,0%,0%,0%,0%,0%,,10%,0%,20%,0%,10%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$0.0m,$6.4m,$0.0m,$0.0m,$0.9m,$0.0m,$3.6m,$0.0m,,$32.8m,,$2.5m,$0.0m,$9.0m,$0.0m,,$0.0m,$21.3m,$11.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
577,Small,Amgen Astellas BioPharma,Private,Asia/Oceania,Japan,Tokyo,Massachusetts,Cambridge,$26.9m,Estimate,Yes,Yes,No,No,0%,$0.0m,$0.0m,$6.6m,$6.5m,$13.0m,,0%,0%,25%,13%,0%,38%,,0%,0%,0%,0%,0%,,0%,0%,25%,13%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.6m,$6.5m,$0.0m,$0.0m,$0.0m,$3.7m,$3.6m,,$32.7m,,$0.0m,$0.0m,$10.4m,$10.3m,,$0.0m,$0.0m,$20.7m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m
578,Small,Morvus Technology,Private,Europe,Wales,Brecon,,,$26.9m,Estimate,No,No,No,No,15%,$4.0m,$1.5m,$3.6m,$7.2m,$12.3m,,29%,14%,14%,14%,0%,71%,,29%,14%,14%,14%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$1.5m,$3.6m,$7.2m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.8m,$2.0m,$4.0m,,$32.6m,,$8.1m,$2.9m,$7.3m,$14.4m,,$0.0m,$0.0m,$32.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
579,Small,Allist Pharmaceuticals,Private,Asia/Oceania,China,Shanghai,,,$26.8m,Estimate,No,No,No,No,47%,$12.6m,$1.5m,$7.6m,$0.0m,$9.1m,,50%,8%,17%,0%,0%,75%,,50%,8%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$12.6m,$1.5m,$7.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.7m,$0.9m,$4.3m,$0.0m,,$32.5m,,$15.5m,$1.9m,$9.3m,$0.0m,,$0.0m,$0.0m,$26.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m
580,Small,REMD Biotherapeutics,Private,North America,California,Camarillo,,,$26.8m,Estimate,No,Yes,No,No,52%,$13.8m,$0.0m,$0.0m,$0.0m,$0.0m,,58%,0%,0%,0%,0%,58%,,58%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$13.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,,$32.5m,,$14.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.0m,$14.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.1m,$0.0m,$10.7m,$0.0m,$0.0m,$0.0m,$0.0m
581,Small,AVROBIO,Public,North America,Massachusetts,Cambridge,Ontario ,Toronto,$26.7m,Estimate,Yes,Yes,Yes,Yes,0%,$0.0m,$1.4m,$0.0m,$0.0m,$1.4m,,0%,8%,0%,0%,0%,8%,,0%,8%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,,$32.4m,,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$28.8m,$0.0m,$0.0m,$0.0m,$0.0m
582,Small,Kelun Pharmaceutical,Public,Asia/Oceania,,,,,$26.7m,Estimate,Yes,Yes,No,No,8%,$2.0m,$1.5m,$7.3m,$7.2m,$16.0m,,14%,14%,29%,14%,0%,71%,,14%,14%,29%,14%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.5m,$7.3m,$7.2m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$4.1m,$4.0m,,$32.4m,,$3.6m,$2.6m,$13.1m,$13.0m,,$0.0m,$0.0m,$32.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
583,Small,SystImmune,Private,North America,Washington,Redmond,,,$26.7m,Estimate,No,Yes,No,No,75%,$20.0m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$20.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$10.6m,$0.0m,$0.0m,$0.0m,,$32.4m,,$32.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$32.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
584,Small,Oncopeptides,Public,Europe,Sweden,Stockholm,,,$26.6m,Estimate,Yes,No,No,No,7%,$2.0m,$0.0m,$3.5m,$7.0m,$10.5m,,14%,0%,14%,14%,0%,43%,,14%,0%,14%,14%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$3.5m,$7.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$2.0m,$3.9m,,$32.3m,,$4.5m,$0.0m,$8.2m,$16.2m,,$0.0m,$0.0m,$28.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m
222,Small,OBI Pharma,Public,Asia/Oceania,,,,,$26.6m,Actual,Yes,Yes,No,No,16%,$4.3m,$2.1m,$5.2m,$5.1m,$12.4m,,23%,15%,15%,8%,0%,62%,,15%,15%,8%,8%,0%,,8%,0%,8%,0%,0%,,,,$2.9m,$2.1m,$2.6m,$5.1m,$0.0m,,$1.4m,$0.0m,$2.6m,$0.0m,$0.0m,$2.3m,$1.2m,$2.9m,$2.9m,,$34.5m,,$7.8m,$3.8m,$9.4m,$9.3m,,$0.0m,$2.0m,$30.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
585,Small,Novan Therapeutics,Public,North America,North Carolina,Morrisville,,,$26.6m,Estimate,Yes,No,No,No,7%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,9%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$60.3m,,$4.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$18.0m,$23.7m,$9.5m,$0.0m,$0.0m,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m
586,Small,Orano Med,Private,North America,Texas,Plano,,,$26.5m,Estimate,Yes,Yes,No,No,25%,$6.6m,$6.4m,$4.0m,$0.0m,$10.4m,,25%,33%,8%,0%,0%,67%,,8%,25%,0%,0%,0%,,17%,8%,8%,0%,0%,,,,$2.2m,$4.8m,$0.0m,$0.0m,$0.0m,,$4.4m,$1.6m,$4.0m,$0.0m,$0.0m,$3.5m,$3.6m,$2.2m,$0.0m,,$32.2m,,$11.0m,$10.6m,$6.6m,$0.0m,,$0.0m,$0.0m,$28.2m,$0.0m,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
587,Small,Ability Pharmaceuticals,Private,Europe,Spain,Barcelona,,,$26.5m,Estimate,Yes,No,No,No,50%,$13.4m,$1.6m,$8.0m,$0.0m,$9.7m,,55%,9%,18%,0%,0%,82%,,45%,9%,9%,0%,0%,,9%,0%,9%,0%,0%,,,,$11.1m,$1.6m,$4.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$4.0m,$0.0m,$0.0m,$7.1m,$0.9m,$4.5m,$0.0m,,$32.2m,,$18.7m,$2.3m,$11.2m,$0.0m,,$0.0m,$0.0m,$32.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
588,Small,Syndax,Public,North America,Massachusetts,Waltham,New York,New York,$26.5m,Estimate,Yes,Yes,No,No,15%,$4.1m,$3.0m,$3.7m,$7.3m,$13.9m,,22%,22%,11%,11%,0%,67%,,11%,0%,0%,0%,0%,,11%,22%,11%,11%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$3.0m,$3.7m,$7.3m,$0.0m,$2.2m,$1.7m,$2.1m,$4.1m,,$41.1m,,$8.1m,$5.9m,$7.3m,$14.5m,,$0.0m,$0.0m,$35.8m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
223,Small,Fate Therapeutics,Public,North America,California,San Diego,,,$26.5m,Actual,Yes,Yes,Yes,Yes,33%,$8.7m,$1.0m,$0.0m,$0.0m,$1.0m,,40%,7%,0%,0%,0%,47%,,40%,7%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.7m,$1.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.6m,$0.0m,$0.0m,,$34.3m,,$11.9m,$1.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.3m,$12.5m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$1.9m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m
589,Small,MedinCell,Public,Europe,France,Paris,,,$26.4m,Estimate,No,No,No,No,5%,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,$0.0m,,$32.0m,,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$17.3m,$1.5m,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$1.5m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
590,Small,Evestra,Private,North America,Texas,San Antonio,Texas,San Antonio,$26.3m,Estimate,No,No,No,No,14%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$32.0m,,$4.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$27.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
591,Small,Pluristem,Public,Middle East/Africa,,,,,$26.3m,Estimate,No,No,No,Yes,6%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,9%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$29.6m,,$1.7m,$0.0m,$0.0m,$0.0m,,$1.7m,$0.0m,$1.7m,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$13.2m,$8.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
592,Small,Carna Biosciences,Public,Asia/Oceania,Japan,Kobe,,,$26.2m,Estimate,No,Yes,No,No,46%,$12.1m,$0.0m,$0.0m,$0.0m,$0.0m,,46%,0%,0%,0%,0%,46%,,38%,0%,0%,0%,0%,,8%,0%,0%,0%,0%,,,,$10.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.4m,$0.0m,$0.0m,$0.0m,,$31.8m,,$16.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$6.1m,$16.3m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$3.9m
593,Small,Regulus Therapeutics,Public,North America,California,San Diego,,,$26.1m,Estimate,No,No,No,No,8%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,9%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$83.4m,,$7.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.9m,$8.0m,$0.0m,$0.0m,$0.0m,$16.1m,$13.7m,$0.0m,$0.0m,$37.8m,$0.0m,$0.0m,$0.0m,$0.0m
594,Small,Cancer Prevention,Private,North America,Arizona,Tuscon,,,$26.1m,Estimate,Yes,No,No,No,7%,$1.9m,$1.4m,$3.5m,$6.9m,$11.8m,,11%,11%,11%,11%,0%,44%,,11%,11%,11%,11%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$1.4m,$3.5m,$6.9m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$2.0m,$3.9m,,$31.7m,,$3.0m,$2.2m,$5.4m,$10.6m,,$0.0m,$0.0m,$21.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$10.6m,$0.0m,$0.0m,$0.0m,$0.0m
595,Small,Xbrane Biopharma,Public,Europe,Sweden,Stockholm,,,$26.1m,Estimate,Yes,No,Yes,No,21%,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,,21%,0%,0%,0%,0%,21%,,21%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,,$31.7m,,$8.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.6m,$8.3m,$2.8m,$2.7m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$2.7m,$7.7m,$0.0m,$2.2m,$0.0m,$0.0m
596,Small,TaiRx,Private,Asia/Oceania,Taiwan,Taipei ,,,$26.0m,Estimate,No,Yes,No,No,21%,$5.5m,$1.3m,$3.3m,$0.0m,$4.7m,,27%,9%,9%,0%,0%,45%,,27%,9%,9%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.5m,$1.3m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.8m,$1.9m,$0.0m,,$31.6m,,$9.0m,$2.2m,$5.4m,$0.0m,,$0.0m,$0.0m,$16.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$10.3m,$2.2m,$0.0m,$0.0m
597,Small,FortuneRock,Private,Asia/Oceania,China,Beijing,,,$26.0m,Estimate,No,No,No,No,0%,$0.0m,$1.3m,$0.0m,$0.0m,$1.3m,,0%,8%,0%,0%,0%,8%,,0%,8%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$31.6m,,$0.0m,$1.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.8m,$0.0m,$1.9m,$0.0m,$2.1m,$8.3m,$0.0m,$0.0m,$2.0m,$1.9m,$12.0m,$1.6m,$0.0m,$0.0m
598,Small,EpiThany,Private,North America,Washington,Seattle,,,$26.0m,Estimate,No,Yes,No,No,33%,$8.5m,$3.1m,$7.7m,$0.0m,$10.8m,,40%,20%,20%,0%,0%,80%,,40%,20%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.5m,$3.1m,$7.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$1.7m,$4.3m,$0.0m,,$31.6m,,$13.9m,$5.1m,$12.6m,$0.0m,,$0.0m,$0.0m,$31.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
599,Small,Sinobioway Cell Therapy,Private,Asia/Oceania,,,,,$25.9m,Estimate,Yes,Yes,Yes,Yes,8%,$2.0m,$0.0m,$10.9m,$0.0m,$10.9m,,14%,0%,43%,0%,0%,57%,,14%,0%,43%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$10.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$6.1m,$0.0m,,$31.5m,,$4.9m,$0.0m,$26.6m,$0.0m,,$0.0m,$0.0m,$31.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
600,Small,Alteogen,Public,Asia/Oceania,,,,,$25.9m,Estimate,No,Yes,No,No,8%,$2.0m,$2.8m,$0.0m,$0.0m,$2.8m,,8%,15%,0%,0%,0%,23%,,8%,15%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$1.6m,$0.0m,$0.0m,,$31.4m,,$3.6m,$5.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.8m,$0.0m,$4.2m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$3.4m,$8.9m,$0.0m,$0.0m
601,Small,Mabion,Public,Europe,Poland,Lodz,,,$25.8m,Estimate,No,Yes,No,No,46%,$11.9m,$0.0m,$0.0m,$0.0m,$0.0m,,35%,0%,0%,0%,6%,41%,,35%,0%,0%,0%,6%,,0%,0%,0%,0%,0%,,,,$11.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.3m,$0.0m,$0.0m,$0.0m,,$31.4m,,$14.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.5m,$14.6m,$7.3m,$2.4m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
602,Small,Anavex Life Sciences,Public,North America,New York,New York,,,$25.8m,Estimate,No,No,No,No,13%,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,,$31.3m,,$4.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$24.5m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
603,Small,Cotinga Pharmaceuticals,Public,North America,Massachusetts,Boston,,,$25.8m,Estimate,Yes,No,No,No,41%,$10.5m,$1.5m,$0.0m,$0.0m,$1.5m,,38%,8%,0%,0%,0%,46%,,38%,8%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.5m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.6m,$0.9m,$0.0m,$0.0m,,$31.3m,,$16.5m,$2.4m,$0.0m,$0.0m,,$0.0m,$5.9m,$18.9m,$0.0m,$0.0m,$0.0m,$0.0m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
224,Small,Protagonist Therapeutics,Public,North America,California,Newark,,,$25.7m,Actual,Yes,No,No,No,10%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$33.3m,,$4.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.5m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$17.5m,$6.7m,$0.0m,$0.0m,$0.0m
604,Small,HaemaLogiX,Private,Asia/Oceania,Australia,Sydney,,,$25.7m,Estimate,No,Yes,Yes,Yes,33%,$8.6m,$0.0m,$3.9m,$0.0m,$3.9m,,40%,0%,10%,0%,0%,50%,,40%,0%,0%,0%,0%,,0%,0%,10%,0%,0%,,,,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$4.6m,$0.0m,$2.2m,$0.0m,,$31.2m,,$21.5m,$0.0m,$9.7m,$0.0m,,$0.0m,$0.0m,$31.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
605,Small,Rheacell,Private,Europe,Germany,Heidelberg,,,$25.7m,Estimate,No,Yes,No,Yes,14%,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$31.2m,,$4.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.6m,$4.8m,$0.0m,$2.3m,$0.0m,$6.7m,$0.0m,$2.4m,$7.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m
606,Small,Magenta Therapeutics,Public,North America,Massachusetts,Cambridge,,,$25.7m,Estimate,No,Yes,No,Yes,21%,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,,23%,0%,0%,0%,0%,23%,,8%,0%,0%,0%,0%,,15%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,,$31.1m,,$5.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.9m,$21.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$1.9m,$0.0m,$0.0m,$0.0m
607,Small,Chiome Bioscience,Public,Asia/Oceania,Japan,Tokyo,Japan,Kawasaki,$25.6m,Estimate,Yes,Yes,No,No,50%,$12.8m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,42%,0%,0%,0%,0%,,8%,0%,0%,0%,0%,,,,$10.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$6.8m,$0.0m,$0.0m,$0.0m,,$31.1m,,$21.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$21.2m,$0.0m,$3.3m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m
608,Small,Trio Medicines,Private,Europe,United Kingdom,London,,,$25.6m,Estimate,Yes,No,No,No,0%,$0.0m,$1.4m,$3.5m,$0.0m,$4.8m,,0%,10%,10%,0%,0%,20%,,0%,10%,0%,0%,0%,,0%,0%,10%,0%,0%,,,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.8m,$1.9m,$0.0m,,$31.1m,,$0.0m,$1.9m,$4.6m,$0.0m,,$8.1m,$0.0m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,$3.0m,$2.1m,$9.8m,$0.0m,$0.0m,$0.0m,$0.0m
609,Small,Genextra,Private,Europe,Italy,Milan,,,$25.6m,Estimate,No,No,No,No,7%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$31.1m,,$1.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.9m,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$17.7m,$0.0m,$0.0m,$0.0m,$0.0m
610,Small,Ube Industries,Public,Asia/Oceania,,,,,$25.5m,Estimate,No,No,No,No,6%,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$31.0m,,$1.6m,$0.0m,$0.0m,$0.0m,,$3.1m,$0.0m,$1.6m,$1.6m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$11.8m,$1.6m,$1.5m,$6.8m,$0.0m,$0.0m,$0.0m
611,Small,UroGen Pharma,Public,Middle East/Africa,,,,,$25.5m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$7.0m,$6.9m,$13.9m,,0%,0%,33%,17%,0%,50%,,0%,0%,17%,17%,0%,,0%,0%,17%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$6.9m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$3.9m,$3.9m,,$30.9m,,$0.0m,$0.0m,$11.2m,$11.0m,,$0.0m,$0.0m,$22.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
612,Small,Abzena,Public,Europe,United Kingdom,Cambridge,,,$25.5m,Estimate,No,Yes,No,No,13%,$3.2m,$0.0m,$2.9m,$0.0m,$2.9m,,14%,0%,7%,0%,0%,21%,,14%,0%,0%,0%,0%,,0%,0%,7%,0%,0%,,,,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$1.7m,$0.0m,$1.6m,$0.0m,,$30.9m,,$3.9m,$0.0m,$3.5m,$0.0m,,$2.5m,$0.0m,$7.4m,$4.2m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$11.1m,$0.0m,$0.0m,$2.6m
613,Small,Cellivery Therapeutics,Private,Asia/Oceania,South Korea,Seoul,,,$25.4m,Estimate,No,No,No,No,31%,$7.8m,$0.0m,$0.0m,$0.0m,$0.0m,,31%,0%,0%,0%,0%,31%,,31%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.0m,$0.0m,$0.0m,,$30.9m,,$12.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.9m,$12.4m,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,$6.2m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m
614,Small,Spring Bank Pharmaceuticals,Public,North America,Massachusetts,Hopkinton,,,$25.4m,Estimate,No,Yes,No,No,33%,$8.3m,$0.0m,$0.0m,$0.0m,$0.0m,,36%,0%,0%,0%,0%,36%,,36%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.4m,$0.0m,$0.0m,$0.0m,,$30.8m,,$10.7m,$0.0m,$0.0m,$0.0m,,$2.6m,$0.0m,$10.7m,$0.0m,$0.0m,$0.0m,$0.0m,$14.9m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
615,Small,PhoreMost,Private,Europe,United Kingdom,Cambridge,,,$25.3m,Estimate,No,Yes,No,No,67%,$16.9m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,58%,0%,0%,0%,0%,,8%,0%,0%,0%,0%,,,,$14.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$8.9m,$0.0m,$0.0m,$0.0m,,$30.7m,,$20.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.3m,$20.5m,$0.0m,$0.0m,$5.3m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
616,Small,PeptiDream,Public,Asia/Oceania,,,,,$25.3m,Estimate,No,Yes,No,No,13%,$3.2m,$1.2m,$0.0m,$0.0m,$1.2m,,13%,6%,0%,0%,0%,19%,,13%,6%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.2m,$1.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.7m,$0.0m,$0.0m,,$30.7m,,$3.7m,$1.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$16.7m,$0.0m,$1.7m,$0.0m,$1.6m,$2.8m,$1.6m,$0.0m,$1.4m,$0.0m,$0.0m
617,Small,Scancell,Public,Europe,United Kingdom,Oxford,,,$25.3m,Estimate,Yes,Yes,Yes,No,46%,$11.7m,$0.0m,$3.5m,$0.0m,$3.5m,,55%,0%,9%,0%,0%,64%,,55%,0%,9%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.7m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.2m,$0.0m,$2.0m,$0.0m,,$30.7m,,$19.6m,$0.0m,$5.9m,$0.0m,,$0.0m,$0.0m,$25.5m,$0.0m,$0.0m,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
618,Small,Sanquin Blood Supply,Private,Europe,Netherlands,Amsterdam,,,$25.3m,Estimate,No,Yes,No,No,7%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$30.7m,,$1.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.8m,$9.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.7m,$0.0m,$0.0m,$9.8m,$0.0m,$0.0m,$0.0m
619,Small,PolyPid,Private,Middle East/Africa,,,,,$25.3m,Estimate,No,No,No,No,7%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$30.7m,,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.6m,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,$13.4m,$0.0m,$0.0m,$14.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
620,Small,Golden Biotechnology,Private,Asia/Oceania,,,,,$25.3m,Estimate,Yes,No,No,No,7%,$1.8m,$0.0m,$3.3m,$0.0m,$3.3m,,10%,0%,10%,0%,0%,20%,,10%,0%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$1.9m,$0.0m,,$30.7m,,$2.8m,$0.0m,$5.1m,$0.0m,,$0.0m,$2.5m,$8.0m,$2.7m,$0.0m,$0.0m,$4.6m,$6.7m,$0.0m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
621,Small,Beta Pharma,Public,Europe,United Kingdom,Essex,,,$25.2m,Estimate,No,Yes,No,No,16%,$4.2m,$4.5m,$3.8m,$0.0m,$8.3m,,18%,27%,9%,0%,0%,55%,,18%,9%,0%,0%,0%,,0%,18%,9%,0%,0%,,,,$4.2m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.0m,$3.8m,$0.0m,$0.0m,$2.2m,$2.5m,$2.1m,$0.0m,,$30.6m,,$7.2m,$7.9m,$6.5m,$0.0m,,$0.0m,$0.0m,$21.6m,$0.0m,$0.0m,$0.0m,$5.8m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
622,Small,Samyang Biopharmaceuticals,Private,Asia/Oceania,,,,,$25.2m,Estimate,No,Yes,No,No,15%,$3.9m,$2.8m,$3.5m,$0.0m,$6.4m,,18%,18%,9%,0%,0%,45%,,18%,18%,9%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$2.8m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$1.6m,$2.0m,$0.0m,,$30.6m,,$5.7m,$4.1m,$5.1m,$0.0m,,$8.6m,$3.6m,$15.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m
225,Small,G1 Therapeutics,Public,North America,North Carolina,Research Triangle Park,,,$25.2m,Actual,No,No,No,No,0%,$0.0m,$4.6m,$11.6m,$0.0m,$16.2m,,0%,29%,29%,0%,0%,57%,,0%,29%,29%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$4.6m,$11.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$6.5m,$0.0m,,$32.6m,,$0.0m,$8.0m,$19.9m,$0.0m,,$0.0m,$0.0m,$27.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$2.0m,$0.0m,$0.0m,$0.0m
623,Small,MultiCell Technologies,Public,North America,Rhode Island,Woonsocket,,,$25.1m,Estimate,No,Yes,No,No,41%,$10.2m,$0.0m,$0.0m,$0.0m,$0.0m,,45%,0%,0%,0%,0%,45%,,45%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.4m,$0.0m,$0.0m,$0.0m,,$30.5m,,$17.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$9.9m,$17.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
624,Small,Immune Biosolutions,Private,North America,Quebec,Sherbrooke,,,$25.0m,Estimate,No,Yes,No,No,42%,$10.4m,$0.0m,$0.0m,$0.0m,$0.0m,,42%,0%,0%,0%,0%,42%,,42%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.5m,$0.0m,$0.0m,$0.0m,,$30.3m,,$14.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$14.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$2.8m,$0.0m,$5.5m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m
625,Small,Immutep,Public,Asia/Oceania,,,,,$25.0m,Estimate,Yes,Yes,No,No,8%,$1.9m,$1.4m,$7.0m,$0.0m,$8.4m,,8%,8%,17%,0%,0%,33%,,8%,8%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$1.4m,$7.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$3.9m,$0.0m,,$30.3m,,$3.2m,$2.3m,$11.6m,$0.0m,,$0.0m,$2.7m,$17.1m,$2.9m,$0.0m,$0.0m,$1.1m,$2.3m,$0.0m,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m
226,Small,Boryung,Public,Asia/Oceania,,,,,$25.0m,Actual,Yes,Yes,Yes,No,2%,$0.5m,$0.8m,$0.9m,$1.9m,$3.5m,,3%,7%,3%,3%,3%,20%,,3%,3%,0%,0%,0%,,0%,3%,3%,3%,3%,,,,$0.5m,$0.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.4m,$0.9m,$1.9m,$0.0m,$0.3m,$0.4m,$0.5m,$1.0m,,$27.2m,,$0.6m,$0.9m,$1.1m,$2.1m,,$0.0m,$3.3m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$10.8m,$0.0m,$2.1m,$2.7m,$0.0m,$2.1m,$0.0m
626,Small,Affibody,Private,Europe,Sweden,Stockholm,,,$24.9m,Estimate,No,No,No,No,0%,$0.0m,$1.3m,$3.3m,$0.0m,$4.6m,,0%,8%,8%,0%,0%,15%,,0%,8%,8%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.3m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$1.9m,$0.0m,,$30.3m,,$0.0m,$1.6m,$3.9m,$0.0m,,$0.0m,$0.0m,$5.4m,$7.6m,$0.0m,$3.9m,$3.2m,$0.0m,$0.0m,$1.7m,$6.7m,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m
627,Small,Abpro,Private,North America,Massachusetts,Woburn,,,$24.8m,Estimate,Yes,Yes,No,No,73%,$18.1m,$0.0m,$0.0m,$0.0m,$0.0m,,73%,0%,0%,0%,0%,73%,,64%,0%,0%,0%,0%,,9%,0%,0%,0%,0%,,,,$15.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,,$30.1m,,$25.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$25.9m,$0.0m,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
628,Small,Delta-Fly Pharma,Public,Asia/Oceania,Japan,Tokushima,,,$24.7m,Estimate,Yes,Yes,No,No,25%,$6.3m,$3.0m,$7.6m,$0.0m,$10.6m,,30%,20%,20%,0%,0%,70%,,20%,10%,20%,0%,0%,,10%,10%,0%,0%,0%,,,,$4.2m,$1.5m,$7.6m,$0.0m,$0.0m,,$2.1m,$1.5m,$0.0m,$0.0m,$0.0m,$3.3m,$1.7m,$4.2m,$0.0m,,$30.0m,,$11.1m,$5.4m,$13.4m,$0.0m,,$0.0m,$0.0m,$30.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
629,Small,Innogene Kalbiotech,Private,Latin America,,,,,$24.7m,Estimate,Yes,Yes,No,No,0%,$0.0m,$2.4m,$5.9m,$5.9m,$14.2m,,0%,22%,22%,11%,0%,56%,,0%,0%,0%,0%,0%,,0%,22%,22%,11%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.4m,$5.9m,$5.9m,$0.0m,$0.0m,$1.3m,$3.3m,$3.3m,,$30.0m,,$0.0m,$5.0m,$12.5m,$12.4m,,$0.0m,$0.0m,$30.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
630,Small,Innovimmune,Private,North America,New York,New York,,,$24.6m,Estimate,No,Yes,No,No,23%,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,,23%,0%,0%,0%,0%,23%,,23%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,,$29.9m,,$7.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$4.4m,$7.0m,$4.7m,$0.0m,$0.0m,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m
631,Small,Reyon Pharmaceutical,Public,Asia/Oceania,,,,,$24.6m,Estimate,No,Yes,Yes,No,0%,$0.0m,$1.1m,$0.0m,$0.0m,$1.1m,,0%,11%,0%,0%,0%,11%,,0%,0%,0%,0%,0%,,0%,11%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$29.9m,,$0.0m,$1.5m,$0.0m,$0.0m,,$0.0m,$11.0m,$1.5m,$0.0m,$0.0m,$0.0m,$4.0m,$0.0m,$0.0m,$13.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
632,Small,iDD biotech,Private,Europe,France,Lyon,,,$24.6m,Estimate,No,Yes,No,No,42%,$10.3m,$0.0m,$3.7m,$0.0m,$3.7m,,50%,0%,10%,0%,0%,60%,,50%,0%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.3m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.5m,$0.0m,$2.1m,$0.0m,,$29.8m,,$15.3m,$0.0m,$5.5m,$0.0m,,$0.0m,$0.0m,$20.9m,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
633,Small,Translate Bio,Public,North America,Massachusetts,Lexington,,,$24.6m,Estimate,No,No,No,No,8%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,0%,0%,0%,0%,0%,,9%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$29.8m,,$3.2m,$0.0m,$0.0m,$0.0m,,$14.6m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m
227,Small,Compugen,Public,Middle East/Africa,Israel,Holon,California,South San Francisco,$24.5m,Actual,No,Yes,No,No,54%,$13.2m,$2.7m,$0.0m,$0.0m,$2.7m,,50%,14%,0%,0%,0%,64%,,50%,14%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$13.2m,$2.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.0m,$1.5m,$0.0m,$0.0m,,$31.8m,,$18.2m,$3.8m,$0.0m,$0.0m,,$0.0m,$2.3m,$22.0m,$2.5m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m
634,Small,Rheos Medicines,Private,North America,Massachusetts,Cambridge,,,$24.5m,Estimate,No,Yes,No,Yes,15%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,15%,0%,0%,0%,0%,15%,,15%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$29.7m,,$5.5m,$0.0m,$0.0m,$0.0m,,$2.7m,$2.6m,$5.5m,$8.3m,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m
635,Small,Nohla Therapeutics,Private,North America,Washington,Seattle,,,$24.5m,Estimate,No,Yes,No,Yes,15%,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,,$29.7m,,$4.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.6m,$4.6m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$14.7m,$0.0m,$3.3m,$0.0m
636,Small,Targovax,Public,Europe,Norway,Oslo,,,$24.4m,Estimate,Yes,Yes,No,No,35%,$8.6m,$3.1m,$3.9m,$0.0m,$7.0m,,40%,20%,10%,0%,0%,70%,,40%,20%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.6m,$3.1m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$1.7m,$2.2m,$0.0m,,$29.7m,,$16.4m,$5.9m,$7.4m,$0.0m,,$0.0m,$0.0m,$29.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
637,Small,A2A Pharmaceuticals,Private,North America,New York,New York,,,$24.4m,Estimate,No,Yes,No,No,42%,$10.2m,$0.0m,$0.0m,$0.0m,$0.0m,,42%,0%,0%,0%,0%,42%,,42%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.4m,$0.0m,$0.0m,$0.0m,,$29.7m,,$13.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.7m,$0.0m,$0.0m,$0.0m,$0.0m,$8.3m,$0.0m,$2.5m,$0.0m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m
638,Small,X-Chem,Private,North America,Massachusetts,Waltham,,,$24.4m,Estimate,No,Yes,No,No,32%,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m,,31%,0%,0%,0%,0%,31%,,23%,0%,0%,0%,0%,,8%,0%,0%,0%,0%,,,,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.0m,$0.0m,$0.0m,,$29.6m,,$8.6m,$0.0m,$0.0m,$0.0m,,$2.0m,$2.1m,$8.6m,$2.0m,$0.0m,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m
639,Small,Arbor Pharmaceuticals,Private,North America,Georgia,Atlanta,,,$24.4m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$2.2m,$0.0m,$2.2m,,0%,0%,9%,0%,0%,9%,,0%,0%,9%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,,$29.6m,,$0.0m,$0.0m,$2.3m,$0.0m,,$0.0m,$10.4m,$2.3m,$0.0m,$0.0m,$3.0m,$4.7m,$0.0m,$0.8m,$8.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
640,Small,GE Healthcare,Public,Europe,Germany,Munich,New York,New York,$24.3m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$2.5m,$4.9m,$7.3m,,0%,0%,14%,14%,0%,29%,,0%,0%,0%,0%,0%,,0%,0%,14%,14%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$4.9m,$0.0m,$0.0m,$0.0m,$1.4m,$2.7m,,$29.5m,,$0.0m,$0.0m,$2.6m,$5.1m,,$0.0m,$0.8m,$7.6m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$4.2m,$7.9m,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
641,Small,Nuance Biotech,Private,Europe,China,Shanghai,,,$24.3m,Estimate,Yes,Yes,No,No,26%,$6.4m,$3.1m,$3.9m,$0.0m,$7.0m,,33%,22%,11%,0%,0%,67%,,0%,0%,0%,0%,0%,,33%,22%,11%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$6.4m,$3.1m,$3.9m,$0.0m,$0.0m,$3.4m,$1.7m,$2.2m,$0.0m,,$29.5m,,$8.8m,$4.3m,$5.3m,$0.0m,,$0.0m,$11.1m,$18.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
642,Small,Symphogen,Private,Europe,Denmark,Copenhagen,,,$24.2m,Estimate,No,Yes,No,No,17%,$4.1m,$4.4m,$11.0m,$0.0m,$15.4m,,18%,27%,27%,0%,0%,73%,,18%,27%,27%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$4.4m,$11.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$2.5m,$6.2m,$0.0m,,$29.4m,,$5.3m,$5.8m,$14.3m,$0.0m,,$0.0m,$0.0m,$25.4m,$0.0m,$0.0m,$0.0m,$0.0m,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
643,Small,Aeglea BioTherapeutics,Public,North America,Texas,Austin,,,$24.2m,Estimate,Yes,No,No,No,17%,$4.1m,$1.5m,$3.7m,$0.0m,$5.2m,,22%,11%,11%,0%,0%,44%,,22%,11%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.8m,$2.1m,$0.0m,,$29.3m,,$7.2m,$2.6m,$6.5m,$0.0m,,$0.0m,$0.0m,$16.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$9.7m,$0.0m,$0.0m,$0.0m,$0.0m
644,Small,ACM Biolabs,Private,Asia/Oceania,Singapore,Singapore,,,$24.1m,Estimate,No,No,No,No,45%,$11.0m,$0.0m,$0.0m,$0.0m,$0.0m,,45%,0%,0%,0%,0%,45%,,45%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,,$29.3m,,$13.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.2m,$0.0m,$0.0m,$0.0m,$0.0m,$16.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
645,Small,Navya Life,Private,Asia/Oceania,India,Karnataka,,,$24.1m,Estimate,No,No,No,No,23%,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,,23%,0%,0%,0%,0%,23%,,23%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,,$29.2m,,$6.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.8m,$9.1m,$2.2m,$0.0m,$0.0m,$0.0m,$4.6m,$2.1m,$0.0m,$2.1m,$2.4m,$0.0m,$0.0m,$0.0m
646,Small,Kineta,Private,North America,Washington,Seattle,,,$24.1m,Estimate,No,Yes,No,No,16%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$29.2m,,$5.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.3m,$5.0m,$6.0m,$0.0m,$0.0m,$1.0m,$12.1m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
647,Small,Cynata Therapeutics,Public,Asia/Oceania,,,,,$24.1m,Estimate,No,No,Yes,Yes,8%,$1.9m,$0.0m,$3.5m,$0.0m,$3.5m,,8%,0%,8%,0%,0%,17%,,0%,0%,0%,0%,0%,,8%,0%,8%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$0.0m,$3.5m,$0.0m,$0.0m,$1.0m,$0.0m,$2.0m,$0.0m,,$29.2m,,$3.6m,$0.0m,$6.5m,$0.0m,,$2.9m,$0.0m,$10.1m,$7.3m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m
648,Small,Cellix Bio,Private,Asia/Oceania,,,,,$24.1m,Estimate,No,No,No,No,7%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,7%,0%,0%,0%,0%,7%,,7%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$29.2m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$12.3m,$2.2m,$0.0m,$2.1m,$0.0m,$2.2m,$2.2m,$0.0m,$2.0m,$0.0m,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m
649,Small,Oncternal Therapeutics,Private,North America,California,San Diego,,,$23.9m,Estimate,Yes,Yes,No,No,36%,$8.5m,$1.5m,$3.8m,$0.0m,$5.4m,,40%,10%,10%,0%,0%,60%,,40%,10%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.5m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$0.9m,$2.2m,$0.0m,,$29.0m,,$17.8m,$3.2m,$8.0m,$0.0m,,$0.0m,$0.0m,$29.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
650,Small,Nordic Nanovector,Public,Europe,Norway,Oslo,,,$23.9m,Estimate,Yes,Yes,No,No,45%,$10.8m,$1.6m,$3.9m,$0.0m,$5.4m,,45%,9%,9%,0%,0%,64%,,45%,9%,9%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.8m,$1.6m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.9m,$2.2m,$0.0m,,$29.0m,,$19.2m,$2.8m,$7.0m,$0.0m,,$0.0m,$0.0m,$29.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
651,Small,Eleison Pharmaceuticals,Private,North America,New Jersey,Princeton,,,$23.9m,Estimate,Yes,No,No,No,9%,$2.1m,$0.0m,$3.7m,$7.3m,$11.0m,,20%,0%,20%,20%,0%,60%,,0%,0%,0%,20%,0%,,20%,0%,20%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$7.3m,$0.0m,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$4.1m,,$29.0m,,$4.5m,$0.0m,$8.2m,$16.2m,,$0.0m,$0.0m,$29.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
652,Small,SAB Biotherapeutics,Private,North America,South Dakota,Sioux Falls,,,$23.8m,Estimate,No,No,No,No,9%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$28.9m,,$3.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.3m,$3.3m,$0.0m,$0.0m,$0.0m,$22.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
228,Small,Corcept Therapeutics,Public,North America,California,Menlo Park,,,$23.8m,Actual,No,No,No,No,0%,$0.0m,$0.0m,$13.1m,$0.0m,$13.1m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$13.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.3m,$0.0m,,$30.9m,,$0.0m,$0.0m,$19.8m,$0.0m,,$0.0m,$0.0m,$19.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$9.3m,$0.0m,$0.0m
653,Small,Shanghai De Novo Pharmatech,Private,Asia/Oceania,China,Shanghai,,,$23.8m,Estimate,No,No,No,No,77%,$18.2m,$3.3m,$0.0m,$0.0m,$3.3m,,73%,18%,0%,0%,0%,91%,,73%,18%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$18.2m,$3.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.6m,$1.8m,$0.0m,$0.0m,,$28.9m,,$24.4m,$4.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$28.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
654,Small,Amryt Pharma,Public,Europe,United Kingdom,London,,,$23.7m,Estimate,No,No,No,No,7%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,9%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$28.8m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$3.2m,$0.0m,$0.0m,$14.1m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m
655,Small,Apceth,Private,Europe,Germany,Munich,,,$23.7m,Estimate,No,Yes,Yes,Yes,17%,$4.0m,$0.0m,$3.6m,$0.0m,$3.6m,,18%,0%,9%,0%,0%,27%,,18%,0%,9%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$2.0m,$0.0m,,$28.8m,,$6.5m,$0.0m,$5.8m,$0.0m,,$3.0m,$0.0m,$12.3m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$4.5m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m
656,Small,Quest PharmaTech,Public,North America,Alberta,Edmonton,,,$23.7m,Estimate,No,Yes,No,No,30%,$7.0m,$0.0m,$3.2m,$6.3m,$9.4m,,50%,0%,13%,13%,0%,75%,,38%,0%,0%,0%,0%,,13%,0%,13%,13%,0%,,,,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$0.0m,$3.2m,$6.3m,$0.0m,$3.7m,$0.0m,$1.8m,$3.5m,,$28.8m,,$12.3m,$0.0m,$5.5m,$10.9m,,$0.0m,$0.0m,$28.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
657,Small,Gradalis,Private,North America,Texas,Carollton,,,$23.6m,Estimate,Yes,Yes,Yes,No,0%,$0.0m,$4.4m,$3.6m,$7.1m,$15.1m,,0%,38%,13%,13%,0%,63%,,0%,38%,13%,13%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$4.4m,$3.6m,$7.1m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$2.0m,$4.0m,,$28.7m,,$0.0m,$8.3m,$6.9m,$13.5m,,$0.0m,$0.0m,$28.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
658,Small,Reliance Life Sciences,Private,Asia/Oceania,,,,,$23.6m,Estimate,Yes,Yes,No,No,6%,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,,10%,0%,0%,0%,0%,10%,,10%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$28.7m,,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.6m,$3.2m,$10.9m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$10.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
659,Small,Hansa Medical,Public,Europe,Sweden,Lund,,,$23.6m,Estimate,No,Yes,No,No,8%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$28.6m,,$1.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.4m,$1.8m,$16.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.9m,$0.0m,$0.0m,$0.0m
660,Small,CARsgen Therapeutics,Private,Asia/Oceania,,,,,$23.5m,Estimate,Yes,Yes,Yes,Yes,18%,$4.3m,$6.2m,$3.9m,$0.0m,$10.1m,,18%,36%,9%,0%,0%,64%,,18%,36%,9%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.3m,$6.2m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$3.5m,$2.2m,$0.0m,,$28.6m,,$8.5m,$12.4m,$7.7m,$0.0m,,$0.0m,$0.0m,$28.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
661,Small,Oncolytics Biotech,Public,North America,Alberta,Calgary,California,San Diego,$23.4m,Estimate,No,No,No,No,0%,$0.0m,$1.4m,$3.6m,$7.0m,$12.0m,,0%,17%,17%,17%,0%,50%,,0%,17%,17%,17%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$3.6m,$7.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.0m,$3.9m,,$28.4m,,$0.0m,$3.4m,$8.4m,$16.6m,,$0.0m,$0.0m,$28.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
662,Small,Bio-Path Holdings,Public,North America,Texas,Bellaire,,,$23.3m,Estimate,Yes,No,No,No,27%,$6.2m,$1.5m,$3.8m,$0.0m,$5.3m,,30%,10%,10%,0%,0%,50%,,30%,10%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.2m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.8m,$2.1m,$0.0m,,$28.3m,,$13.1m,$3.2m,$7.9m,$0.0m,,$0.0m,$0.0m,$24.2m,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
663,Small,Vaximm,Private,Europe,Switzerland,Basel,,,$23.3m,Estimate,No,Yes,No,No,66%,$15.5m,$1.6m,$4.0m,$0.0m,$5.6m,,70%,10%,10%,0%,0%,90%,,70%,10%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$15.5m,$1.6m,$4.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.2m,$0.9m,$2.2m,$0.0m,,$28.3m,,$20.8m,$2.2m,$5.4m,$0.0m,,$0.0m,$0.0m,$28.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
664,Small,Noxxon,Public,Europe,Germany,Berlin,,,$23.3m,Estimate,Yes,No,No,No,18%,$4.2m,$3.0m,$3.8m,$0.0m,$6.8m,,22%,22%,11%,0%,0%,56%,,22%,22%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$3.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$1.7m,$2.1m,$0.0m,,$28.3m,,$6.9m,$5.0m,$6.2m,$0.0m,,$0.0m,$0.0m,$18.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.0m,$1.3m,$0.0m,$0.0m,$0.0m
665,Small,Helix BioPharma,Public,North America,Ontario,Richmond Hill,Poland,Warsaw,$23.3m,Estimate,No,Yes,Yes,Yes,50%,$11.7m,$0.0m,$3.5m,$0.0m,$3.5m,,60%,0%,10%,0%,0%,70%,,60%,0%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.7m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.2m,$0.0m,$2.0m,$0.0m,,$28.3m,,$18.0m,$0.0m,$5.4m,$0.0m,,$0.0m,$0.0m,$23.5m,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
666,Small,Eloxx Pharmaceuticals,Public,Middle East/Africa,,,,,$23.3m,Estimate,No,Yes,No,No,10%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,8%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$28.3m,,$2.4m,$0.0m,$0.0m,$0.0m,,$3.1m,$7.3m,$2.4m,$10.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.2m,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m
229,Small,Alpine Immune Sciences,Public,North America,Washington,Seattle,,,$23.3m,Actual,No,Yes,Yes,Yes,38%,$8.9m,$0.0m,$0.0m,$0.0m,$0.0m,,45%,0%,0%,0%,0%,45%,,45%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,,$30.2m,,$13.8m,$0.0m,$0.0m,$0.0m,,$8.1m,$0.0m,$13.8m,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
667,Small,Allogene Therapeutics,Private,North America,California,San Francisco,,,$23.3m,Estimate,Yes,Yes,Yes,Yes,56%,$13.0m,$1.6m,$0.0m,$0.0m,$1.6m,,55%,9%,0%,0%,0%,64%,,45%,0%,0%,0%,0%,,9%,9%,0%,0%,0%,,,,$10.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,$6.9m,$0.9m,$0.0m,$0.0m,,$28.3m,,$25.2m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$28.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
230,Small,Leap Therapeutics,Public,North America,Massachusetts,Cambridge,,,$23.3m,Actual,No,Yes,No,No,13%,$2.9m,$4.2m,$5.3m,$0.0m,$9.5m,,14%,29%,14%,0%,0%,57%,,0%,0%,0%,0%,0%,,14%,29%,14%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.9m,$4.2m,$5.3m,$0.0m,$0.0m,$1.5m,$2.4m,$3.0m,$0.0m,,$30.2m,,$7.1m,$10.3m,$12.8m,$0.0m,,$0.0m,$0.0m,$30.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
668,Small,NuCana BioMed,Public,Europe,United Kingdom,Edinburgh,,,$23.2m,Estimate,Yes,No,No,No,15%,$3.5m,$1.3m,$3.1m,$6.2m,$10.6m,,29%,14%,14%,14%,0%,71%,,14%,14%,0%,0%,0%,,14%,0%,14%,14%,0%,,,,$1.7m,$1.3m,$0.0m,$0.0m,$0.0m,,$1.7m,$0.0m,$3.1m,$6.2m,$0.0m,$1.8m,$0.7m,$1.8m,$3.5m,,$28.2m,,$7.0m,$2.5m,$6.3m,$12.4m,,$0.0m,$0.0m,$28.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
669,Small,IO Biotech,Private,Europe,Denmark,Copenhagen,,,$23.2m,Estimate,Yes,Yes,No,No,18%,$4.3m,$6.2m,$11.5m,$0.0m,$17.7m,,20%,40%,30%,0%,0%,90%,,20%,40%,30%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.3m,$6.2m,$11.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$3.5m,$6.5m,$0.0m,,$28.1m,,$5.4m,$7.9m,$14.8m,$0.0m,,$0.0m,$0.0m,$28.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
670,Small,Kezar Life Sciences,Public,North America,California,South San Francisco,,,$23.1m,Estimate,No,Yes,No,No,16%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,18%,0%,0%,0%,0%,18%,,18%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$28.1m,,$4.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.1m,$18.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
671,Small,Clovis Oncology,Public,North America,Colorado,Boulder,California,South San Francisco,$23.1m,Estimate,No,No,No,No,8%,$1.9m,$1.4m,$6.9m,$6.8m,$15.2m,,14%,14%,29%,14%,0%,71%,,0%,0%,0%,0%,0%,,14%,14%,29%,14%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$1.4m,$6.9m,$6.8m,$0.0m,$1.0m,$0.8m,$3.9m,$3.8m,,$28.0m,,$3.1m,$2.3m,$11.4m,$11.2m,,$0.0m,$0.0m,$28.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
672,Small,Apogenix,Private,Europe,Germany,Heidelberg,,,$23.0m,Estimate,Yes,Yes,No,No,58%,$13.3m,$3.2m,$4.0m,$0.0m,$7.2m,,55%,18%,9%,0%,0%,82%,,55%,18%,9%,0%,0%,,0%,0%,0%,0%,0%,,,,$13.3m,$3.2m,$4.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.0m,$1.8m,$2.2m,$0.0m,,$28.0m,,$18.1m,$4.4m,$5.5m,$0.0m,,$0.0m,$0.0m,$28.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
673,Small,ISA Pharmaceuticals,Private,Europe,Netherlands,Leiden,,,$22.9m,Estimate,No,Yes,No,No,17%,$4.0m,$0.0m,$7.2m,$0.0m,$7.2m,,29%,0%,29%,0%,0%,57%,,29%,0%,29%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$7.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$4.0m,$0.0m,,$27.8m,,$4.8m,$0.0m,$8.6m,$0.0m,,$0.0m,$0.0m,$13.4m,$0.0m,$0.0m,$0.0m,$0.0m,$7.9m,$0.0m,$0.0m,$0.0m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m
674,Small,Trillium Therapeutics,Public,North America,Ontario,Mississauga,,,$22.9m,Estimate,Yes,Yes,No,No,47%,$10.8m,$3.1m,$0.0m,$0.0m,$3.1m,,42%,17%,0%,0%,0%,58%,,42%,17%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.8m,$3.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$1.8m,$0.0m,$0.0m,,$27.8m,,$18.6m,$5.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$24.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m
231,Small,Sunesis,Public,North America,California,South San Francisco,,,$22.9m,Actual,Yes,No,No,No,13%,$3.0m,$1.1m,$5.5m,$5.4m,$11.9m,,25%,13%,25%,13%,0%,75%,,25%,13%,25%,0%,0%,,0%,0%,0%,13%,0%,,,,$3.0m,$1.1m,$5.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$5.4m,$0.0m,$1.6m,$0.6m,$3.1m,$3.0m,,$29.7m,,$6.0m,$2.2m,$10.8m,$10.7m,,$0.0m,$0.0m,$29.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
675,Small,Clover Biopharmaceuticals,Private,Asia/Oceania,,,,,$22.8m,Estimate,No,Yes,No,No,18%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,15%,0%,0%,0%,0%,15%,,15%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$27.7m,,$5.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.3m,$3.8m,$2.5m,$0.0m,$1.0m,$8.0m,$0.0m,$0.0m,$4.2m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m
676,Small,Fuji Pharma,Public,Europe,Germany,Dusseldorf,,,$22.7m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$2.8m,$0.0m,$2.8m,,0%,0%,10%,0%,0%,10%,,0%,0%,0%,0%,0%,,0%,0%,10%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,,$27.6m,,$0.0m,$0.0m,$2.8m,$0.0m,,$0.0m,$3.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$17.1m,$0.0m,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
677,Small,Scholar Rock,Public,North America,Massachusetts,Cambridge,,,$22.6m,Estimate,No,Yes,No,No,36%,$8.1m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,,$27.5m,,$11.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.8m,$11.3m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$2.6m,$3.1m,$0.0m,$0.0m,$0.0m
678,Small,Aurora BioPharma,Private,North America,Massachusetts,Cambridge,,,$22.6m,Estimate,Yes,Yes,Yes,Yes,37%,$8.4m,$0.0m,$7.6m,$0.0m,$7.6m,,50%,0%,25%,0%,0%,75%,,50%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.4m,$0.0m,$7.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$4.3m,$0.0m,,$27.5m,,$14.4m,$0.0m,$13.0m,$0.0m,,$0.0m,$0.0m,$27.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
679,Small,MediaPharma,Private,Europe,Italy,Chieti,,,$22.6m,Estimate,Yes,Yes,No,No,70%,$15.8m,$0.0m,$0.0m,$0.0m,$0.0m,,70%,0%,0%,0%,0%,70%,,60%,0%,0%,0%,0%,,10%,0%,0%,0%,0%,,,,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,,$27.4m,,$27.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$27.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
680,Small,Vakzine Projekt Management,Private,Europe,Germany,Hannover,,,$22.6m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,17%,0%,0%,17%,,0%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$27.4m,,$0.0m,$0.0m,$5.3m,$0.0m,,$0.0m,$2.5m,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,$19.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
681,Small,Adgero Biopharmaceuticals,Private,North America,,,,,$22.6m,Estimate,Yes,No,No,No,0%,$0.0m,$1.4m,$3.6m,$7.1m,$12.1m,,0%,17%,17%,17%,0%,50%,,0%,17%,17%,17%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$3.6m,$7.1m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.0m,$4.0m,,$27.4m,,$0.0m,$2.4m,$5.9m,$11.7m,,$0.0m,$0.0m,$20.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.4m,$0.0m,$0.0m,$0.0m,$0.0m
232,Small,ReNeuron,Public,Europe,United Kingdom,Bridgend,,,$22.5m,Actual,No,Yes,No,Yes,11%,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$29.2m,,$4.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.6m,$0.0m,$15.9m,$0.0m,$0.0m,$0.0m,$0.0m,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
682,Small,BioLite,Private,Asia/Oceania,,,,,$22.4m,Estimate,Yes,No,No,No,17%,$3.8m,$0.0m,$3.4m,$0.0m,$3.4m,,22%,0%,11%,0%,0%,33%,,22%,0%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$1.9m,$0.0m,,$27.2m,,$6.4m,$0.0m,$5.7m,$0.0m,,$0.0m,$9.3m,$12.1m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m
683,Small,4D Pharma,Public,Europe,United Kingdom,Leeds,,,$22.4m,Estimate,No,Yes,No,No,8%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,7%,0%,0%,0%,0%,7%,,7%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$27.2m,,$2.3m,$0.0m,$0.0m,$0.0m,,$4.5m,$6.4m,$2.3m,$4.6m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m
684,Small,Nitto Denko,Public,Asia/Oceania,,,,,$22.4m,Estimate,No,No,No,No,18%,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$27.2m,,$4.9m,$0.0m,$0.0m,$0.0m,,$7.2m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$4.4m,$0.0m,$0.0m,$2.0m,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m
685,Small,CZ BioMed,Private,North America,Florida,Tampa,,,$22.4m,Estimate,No,No,No,No,80%,$17.9m,$0.0m,$0.0m,$0.0m,$0.0m,,80%,0%,0%,0%,0%,80%,,80%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$17.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,,$27.2m,,$27.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$27.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
686,Small,3M Drug Delivery Systems,Private,North America,,,,,$22.3m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$3.3m,$0.0m,$3.3m,,0%,0%,14%,0%,0%,14%,,0%,0%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,,$27.1m,,$0.0m,$0.0m,$3.8m,$0.0m,,$12.4m,$11.0m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
687,Small,BeyondSpring Pharmaceuticals,Public,North America,New York,New York,,,$22.3m,Estimate,No,Yes,No,No,31%,$7.0m,$0.0m,$3.2m,$6.2m,$9.4m,,50%,0%,13%,13%,0%,75%,,38%,0%,0%,0%,0%,,13%,0%,13%,13%,0%,,,,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.7m,$0.0m,$3.2m,$6.2m,$0.0m,$3.7m,$0.0m,$1.8m,$3.5m,,$27.1m,,$8.4m,$0.0m,$3.8m,$7.5m,,$0.0m,$0.0m,$19.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.4m,$0.0m,$0.0m,$0.0m
688,Small,Generon,Private,Asia/Oceania,,,,,$22.2m,Estimate,Yes,Yes,No,No,16%,$3.5m,$1.3m,$0.0m,$0.0m,$1.3m,,22%,11%,0%,0%,0%,33%,,22%,11%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.5m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.7m,$0.0m,$0.0m,,$27.0m,,$4.5m,$1.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.1m,$9.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$7.8m,$1.7m,$0.0m,$0.0m
689,Small,Singh Biotechnology,Private,North America,Florida,Hudsom,,,$22.2m,Estimate,No,Yes,No,No,36%,$8.1m,$0.0m,$0.0m,$0.0m,$0.0m,,36%,0%,0%,0%,0%,36%,,36%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,,$27.0m,,$12.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$12.1m,$3.0m,$2.9m,$0.0m,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m
690,Small,Exicure,Public,North America,Illinois,Skokie,,,$22.2m,Estimate,No,Yes,No,No,18%,$3.9m,$1.4m,$0.0m,$0.0m,$1.4m,,15%,8%,0%,0%,0%,23%,,15%,8%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.8m,$0.0m,$0.0m,,$27.0m,,$6.7m,$2.4m,$0.0m,$0.0m,,$0.0m,$2.9m,$9.2m,$0.0m,$3.1m,$0.0m,$8.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m
691,Small,Jiangsu T-mab BioPharma,Private,Asia/Oceania,,,,,$22.2m,Estimate,No,Yes,No,No,0%,$0.0m,$3.1m,$3.8m,$0.0m,$6.9m,,0%,17%,8%,0%,0%,25%,,0%,8%,0%,0%,0%,,0%,8%,8%,0%,0%,,,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.5m,$3.8m,$0.0m,$0.0m,$0.0m,$1.7m,$2.1m,$0.0m,,$26.9m,,$0.0m,$4.1m,$5.2m,$0.0m,,$0.0m,$0.0m,$9.3m,$6.0m,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$4.3m,$1.0m,$0.0m,$0.0m,$0.0m
692,Small,Cerenis,Public,North America,Missouri,Lakeland,France,Balma,$22.2m,Estimate,No,No,No,No,8%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$26.9m,,$1.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$15.8m,$0.0m,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m
693,Small,Targazyme,Private,North America,California,Carlsbad,,,$22.1m,Estimate,No,Yes,Yes,Yes,17%,$3.8m,$0.0m,$3.4m,$0.0m,$3.4m,,33%,0%,17%,0%,0%,50%,,33%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$1.9m,$0.0m,,$26.9m,,$4.2m,$0.0m,$3.8m,$0.0m,,$0.0m,$0.0m,$8.1m,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.8m,$0.0m,$0.0m,$0.0m
694,Small,Poseida Therapeutics,Private,North America,California,San Diego,,,$22.0m,Estimate,No,Yes,Yes,Yes,49%,$10.7m,$1.6m,$0.0m,$0.0m,$1.6m,,45%,9%,0%,0%,0%,55%,,45%,9%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.7m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.9m,$0.0m,$0.0m,,$26.7m,,$19.8m,$2.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$22.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.0m,$0.0m,$0.0m
695,Small,Senhwa Biosciences,Public,Asia/Oceania,Taiwan,Taipei,,,$22.0m,Estimate,Yes,No,No,No,20%,$4.4m,$1.6m,$7.9m,$0.0m,$9.5m,,25%,13%,25%,0%,0%,63%,,0%,0%,0%,0%,0%,,25%,13%,25%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.4m,$1.6m,$7.9m,$0.0m,$0.0m,$2.3m,$0.9m,$4.4m,$0.0m,,$26.7m,,$8.4m,$3.1m,$15.2m,$0.0m,,$0.0m,$0.0m,$26.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
696,Small,Samsung Pharmaceutical,Public,Asia/Oceania,,,,,$22.0m,Estimate,No,Yes,No,No,9%,$2.0m,$1.4m,$3.5m,$0.0m,$4.9m,,14%,14%,14%,0%,0%,43%,,0%,0%,0%,0%,0%,,14%,14%,14%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$1.4m,$3.5m,$0.0m,$0.0m,$1.0m,$0.8m,$2.0m,$0.0m,,$26.7m,,$2.6m,$1.9m,$4.8m,$0.0m,,$0.0m,$6.2m,$9.4m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$8.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
697,Small,Cellerant Therapeutics,Private,North America,California,San Carlos,,,$22.0m,Estimate,Yes,Yes,No,Yes,18%,$3.9m,$0.0m,$3.5m,$0.0m,$3.5m,,20%,0%,10%,0%,0%,30%,,20%,0%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$2.0m,$0.0m,,$26.7m,,$7.8m,$0.0m,$7.0m,$0.0m,,$0.0m,$0.0m,$14.8m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.5m,$0.0m,$2.7m,$0.0m
698,Small,Lidds Pharma,Public,Europe,Sweden,Uppsala,,,$22.0m,Estimate,No,Yes,No,No,82%,$17.9m,$0.0m,$4.0m,$0.0m,$4.0m,,89%,0%,11%,0%,0%,100%,,89%,0%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$17.9m,$0.0m,$4.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.5m,$0.0m,$2.3m,$0.0m,,$26.6m,,$21.7m,$0.0m,$4.9m,$0.0m,,$0.0m,$0.0m,$26.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
699,Small,Immunicum,Public,Europe,Sweden,Stockholm,,,$21.9m,Estimate,No,Yes,No,Yes,39%,$8.6m,$1.6m,$3.9m,$0.0m,$5.4m,,44%,11%,11%,0%,0%,67%,,44%,11%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.6m,$1.6m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$0.9m,$2.2m,$0.0m,,$26.6m,,$16.3m,$3.0m,$7.4m,$0.0m,,$0.0m,$0.0m,$26.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
700,Small,Rubicon Biotechnology,Private,North America,California,Anaheim,,,$21.9m,Estimate,No,Yes,No,No,33%,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,,$26.6m,,$11.3m,$0.0m,$0.0m,$0.0m,,$2.7m,$5.3m,$11.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m
701,Small,Jupiter Orphan Therapeutics,Private,North America,Florida,Jupiter,,,$21.9m,Estimate,No,No,No,No,8%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$26.5m,,$3.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$19.7m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m
702,Small,AbClon,Public,Asia/Oceania,South Korea,Seoul,,,$21.8m,Estimate,No,Yes,Yes,Yes,60%,$13.1m,$0.0m,$0.0m,$0.0m,$0.0m,,60%,0%,0%,0%,0%,60%,,50%,0%,0%,0%,0%,,10%,0%,0%,0%,0%,,,,$10.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$6.9m,$0.0m,$0.0m,$0.0m,,$26.5m,,$20.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$20.0m,$3.2m,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
233,Small,Oncobiologics,Public,North America,New Jersey,Cranbury,,,$21.8m,Actual,No,Yes,No,No,15%,$3.3m,$1.2m,$0.0m,$0.0m,$1.2m,,13%,7%,0%,0%,0%,20%,,13%,7%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.3m,$1.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.7m,$0.0m,$0.0m,,$28.2m,,$4.5m,$1.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.1m,$11.6m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$6.3m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m
703,Small,TeneoBio,Private,North America,California,Menlo Park,,,$21.7m,Estimate,No,Yes,No,No,60%,$13.0m,$0.0m,$0.0m,$0.0m,$0.0m,,60%,0%,0%,0%,0%,60%,,60%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$13.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.9m,$0.0m,$0.0m,$0.0m,,$26.4m,,$17.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$17.5m,$2.9m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
704,Small,Kangen Pharmaceuticals,Private,Asia/Oceania,Japan,Tokyo,,,$21.7m,Estimate,No,No,No,No,44%,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,,56%,0%,0%,0%,0%,56%,,56%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,,$26.3m,,$12.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$12.7m,$0.0m,$0.0m,$0.0m,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,$7.4m,$0.0m,$0.0m,$0.0m,$0.0m
705,Small,Evgen Pharma,Public,Europe,United Kingdom,Wilmslow,,,$21.7m,Estimate,Yes,No,No,No,9%,$1.9m,$1.3m,$3.3m,$0.0m,$4.7m,,11%,11%,11%,0%,0%,33%,,11%,11%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$1.3m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$1.9m,$0.0m,,$26.3m,,$2.3m,$1.7m,$4.2m,$0.0m,,$0.0m,$1.9m,$8.1m,$0.0m,$2.0m,$0.0m,$0.0m,$2.1m,$0.0m,$1.9m,$0.0m,$0.0m,$10.2m,$0.0m,$0.0m,$0.0m
706,Small,Advantagene,Private,North America,,,,,$21.7m,Estimate,No,Yes,Yes,No,0%,$0.0m,$1.4m,$7.2m,$7.1m,$15.7m,,0%,17%,33%,17%,0%,67%,,0%,17%,33%,17%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$7.2m,$7.1m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$4.0m,$4.0m,,$26.3m,,$0.0m,$2.1m,$10.6m,$10.5m,,$3.1m,$0.0m,$23.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
707,Small,Adimab,Private,North America,New Hampshire,Lebanon,,,$21.6m,Estimate,No,Yes,No,No,24%,$5.3m,$1.3m,$0.0m,$0.0m,$1.3m,,23%,8%,0%,0%,0%,31%,,15%,0%,0%,0%,0%,,8%,8%,0%,0%,0%,,,,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$1.3m,$0.0m,$0.0m,$0.0m,$2.8m,$0.7m,$0.0m,$0.0m,,$26.3m,,$6.2m,$1.5m,$0.0m,$0.0m,,$0.0m,$2.6m,$7.7m,$0.0m,$0.0m,$14.1m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
708,Small,PsiOxus,Private,Europe,United Kingdom,Oxford,,,$21.6m,Estimate,No,Yes,Yes,No,40%,$8.7m,$3.1m,$3.9m,$0.0m,$7.1m,,44%,22%,11%,0%,0%,78%,,44%,22%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.7m,$3.1m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$1.8m,$2.2m,$0.0m,,$26.2m,,$14.5m,$5.2m,$6.5m,$0.0m,,$0.0m,$0.0m,$26.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
234,Small,Tracon Pharmaceuticals,Public,North America,California,San Diego,,,$21.6m,Actual,Yes,Yes,No,No,3%,$0.7m,$0.5m,$4.0m,$2.7m,$7.2m,,5%,5%,16%,5%,0%,32%,,0%,5%,11%,5%,0%,,5%,0%,5%,0%,0%,,,,$0.0m,$0.5m,$2.7m,$2.7m,$0.0m,,$0.7m,$0.0m,$1.3m,$0.0m,$0.0m,$0.4m,$0.3m,$2.3m,$1.5m,,$28.0m,,$1.7m,$1.2m,$9.2m,$6.0m,,$1.3m,$1.3m,$18.1m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m
709,Small,Non-industrial source,Private,Unspecified,Unspecified,Unspecified,Unspecified,Unspecified,$21.6m,Estimate,No,Yes,No,Yes,0%,$0.0m,$1.0m,$2.5m,$5.0m,$8.5m,,0%,13%,13%,13%,0%,38%,,0%,0%,0%,0%,0%,,0%,13%,13%,13%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.0m,$2.5m,$5.0m,$0.0m,$0.0m,$0.6m,$1.4m,$2.8m,,$26.2m,,$0.0m,$1.7m,$4.1m,$8.2m,,$0.0m,$0.0m,$14.0m,$0.0m,$0.0m,$0.0m,$0.0m,$12.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
710,Small,Surface Oncology,Public,North America,Massachusetts,Cambridge,,,$21.5m,Estimate,Yes,Yes,No,No,60%,$12.9m,$3.1m,$0.0m,$0.0m,$3.1m,,55%,18%,0%,0%,0%,73%,,55%,18%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$12.9m,$3.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.8m,$1.7m,$0.0m,$0.0m,,$26.1m,,$16.3m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$20.2m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
711,Small,Biovista,Private,North America,Virginia,Charlottesville,,,$21.5m,Estimate,No,No,No,No,17%,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,,$26.1m,,$5.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$15.3m,$5.5m,$0.0m,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
712,Small,Xynomic Pharmaceuticals,Private,North America,Delaware,Dover,China,Shanghai,$21.5m,Estimate,Yes,No,No,No,16%,$3.4m,$0.0m,$3.1m,$6.1m,$9.2m,,33%,0%,17%,17%,0%,67%,,17%,0%,0%,0%,0%,,17%,0%,17%,17%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.7m,$0.0m,$3.1m,$6.1m,$0.0m,$1.8m,$0.0m,$1.7m,$3.4m,,$26.1m,,$7.1m,$0.0m,$6.4m,$12.6m,,$0.0m,$0.0m,$26.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
713,Small,Plex Pharmaceuticals,Private,North America,California,San Diego,,,$21.4m,Estimate,No,No,No,No,9%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,9%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$26.0m,,$3.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$7.1m,$3.8m,$0.0m,$3.7m,$0.0m,$0.0m,$11.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
714,Small,ST Pharm,Public,Asia/Oceania,,,,,$21.4m,Estimate,No,No,No,No,16%,$3.5m,$0.0m,$3.1m,$0.0m,$3.1m,,22%,0%,11%,0%,0%,33%,,22%,0%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.5m,$0.0m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$1.8m,$0.0m,,$26.0m,,$3.9m,$0.0m,$3.5m,$0.0m,,$0.0m,$0.0m,$7.4m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$5.3m,$0.7m,$0.0m,$8.1m,$0.0m,$0.0m,$0.0m,$0.0m
715,Small,Cannabis Science,Public,North America,California,Irvine,,,$21.4m,Estimate,Yes,No,No,No,27%,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,,27%,0%,0%,0%,0%,27%,,27%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,,$26.0m,,$8.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$8.2m,$8.8m,$0.0m,$0.0m,$3.1m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
716,Small,FORMA Therapeutics,Private,North America,Connecticut,Branford,Massachusetts,Watertown,$21.4m,Estimate,Yes,No,No,No,19%,$4.0m,$1.5m,$3.6m,$0.0m,$5.1m,,20%,10%,10%,0%,0%,40%,,20%,10%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$1.5m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.8m,$2.0m,$0.0m,,$26.0m,,$7.7m,$2.8m,$6.9m,$0.0m,,$0.0m,$3.3m,$17.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m
717,Small,GTx,Public,North America,Tennessee,Memphis,,,$21.4m,Estimate,No,No,No,No,16%,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,,$26.0m,,$3.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.7m,$0.0m,$15.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
718,Small,Timmune Biotech,Private,Asia/Oceania,China,Tianjin,,,$21.3m,Estimate,Yes,Yes,Yes,Yes,73%,$15.7m,$1.6m,$4.0m,$0.0m,$5.7m,,78%,11%,11%,0%,0%,100%,,78%,11%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$15.7m,$1.6m,$4.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.3m,$0.9m,$2.3m,$0.0m,,$25.9m,,$19.0m,$2.0m,$4.9m,$0.0m,,$0.0m,$0.0m,$25.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
719,Small,AngioChem,Private,North America,Quebec,Westmount,,,$21.3m,Estimate,No,Yes,No,No,8%,$1.8m,$0.0m,$3.2m,$0.0m,$3.2m,,11%,0%,11%,0%,0%,22%,,11%,0%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$3.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$1.8m,$0.0m,,$25.8m,,$3.7m,$0.0m,$6.7m,$0.0m,,$0.0m,$3.2m,$10.4m,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m
720,Small,Proteo,Private,Europe,Germany,Kiel,,,$21.2m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.3m,$0.0m,$3.3m,,0%,0%,14%,0%,0%,14%,,0%,0%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,,$25.8m,,$0.0m,$0.0m,$5.1m,$0.0m,,$0.0m,$0.0m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.0m,$7.4m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m
721,Small,CHA Vaccine Institute,Private,Asia/Oceania,,,,,$21.1m,Estimate,No,Yes,No,No,9%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$25.7m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$23.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
722,Small,AbGenomics,Private,North America,California,Los Altos,Taiwan,Taipei,$21.1m,Estimate,No,Yes,No,No,9%,$1.9m,$1.4m,$0.0m,$0.0m,$1.4m,,11%,11%,0%,0%,0%,22%,,11%,11%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$0.0m,$0.0m,,$25.6m,,$2.4m,$1.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.2m,$12.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m
723,Small,eTheRNA,Private,Europe,Belgium,Niel,,,$21.1m,Estimate,No,No,No,Yes,20%,$4.3m,$3.1m,$7.7m,$0.0m,$10.8m,,20%,20%,20%,0%,0%,60%,,10%,20%,20%,0%,0%,,10%,0%,0%,0%,0%,,,,$2.1m,$3.1m,$7.7m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$1.7m,$4.3m,$0.0m,,$25.6m,,$5.9m,$4.3m,$10.7m,$0.0m,,$0.0m,$0.0m,$20.9m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
724,Small,Apogee Biotechnology,Private,North America,Pennsylvania,Hummelstown,,,$21.0m,Estimate,No,No,No,No,20%,$4.1m,$1.5m,$3.7m,$0.0m,$5.2m,,22%,11%,11%,0%,0%,44%,,22%,11%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.8m,$2.1m,$0.0m,,$25.5m,,$8.1m,$2.9m,$7.3m,$0.0m,,$0.0m,$0.0m,$18.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m
725,Small,TC Biopharm,Private,Europe,United Kingdom,Glasgow,,,$20.9m,Estimate,No,Yes,Yes,Yes,40%,$8.4m,$0.0m,$3.8m,$0.0m,$3.8m,,50%,0%,13%,0%,0%,63%,,50%,0%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.4m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$2.1m,$0.0m,,$25.4m,,$13.1m,$0.0m,$5.9m,$0.0m,,$0.0m,$0.0m,$19.0m,$3.2m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
726,Small,PharmAbcine,Private,Asia/Oceania,South Korea,Daejeon,,,$20.8m,Estimate,No,Yes,No,No,61%,$12.7m,$0.0m,$3.8m,$0.0m,$3.8m,,67%,0%,11%,0%,0%,78%,,67%,0%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$12.7m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.8m,$0.0m,$2.1m,$0.0m,,$25.3m,,$17.2m,$0.0m,$5.2m,$0.0m,,$0.0m,$0.0m,$22.3m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
727,Small,Vitality Biopharma,Public,North America,California,Los Angeles,,,$20.8m,Estimate,No,No,No,No,9%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,9%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$25.2m,,$2.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$8.1m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$2.9m,$5.4m,$0.0m,$0.0m,$0.0m,$0.0m
728,Small,UbiVac,Private,North America,Oregon,Portland,,,$20.7m,Estimate,No,Yes,No,No,52%,$10.9m,$1.6m,$3.9m,$0.0m,$5.5m,,56%,11%,11%,0%,0%,78%,,56%,11%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.9m,$1.6m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.8m,$0.9m,$2.2m,$0.0m,,$25.2m,,$16.7m,$2.4m,$6.0m,$0.0m,,$0.0m,$0.0m,$25.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
729,Small,InnoCare,Private,Asia/Oceania,China,Beijing,China,Shanghai,$20.7m,Estimate,Yes,No,No,No,30%,$6.2m,$0.0m,$3.7m,$0.0m,$3.7m,,38%,0%,13%,0%,0%,50%,,38%,0%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.2m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$2.1m,$0.0m,,$25.1m,,$12.1m,$0.0m,$7.3m,$0.0m,,$0.0m,$0.0m,$19.4m,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
730,Small,Phylogica,Public,Asia/Oceania,Australia,Mount Pleasant,,,$20.7m,Estimate,Yes,No,No,No,50%,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.5m,$0.0m,$0.0m,$0.0m,,$25.1m,,$17.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$17.2m,$0.0m,$0.0m,$7.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
731,Small,Neovacs,Public,Europe,France,Paris,,,$20.7m,Estimate,No,Yes,No,No,8%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$25.1m,,$2.2m,$0.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$2.2m,$10.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.5m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m
732,Small,Proximagen,Private,Europe,United Kingdom,London,,,$20.7m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$3.0m,$0.0m,$4.2m,,0%,10%,10%,0%,0%,20%,,0%,10%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.2m,$3.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$1.7m,$0.0m,,$25.1m,,$0.0m,$1.3m,$3.1m,$0.0m,,$0.0m,$12.0m,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m
733,Small,PDS Biotechnology,Private,North America,New Jersey,Princeton,,,$20.7m,Estimate,No,Yes,Yes,No,29%,$6.0m,$1.4m,$0.0m,$0.0m,$1.4m,,38%,13%,0%,0%,0%,50%,,38%,13%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.8m,$0.0m,$0.0m,,$25.1m,,$7.7m,$1.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$6.2m,$7.1m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m
734,Small,BCWorld Pharm,Public,Asia/Oceania,South Korea,Seoul,,,$20.7m,Estimate,No,No,No,No,37%,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.0m,$0.0m,$0.0m,,$25.1m,,$9.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.4m,$9.4m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$2.4m,$3.1m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m
735,Small,Synthon,Private,Europe,Netherlands,Nijmegen,,,$20.6m,Estimate,No,Yes,No,No,30%,$6.3m,$1.5m,$0.0m,$7.5m,$9.0m,,38%,13%,0%,13%,0%,63%,,13%,13%,0%,13%,0%,,25%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$0.0m,$7.5m,$0.0m,,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.9m,$0.0m,$4.2m,,$25.1m,,$8.2m,$2.0m,$0.0m,$9.7m,,$0.0m,$3.0m,$19.9m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
736,Small,Affilogic,Private,Europe,France,Nantes,,,$20.6m,Estimate,No,No,No,No,9%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,9%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$25.1m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.2m,$2.3m,$2.3m,$2.3m,$0.0m,$2.4m,$4.7m,$0.0m,$0.0m,$2.3m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m
737,Small,Synermore Biologics,Private,Asia/Oceania,,,,,$20.6m,Estimate,No,Yes,No,No,10%,$2.0m,$1.4m,$0.0m,$0.0m,$1.4m,,11%,11%,0%,0%,0%,22%,,11%,11%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$0.0m,$0.0m,,$25.0m,,$2.9m,$2.1m,$0.0m,$0.0m,,$3.4m,$0.0m,$5.0m,$3.8m,$0.0m,$0.0m,$1.0m,$9.2m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
738,Small,Millendo Therapeutics,Private,North America,,,,,$20.6m,Estimate,No,No,No,No,0%,$0.0m,$1.4m,$0.0m,$0.0m,$1.4m,,0%,14%,0%,0%,0%,14%,,0%,14%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,,$25.0m,,$0.0m,$2.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$10.7m,$0.0m,$8.7m,$0.0m,$0.0m
739,Small,Q BioMed,Public,North America,New York,New York,,,$20.5m,Estimate,No,No,No,No,9%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$24.9m,,$1.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$15.3m,$1.8m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
740,Small,NoNO,Private,North America,Ontario,Toronto,,,$20.5m,Estimate,No,No,No,No,7%,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,,10%,0%,0%,0%,0%,10%,,10%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$24.9m,,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$6.1m,$1.3m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$14.1m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m
741,Small,Oncoceutics,Private,North America,Pennsylvania,Philadelphia,New York,New York,$20.5m,Estimate,Yes,No,No,No,31%,$6.3m,$1.5m,$3.8m,$0.0m,$5.4m,,38%,13%,13%,0%,0%,63%,,38%,13%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.3m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.9m,$2.1m,$0.0m,,$24.8m,,$13.5m,$3.3m,$8.1m,$0.0m,,$0.0m,$0.0m,$24.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
742,Small,Zensun,Private,Asia/Oceania,,,,,$20.5m,Estimate,No,Yes,No,No,8%,$1.7m,$1.3m,$0.0m,$0.0m,$1.3m,,11%,11%,0%,0%,0%,22%,,11%,11%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.7m,$0.0m,$0.0m,,$24.8m,,$2.3m,$1.7m,$0.0m,$0.0m,,$0.0m,$1.9m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$13.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m
235,Small,Kura Oncology,Public,North America,Massachusetts,Cambridge,California,San Diego,$20.4m,Actual,Yes,No,No,No,18%,$3.6m,$2.6m,$6.5m,$0.0m,$9.1m,,25%,25%,25%,0%,0%,75%,,25%,25%,0%,0%,0%,,0%,0%,25%,0%,0%,,,,$3.6m,$2.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.5m,$0.0m,$0.0m,$1.9m,$1.5m,$3.6m,$0.0m,,$26.5m,,$7.5m,$5.4m,$13.5m,$0.0m,,$0.0m,$0.0m,$26.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
743,Small,Crescendo Biologics,Private,Europe,United Kingdom,Cambridge,,,$20.4m,Estimate,No,Yes,No,No,89%,$18.1m,$0.0m,$0.0m,$0.0m,$0.0m,,89%,0%,0%,0%,0%,89%,,89%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$18.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,,$24.7m,,$21.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$21.9m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
744,Small,Laboratorio Elea,Private,Latin America,,,,,$20.4m,Estimate,Yes,Yes,No,No,0%,$0.0m,$1.2m,$6.1m,$0.0m,$7.4m,,0%,17%,33%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,17%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$6.1m,$0.0m,$0.0m,$0.0m,$0.7m,$3.4m,$0.0m,,$24.7m,,$0.0m,$1.8m,$9.1m,$0.0m,,$0.0m,$0.0m,$10.9m,$0.0m,$13.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
745,Small,Boston Pharmaceuticals,Public,North America,Massachusetts,Cambridge,,,$20.3m,Estimate,No,No,No,No,9%,$1.9m,$1.4m,$0.0m,$0.0m,$1.4m,,9%,9%,0%,0%,0%,18%,,0%,9%,0%,0%,0%,,9%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$0.0m,$0.0m,,$24.7m,,$2.1m,$1.5m,$0.0m,$0.0m,,$0.0m,$1.8m,$3.6m,$12.6m,$1.7m,$0.0m,$0.7m,$1.7m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
236,Small,Conatus Pharmaceuticals,Public,North America,California,San Diego,,,$20.3m,Actual,No,No,No,No,6%,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,,7%,0%,0%,0%,0%,7%,,7%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,$0.0m,,$26.3m,,$1.2m,$0.0m,$0.0m,$0.0m,,$1.1m,$1.6m,$1.2m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$3.9m,$0.0m,$11.6m,$0.0m,$0.0m,$0.0m,$0.0m
746,Small,Context Therapeutics,Private,North America,Pennsylvania,Philadelphia,,,$20.3m,Estimate,No,No,No,No,10%,$2.0m,$0.0m,$3.6m,$0.0m,$3.6m,,14%,0%,14%,0%,0%,29%,,14%,0%,0%,0%,0%,,0%,0%,14%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,$1.0m,$0.0m,$2.0m,$0.0m,,$24.6m,,$2.8m,$0.0m,$5.1m,$0.0m,,$0.0m,$2.3m,$7.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$12.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
747,Small,CanBas,Public,Asia/Oceania,Japan,Numazu,,,$20.3m,Estimate,Yes,Yes,No,No,43%,$8.6m,$3.1m,$3.9m,$0.0m,$7.0m,,50%,25%,13%,0%,0%,88%,,38%,13%,13%,0%,0%,,13%,13%,0%,0%,0%,,,,$6.5m,$1.6m,$3.9m,$0.0m,$0.0m,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,$4.6m,$1.8m,$2.2m,$0.0m,,$24.6m,,$13.6m,$4.9m,$6.1m,$0.0m,,$0.0m,$0.0m,$24.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
748,Small,ISR Immune System Regulation,Public,Europe,Sweden,Stockholm,,,$20.2m,Estimate,No,Yes,No,No,9%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$24.6m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$4.9m,$0.0m,$17.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
749,Small,Codagenix,Private,North America,New York,Farmingdale,,,$20.2m,Estimate,Yes,Yes,No,No,21%,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$24.5m,,$7.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,$17.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
750,Small,Navipharm,Private,Asia/Oceania,,,,,$20.2m,Estimate,No,No,No,No,8%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$24.5m,,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.9m,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,$8.6m,$0.0m,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m
751,Small,Arog Pharmaceuticals,Private,North America,Texas,Dallas,,,$20.1m,Estimate,Yes,No,No,No,8%,$1.6m,$1.1m,$2.9m,$5.6m,$9.6m,,13%,13%,13%,13%,0%,50%,,0%,0%,0%,0%,0%,,13%,13%,13%,13%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.6m,$1.1m,$2.9m,$5.6m,$0.0m,$0.8m,$0.6m,$1.6m,$3.2m,,$24.5m,,$3.0m,$2.2m,$5.4m,$10.8m,,$0.0m,$0.0m,$21.4m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
752,Small,Tessa Therapeutics,Private,Asia/Oceania,Singapore,Singapore,,,$20.1m,Estimate,No,Yes,Yes,Yes,20%,$4.0m,$1.5m,$0.0m,$7.2m,$8.7m,,33%,17%,0%,17%,0%,67%,,33%,17%,0%,17%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$1.5m,$0.0m,$7.2m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.8m,$0.0m,$4.0m,,$24.4m,,$7.8m,$2.8m,$0.0m,$13.9m,,$0.0m,$0.0m,$24.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
753,Small,Phoenix Biotechnology,Private,North America,Texas,San Antonio,,,$20.1m,Estimate,No,No,No,No,10%,$2.0m,$0.0m,$3.6m,$0.0m,$3.6m,,13%,0%,13%,0%,0%,25%,,13%,0%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.0m,$0.0m,,$24.4m,,$3.7m,$0.0m,$6.8m,$0.0m,,$0.0m,$3.2m,$10.5m,$0.0m,$0.0m,$0.0m,$0.0m,$10.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
754,Small,Maxinovel Pharmaceuticals,Private,Asia/Oceania,China,Shanghai,,,$20.1m,Estimate,Yes,Yes,No,No,78%,$15.6m,$0.0m,$0.0m,$0.0m,$0.0m,,78%,0%,0%,0%,0%,78%,,78%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$15.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.3m,$0.0m,$0.0m,$0.0m,,$24.3m,,$21.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$21.2m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
755,Small,Enochian Biosciences,Public,Europe,California,Los Angeles,,,$20.0m,Estimate,No,Yes,No,Yes,31%,$6.3m,$0.0m,$0.0m,$7.5m,$7.5m,,43%,0%,0%,14%,0%,57%,,43%,0%,0%,14%,0%,,0%,0%,0%,0%,0%,,,,$6.3m,$0.0m,$0.0m,$7.5m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$4.2m,,$24.3m,,$8.9m,$0.0m,$0.0m,$10.5m,,$0.0m,$0.0m,$19.4m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
237,Small,ArQule,Public,North America,,,,,$20.0m,Actual,Yes,No,No,No,0%,$0.0m,$2.7m,$2.7m,$2.7m,$8.1m,,0%,25%,10%,5%,0%,40%,,0%,25%,10%,5%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$2.7m,$2.7m,$2.7m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.5m,$1.5m,$1.5m,,$26.0m,,$0.0m,$5.9m,$5.9m,$5.8m,,$0.0m,$0.0m,$17.7m,$0.0m,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m
756,Small,CIGB,Private,Latin America,Cuba,Havana,,,$20.0m,Estimate,No,Yes,No,No,21%,$4.1m,$1.5m,$3.7m,$0.0m,$5.2m,,22%,11%,11%,0%,0%,44%,,22%,11%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.8m,$2.1m,$0.0m,,$24.3m,,$4.9m,$1.8m,$4.4m,$0.0m,,$0.0m,$0.0m,$11.0m,$3.3m,$2.2m,$0.0m,$0.0m,$4.5m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
757,Small,Vect-Horus,Private,Europe,France,Marseille,,,$19.9m,Estimate,No,No,No,No,36%,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,,36%,0%,0%,0%,0%,36%,,36%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,,$24.2m,,$9.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$7.8m,$9.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m
758,Small,Mateon Therapeutics,Public,North America,California,South San Francisco,,,$19.9m,Estimate,Yes,No,No,No,43%,$8.6m,$1.6m,$3.9m,$0.0m,$5.5m,,50%,13%,13%,0%,0%,75%,,50%,13%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.6m,$1.6m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.9m,$2.2m,$0.0m,,$24.2m,,$14.8m,$2.7m,$6.7m,$0.0m,,$0.0m,$0.0m,$24.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
759,Small,C4X Discovery,Public,Europe,United Kingdom,Manchester,,,$19.9m,Estimate,No,No,No,No,18%,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,18%,0%,0%,0%,0%,18%,,18%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,,$24.2m,,$4.4m,$0.0m,$0.0m,$0.0m,,$2.1m,$7.1m,$4.4m,$4.4m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m
122,Small,Hetero Drugs,Private,Asia/Oceania,,,,,$19.9m,Estimate,Yes,Yes,No,No,9%,$1.9m,$0.0m,$0.0m,$6.6m,$6.6m,,17%,0%,0%,17%,0%,33%,,17%,0%,0%,17%,0%,,0%,0%,0%,0%,0%,,,,1.86347768567384,$0.0m,$0.0m,$6.6m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$3.7m,,$24.1m,,$4.0m,$0.0m,$0.0m,$14.2m,,$0.0m,$0.0m,$18.2m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
760,Small,Nihon Medi-Physics,Private,Asia/Oceania,,,,,$19.8m,Estimate,No,Yes,No,No,8%,$1.6m,$0.0m,$2.8m,$5.6m,$8.5m,,20%,0%,20%,20%,0%,60%,,0%,0%,0%,0%,0%,,20%,0%,20%,20%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.6m,$0.0m,$2.8m,$5.6m,$0.0m,$0.8m,$0.0m,$1.6m,$3.1m,,$24.1m,,$2.0m,$0.0m,$3.6m,$7.1m,,$0.0m,$0.0m,$12.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$11.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
761,Small,Immunovative Therapies,Private,Middle East/Africa,,,,,$19.8m,Estimate,No,Yes,No,Yes,10%,$2.0m,$1.5m,$7.3m,$0.0m,$8.8m,,13%,13%,25%,0%,0%,50%,,13%,13%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.5m,$7.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$4.1m,$0.0m,,$24.0m,,$4.0m,$2.9m,$14.3m,$0.0m,,$0.0m,$0.0m,$21.2m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
762,Small,Nanology,Private,North America,Texas,Fort Worth,,,$19.7m,Estimate,No,No,No,No,21%,$4.1m,$0.0m,$3.7m,$0.0m,$3.7m,,25%,0%,13%,0%,0%,38%,,13%,0%,0%,0%,0%,,13%,0%,13%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$0.0m,$3.7m,$0.0m,$0.0m,$2.2m,$0.0m,$2.1m,$0.0m,,$23.9m,,$6.6m,$0.0m,$5.9m,$0.0m,,$0.0m,$0.0m,$12.5m,$0.0m,$0.0m,$0.0m,$6.4m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
763,Small,Shanghai PerHum Therapeutics,Private,Asia/Oceania,China,Shanghai,,,$19.7m,Estimate,No,Yes,Yes,Yes,11%,$2.2m,$0.0m,$8.0m,$0.0m,$8.0m,,20%,0%,40%,0%,0%,60%,,0%,0%,0%,0%,0%,,20%,0%,40%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$8.0m,$0.0m,$0.0m,$1.2m,$0.0m,$4.5m,$0.0m,,$23.9m,,$5.2m,$0.0m,$18.7m,$0.0m,,$0.0m,$0.0m,$23.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
764,Small,BioIntegrator,Private,Europe,Russia,Moscow,,,$19.6m,Estimate,Yes,Yes,No,No,20%,$4.0m,$4.4m,$0.0m,$0.0m,$4.4m,,18%,27%,0%,0%,0%,45%,,18%,27%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$4.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$2.4m,$0.0m,$0.0m,,$23.8m,,$6.6m,$7.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.8m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
765,Small,Provectus Biopharmaceuticals,Public,North America,Tennessee,Knoxville,,,$19.6m,Estimate,No,Yes,No,No,10%,$1.9m,$1.4m,$3.5m,$6.9m,$11.8m,,14%,14%,14%,14%,0%,57%,,14%,14%,14%,14%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$1.4m,$3.5m,$6.9m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$2.0m,$3.9m,,$23.8m,,$2.8m,$2.0m,$5.1m,$10.0m,,$0.0m,$0.0m,$19.9m,$0.0m,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
766,Small,Nordic Group,Public,Asia/Oceania,,,,,$19.6m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$2.9m,$5.8m,$8.7m,,0%,0%,20%,20%,0%,40%,,0%,0%,0%,0%,0%,,0%,0%,20%,20%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.9m,$5.8m,$0.0m,$0.0m,$0.0m,$1.6m,$3.3m,,$23.8m,,$0.0m,$0.0m,$6.3m,$12.5m,,$0.0m,$0.0m,$18.8m,$0.0m,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
767,Small,Esperance Pharmaceuticals,Private,North America,Texas,Houston,,,$19.6m,Estimate,No,Yes,No,No,32%,$6.4m,$1.5m,$3.8m,$0.0m,$5.4m,,38%,13%,13%,0%,0%,63%,,38%,13%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.4m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.9m,$2.1m,$0.0m,,$23.8m,,$12.9m,$3.1m,$7.8m,$0.0m,,$0.0m,$0.0m,$23.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
768,Small,CinnaGen,Private,Middle East/Africa,,,,,$19.5m,Estimate,No,Yes,No,No,9%,$1.8m,$0.0m,$0.0m,$6.3m,$6.3m,,20%,0%,0%,20%,0%,40%,,20%,0%,0%,20%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$6.3m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$3.5m,,$23.7m,,$2.9m,$0.0m,$0.0m,$10.4m,,$0.0m,$0.0m,$13.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$8.3m,$0.0m,$0.0m,$0.0m
769,Small,Biogenera,Private,Europe,Italy,Bologna,,,$19.5m,Estimate,Yes,No,Yes,No,67%,$13.0m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$13.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.9m,$0.0m,$0.0m,$0.0m,,$23.7m,,$17.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$17.9m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m
770,Small,Harpoon Therapeutics,Private,North America,California,South San Francisco,,,$19.5m,Estimate,No,Yes,No,No,69%,$13.4m,$1.6m,$0.0m,$0.0m,$1.6m,,67%,11%,0%,0%,0%,78%,,67%,11%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$13.4m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.1m,$0.9m,$0.0m,$0.0m,,$23.6m,,$21.1m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$23.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
771,Small,Treos Bio,Private,North America,California,San Francisco,United Kingdom,London,$19.5m,Estimate,Yes,Yes,No,No,69%,$13.4m,$1.6m,$0.0m,$0.0m,$1.6m,,67%,11%,0%,0%,0%,78%,,67%,11%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$13.4m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.1m,$0.9m,$0.0m,$0.0m,,$23.6m,,$21.1m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$23.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
772,Small,Oncomatryx,Private,Europe,Spain,Bilbao,,,$19.5m,Estimate,Yes,Yes,No,No,56%,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,,56%,0%,0%,0%,0%,56%,,56%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,,$23.6m,,$23.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$23.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
773,Small,Wakunaga,Private,Asia/Oceania,,,,,$19.4m,Estimate,No,No,No,No,10%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$23.6m,,$2.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$21.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
774,Small,Cantex,Private,North America,Florida,Weston,,,$19.4m,Estimate,Yes,No,No,No,11%,$2.1m,$3.0m,$7.5m,$0.0m,$10.5m,,13%,25%,25%,0%,0%,63%,,13%,25%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$3.0m,$7.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$1.7m,$4.2m,$0.0m,,$23.6m,,$3.9m,$5.6m,$14.0m,$0.0m,,$0.0m,$0.0m,$23.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
775,Small,Jounce Therapeutics,Public,North America,Massachusetts,Cambridge,,,$19.4m,Estimate,No,Yes,No,No,56%,$10.8m,$0.0m,$3.9m,$0.0m,$3.9m,,71%,0%,14%,0%,0%,86%,,71%,0%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.8m,$0.0m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.0m,$2.2m,$0.0m,,$23.5m,,$17.3m,$0.0m,$6.2m,$0.0m,,$0.0m,$0.0m,$23.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
776,Small,Vedanta Biosciences,Private,North America,Massachusetts,Cambridge,,,$19.4m,Estimate,No,Yes,No,No,10%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,9%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$23.5m,,$2.7m,$0.0m,$0.0m,$0.0m,,$2.6m,$0.0m,$2.7m,$5.5m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$2.7m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m
777,Small,Oryx,Private,Europe,Germany,Munich,,,$19.3m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$10.8m,$0.0m,$10.8m,,0%,0%,60%,0%,0%,60%,,0%,0%,60%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$10.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.0m,$0.0m,,$23.4m,,$0.0m,$0.0m,$23.4m,$0.0m,,$0.0m,$0.0m,$23.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
778,Small,AiVita Biomedical,Private,North America,,,,,$19.2m,Estimate,No,Yes,No,Yes,0%,$0.0m,$0.0m,$10.9m,$0.0m,$10.9m,,0%,0%,50%,0%,0%,50%,,0%,0%,33%,0%,0%,,0%,0%,17%,0%,0%,,,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,$6.1m,$0.0m,,$23.4m,,$0.0m,$0.0m,$20.2m,$0.0m,,$0.0m,$0.0m,$20.2m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
779,Small,Tarveda Therapeutics,Private,North America,,,,,$19.2m,Estimate,Yes,No,No,No,0%,$0.0m,$1.5m,$7.6m,$0.0m,$9.1m,,0%,17%,33%,0%,0%,50%,,0%,17%,17%,0%,0%,,0%,0%,17%,0%,0%,,,,$0.0m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,$0.9m,$4.2m,$0.0m,,$23.3m,,$0.0m,$3.9m,$19.4m,$0.0m,,$0.0m,$0.0m,$23.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
780,Small,Pantarhei Bioscience,Private,Europe,Netherlands,Utrecht,,,$19.2m,Estimate,No,Yes,No,No,10%,$1.8m,$0.0m,$3.3m,$0.0m,$3.3m,,13%,0%,13%,0%,0%,25%,,13%,0%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$1.9m,$0.0m,,$23.3m,,$2.2m,$0.0m,$4.0m,$0.0m,,$0.0m,$3.5m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.5m,$0.0m,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
781,Small,BONAC Corporation,Private,Asia/Oceania,Japan,Okinawa,Japan,Fukuoka,$19.2m,Estimate,No,No,No,No,20%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$23.3m,,$6.8m,$0.0m,$0.0m,$0.0m,,$3.3m,$0.0m,$6.8m,$0.0m,$9.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
782,Small,3D Medicines (Sichuan),Private,Asia/Oceania,China,Shanghai,China,Beijing,$19.1m,Estimate,No,Yes,No,No,59%,$11.2m,$1.6m,$4.0m,$0.0m,$5.7m,,63%,13%,13%,0%,0%,88%,,50%,0%,0%,0%,0%,,13%,13%,13%,0%,0%,,,,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.2m,$1.6m,$4.0m,$0.0m,$0.0m,$5.9m,$0.9m,$2.3m,$0.0m,,$23.2m,,$15.4m,$2.2m,$5.6m,$0.0m,,$0.0m,$0.0m,$23.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
783,Small,Tella,Public,Asia/Oceania,,,,,$19.1m,Estimate,No,Yes,No,Yes,0%,$0.0m,$1.4m,$3.5m,$7.0m,$11.9m,,0%,20%,20%,20%,0%,60%,,0%,20%,20%,20%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$3.5m,$7.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.0m,$3.9m,,$23.2m,,$0.0m,$2.8m,$6.9m,$13.5m,,$0.0m,$0.0m,$23.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
784,Small,BerGenBio,Public,Europe,Norway,Bergen,,,$19.1m,Estimate,Yes,Yes,No,No,35%,$6.6m,$1.6m,$4.0m,$0.0m,$5.6m,,43%,14%,14%,0%,0%,71%,,29%,0%,0%,0%,0%,,14%,14%,14%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.2m,$1.6m,$4.0m,$0.0m,$0.0m,$3.5m,$0.9m,$2.2m,$0.0m,,$23.2m,,$12.6m,$3.0m,$7.6m,$0.0m,,$0.0m,$0.0m,$23.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
785,Small,Samumed,Private,North America,,,,,$19.1m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,9%,0%,0%,0%,9%,,0%,9%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$23.1m,,$0.0m,$1.6m,$0.0m,$0.0m,,$2.3m,$1.6m,$1.6m,$1.8m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,$12.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
786,Small,Paras Biopharmaceuticals Finland,Private,Europe,Finland,Oulu,,,$19.0m,Estimate,No,Yes,No,No,20%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$23.1m,,$4.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$2.4m,$2.3m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$2.4m,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m
787,Small,Berg,Private,North America,,,,,$19.0m,Estimate,No,No,No,No,0%,$0.0m,$1.4m,$3.4m,$0.0m,$4.8m,,0%,11%,11%,0%,0%,22%,,0%,11%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$1.9m,$0.0m,,$23.1m,,$0.0m,$2.7m,$6.7m,$0.0m,,$0.0m,$6.0m,$9.5m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m
788,Small,miRagen Therapeutics,Public,North America,,,,,$18.9m,Estimate,Yes,No,No,No,0%,$0.0m,$1.3m,$0.0m,$0.0m,$1.3m,,0%,8%,0%,0%,0%,8%,,0%,8%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$23.0m,,$0.0m,$2.1m,$0.0m,$0.0m,,$3.0m,$2.1m,$2.1m,$3.3m,$2.2m,$0.0m,$6.3m,$0.0m,$0.0m,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
789,Small,IntelGenx,Public,North America,,,,,$18.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$22.9m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$14.2m,$0.0m,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,$1.0m,$0.6m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m
790,Small,Asana BioSciences,Private,North America,New Jersey,Lawrenceville,,,$18.8m,Estimate,No,Yes,No,No,20%,$3.8m,$2.8m,$0.0m,$0.0m,$2.8m,,20%,20%,0%,0%,0%,40%,,20%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$1.5m,$0.0m,$0.0m,,$22.9m,,$4.8m,$3.5m,$0.0m,$0.0m,,$2.1m,$4.1m,$8.4m,$0.0m,$0.0m,$0.0m,$6.1m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
791,Small,Abide Therapeutics,Private,North America,California,San Diego,New Jersey,Princeton,$18.8m,Estimate,No,Yes,No,No,12%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,9%,0%,0%,0%,0%,9%,,9%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$22.9m,,$2.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$7.1m,$2.7m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$4.8m,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m
792,Small,Cancer Therapeutics CRC,Private,Asia/Oceania,Australia,Melbourne,,,$18.8m,Estimate,Yes,No,No,No,44%,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,,44%,0%,0%,0%,0%,44%,,44%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.4m,$0.0m,$0.0m,$0.0m,,$22.9m,,$15.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$15.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$4.1m,$0.0m,$0.0m,$0.0m
793,Small,Synairgen,Public,Europe,United Kingdom,Southampton,,,$18.8m,Estimate,No,No,No,No,9%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,8%,0%,0%,0%,0%,8%,,0%,0%,0%,0%,0%,,8%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$22.8m,,$1.9m,$0.0m,$0.0m,$0.0m,,$9.3m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$4.0m,$2.9m,$2.4m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m
794,Small,Lycera,Private,North America,Michigan,Ann Arbor,New York,New York,$18.8m,Estimate,No,Yes,No,No,10%,$1.9m,$0.0m,$3.4m,$0.0m,$3.4m,,17%,0%,17%,0%,0%,33%,,17%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$1.9m,$0.0m,,$22.8m,,$2.8m,$0.0m,$5.1m,$0.0m,,$0.0m,$0.0m,$7.9m,$2.6m,$0.0m,$0.0m,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m
795,Small,Hybrigenics,Public,Europe,France,Paris,,,$18.8m,Estimate,Yes,No,No,No,34%,$6.3m,$0.0m,$3.8m,$0.0m,$3.8m,,43%,0%,14%,0%,0%,57%,,29%,0%,0%,0%,0%,,14%,0%,14%,0%,0%,,,,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$3.8m,$0.0m,$0.0m,$3.3m,$0.0m,$2.1m,$0.0m,,$22.8m,,$12.4m,$0.0m,$7.5m,$0.0m,,$0.0m,$0.0m,$19.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m
796,Small,Tetra Bio-Pharma,Public,North America,,,,,$18.8m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$22.8m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$18.3m,$0.0m,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m
797,Small,3B Pharmaceuticals,Private,Europe,Germany,Berlin,,,$18.8m,Estimate,No,No,No,No,46%,$8.7m,$1.6m,$3.9m,$0.0m,$5.5m,,57%,14%,14%,0%,0%,86%,,57%,14%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.7m,$1.6m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.9m,$2.2m,$0.0m,,$22.8m,,$14.0m,$2.5m,$6.3m,$0.0m,,$0.0m,$0.0m,$22.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
798,Small,SBI Biotech,Private,Asia/Oceania,,,,,$18.8m,Estimate,No,No,No,No,11%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,10%,0%,0%,0%,0%,10%,,10%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$22.8m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.2m,$11.0m,$0.0m,$0.0m,$2.8m,$0.0m,$2.2m,$0.0m,$1.7m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m
799,Small,OncBioMune Pharmaceuticals,Public,North America,California,Los Angeles,,,$18.7m,Estimate,Yes,Yes,No,Yes,45%,$8.5m,$0.0m,$3.8m,$0.0m,$3.8m,,50%,0%,13%,0%,0%,63%,,50%,0%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.5m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$2.2m,$0.0m,,$22.7m,,$15.7m,$0.0m,$7.1m,$0.0m,,$0.0m,$0.0m,$22.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
800,Small,FirstString Research,Private,North America,South Carolina,Mount Pleasant,,,$18.7m,Estimate,No,No,No,No,8%,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$22.7m,,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.3m,$1.5m,$0.0m,$2.8m,$0.0m,$6.1m,$0.0m,$0.0m,$7.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
801,Small,Mersana Therapeutics,Public,North America,Massachusetts,Cambridge,,,$18.7m,Estimate,No,Yes,No,No,47%,$8.8m,$4.8m,$0.0m,$0.0m,$4.8m,,36%,27%,0%,0%,0%,64%,,27%,27%,0%,0%,0%,,9%,0%,0%,0%,0%,,,,$6.6m,$4.8m,$0.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$2.7m,$0.0m,$0.0m,,$22.7m,,$12.8m,$7.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$19.7m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
802,Small,Aileron Therapeutics,Public,North America,Massachusetts,Watertown,,,$18.6m,Estimate,Yes,No,No,No,11%,$2.0m,$1.5m,$3.6m,$0.0m,$5.1m,,13%,13%,13%,0%,0%,38%,,13%,13%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.5m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$2.0m,$0.0m,,$22.6m,,$3.7m,$2.6m,$6.6m,$0.0m,,$0.0m,$0.0m,$12.9m,$3.3m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m
803,Small,Allakos,Public,North America,California,Redwood City,,,$18.6m,Estimate,No,Yes,No,No,11%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$22.6m,,$2.2m,$0.0m,$0.0m,$0.0m,,$8.7m,$0.0m,$2.2m,$0.0m,$2.6m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$2.2m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m
804,Small,Shuttle Pharmaceuticals,Private,North America,Maryland,Germantown,Maryland,Rockville,$18.6m,Estimate,No,No,No,No,14%,$2.5m,$0.0m,$2.3m,$4.5m,$6.8m,,29%,0%,14%,14%,0%,57%,,29%,0%,0%,0%,0%,,0%,0%,14%,14%,0%,,,,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.3m,$4.5m,$0.0m,$1.4m,$0.0m,$1.3m,$2.5m,,$22.5m,,$5.1m,$0.0m,$4.6m,$9.1m,,$0.0m,$0.0m,$18.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m
805,Small,Vaccibody,Private,Europe,Norway,Oslo,,,$18.5m,Estimate,No,Yes,Yes,No,10%,$1.9m,$0.0m,$3.5m,$0.0m,$3.5m,,20%,0%,20%,0%,0%,40%,,20%,0%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$2.0m,$0.0m,,$22.5m,,$2.9m,$0.0m,$5.2m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.7m,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
806,Small,Lytix Biopharma,Private,Europe,Norway,Tromso,,,$18.5m,Estimate,Yes,Yes,No,No,35%,$6.4m,$1.5m,$3.8m,$0.0m,$5.4m,,43%,14%,14%,0%,0%,71%,,43%,14%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.4m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.9m,$2.2m,$0.0m,,$22.4m,,$12.2m,$2.9m,$7.3m,$0.0m,,$0.0m,$0.0m,$22.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
807,Small,ManRos Therapeutics,Private,North America,,,,,$18.4m,Estimate,No,No,No,No,0%,$0.0m,$1.1m,$2.8m,$0.0m,$4.0m,,0%,14%,14%,0%,0%,29%,,0%,0%,0%,0%,0%,,0%,14%,14%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.1m,$2.8m,$0.0m,$0.0m,$0.0m,$0.6m,$1.6m,$0.0m,,$22.4m,,$0.0m,$1.3m,$3.3m,$0.0m,,$4.9m,$0.0m,$4.6m,$8.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m,$0.0m
808,Small,OncoImmune,Private,North America,Maryland,Rockville,,,$18.4m,Estimate,Yes,Yes,No,No,21%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,29%,0%,0%,0%,0%,29%,,29%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$22.3m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$14.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m
809,Small,HUYA Bioscience,Private,North America,,,,,$18.4m,Estimate,Yes,No,No,No,0%,$0.0m,$1.2m,$3.1m,$6.1m,$10.5m,,0%,14%,14%,14%,0%,43%,,0%,0%,0%,0%,0%,,0%,14%,14%,14%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$3.1m,$6.1m,$0.0m,$0.0m,$0.7m,$1.7m,$3.4m,,$22.3m,,$0.0m,$2.0m,$4.9m,$9.7m,,$0.0m,$0.0m,$16.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
810,Small,Praxis,Public,Asia/Oceania,,,,,$18.3m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$3.4m,$0.0m,$3.4m,,0%,0%,17%,0%,0%,17%,,0%,0%,0%,0%,0%,,0%,0%,17%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,,$22.3m,,$0.0m,$0.0m,$7.0m,$0.0m,,$0.0m,$5.3m,$7.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.9m,$0.0m,$0.0m
811,Small,Immune Therapeutics,Public,North America,Florida,Orlando,,,$18.3m,Estimate,Yes,Yes,No,Yes,11%,$2.0m,$0.0m,$3.6m,$0.0m,$3.6m,,17%,0%,17%,0%,0%,33%,,17%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.0m,$0.0m,,$22.3m,,$3.7m,$0.0m,$6.6m,$0.0m,,$0.0m,$0.0m,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m,$8.6m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
812,Small,Kolon Life Science,Public,Asia/Oceania,South Korea,Seoul,,,$18.3m,Estimate,No,No,Yes,No,22%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$22.2m,,$3.7m,$0.0m,$0.0m,$0.0m,,$4.2m,$1.7m,$3.7m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
813,Small,Neumedicines,Private,North America,California,Pasadena,,,$18.3m,Estimate,Yes,Yes,No,No,17%,$3.2m,$0.0m,$2.9m,$0.0m,$2.9m,,25%,0%,13%,0%,0%,38%,,13%,0%,13%,0%,0%,,13%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$2.9m,$0.0m,$0.0m,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,$1.6m,$0.0m,,$22.2m,,$5.3m,$0.0m,$4.8m,$0.0m,,$0.0m,$0.0m,$10.1m,$0.0m,$0.0m,$0.0m,$4.1m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.1m,$0.0m
814,Small,Galera Therapeutics,Private,North America,,,,,$18.2m,Estimate,No,No,No,No,0%,$0.0m,$2.9m,$3.6m,$0.0m,$6.5m,,0%,29%,14%,0%,0%,43%,,0%,29%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$2.9m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$2.0m,$0.0m,,$22.1m,,$0.0m,$4.4m,$5.5m,$0.0m,,$0.0m,$0.0m,$9.9m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$7.5m,$0.0m,$0.0m,$0.0m,$0.0m
815,Small,Ichor Medical Systems,Private,Asia/Oceania,,,,,$18.1m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$2.8m,$0.0m,$2.8m,,0%,0%,11%,0%,0%,11%,,0%,0%,0%,0%,0%,,0%,0%,11%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,,$22.0m,,$0.0m,$0.0m,$3.1m,$0.0m,,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$13.5m,$5.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
816,Small,Zhejiang Haichang Biotechnology,Private,Asia/Oceania,China,Hangzhou,,,$18.1m,Estimate,No,No,No,No,25%,$4.6m,$0.0m,$4.1m,$0.0m,$4.1m,,33%,0%,17%,0%,0%,50%,,0%,0%,0%,0%,0%,,33%,0%,17%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.6m,$0.0m,$4.1m,$0.0m,$0.0m,$2.4m,$0.0m,$2.3m,$0.0m,,$22.0m,,$11.6m,$0.0m,$10.4m,$0.0m,,$0.0m,$0.0m,$22.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
817,Small,Alligator Bioscience,Public,Europe,Sweden,Lund,,,$18.0m,Estimate,No,Yes,No,No,78%,$14.0m,$1.7m,$0.0m,$0.0m,$1.7m,,75%,13%,0%,0%,0%,88%,,63%,13%,0%,0%,0%,,13%,0%,0%,0%,0%,,,,$11.7m,$1.7m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$7.4m,$0.9m,$0.0m,$0.0m,,$21.9m,,$19.5m,$2.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$21.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
818,Small,Rafa Laboratories,Private,Asia/Oceania,,,,,$18.0m,Estimate,Yes,Yes,No,No,11%,$1.9m,$0.0m,$3.4m,$6.7m,$10.2m,,20%,0%,20%,20%,0%,60%,,0%,0%,0%,0%,0%,,20%,0%,20%,20%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$0.0m,$3.4m,$6.7m,$0.0m,$1.0m,$0.0m,$1.9m,$3.8m,,$21.9m,,$3.4m,$0.0m,$6.2m,$12.2m,,$0.0m,$0.0m,$21.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
819,Small,Sophiris Bio,Public,North America,California,La Jolla,,,$18.0m,Estimate,No,No,No,No,10%,$1.8m,$0.0m,$6.6m,$0.0m,$6.6m,,20%,0%,40%,0%,0%,60%,,0%,0%,20%,0%,0%,,20%,0%,20%,0%,0%,,,,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,,$1.8m,$0.0m,$3.3m,$0.0m,$0.0m,$1.0m,$0.0m,$3.7m,$0.0m,,$21.8m,,$2.2m,$0.0m,$7.9m,$0.0m,,$0.0m,$0.0m,$10.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$11.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
820,Small,Monopar Therapeutics,Private,North America,Illinois,Chicago,,,$18.0m,Estimate,Yes,Yes,No,No,11%,$1.9m,$1.4m,$3.5m,$0.0m,$4.9m,,17%,17%,17%,0%,0%,50%,,0%,0%,0%,0%,0%,,17%,17%,17%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$1.4m,$3.5m,$0.0m,$0.0m,$1.0m,$0.8m,$2.0m,$0.0m,,$21.8m,,$2.7m,$2.0m,$4.9m,$0.0m,,$0.0m,$0.0m,$9.7m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m
821,Small,4P-Pharma,Private,Europe,France,Lille,,,$17.9m,Estimate,No,No,No,No,46%,$8.3m,$0.0m,$0.0m,$0.0m,$0.0m,,44%,0%,0%,0%,0%,44%,,44%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.4m,$0.0m,$0.0m,$0.0m,,$21.7m,,$10.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$6.6m,$10.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
822,Small,Splash Pharmaceuticals,Private,North America,California,San Diego,,,$17.9m,Estimate,No,No,No,No,22%,$4.0m,$0.0m,$3.6m,$0.0m,$3.6m,,29%,0%,14%,0%,0%,43%,,29%,0%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$2.0m,$0.0m,,$21.7m,,$7.6m,$0.0m,$6.9m,$0.0m,,$0.0m,$0.0m,$14.5m,$3.6m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
823,Small,RS Research,Private,Europe,Switzerland,Lozan,,,$17.8m,Estimate,No,No,No,No,75%,$13.3m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$13.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.1m,$0.0m,$0.0m,$0.0m,,$21.6m,,$21.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$21.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
824,Small,VLP Therapeutics,Private,North America,Maryland,Gaithersburg,,,$17.8m,Estimate,No,Yes,No,No,22%,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,22%,0%,0%,0%,0%,22%,,22%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$21.5m,,$6.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.1m,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,$6.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.0m
825,Small,Beijing Tri-Prime Genetic,Private,Asia/Oceania,,,,,$17.7m,Estimate,No,No,No,No,11%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$21.5m,,$2.5m,$0.0m,$0.0m,$0.0m,,$7.5m,$0.0m,$2.5m,$2.5m,$0.0m,$0.0m,$0.0m,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
826,Small,Polyphor,Public,Europe,Switzerland,Basel,,,$17.7m,Estimate,No,No,No,No,0%,$0.0m,$1.5m,$0.0m,$0.0m,$1.5m,,0%,14%,0%,0%,0%,14%,,0%,14%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,,$21.5m,,$0.0m,$2.0m,$0.0m,$0.0m,,$5.1m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$14.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
827,Small,Samsung Bioepis,Private,Asia/Oceania,,,,,$17.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.1m,$0.0m,$5.6m,$6.8m,,0%,17%,0%,17%,0%,33%,,0%,17%,0%,17%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.1m,$0.0m,$5.6m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$3.2m,,$21.5m,,$0.0m,$1.5m,$0.0m,$7.3m,,$0.0m,$0.0m,$8.8m,$0.0m,$11.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m
828,Small,Generex,Public,North America,,,,,$17.7m,Estimate,No,Yes,No,Yes,0%,$0.0m,$2.8m,$3.5m,$0.0m,$6.3m,,0%,20%,10%,0%,0%,30%,,0%,20%,10%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$2.8m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$1.9m,$0.0m,,$21.5m,,$0.0m,$4.0m,$4.9m,$0.0m,,$2.3m,$2.2m,$8.9m,$0.0m,$0.0m,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m
829,Small,Galectin Therapeutics,Public,North America,,,,,$17.7m,Estimate,No,No,No,No,0%,$0.0m,$1.3m,$0.0m,$0.0m,$1.3m,,0%,11%,0%,0%,0%,11%,,0%,11%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$21.4m,,$0.0m,$2.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$2.0m,$2.2m,$0.0m,$0.0m,$4.6m,$0.0m,$2.2m,$2.0m,$0.0m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m
830,Small,Symic Biomedical,Private,North America,California,Emeryville,,,$17.6m,Estimate,No,No,No,No,10%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$21.4m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$5.2m,$6.3m,$2.0m,$0.0m,$0.0m,$1.6m,$0.0m
831,Small,Bioneer,Public,Asia/Oceania,South Korea,Daejeon,,,$17.6m,Estimate,No,No,No,No,22%,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,22%,0%,0%,0%,0%,22%,,22%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$21.4m,,$7.2m,$0.0m,$0.0m,$0.0m,,$3.5m,$0.0m,$7.2m,$0.0m,$0.0m,$3.8m,$0.0m,$3.6m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m
832,Small,PharmaCyte Biotech,Public,North America,California,Laguna Hills,,,$17.6m,Estimate,No,No,No,Yes,11%,$2.0m,$0.0m,$3.6m,$0.0m,$3.6m,,14%,0%,14%,0%,0%,29%,,14%,0%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$2.0m,$0.0m,,$21.4m,,$3.9m,$0.0m,$7.1m,$0.0m,,$0.0m,$0.0m,$11.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.6m,$6.8m,$0.0m,$0.0m,$0.0m,$0.0m
833,Small,Pharmsynthez,Public,Europe,Russia,St Petersburg,,,$17.6m,Estimate,No,No,No,No,8%,$1.5m,$0.0m,$2.7m,$0.0m,$2.7m,,20%,0%,20%,0%,0%,40%,,20%,0%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.5m,$0.0m,$2.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$1.5m,$0.0m,,$21.4m,,$1.8m,$0.0m,$3.3m,$0.0m,,$12.4m,$3.9m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
834,Small,Kiromic,Private,North America,Texas,Houston,,,$17.6m,Estimate,Yes,Yes,No,Yes,34%,$6.0m,$0.0m,$3.6m,$0.0m,$3.6m,,38%,0%,13%,0%,0%,50%,,38%,0%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$2.0m,$0.0m,,$21.3m,,$11.2m,$0.0m,$6.8m,$0.0m,,$0.0m,$0.0m,$18.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
835,Small,BioXcel Therapeutics,Public,North America,Connecticut,New Haven,,,$17.5m,Estimate,Yes,Yes,No,No,12%,$2.1m,$1.5m,$3.8m,$0.0m,$5.3m,,11%,11%,11%,0%,0%,33%,,11%,11%,11%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$2.1m,$0.0m,,$21.2m,,$3.6m,$2.6m,$6.5m,$0.0m,,$0.0m,$4.9m,$12.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m
836,Small,Mayne Pharma,Public,Asia/Oceania,,,,,$17.4m,Estimate,Yes,No,No,No,11%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$21.2m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$7.1m,$0.0m,$0.0m,$0.0m,$8.2m,$3.0m,$0.0m,$0.0m,$0.0m
837,Small,Faron Pharmaceuticals,Public,Europe,Finland,Turku,,,$17.4m,Estimate,No,Yes,No,No,9%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$21.2m,,$2.0m,$0.0m,$0.0m,$0.0m,,$14.4m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
838,Small,PureTech Health,Public,North America,Massachusetts,Cambridge,Masschusetts,Boston,$17.4m,Estimate,Yes,Yes,Yes,Yes,23%,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,22%,0%,0%,0%,0%,22%,,22%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$21.1m,,$6.3m,$0.0m,$0.0m,$0.0m,,$3.1m,$5.3m,$6.3m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
839,Small,Sphaera Pharma,Private,Asia/Oceania,India,Haryana,Singapore,Singapore,$17.4m,Estimate,No,No,No,No,33%,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,,38%,0%,0%,0%,0%,38%,,38%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,,$21.1m,,$7.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.5m,$7.6m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$7.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
840,Small,Ampio Pharmaceuticals,Public,North America,Colorado,Englewood,,,$17.4m,Estimate,Yes,No,No,No,9%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$21.1m,,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$6.7m,$1.5m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
841,Small,Turnstone Biologics,Private,North America,Ontario,Ottawa,New York,New York,$17.4m,Estimate,No,Yes,No,No,37%,$6.5m,$3.1m,$7.8m,$0.0m,$10.9m,,43%,29%,29%,0%,0%,100%,,43%,29%,29%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.5m,$3.1m,$7.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$1.8m,$4.4m,$0.0m,,$21.1m,,$7.8m,$3.8m,$9.5m,$0.0m,,$0.0m,$0.0m,$21.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
842,Small,Rafael Pharmaceuticals,Private,North America,New Jersey,Newark,,,$17.3m,Estimate,Yes,No,No,No,24%,$4.2m,$1.5m,$3.8m,$0.0m,$5.3m,,29%,14%,14%,0%,0%,57%,,29%,14%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.9m,$2.1m,$0.0m,,$21.0m,,$9.3m,$3.4m,$8.4m,$0.0m,,$0.0m,$0.0m,$21.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
843,Small,AnewPharma,Private,North America,Arizona,Scottsdale,,,$17.3m,Estimate,No,No,No,No,8%,$1.3m,$1.9m,$0.0m,$4.8m,$6.7m,,13%,25%,0%,13%,0%,50%,,0%,0%,0%,0%,0%,,13%,25%,0%,13%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.3m,$1.9m,$0.0m,$4.8m,$0.0m,$0.7m,$1.1m,$0.0m,$2.7m,,$21.0m,,$2.4m,$3.5m,$0.0m,$8.5m,,$0.0m,$0.0m,$14.4m,$0.0m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
844,Small,Bioniz Therapeutics,Private,North America,,,,,$17.2m,Estimate,Yes,No,No,No,0%,$0.0m,$1.4m,$3.5m,$0.0m,$4.9m,,0%,13%,13%,0%,0%,25%,,0%,13%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$1.9m,$0.0m,,$20.9m,,$0.0m,$2.8m,$7.0m,$0.0m,,$3.3m,$0.0m,$9.9m,$3.4m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m
845,Small,TapImmune,Public,North America,Texas,Houston,,,$17.2m,Estimate,No,Yes,No,No,13%,$2.2m,$3.1m,$3.9m,$0.0m,$7.0m,,14%,29%,14%,0%,0%,57%,,0%,29%,0%,0%,0%,,14%,0%,14%,0%,0%,,,,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$3.9m,$0.0m,$0.0m,$1.1m,$1.8m,$2.2m,$0.0m,,$20.9m,,$4.1m,$5.9m,$7.4m,$0.0m,,$0.0m,$0.0m,$17.4m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
846,Small,Pivot Pharmaceuticals,Public,North America,British Columbia,Vancouver,California,Costa Mesa,$17.2m,Estimate,No,No,No,No,22%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,22%,0%,0%,0%,0%,22%,,22%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$20.9m,,$4.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.7m,$0.0m,$2.3m,$2.5m,$2.4m,$0.0m,$4.7m,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m
847,Small,Biosceptre,Private,Asia/Oceania,Australia,Sydney,United Kingdom,Cambridge,$17.2m,Estimate,No,Yes,No,No,81%,$13.8m,$3.3m,$0.0m,$0.0m,$3.3m,,75%,25%,0%,0%,0%,100%,,75%,25%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$13.8m,$3.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.3m,$1.9m,$0.0m,$0.0m,,$20.9m,,$16.8m,$4.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$20.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
848,Small,Neovia Oncology,Private,North America,Washington,Bellevue,,,$17.2m,Estimate,Yes,No,No,No,65%,$11.1m,$1.6m,$0.0m,$0.0m,$1.6m,,63%,13%,0%,0%,0%,75%,,63%,13%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.1m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.9m,$0.0m,$0.0m,,$20.9m,,$18.2m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$20.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
849,Small,Hummingbird Bioscience,Private,Asia/Oceania,Singapore,Singapore,California,South San Francisco,$17.2m,Estimate,Yes,Yes,No,No,50%,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m,$0.0m,$0.0m,,$20.8m,,$20.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$20.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
850,Small,Jivana Biotechnology,Private,North America,Illinois,River Forest,,,$17.2m,Estimate,No,No,No,No,50%,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m,$0.0m,$0.0m,,$20.8m,,$20.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$20.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
851,Small,Go Therapeutics,Private,North America,Massachusetts,Cambridge,,,$17.2m,Estimate,Yes,Yes,No,No,50%,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m,$0.0m,$0.0m,,$20.8m,,$20.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$20.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
852,Small,BiVictriX Therapeutics,Private,Europe,United Kingdom,Wilmslow,,,$17.2m,Estimate,Yes,Yes,No,No,50%,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m,$0.0m,$0.0m,,$20.8m,,$20.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$20.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
853,Small,Beijing Pearl Biotechnology,Private,Asia/Oceania,,,,,$17.1m,Estimate,No,No,No,No,13%,$2.1m,$3.1m,$3.9m,$0.0m,$7.0m,,14%,29%,14%,0%,0%,57%,,0%,14%,0%,0%,0%,,14%,14%,14%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$2.1m,$1.6m,$3.9m,$0.0m,$0.0m,$1.1m,$1.7m,$2.2m,$0.0m,,$20.8m,,$4.9m,$7.1m,$8.8m,$0.0m,,$0.0m,$0.0m,$20.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
854,Small,Sinovent,Private,Asia/Oceania,China,Suzhou,Massachusetts,Boston,$17.1m,Estimate,No,No,No,No,63%,$10.7m,$0.0m,$0.0m,$0.0m,$0.0m,,63%,0%,0%,0%,0%,63%,,63%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,,$20.7m,,$13.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.1m,$2.6m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m
855,Small,Almac Discovery,Private,Europe,United Kingdom,Belfast,,,$17.0m,Estimate,No,Yes,No,No,63%,$10.7m,$0.0m,$0.0m,$0.0m,$0.0m,,63%,0%,0%,0%,0%,63%,,63%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,,$20.7m,,$14.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.8m,$14.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
856,Small,Veru Healthcare,Public,North America,Florida,Miami,United Kingdom,London,$17.0m,Estimate,No,No,No,No,10%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$20.6m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$13.6m,$0.0m,$2.5m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m
857,Small,Synthex Labs,Private,North America,California,San Francisco,,,$16.9m,Estimate,No,No,No,No,50%,$8.5m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$0.0m,$0.0m,,$20.5m,,$16.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$16.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m
858,Small,Moberg Pharma,Public,Europe,Sweden,Stockholm,,,$16.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$20.5m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$13.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
859,Small,Qurient,Public,Asia/Oceania,South Korea,Seongnam,,,$16.8m,Estimate,No,Yes,No,No,23%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$20.4m,,$5.7m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,$4.9m,$7.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
860,Small,Archigen Biotech,Private,Asia/Oceania,,,,,$16.8m,Estimate,Yes,Yes,No,No,11%,$1.8m,$0.0m,$0.0m,$6.3m,$6.3m,,17%,0%,0%,17%,0%,33%,,0%,0%,0%,0%,0%,,17%,0%,0%,17%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$0.0m,$0.0m,$6.3m,$0.0m,$0.9m,$0.0m,$0.0m,$3.5m,,$20.4m,,$2.0m,$0.0m,$0.0m,$7.3m,,$0.0m,$0.0m,$9.3m,$8.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
861,Small,American Gene Technologies,Private,North America,Maryland,Rockville,,,$16.8m,Estimate,No,Yes,Yes,No,11%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$20.4m,,$3.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$6.3m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$7.6m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m
862,Small,Avidin,Private,Europe,Hungary,Szeged,,,$16.8m,Estimate,No,No,No,No,36%,$6.0m,$1.5m,$0.0m,$0.0m,$1.5m,,33%,11%,0%,0%,0%,44%,,33%,11%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.8m,$0.0m,$0.0m,,$20.4m,,$7.6m,$1.8m,$0.0m,$0.0m,,$2.4m,$6.3m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m
863,Small,MimiVax,Private,North America,New York,Buffalo,,,$16.8m,Estimate,No,Yes,Yes,Yes,37%,$6.2m,$1.5m,$3.7m,$0.0m,$5.2m,,38%,13%,13%,0%,0%,63%,,38%,13%,13%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.2m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.8m,$2.1m,$0.0m,,$20.3m,,$8.2m,$2.0m,$5.0m,$0.0m,,$0.0m,$0.0m,$15.2m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
864,Small,PlantForm,Public,North America,Ontario,Toronto,Ontario,Sarnia,$16.8m,Estimate,No,Yes,No,No,11%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$20.3m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.0m,$3.2m,$0.0m,$3.1m,$0.0m,$0.0m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m
865,Small,EpicentRx,Private,North America,California,La Jolla,,,$16.7m,Estimate,No,No,No,No,13%,$2.1m,$3.0m,$3.8m,$0.0m,$6.8m,,14%,29%,14%,0%,0%,57%,,14%,29%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$3.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$1.7m,$2.1m,$0.0m,,$20.3m,,$4.8m,$6.9m,$8.6m,$0.0m,,$0.0m,$0.0m,$20.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
866,Small,Anima Biotech,Private,Middle East/Africa,,,,,$16.7m,Estimate,No,No,No,No,11%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$20.2m,,$2.9m,$0.0m,$0.0m,$0.0m,,$2.8m,$2.7m,$2.9m,$2.9m,$0.0m,$3.1m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m
867,Small,Dicerna,Public,North America,Massachusetts,Cambridge,,,$16.6m,Estimate,No,No,No,No,33%,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,,30%,0%,0%,0%,0%,30%,,30%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,,$54.1m,,$18.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$18.3m,$0.0m,$0.0m,$6.5m,$0.0m,$6.2m,$0.0m,$5.7m,$0.0m,$17.5m,$0.0m,$0.0m,$0.0m,$0.0m
868,Small,Vaxil BioTherapeutics,Public,Middle East/Africa,Israel,Ness Ziona,,,$16.6m,Estimate,No,Yes,No,No,25%,$4.2m,$0.0m,$3.8m,$0.0m,$3.8m,,33%,0%,17%,0%,0%,50%,,33%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$2.1m,$0.0m,,$20.1m,,$8.4m,$0.0m,$7.6m,$0.0m,,$0.0m,$0.0m,$16.1m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
869,Small,Imugene,Public,Asia/Oceania,Australia,Sydney,,,$16.5m,Estimate,No,Yes,No,No,39%,$6.4m,$1.6m,$3.9m,$0.0m,$5.4m,,50%,17%,17%,0%,0%,83%,,50%,17%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.4m,$1.6m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.9m,$2.2m,$0.0m,,$20.0m,,$10.8m,$2.6m,$6.5m,$0.0m,,$0.0m,$0.0m,$20.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
870,Small,Precision Biologics,Private,North America,Maryland,Rockville,,,$16.5m,Estimate,No,Yes,No,No,25%,$4.1m,$0.0m,$3.7m,$0.0m,$3.7m,,33%,0%,17%,0%,0%,50%,,33%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$2.1m,$0.0m,,$20.0m,,$10.5m,$0.0m,$9.5m,$0.0m,,$0.0m,$0.0m,$20.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
871,Small,Genoscience Pharma,Private,Europe,France,Marseille,,,$16.5m,Estimate,Yes,No,No,No,25%,$4.1m,$0.0m,$3.7m,$0.0m,$3.7m,,33%,0%,17%,0%,0%,50%,,33%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$2.1m,$0.0m,,$20.0m,,$10.5m,$0.0m,$9.5m,$0.0m,,$0.0m,$0.0m,$20.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
872,Small,Rasna Therapeutics,Public,North America,Pennsylvania,Doylestown,New York,New York,$16.5m,Estimate,Yes,No,No,No,25%,$4.1m,$0.0m,$3.7m,$0.0m,$3.7m,,33%,0%,17%,0%,0%,50%,,33%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$2.1m,$0.0m,,$20.0m,,$10.5m,$0.0m,$9.5m,$0.0m,,$0.0m,$0.0m,$20.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
873,Small,Ibex Biosciences,Private,North America,Maryland,Cumberland,,,$16.5m,Estimate,No,Yes,No,No,11%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$20.0m,,$2.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.9m,$2.9m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$5.8m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m
874,Small,Collaborative Medicinal,Private,Asia/Oceania,,,,,$16.4m,Estimate,No,No,No,No,11%,$1.9m,$1.4m,$0.0m,$0.0m,$1.4m,,14%,14%,0%,0%,0%,29%,,14%,14%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$0.0m,$0.0m,,$19.9m,,$3.7m,$2.7m,$0.0m,$0.0m,,$0.0m,$13.5m,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
875,Small,Rovi Pharmaceutical,Public,Europe,Spain,Madrid,,,$16.4m,Estimate,No,No,No,No,0%,$0.0m,$1.1m,$0.0m,$0.0m,$1.1m,,0%,25%,0%,0%,0%,25%,,0%,25%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$19.9m,,$0.0m,$1.1m,$0.0m,$0.0m,,$7.2m,$11.6m,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
876,Small,Biosortia Pharmaceuticals,Private,North America,California,San Diego,,,$16.4m,Estimate,No,Yes,No,No,50%,$8.2m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,,$19.9m,,$10.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.4m,$10.1m,$2.5m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m
877,Small,Shanghai Hengrui Pharmaceutical,Private,Asia/Oceania,China,Shanghai,,,$16.4m,Estimate,Yes,Yes,No,No,25%,$4.2m,$1.5m,$0.0m,$7.4m,$8.9m,,33%,17%,0%,17%,0%,67%,,33%,17%,0%,17%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$1.5m,$0.0m,$7.4m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.8m,$0.0m,$4.2m,,$19.9m,,$6.3m,$2.3m,$0.0m,$11.3m,,$0.0m,$0.0m,$19.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
878,Small,Cancer Advances,Private,North America,,,,,$16.4m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$2.7m,$5.3m,$8.0m,,0%,0%,25%,25%,0%,50%,,0%,0%,0%,0%,0%,,0%,0%,25%,25%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$5.3m,$0.0m,$0.0m,$0.0m,$1.5m,$3.0m,,$19.9m,,$0.0m,$0.0m,$4.2m,$8.3m,,$0.0m,$0.0m,$12.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.4m,$0.0m,$0.0m,$0.0m,$0.0m
879,Small,Strides Pharma Science,Public,Asia/Oceania,,,,,$16.3m,Estimate,Yes,No,No,No,9%,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,0%,0%,0%,0%,0%,,11%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$134.8m,,$11.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.5m,$0.0m,$0.0m,$0.0m,$0.0m,$67.7m,$16.9m,$0.0m,$23.1m,$8.8m,$0.0m,$6.7m,$0.0m,$0.0m
880,Small,Apexian Pharmaceuticals,Private,North America,Indiana,Indianapolis,,,$16.3m,Estimate,No,No,No,No,23%,$3.7m,$1.4m,$0.0m,$0.0m,$1.4m,,22%,11%,0%,0%,0%,33%,,11%,0%,0%,0%,0%,,11%,11%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$1.4m,$0.0m,$0.0m,$0.0m,$2.0m,$0.8m,$0.0m,$0.0m,,$19.8m,,$5.0m,$1.8m,$0.0m,$0.0m,,$0.0m,$3.0m,$6.9m,$0.0m,$2.9m,$7.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
881,Small,ConverGene,Private,North America,Maryland,Cambridge,,,$16.3m,Estimate,Yes,No,No,No,50%,$8.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,,$19.8m,,$13.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.1m,$13.2m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
882,Small,Heat Biologics,Public,North America,North Carolina,Durham,,,$16.3m,Estimate,No,Yes,No,No,38%,$6.3m,$0.0m,$3.8m,$0.0m,$3.8m,,43%,0%,14%,0%,0%,57%,,43%,0%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.3m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$2.1m,$0.0m,,$19.8m,,$8.8m,$0.0m,$5.3m,$0.0m,,$0.0m,$0.0m,$14.1m,$2.8m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
883,Small,Laekna,Private,Asia/Oceania,China,Shanghai,,,$16.3m,Estimate,No,No,No,No,25%,$4.0m,$1.5m,$3.6m,$0.0m,$5.1m,,25%,13%,13%,0%,0%,50%,,13%,0%,0%,0%,0%,,13%,13%,13%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$1.5m,$3.6m,$0.0m,$0.0m,$2.1m,$0.8m,$2.0m,$0.0m,,$19.7m,,$5.7m,$2.1m,$5.2m,$0.0m,,$0.0m,$0.0m,$13.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m
884,Small,Pola,Public,Asia/Oceania,,,,,$16.2m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$2.5m,$5.0m,$7.5m,,0%,0%,25%,25%,0%,50%,,0%,0%,25%,25%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$2.5m,$5.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$2.8m,,$19.7m,,$0.0m,$0.0m,$5.0m,$9.8m,,$0.0m,$0.0m,$14.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.0m,$0.0m
885,Small,Delcath Systems,Public,North America,,,,,$16.2m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$6.8m,$10.3m,,0%,0%,33%,33%,0%,67%,,0%,0%,33%,33%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$6.8m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$3.8m,,$19.7m,,$0.0m,$0.0m,$6.6m,$13.1m,,$0.0m,$0.0m,$19.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
886,Small,CreaGene,Private,Asia/Oceania,,,,,$16.2m,Estimate,No,Yes,No,Yes,0%,$0.0m,$0.0m,$3.5m,$6.8m,$10.3m,,0%,0%,33%,33%,0%,67%,,0%,0%,33%,33%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$6.8m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$3.8m,,$19.7m,,$0.0m,$0.0m,$6.6m,$13.1m,,$0.0m,$0.0m,$19.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
887,Small,RadioMedix,Private,North America,,,,,$16.2m,Estimate,No,No,No,No,0%,$0.0m,$2.7m,$0.0m,$13.5m,$16.2m,,0%,50%,0%,50%,0%,100%,,0%,0%,0%,50%,0%,,0%,50%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$13.5m,$0.0m,,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.5m,$0.0m,$7.5m,,$19.7m,,$0.0m,$3.3m,$0.0m,$16.3m,,$0.0m,$0.0m,$19.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
888,Small,HedgePath Pharmaceuticals,Public,Asia/Oceania,,,,,$16.2m,Estimate,Yes,No,No,No,11%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,0%,0%,0%,0%,0%,,14%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$19.7m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,$8.1m,$3.4m,$0.0m,$0.0m,$0.0m
889,Small,ISDIN,Private,Asia/Oceania,,,,,$16.2m,Estimate,Yes,No,No,No,11%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,0%,0%,0%,0%,0%,,14%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$19.7m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,$8.1m,$3.4m,$0.0m,$0.0m,$0.0m
890,Small,Incanthera,Private,Europe,United Kingdom,Manchester,,,$16.2m,Estimate,No,No,No,No,38%,$6.2m,$0.0m,$3.7m,$0.0m,$3.7m,,43%,0%,14%,0%,0%,57%,,43%,0%,0%,0%,0%,,0%,0%,14%,0%,0%,,,,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$3.3m,$0.0m,$2.1m,$0.0m,,$19.6m,,$8.1m,$0.0m,$4.9m,$0.0m,,$0.0m,$0.0m,$13.0m,$0.0m,$3.3m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
891,Small,PCI Biotech,Public,Europe,Norway,Oslo,,,$16.2m,Estimate,No,Yes,No,No,23%,$3.7m,$1.3m,$3.3m,$0.0m,$4.6m,,33%,17%,17%,0%,0%,67%,,33%,17%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.7m,$1.3m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.7m,$1.9m,$0.0m,,$19.6m,,$6.5m,$2.3m,$5.8m,$0.0m,,$0.0m,$0.0m,$14.7m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
892,Small,Cellenkos,Private,North America,Texas,Houston,,,$16.1m,Estimate,Yes,No,No,Yes,12%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$19.6m,,$2.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.5m,$2.6m,$6.5m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$2.8m,$0.0m,$0.0m,$0.0m
893,Small,Orion Biotechnology,Private,North America,Ontario,Ottawa,Switzerland,geneva,$16.1m,Estimate,No,No,No,No,25%,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$19.6m,,$4.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.6m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$7.5m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
894,Small,Unum Therapeutics,Public,North America,Massachusetts,Cambridge,,,$16.1m,Estimate,Yes,Yes,Yes,Yes,57%,$9.2m,$3.3m,$0.0m,$0.0m,$3.3m,,50%,25%,0%,0%,0%,75%,,38%,25%,0%,0%,0%,,13%,0%,0%,0%,0%,,,,$6.9m,$3.3m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$1.9m,$0.0m,$0.0m,,$19.5m,,$14.3m,$5.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$19.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
895,Small,Sinil Pharmaceutical,Public,Asia/Oceania,,,,,$16.1m,Estimate,No,No,No,No,10%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$19.5m,,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.4m,$1.7m,$7.4m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m
896,Small,Salarius Pharmaceuticals,Private,North America,Texas,Houston,,,$16.0m,Estimate,Yes,No,No,No,55%,$8.8m,$1.6m,$0.0m,$0.0m,$1.6m,,50%,13%,0%,0%,0%,63%,,50%,13%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.8m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.9m,$0.0m,$0.0m,,$19.5m,,$16.5m,$3.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$19.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
897,Small,Solasia,Public,Asia/Oceania,Japan,Tokyo,,,$16.0m,Estimate,Yes,No,No,No,10%,$1.5m,$1.1m,$2.8m,$0.0m,$3.9m,,14%,14%,14%,0%,0%,43%,,0%,0%,0%,0%,0%,,14%,14%,14%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.5m,$1.1m,$2.8m,$0.0m,$0.0m,$0.8m,$0.6m,$1.6m,$0.0m,,$19.5m,,$2.3m,$1.7m,$4.1m,$0.0m,,$0.0m,$0.0m,$8.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$10.6m,$0.0m,$0.7m,$0.0m
898,Small,Vaxon Biotech,Private,Europe,France,Paris,,,$16.0m,Estimate,No,Yes,No,No,26%,$4.1m,$0.0m,$7.5m,$0.0m,$7.5m,,40%,0%,40%,0%,0%,80%,,40%,0%,40%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$7.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$4.2m,$0.0m,,$19.4m,,$6.9m,$0.0m,$12.5m,$0.0m,,$0.0m,$0.0m,$19.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
899,Small,Suzhou Connect Biopharmaceutical,Private,Asia/Oceania,,,,,$15.9m,Estimate,No,No,No,No,12%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,10%,0%,0%,0%,0%,10%,,10%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$19.3m,,$2.5m,$0.0m,$0.0m,$0.0m,,$4.9m,$1.9m,$2.5m,$2.5m,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m
900,Small,Altimmune,Public,North America,Maryland,Gaithersburg,,,$15.9m,Estimate,No,Yes,No,No,12%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$19.2m,,$2.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$16.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
901,Small,Cantargia,Public,Europe,Sweden,Lund,,,$15.8m,Estimate,Yes,Yes,No,No,13%,$2.0m,$0.0m,$3.6m,$0.0m,$3.6m,,17%,0%,17%,0%,0%,33%,,17%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.0m,$0.0m,,$19.2m,,$4.1m,$0.0m,$7.4m,$0.0m,,$0.0m,$0.0m,$11.6m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
902,Small,Imago Biosciences,Private,North America,California,South San Francisco,Massachusetts,Boston,$15.8m,Estimate,Yes,No,No,No,12%,$1.9m,$0.0m,$3.5m,$0.0m,$3.5m,,25%,0%,25%,0%,0%,50%,,25%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$2.0m,$0.0m,,$19.2m,,$2.6m,$0.0m,$4.7m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$11.9m,$0.0m,$0.0m,$0.0m
903,Small,Curadev Pharma,Private,Asia/Oceania,India,New Delhi,United Kingdom,Kent,$15.7m,Estimate,No,Yes,No,No,86%,$13.5m,$0.0m,$0.0m,$0.0m,$0.0m,,86%,0%,0%,0%,0%,86%,,86%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$13.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.2m,$0.0m,$0.0m,$0.0m,,$19.1m,,$16.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$16.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
904,Small,Lixte Biotechnology,Public,North America,New York,New York,,,$15.7m,Estimate,Yes,No,No,No,12%,$1.9m,$1.4m,$0.0m,$0.0m,$1.4m,,11%,11%,0%,0%,0%,22%,,11%,11%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$0.0m,$0.0m,,$19.1m,,$3.7m,$2.7m,$0.0m,$0.0m,,$0.0m,$3.1m,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$3.1m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m
905,Small,Cristal Therapeutics,Private,Europe,Netherlands,Maastricht,,,$15.7m,Estimate,No,Yes,No,No,39%,$6.1m,$1.5m,$0.0m,$0.0m,$1.5m,,38%,13%,0%,0%,0%,50%,,38%,13%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.1m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.8m,$0.0m,$0.0m,,$19.1m,,$7.7m,$1.9m,$0.0m,$0.0m,,$2.4m,$0.0m,$9.5m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m
906,Small,Invectys,Private,Europe,France,Paris,,,$15.7m,Estimate,Yes,Yes,Yes,Yes,41%,$6.4m,$1.6m,$7.7m,$0.0m,$9.3m,,50%,17%,33%,0%,0%,100%,,50%,17%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.4m,$1.6m,$7.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.9m,$4.3m,$0.0m,,$19.0m,,$7.8m,$1.9m,$9.4m,$0.0m,,$0.0m,$0.0m,$19.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
907,Small,Terns Pharmaceuticals,Private,North America,California,San Mateo,,,$15.7m,Estimate,Yes,No,No,No,36%,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,,$19.0m,,$7.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$11.3m,$0.0m,$0.0m,$0.0m,$0.0m
908,Small,Bio-Cancer Treatment,Private,Asia/Oceania,,,,,$15.6m,Estimate,Yes,No,No,No,13%,$2.0m,$1.5m,$3.7m,$0.0m,$5.2m,,17%,17%,17%,0%,0%,50%,,17%,17%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$2.1m,$0.0m,,$18.9m,,$4.3m,$3.1m,$7.8m,$0.0m,,$0.0m,$0.0m,$15.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m
909,Small,ElsaLys Biotech,Private,Europe,France,Illkirch,,,$15.6m,Estimate,Yes,Yes,No,No,30%,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,,43%,0%,0%,0%,0%,43%,,29%,0%,0%,0%,0%,,14%,0%,0%,0%,0%,,,,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,,$18.9m,,$6.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.7m,$8.3m,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
910,Small,Aprilbio,Private,Asia/Oceania,South Korea,Gangwon-do,,,$15.6m,Estimate,No,Yes,No,No,25%,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$18.9m,,$5.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.5m,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$2.7m,$2.5m,$2.9m,$0.0m,$0.0m,$0.0m
911,Small,Nouscom,Private,Europe,Switzerland,Basel,,,$15.6m,Estimate,No,Yes,Yes,No,71%,$11.1m,$0.0m,$0.0m,$0.0m,$0.0m,,71%,0%,0%,0%,0%,71%,,71%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,,$18.9m,,$15.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$15.7m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
912,Small,Starpharma,Public,Asia/Oceania,Australia,Melbourne,,,$15.6m,Estimate,No,No,No,No,39%,$6.1m,$0.0m,$7.4m,$0.0m,$7.4m,,50%,0%,33%,0%,0%,83%,,33%,0%,33%,0%,0%,,17%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$7.4m,$0.0m,$0.0m,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$4.1m,$0.0m,,$18.9m,,$6.5m,$0.0m,$7.9m,$0.0m,,$0.0m,$0.0m,$14.4m,$0.0m,$0.0m,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
913,Small,Dizal (Jiangsu) Pharmaceutical,Private,Asia/Oceania,China,Shanghai,,,$15.5m,Estimate,No,No,No,No,26%,$4.0m,$0.0m,$3.6m,$0.0m,$3.6m,,29%,0%,14%,0%,0%,43%,,14%,0%,0%,0%,0%,,14%,0%,14%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$0.0m,$3.6m,$0.0m,$0.0m,$2.1m,$0.0m,$2.0m,$0.0m,,$18.8m,,$5.3m,$0.0m,$4.8m,$0.0m,,$2.2m,$0.0m,$10.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$2.1m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m
914,Small,OncoTartis,Private,North America,New York,Buffalo,,,$15.5m,Estimate,Yes,No,No,No,71%,$11.1m,$0.0m,$0.0m,$0.0m,$0.0m,,71%,0%,0%,0%,0%,71%,,71%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,,$18.8m,,$18.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$18.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
915,Small,Triumvira Immunologics,Private,North America,Ontario,Hamilton,Texas,Austin,$15.5m,Estimate,No,Yes,Yes,Yes,71%,$11.1m,$0.0m,$0.0m,$0.0m,$0.0m,,71%,0%,0%,0%,0%,71%,,71%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,,$18.8m,,$18.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$18.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
916,Small,Abbisko Therapeutics,Private,Asia/Oceania,China,Shanghai,,,$15.5m,Estimate,No,Yes,No,No,71%,$11.1m,$0.0m,$0.0m,$0.0m,$0.0m,,71%,0%,0%,0%,0%,71%,,71%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,,$18.8m,,$18.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$18.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
917,Small,CMG Pharma,Public,Asia/Oceania,South Korea,Seoul,,,$15.5m,Estimate,No,No,No,No,71%,$11.1m,$0.0m,$0.0m,$0.0m,$0.0m,,71%,0%,0%,0%,0%,71%,,57%,0%,0%,0%,0%,,14%,0%,0%,0%,0%,,,,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,,$18.8m,,$15.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.8m,$15.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
918,Small,Life Science Pharmaceuticals,Private,North America,,,,,$15.5m,Estimate,No,Yes,No,No,0%,$0.0m,$2.5m,$3.2m,$6.2m,$12.0m,,0%,33%,17%,17%,0%,67%,,0%,33%,0%,0%,0%,,0%,0%,17%,17%,0%,,,,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$6.2m,$0.0m,$0.0m,$1.4m,$1.8m,$3.5m,,$18.8m,,$0.0m,$3.2m,$4.0m,$7.9m,,$0.0m,$0.0m,$15.2m,$0.0m,$0.0m,$1.8m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
919,Small,Arvinas,Public,North America,Connecticut,New Haven,,,$15.4m,Estimate,No,No,No,No,50%,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.0m,$0.0m,$0.0m,,$18.7m,,$9.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.4m,$9.4m,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
920,Small,VBI Vaccines,Public,North America,Ontario,Ottawa,Massachusetts,Cambridge,$15.4m,Estimate,No,Yes,No,No,13%,$2.1m,$0.0m,$3.7m,$0.0m,$3.7m,,14%,0%,14%,0%,0%,29%,,14%,0%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$18.7m,,$2.9m,$0.0m,$5.3m,$0.0m,,$0.0m,$0.0m,$8.2m,$0.0m,$0.0m,$0.0m,$0.0m,$10.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
921,Micro,Inhibikase,Private,North America,Georgia,Atlanta,Massachusetts,Cambridge,$15.3m,Estimate,Yes,No,No,No,13%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$18.6m,,$3.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$7.2m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m
922,Micro,Recepta biopharma,Private,Latin America,Brazil,Sao Paulo,,,$15.3m,Estimate,Yes,Yes,No,No,29%,$4.4m,$1.6m,$8.0m,$0.0m,$9.6m,,33%,17%,33%,0%,0%,83%,,0%,0%,0%,0%,0%,,33%,17%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.4m,$1.6m,$8.0m,$0.0m,$0.0m,$2.4m,$0.9m,$4.5m,$0.0m,,$18.6m,,$5.9m,$2.1m,$10.6m,$0.0m,,$0.0m,$0.0m,$18.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
923,Micro,Virometix,Private,Europe,Switzerland,Zurich,,,$15.3m,Estimate,No,Yes,No,No,43%,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,,43%,0%,0%,0%,0%,43%,,43%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$18.6m,,$7.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.9m,$0.0m,$0.0m,$0.0m,$0.0m,$10.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
924,Micro,Hookipa Biotech,Private,Europe,Austria,Vienna,,,$15.3m,Estimate,No,Yes,No,No,39%,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,,38%,0%,0%,0%,0%,38%,,38%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,,$18.5m,,$6.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,$11.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
925,Micro,Besins Healthcare,Private,Europe,Monaco,Monaco,,,$15.3m,Estimate,No,No,No,No,24%,$3.6m,$0.0m,$0.0m,$6.5m,$6.5m,,50%,0%,0%,25%,0%,75%,,50%,0%,0%,25%,0%,,0%,0%,0%,0%,0%,,,,$3.6m,$0.0m,$0.0m,$6.5m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$3.6m,,$18.5m,,$4.5m,$0.0m,$0.0m,$8.0m,,$0.0m,$0.0m,$12.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
926,Micro,DisperSol Technologies,Private,North America,Texas,Georgetown,,,$15.1m,Estimate,No,No,No,No,13%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$18.3m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$1.4m,$12.0m,$0.0m,$0.0m,$0.0m
927,Micro,Genochem,Private,Europe,France,Grasse,,,$15.1m,Estimate,No,Yes,No,No,71%,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,,71%,0%,0%,0%,0%,71%,,71%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,,$18.3m,,$13.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.5m,$13.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
928,Micro,Verseon,Public,North America,California,Fremont,,,$15.0m,Estimate,No,No,No,No,25%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$18.3m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$2.6m,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.5m,$0.0m,$0.0m,$0.0m
929,Micro,MedPacto,Private,Asia/Oceania,,,,,$15.0m,Estimate,Yes,No,No,No,14%,$2.1m,$1.5m,$3.7m,$0.0m,$5.2m,,17%,17%,17%,0%,0%,50%,,17%,17%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$2.1m,$0.0m,,$18.2m,,$5.2m,$3.7m,$9.3m,$0.0m,,$0.0m,$0.0m,$18.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
930,Micro,Genelux Corporation,Private,North America,California,San Diego,,,$15.0m,Estimate,Yes,Yes,No,No,14%,$2.1m,$1.5m,$3.7m,$0.0m,$5.2m,,17%,17%,17%,0%,0%,50%,,17%,17%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$2.1m,$0.0m,,$18.2m,,$5.2m,$3.7m,$9.3m,$0.0m,,$0.0m,$0.0m,$18.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
931,Micro,Calico,Private,North America,California,South San Francisco,,,$15.0m,Estimate,No,No,No,No,29%,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,29%,0%,0%,0%,0%,29%,,14%,0%,0%,0%,0%,,14%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$18.2m,,$4.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.7m,$4.4m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m
932,Micro,Zhejiang Medicine Co.,Public,North America,,,,,$14.9m,Estimate,No,Yes,No,No,0%,$0.0m,$1.1m,$0.0m,$0.0m,$1.1m,,0%,14%,0%,0%,0%,14%,,0%,0%,0%,0%,0%,,0%,14%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$18.1m,,$0.0m,$1.2m,$0.0m,$0.0m,,$6.3m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$5.5m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
933,Micro,Bensheng Pharma,Private,Asia/Oceania,China,Zhejiang,China,Shanghai,$14.9m,Estimate,No,No,No,No,57%,$8.5m,$0.0m,$0.0m,$0.0m,$0.0m,,57%,0%,0%,0%,0%,57%,,57%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$0.0m,$0.0m,,$18.1m,,$14.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$14.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m
934,Micro,InCellArt,Private,Europe,France,Nantes,,,$14.9m,Estimate,No,Yes,No,No,29%,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,29%,0%,0%,0%,0%,29%,,29%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$18.1m,,$7.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,$10.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
935,Micro,Carmot Therapeutics,Private,North America,California,Berkeley,California,San Francico,$14.9m,Estimate,No,Yes,No,No,25%,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$18.1m,,$4.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.2m,$4.7m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m
936,Micro,DCPrime,Private,Europe,Netherlands,Leiden,,,$14.8m,Estimate,Yes,Yes,No,Yes,29%,$4.3m,$0.0m,$3.9m,$0.0m,$3.9m,,40%,0%,20%,0%,0%,60%,,20%,0%,20%,0%,0%,,20%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.9m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$2.2m,$0.0m,,$18.0m,,$9.5m,$0.0m,$8.5m,$0.0m,,$0.0m,$0.0m,$18.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
937,Micro,ASDERA,Private,North America,New York,New York,,,$14.8m,Estimate,No,No,No,No,11%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$17.9m,,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$9.3m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m
938,Micro,eFFECTOR Therapeutics,Private,North America,California,San Diego,,,$14.8m,Estimate,Yes,No,No,No,43%,$6.4m,$0.0m,$3.8m,$0.0m,$3.8m,,60%,0%,20%,0%,0%,80%,,60%,0%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.4m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$2.2m,$0.0m,,$17.9m,,$11.2m,$0.0m,$6.7m,$0.0m,,$0.0m,$0.0m,$17.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
939,Micro,OxStem,Private,Europe,United Kingdom,Oxford,,,$14.7m,Estimate,Yes,No,No,Yes,25%,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$17.9m,,$6.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.9m,$6.2m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m
940,Micro,SignalChem Lifesciences,Private,North America,British Columbia,Richmond,,,$14.7m,Estimate,No,Yes,No,No,59%,$8.7m,$0.0m,$3.9m,$0.0m,$3.9m,,67%,0%,17%,0%,0%,83%,,67%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.7m,$0.0m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m,$2.2m,$0.0m,,$17.9m,,$12.3m,$0.0m,$5.6m,$0.0m,,$0.0m,$0.0m,$17.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
941,Micro,Formula Pharmaceuticals,Private,North America,Pennsylvania,Berwyn,,,$14.7m,Estimate,Yes,Yes,Yes,Yes,59%,$8.7m,$0.0m,$3.9m,$0.0m,$3.9m,,67%,0%,17%,0%,0%,83%,,67%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.7m,$0.0m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m,$2.2m,$0.0m,,$17.9m,,$12.3m,$0.0m,$5.6m,$0.0m,,$0.0m,$0.0m,$17.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
942,Micro,Forbius,Private,North America,Texas,Austin,Quebec,Montreal,$14.7m,Estimate,No,Yes,No,No,13%,$1.9m,$0.0m,$3.4m,$0.0m,$3.4m,,14%,0%,14%,0%,0%,29%,,14%,0%,14%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$1.9m,$0.0m,,$17.9m,,$2.7m,$0.0m,$4.8m,$0.0m,,$0.0m,$0.0m,$7.5m,$2.5m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m
943,Micro,Chengdu Kanghua Biological,Private,Asia/Oceania,,,,,$14.7m,Estimate,No,Yes,No,No,14%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$17.8m,,$3.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$14.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
944,Micro,Domain Therapeutics,Private,Europe,France,Illkirch,,,$14.7m,Estimate,No,Yes,No,No,36%,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,,43%,0%,0%,0%,0%,43%,,43%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,,$17.8m,,$6.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$11.2m,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
945,Micro,BioMarck,Private,North America,,,,,$14.6m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.3m,$0.0m,$3.3m,,0%,0%,20%,0%,0%,20%,,0%,0%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,,$17.7m,,$0.0m,$0.0m,$6.0m,$0.0m,,$11.7m,$0.0m,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
946,Micro,Ahn-Gook Pharmaceutical,Public,Asia/Oceania,,,,,$14.6m,Estimate,No,Yes,No,No,11%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,10%,0%,0%,0%,0%,10%,,10%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$17.7m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.3m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.2m,$1.9m,$2.1m,$0.0m,$1.8m,$0.0m,$0.0m
947,Micro,Clene Nanomedicine,Private,North America,Utah,Salt Lake City,,,$14.6m,Estimate,No,No,No,No,17%,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$17.7m,,$3.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.1m,$3.0m,$0.0m,$6.5m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
948,Micro,OncoSec Medical,Public,North America,New Jersey,Pennington,California,San Diego,$14.5m,Estimate,Yes,Yes,Yes,No,30%,$4.4m,$1.6m,$3.9m,$0.0m,$5.5m,,40%,20%,20%,0%,0%,80%,,20%,20%,20%,0%,0%,,20%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$3.9m,$0.0m,$0.0m,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.9m,$2.2m,$0.0m,,$17.6m,,$7.8m,$2.8m,$7.0m,$0.0m,,$0.0m,$0.0m,$17.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
949,Micro,ExCellThera,Private,North America,,,,,$14.5m,Estimate,Yes,Yes,No,Yes,0%,$0.0m,$0.0m,$3.3m,$0.0m,$3.3m,,0%,0%,17%,0%,0%,17%,,0%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,,$17.6m,,$0.0m,$0.0m,$5.7m,$0.0m,,$0.0m,$0.0m,$5.7m,$2.8m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.1m,$0.0m,$0.0m,$0.0m
950,Micro,BrightPath Biotherapeutics,Public,Asia/Oceania,,,,,$14.5m,Estimate,No,Yes,No,No,14%,$2.0m,$1.5m,$3.7m,$7.3m,$12.4m,,25%,25%,25%,25%,0%,100%,,25%,25%,25%,25%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.5m,$3.7m,$7.3m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$2.1m,$4.1m,,$17.6m,,$2.5m,$1.8m,$4.5m,$8.8m,,$0.0m,$0.0m,$17.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
951,Micro,TOT Biopharm,Private,Asia/Oceania,,,,,$14.5m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$8.4m,$10.1m,,0%,25%,0%,25%,0%,50%,,0%,25%,0%,25%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$8.4m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$4.7m,,$17.6m,,$0.0m,$2.2m,$0.0m,$10.7m,,$0.0m,$0.0m,$12.9m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
952,Micro,Synimmune,Private,Europe,Germany,Tubingen,,,$14.5m,Estimate,Yes,Yes,No,No,29%,$4.2m,$0.0m,$3.8m,$0.0m,$3.8m,,40%,0%,20%,0%,0%,60%,,40%,0%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$2.1m,$0.0m,,$17.6m,,$9.2m,$0.0m,$8.3m,$0.0m,,$0.0m,$0.0m,$17.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
953,Micro,Kaleido Biosciences,Private,North America,Massachusetts,Lexington,,,$14.4m,Estimate,No,Yes,No,No,13%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,11%,0%,0%,0%,0%,11%,,11%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$17.5m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$2.2m,$2.1m,$2.2m,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m
954,Micro,Piqur,Private,Europe,Switzerland,Basel,,,$14.4m,Estimate,Yes,No,No,No,44%,$6.3m,$0.0m,$3.8m,$0.0m,$3.8m,,50%,0%,17%,0%,0%,67%,,50%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.3m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$2.1m,$0.0m,,$17.5m,,$9.1m,$0.0m,$5.5m,$0.0m,,$0.0m,$0.0m,$14.5m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
955,Micro,Atossa Genetics,Public,North America,Washington,Seattle,,,$14.4m,Estimate,No,Yes,Yes,Yes,25%,$3.7m,$0.0m,$3.3m,$6.5m,$9.8m,,40%,0%,20%,20%,0%,80%,,20%,0%,20%,0%,0%,,20%,0%,0%,20%,0%,,,,$1.8m,$0.0m,$3.3m,$0.0m,$0.0m,,$1.8m,$0.0m,$0.0m,$6.5m,$0.0m,$1.9m,$0.0m,$1.8m,$3.6m,,$17.5m,,$4.4m,$0.0m,$4.0m,$7.8m,,$0.0m,$0.0m,$16.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
956,Micro,Domainex,Private,Europe,United Kingdom,Cambridge,,,$14.4m,Estimate,No,No,No,No,57%,$8.2m,$0.0m,$0.0m,$0.0m,$0.0m,,57%,0%,0%,0%,0%,57%,,57%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.4m,$0.0m,$0.0m,$0.0m,,$17.5m,,$10.1m,$0.0m,$0.0m,$0.0m,,$2.5m,$0.0m,$10.1m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m
957,Micro,Interprotein,Private,Asia/Oceania,Japan,Osaka,,,$14.4m,Estimate,No,Yes,No,No,57%,$8.2m,$0.0m,$0.0m,$0.0m,$0.0m,,57%,0%,0%,0%,0%,57%,,57%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.4m,$0.0m,$0.0m,$0.0m,,$17.4m,,$9.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$9.9m,$2.5m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
958,Micro,Double Bond Pharmaceutical,Public,Europe,Sweden,Uppsala,,,$14.3m,Estimate,No,No,No,No,29%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,29%,0%,0%,0%,0%,29%,,29%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$17.3m,,$6.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.8m,$0.0m,$0.0m,$3.6m,$0.0m,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
959,Micro,Guangzhou Pharmaceuticals,Private,Asia/Oceania,,,,,$14.3m,Estimate,Yes,No,No,No,0%,$0.0m,$1.5m,$7.3m,$0.0m,$8.8m,,0%,20%,40%,0%,0%,60%,,0%,20%,40%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$7.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$4.1m,$0.0m,,$17.3m,,$0.0m,$2.9m,$14.4m,$0.0m,,$0.0m,$0.0m,$17.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
960,Micro,Zenyaku Kogyo,Private,North America,,,,,$14.3m,Estimate,Yes,Yes,No,No,0%,$0.0m,$0.0m,$2.6m,$0.0m,$2.6m,,0%,0%,25%,0%,0%,25%,,0%,0%,0%,0%,0%,,0%,0%,25%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$1.5m,$0.0m,,$17.3m,,$0.0m,$0.0m,$5.7m,$0.0m,,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$11.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
961,Micro,Lion TCR,Private,Asia/Oceania,,,,,$14.2m,Estimate,No,Yes,Yes,Yes,14%,$2.0m,$1.5m,$0.0m,$0.0m,$1.5m,,13%,13%,0%,0%,0%,25%,,13%,13%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$0.0m,$0.0m,,$17.2m,,$4.0m,$2.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.0m,$3.7m,$0.0m,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
962,Micro,Alpha Cancer Technologies,Private,North America,Ontario,Toronto,,,$14.2m,Estimate,No,Yes,No,No,42%,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,22%,0%,0%,0%,0%,,11%,0%,0%,0%,0%,,,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,,$17.2m,,$6.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.1m,$6.5m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m
963,Micro,Unigene,Public,North America,,,,,$14.1m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$2.5m,$0.0m,$2.5m,,0%,0%,13%,0%,0%,13%,,0%,0%,0%,0%,0%,,0%,0%,13%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,,$17.2m,,$0.0m,$0.0m,$2.6m,$0.0m,,$0.0m,$0.0m,$2.6m,$2.8m,$0.0m,$0.0m,$1.5m,$0.0m,$0.0m,$1.8m,$1.9m,$0.0m,$6.7m,$0.0m,$0.0m,$0.0m
964,Micro,Bioway,Private,Asia/Oceania,South Korea,Chuncheon-si,,,$14.1m,Estimate,No,No,No,No,43%,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m,,43%,0%,0%,0%,0%,43%,,43%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,,$17.2m,,$8.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.3m,$0.0m,$0.0m,$0.0m,$0.0m
965,Micro,Aluda Pharmaceuticals,Private,North America,California,Menlo Park,,,$14.1m,Estimate,No,No,No,No,29%,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,29%,0%,0%,0%,0%,29%,,29%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$17.2m,,$5.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.8m,$2.9m,$0.0m,$0.0m,$2.9m,$2.9m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m
966,Micro,Oncoscience,Private,Latin America,,,,,$14.1m,Estimate,No,Yes,No,No,0%,$0.0m,$1.0m,$2.6m,$5.1m,$8.8m,,0%,20%,20%,20%,0%,60%,,0%,0%,0%,0%,0%,,0%,20%,20%,20%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.0m,$2.6m,$5.1m,$0.0m,$0.0m,$0.6m,$1.5m,$2.9m,,$17.1m,,$0.0m,$2.0m,$5.1m,$10.0m,,$0.0m,$0.0m,$17.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
967,Micro,ValiRx,Public,Europe,United Kingdom,London,,,$14.0m,Estimate,No,No,No,No,29%,$4.1m,$0.0m,$3.7m,$0.0m,$3.7m,,33%,0%,17%,0%,0%,50%,,17%,0%,0%,0%,0%,,17%,0%,17%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,$2.2m,$0.0m,$2.1m,$0.0m,,$17.0m,,$5.5m,$0.0m,$4.9m,$0.0m,,$0.0m,$0.0m,$10.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
968,Micro,Vyriad,Private,North America,Minnesota,Rochester,,,$14.0m,Estimate,No,Yes,Yes,No,32%,$4.4m,$4.8m,$0.0m,$0.0m,$4.8m,,25%,38%,0%,0%,0%,63%,,25%,38%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$4.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$2.7m,$0.0m,$0.0m,,$17.0m,,$8.1m,$8.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$17.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
969,Micro,Artelo Biosciences,Public,North America,California,La Jolla,,,$14.0m,Estimate,No,No,No,No,28%,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,13%,0%,0%,0%,0%,,13%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$17.0m,,$4.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.1m,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$4.4m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m
970,Micro,Novatarg,Private,North America,North Carolina,Research Triangle Park,,,$13.9m,Estimate,No,No,No,No,14%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$16.9m,,$3.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$3.5m,$0.0m,$0.0m,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m
971,Micro,MaxCyte,Public,North America,Maryland,Gaithersburg,United Kingdom,Cheshire,$13.9m,Estimate,Yes,Yes,Yes,Yes,15%,$2.1m,$1.5m,$0.0m,$0.0m,$1.5m,,17%,17%,0%,0%,0%,33%,,17%,17%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$0.0m,$0.0m,,$16.8m,,$5.5m,$4.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
972,Micro,Metagone Biotech,Private,Asia/Oceania,,,,,$13.9m,Estimate,No,No,No,No,14%,$2.0m,$0.0m,$3.6m,$0.0m,$3.6m,,20%,0%,20%,0%,0%,40%,,20%,0%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.0m,$0.0m,,$16.8m,,$4.5m,$0.0m,$8.2m,$0.0m,,$4.1m,$0.0m,$12.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
973,Micro,AptaBio,Private,Asia/Oceania,South Korea,Suwon,,,$13.9m,Estimate,Yes,No,No,No,27%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$16.8m,,$6.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.2m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m
974,Micro,Immune System Key,Private,Middle East/Africa,,,,,$13.9m,Estimate,Yes,No,No,No,15%,$2.1m,$1.5m,$3.8m,$0.0m,$5.3m,,20%,20%,20%,0%,0%,60%,,20%,20%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$2.1m,$0.0m,,$16.8m,,$4.8m,$3.5m,$8.6m,$0.0m,,$0.0m,$0.0m,$16.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
975,Micro,Advanced Proteome Therapeutics,Public,North America,Ontario,Toronto,Massachusetts,Boston,$13.8m,Estimate,No,Yes,No,No,28%,$3.9m,$0.0m,$3.5m,$0.0m,$3.5m,,40%,0%,20%,0%,0%,60%,,20%,0%,20%,0%,0%,,20%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$2.0m,$0.0m,,$16.8m,,$4.3m,$0.0m,$3.9m,$0.0m,,$0.0m,$0.0m,$8.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
976,Micro,Immodulon Therapeutics,Private,North America,New Jersey,,,,$13.8m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,17%,0%,0%,17%,,0%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,,$16.8m,,$0.0m,$0.0m,$7.1m,$0.0m,,$0.0m,$3.3m,$7.1m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
977,Micro,Cytlimic,Private,Asia/Oceania,Japan,Tokyo,,,$13.7m,Estimate,No,Yes,No,No,31%,$4.2m,$0.0m,$3.8m,$0.0m,$3.8m,,33%,0%,17%,0%,0%,50%,,17%,0%,0%,0%,0%,,17%,0%,17%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$3.8m,$0.0m,$0.0m,$2.2m,$0.0m,$2.1m,$0.0m,,$16.7m,,$7.3m,$0.0m,$6.6m,$0.0m,,$0.0m,$0.0m,$13.8m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
978,Micro,OGD2 Pharma,Private,Europe,France,Nantes,,,$13.7m,Estimate,Yes,Yes,No,Yes,67%,$9.1m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,50%,0%,0%,0%,0%,,17%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,,$16.6m,,$16.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$16.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
979,Micro,Northern Biologics,Private,North America,Ontario,Toronto,,,$13.7m,Estimate,Yes,Yes,No,No,48%,$6.5m,$1.6m,$0.0m,$0.0m,$1.6m,,43%,14%,0%,0%,0%,57%,,43%,14%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.5m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.9m,$0.0m,$0.0m,,$16.6m,,$10.7m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
980,Micro,Evelo Biosciences,Public,North America,Massachusetts,Cambridge,,,$13.7m,Estimate,No,Yes,No,No,14%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$16.6m,,$2.7m,$0.0m,$0.0m,$0.0m,,$2.6m,$0.0m,$2.7m,$2.7m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m
981,Micro,Cetya Therapeutics,Private,North America,Colorado,Fort Collins,,,$13.7m,Estimate,Yes,Yes,No,No,14%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$16.6m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.6m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$2.8m,$0.0m,$2.7m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m
982,Micro,Humanetics,Private,North America,Ohio,Huron,Missouri,Farmington Hills,$13.6m,Estimate,No,No,No,No,14%,$1.9m,$0.0m,$3.4m,$0.0m,$3.4m,,17%,0%,17%,0%,0%,33%,,17%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$1.9m,$0.0m,,$16.6m,,$2.3m,$0.0m,$4.2m,$0.0m,,$0.0m,$5.0m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m
983,Micro,Vaccitech,Private,Europe,United Kingdom,Oxford,,,$13.6m,Estimate,No,No,Yes,No,15%,$2.0m,$1.5m,$0.0m,$0.0m,$1.5m,,17%,17%,0%,0%,0%,33%,,17%,17%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$0.0m,$0.0m,,$16.6m,,$2.5m,$1.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$12.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
984,Micro,Petra Pharma,Private,North America,New York,New York,,,$13.6m,Estimate,No,No,No,No,83%,$11.3m,$0.0m,$0.0m,$0.0m,$0.0m,,83%,0%,0%,0%,0%,83%,,67%,0%,0%,0%,0%,,17%,0%,0%,0%,0%,,,,$9.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,$0.0m,,$16.5m,,$14.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$14.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m
985,Micro,RECOMBIO,Private,Latin America,,,,,$13.6m,Estimate,Yes,Yes,No,No,0%,$0.0m,$1.3m,$3.3m,$0.0m,$4.6m,,0%,20%,20%,0%,0%,40%,,0%,0%,0%,0%,0%,,0%,20%,20%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.3m,$3.3m,$0.0m,$0.0m,$0.0m,$0.7m,$1.8m,$0.0m,,$16.5m,,$0.0m,$2.5m,$6.1m,$0.0m,,$0.0m,$0.0m,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,$7.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
986,Micro,Toray,Public,Asia/Oceania,,,,,$13.6m,Estimate,No,No,No,No,0%,$0.0m,$1.3m,$0.0m,$0.0m,$1.3m,,0%,14%,0%,0%,0%,14%,,0%,14%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$16.5m,,$0.0m,$2.0m,$0.0m,$0.0m,,$3.5m,$8.8m,$2.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
987,Micro,Xenikos,Private,Europe,Netherlands,Nijmegen,,,$13.5m,Estimate,No,No,No,No,15%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,0%,0%,0%,0%,0%,,25%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$16.4m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.3m,$14.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
988,Micro,Crinetics Pharmaceuticals,Public,North America,California,San Diego,,,$13.5m,Estimate,No,No,No,No,13%,$1.8m,$1.3m,$0.0m,$0.0m,$1.3m,,11%,11%,0%,0%,0%,22%,,11%,11%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.7m,$0.0m,$0.0m,,$16.4m,,$3.0m,$2.2m,$0.0m,$0.0m,,$0.0m,$2.5m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$2.5m,$0.0m,$3.5m,$0.0m,$0.0m
989,Micro,iCell Gene Therapeutics,Private,North America,New York,Stony Brook,,,$13.5m,Estimate,Yes,Yes,Yes,Yes,83%,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,,83%,0%,0%,0%,0%,83%,,83%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,$0.0m,,$16.4m,,$16.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$16.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
990,Micro,TCR2 Therapeutics,Private,North America,Massachusetts,Cambridge,,,$13.5m,Estimate,Yes,Yes,No,Yes,83%,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,,83%,0%,0%,0%,0%,83%,,83%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,$0.0m,,$16.4m,,$16.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$16.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
991,Micro,Shanghai Unicar-Therapy Biomed,Private,Asia/Oceania,,,,,$13.5m,Estimate,Yes,Yes,Yes,Yes,0%,$0.0m,$1.5m,$10.9m,$0.0m,$12.3m,,0%,20%,60%,0%,0%,80%,,0%,20%,60%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$10.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$6.1m,$0.0m,,$16.4m,,$0.0m,$1.9m,$14.4m,$0.0m,,$0.0m,$0.0m,$16.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
992,Micro,Shenogen,Private,Asia/Oceania,China,Beijing,,,$13.5m,Estimate,No,No,No,No,34%,$4.5m,$0.0m,$4.1m,$0.0m,$4.1m,,33%,0%,17%,0%,17%,67%,,17%,0%,0%,0%,17%,,17%,0%,17%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$4.1m,$0.0m,$0.0m,$2.4m,$0.0m,$2.3m,$0.0m,,$16.4m,,$8.6m,$0.0m,$7.8m,$0.0m,,$0.0m,$0.0m,$16.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
993,Micro,Primetime Life Sciences,Private,North America,Maryland,Gaithersburg,,,$13.5m,Estimate,No,No,No,No,43%,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,,43%,0%,0%,0%,0%,43%,,43%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,,$16.4m,,$7.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.8m,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m
994,Micro,Nemucore Medical Innovations,Private,North America,,,,,$13.5m,Estimate,Yes,No,No,No,0%,$0.0m,$3.0m,$3.7m,$0.0m,$6.7m,,0%,33%,17%,0%,0%,50%,,0%,17%,0%,0%,0%,,0%,17%,17%,0%,0%,,,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,$0.0m,$1.7m,$2.1m,$0.0m,,$16.3m,,$0.0m,$7.3m,$9.1m,$0.0m,,$0.0m,$0.0m,$16.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
995,Micro,Innate Immunotherapeutics,Public,Asia/Oceania,Australia,Melbourne,,,$13.5m,Estimate,Yes,Yes,No,No,29%,$3.9m,$1.4m,$0.0m,$0.0m,$1.4m,,33%,17%,0%,0%,0%,50%,,0%,17%,0%,0%,0%,,33%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.8m,$0.0m,$0.0m,,$16.3m,,$5.5m,$2.0m,$0.0m,$0.0m,,$0.0m,$5.2m,$7.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
996,Micro,Intezyne Technologies,Private,North America,Florida,Tampa,,,$13.4m,Estimate,No,No,No,No,50%,$6.7m,$3.2m,$0.0m,$0.0m,$3.2m,,43%,29%,0%,0%,0%,71%,,43%,29%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$1.8m,$0.0m,$0.0m,,$16.3m,,$11.0m,$5.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$16.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
997,Micro,Cellid,Private,Asia/Oceania,South Korea,Seoul,,,$13.4m,Estimate,No,Yes,No,Yes,50%,$6.7m,$3.2m,$0.0m,$0.0m,$3.2m,,43%,29%,0%,0%,0%,71%,,43%,29%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$1.8m,$0.0m,$0.0m,,$16.3m,,$11.0m,$5.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$16.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
998,Micro,1st Biotherapeutics,Private,Asia/Oceania,South Korea,Seongnam,,,$13.4m,Estimate,No,Yes,No,No,29%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,29%,0%,0%,0%,0%,29%,,29%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$16.3m,,$6.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$9.5m,$6.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
999,Micro,SAJE Pharma,Public,North America,Maryland,Baltimore,,,$13.4m,Estimate,No,No,No,No,14%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$16.2m,,$2.7m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$2.7m,$2.7m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$2.7m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m
1000,Micro,ImmuPharma,Public,Europe,United Kingdom,London,,,$13.4m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.1m,$0.0m,$3.1m,,0%,0%,17%,0%,0%,17%,,0%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,,$16.2m,,$0.0m,$0.0m,$3.5m,$0.0m,,$0.0m,$1.6m,$3.5m,$6.2m,$1.7m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m
1001,Micro,Fosun Pharma Kite Biotechnology,Public,Asia/Oceania,China,Shanghai,,,$13.3m,Estimate,Yes,Yes,Yes,Yes,17%,$2.2m,$0.0m,$4.0m,$0.0m,$4.0m,,25%,0%,25%,0%,0%,50%,,0%,0%,0%,0%,0%,,25%,0%,25%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$4.0m,$0.0m,$0.0m,$1.2m,$0.0m,$2.3m,$0.0m,,$16.2m,,$5.8m,$0.0m,$10.4m,$0.0m,,$0.0m,$0.0m,$16.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1002,Micro,Cue Biopharma,Public,North America,Massachusetts,Cambridge,,,$13.3m,Estimate,Yes,Yes,No,No,67%,$8.9m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,,$16.1m,,$12.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$12.9m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1003,Micro,Elixirgen,Private,North America,Maryland,Baltimore,,,$13.3m,Estimate,Yes,No,Yes,No,14%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$16.1m,,$3.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$3.0m,$3.5m,$0.0m,$0.0m,$0.0m
1004,Micro,GamaMabs Pharma,Private,Europe,France,Toulouse,,,$13.3m,Estimate,No,Yes,No,No,49%,$6.5m,$1.6m,$3.9m,$0.0m,$5.5m,,50%,17%,17%,0%,0%,83%,,50%,17%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.5m,$1.6m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.9m,$2.2m,$0.0m,,$16.1m,,$8.8m,$2.1m,$5.3m,$0.0m,,$0.0m,$0.0m,$16.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1005,Micro,NTRC,Private,Europe,Netherlands,Oss,,,$13.3m,Estimate,No,Yes,No,No,67%,$8.9m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,33%,0%,0%,0%,0%,,33%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,,$16.1m,,$11.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.4m,$11.2m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1006,Micro,HB Human BioScience,Private,North America,Florida,Boca Raton,Columbia,Bogota,$13.3m,Estimate,Yes,No,No,No,16%,$2.1m,$1.5m,$3.8m,$0.0m,$5.4m,,20%,20%,20%,0%,0%,60%,,0%,0%,0%,0%,0%,,20%,20%,20%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$1.5m,$3.8m,$0.0m,$0.0m,$1.1m,$0.9m,$2.2m,$0.0m,,$16.1m,,$4.6m,$3.3m,$8.2m,$0.0m,,$0.0m,$0.0m,$16.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1007,Micro,CytoTools,Public,Europe,Germany,Darmstadt,,,$13.3m,Estimate,No,No,No,No,12%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$16.1m,,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$11.0m,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m
1008,Micro,Insud Pharma,Private,Europe,Spain,Madrid,,,$13.3m,Estimate,No,Yes,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,10%,0%,0%,0%,10%,,0%,10%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$16.1m,,$0.0m,$1.3m,$0.0m,$0.0m,,$0.0m,$2.0m,$1.3m,$2.8m,$0.0m,$4.6m,$1.4m,$1.4m,$1.4m,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1009,Micro,Sprint Bioscience,Public,Europe,Sweden,Stockholm,,,$13.3m,Estimate,No,Yes,No,No,83%,$11.0m,$0.0m,$0.0m,$0.0m,$0.0m,,83%,0%,0%,0%,0%,83%,,83%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,,$16.1m,,$13.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m
1010,Micro,enGene,Private,North America,Quebec,Montreal,,,$13.2m,Estimate,No,No,No,No,14%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$16.0m,,$2.7m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$2.7m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m
1011,Micro,OncoTrap,Private,North America,North Carolina,Chapel Hill,,,$13.2m,Estimate,No,Yes,No,No,67%,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,,$16.0m,,$16.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$16.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1012,Micro,Inflection Biosciences,Private,Europe,Ireland,Dublin,,,$13.2m,Estimate,Yes,No,No,No,67%,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,,$16.0m,,$16.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$16.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1013,Micro,Tanvex BioPharma,Public,North America,,,,,$13.2m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$6.1m,$7.3m,,0%,25%,0%,25%,0%,50%,,0%,25%,0%,25%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.2m,$0.0m,$6.1m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$3.4m,,$16.0m,,$0.0m,$1.5m,$0.0m,$7.4m,,$0.0m,$0.0m,$8.9m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m
1014,Micro,Virtici,Private,North America,Washington,Seattle,,,$13.2m,Estimate,No,Yes,No,No,14%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$16.0m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.2m,$2.4m,$2.4m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$2.3m,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m
1015,Micro,Xenetic Biosciences,Public,North America,Massachusetts,Lexington,,,$13.1m,Estimate,No,No,No,No,13%,$1.8m,$0.0m,$3.2m,$0.0m,$3.2m,,25%,0%,25%,0%,0%,50%,,0%,0%,0%,0%,0%,,25%,0%,25%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$0.0m,$3.2m,$0.0m,$0.0m,$0.9m,$0.0m,$1.8m,$0.0m,,$15.9m,,$1.9m,$0.0m,$3.5m,$0.0m,,$0.0m,$4.6m,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m
1016,Micro,Sparrow Pharmaceuticals,Private,North America,Illinois,Chicago,,,$13.1m,Estimate,No,No,No,No,19%,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$15.9m,,$3.0m,$0.0m,$0.0m,$0.0m,,$2.9m,$0.0m,$3.0m,$3.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1017,Micro,Jiangsu Asieris Pharmaceuticals,Private,Asia/Oceania,,,,,$13.0m,Estimate,No,Yes,No,No,16%,$2.1m,$1.5m,$0.0m,$7.4m,$8.9m,,25%,25%,0%,25%,0%,75%,,25%,25%,0%,25%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$0.0m,$7.4m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$0.0m,$4.1m,,$15.8m,,$2.6m,$1.9m,$0.0m,$9.3m,,$0.0m,$0.0m,$13.8m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1018,Micro,CytoDyn,Public,North America,Washington,Vancouver,,,$13.0m,Estimate,No,No,No,No,11%,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,0%,0%,0%,0%,0%,,25%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,$0.0m,,$15.8m,,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.5m,$7.0m,$0.0m,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1019,Micro,DeuteRx,Private,North America,Massachusetts,Andover,,,$13.0m,Estimate,No,Yes,No,No,15%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$15.8m,,$3.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$6.2m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$3.9m,$0.0m,$0.0m,$0.0m
1020,Micro,SignPath Pharma,Private,North America,Pennsylvania,Center Path,,,$13.0m,Estimate,No,No,No,No,14%,$1.9m,$0.0m,$3.4m,$0.0m,$3.4m,,20%,0%,20%,0%,0%,40%,,20%,0%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$1.9m,$0.0m,,$15.8m,,$3.4m,$0.0m,$6.1m,$0.0m,,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m
1021,Micro,Admedus,Public,Asia/Oceania,Australia,Brisbane,,,$13.0m,Estimate,No,Yes,No,No,32%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,40%,0%,0%,0%,0%,40%,,40%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$15.8m,,$4.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$11.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1022,Micro,Crystal Bioscience,Private,North America,California,Emeryville,,,$13.0m,Estimate,No,Yes,No,No,20%,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$15.8m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.3m,$2.4m,$7.7m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1023,Micro,Inspyr Therapeutics,Public,North America,California,Westlake Village,,,$13.0m,Estimate,No,No,No,No,15%,$2.0m,$1.4m,$3.5m,$0.0m,$4.9m,,20%,20%,20%,0%,0%,60%,,20%,20%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.4m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$2.0m,$0.0m,,$15.8m,,$3.6m,$2.6m,$6.5m,$0.0m,,$0.0m,$0.0m,$12.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1024,Micro,Susavion,Private,North America,Arizona,Tempe,,,$13.0m,Estimate,No,Yes,No,No,33%,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$15.8m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$10.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1025,Micro,Mabworks Biotech,Private,Asia/Oceania,,,,,$12.9m,Estimate,Yes,Yes,No,No,16%,$2.1m,$1.5m,$0.0m,$7.3m,$8.8m,,25%,25%,0%,25%,0%,75%,,25%,25%,0%,25%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$0.0m,$7.3m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$0.0m,$4.1m,,$15.7m,,$3.0m,$2.2m,$0.0m,$10.6m,,$0.0m,$0.0m,$15.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1026,Micro,Taris Biomedical,Private,North America,,,,,$12.9m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,17%,0%,0%,0%,17%,,0%,17%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$15.7m,,$0.0m,$1.6m,$0.0m,$0.0m,,$0.0m,$4.1m,$1.6m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1027,Micro,Mentrik,Private,North America,Texas,Dallas,,,$12.9m,Estimate,Yes,Yes,No,No,16%,$2.0m,$0.0m,$3.7m,$0.0m,$3.7m,,25%,0%,25%,0%,0%,50%,,0%,0%,0%,0%,0%,,25%,0%,25%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$0.0m,$3.7m,$0.0m,$0.0m,$1.1m,$0.0m,$2.0m,$0.0m,,$15.7m,,$1.8m,$0.0m,$3.2m,$0.0m,,$0.0m,$0.0m,$5.0m,$10.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1028,Micro,Nucorion Pharmaceuticals,Private,North America,California,San Diego,,,$12.9m,Estimate,No,No,No,No,33%,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$15.7m,,$6.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,$9.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1029,Micro,Elasmogen,Private,Europe,United Kingdom,Aberdeen,,,$12.9m,Estimate,No,No,No,No,14%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,0%,0%,0%,0%,0%,,14%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$15.6m,,$3.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.0m,$2.4m,$4.7m,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1030,Micro,Shanghai Miracogen,Private,Asia/Oceania,China,Shanghai,United Kingdom,London,$12.9m,Estimate,Yes,No,No,No,70%,$9.0m,$1.6m,$0.0m,$0.0m,$1.6m,,67%,17%,0%,0%,0%,83%,,67%,17%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.8m,$0.9m,$0.0m,$0.0m,,$15.6m,,$13.2m,$2.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$15.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1031,Micro,Saronic Biotechnology,Private,North America,New York,New York,,,$12.9m,Estimate,No,Yes,No,Yes,50%,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,,$15.6m,,$15.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$15.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1032,Micro,InteRNA Technologies,Private,Europe,Netherlands,Nijmegen,,,$12.9m,Estimate,No,No,No,No,50%,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,,$15.6m,,$15.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$15.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1033,Micro,Opus Bio,Public,North America,California,San Francisco,Connecticut,Greenwich,$12.9m,Estimate,Yes,Yes,Yes,Yes,18%,$2.3m,$1.6m,$4.1m,$0.0m,$5.7m,,25%,25%,25%,0%,0%,75%,,0%,25%,0%,0%,0%,,25%,0%,25%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$4.1m,$0.0m,$0.0m,$1.2m,$0.9m,$2.3m,$0.0m,,$15.6m,,$4.4m,$3.2m,$8.0m,$0.0m,,$0.0m,$0.0m,$15.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1034,Micro,Trethera,Private,North America,California,Los Angeles,,,$12.8m,Estimate,Yes,No,No,No,17%,$2.2m,$0.0m,$3.9m,$0.0m,$3.9m,,25%,0%,25%,0%,0%,50%,,25%,0%,0%,0%,0%,,0%,0%,25%,0%,0%,,,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$1.1m,$0.0m,$2.2m,$0.0m,,$15.5m,,$5.5m,$0.0m,$10.0m,$0.0m,,$0.0m,$0.0m,$15.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1035,Micro,Shanghai Fudan-Zhangjiang,Public,Asia/Oceania,,,,,$12.8m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.7m,$0.0m,$3.7m,,0%,0%,20%,0%,0%,20%,,0%,0%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,,$15.5m,,$0.0m,$0.0m,$6.1m,$0.0m,,$0.0m,$0.0m,$6.1m,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1036,Micro,PellePharm,Private,North America,,,,,$12.8m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,33%,0%,0%,33%,,0%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$15.5m,,$0.0m,$0.0m,$6.3m,$0.0m,,$0.0m,$0.0m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m
1037,Micro,Kringle Pharma,Private,Asia/Oceania,,,,,$12.8m,Estimate,No,No,Yes,No,14%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$15.5m,,$2.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$6.3m,$2.7m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1038,Micro,TaiwanJ Pharmaceuticals,Private,Asia/Oceania,,,,,$12.8m,Estimate,No,No,No,No,14%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$15.5m,,$1.5m,$0.0m,$0.0m,$0.0m,,$1.5m,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$12.5m,$0.0m,$0.0m,$0.0m,$0.0m
1039,Micro,ViroStatics,Private,Europe,Italy,Sassari,,,$12.7m,Estimate,Yes,No,No,No,17%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$15.4m,,$3.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$12.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1040,Micro,Compass Therapeutics,Private,North America,Massachusetts,Cambridge,,,$12.7m,Estimate,No,Yes,No,No,67%,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$0.0m,$0.0m,,$15.4m,,$10.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.2m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1041,Micro,2A Pharma,Private,Europe,Denmark,Aalborg,,,$12.7m,Estimate,No,Yes,No,No,14%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$15.4m,,$2.5m,$0.0m,$0.0m,$0.0m,,$2.4m,$2.3m,$2.5m,$0.0m,$0.0m,$2.6m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1042,Micro,RMX Pharmaceutical Technology,Private,Asia/Oceania,,,,,$12.7m,Estimate,No,No,No,No,0%,$0.0m,$1.1m,$0.0m,$0.0m,$1.1m,,0%,17%,0%,0%,0%,17%,,0%,0%,0%,0%,0%,,0%,17%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$15.4m,,$0.0m,$1.2m,$0.0m,$0.0m,,$1.9m,$7.5m,$1.2m,$3.1m,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1043,Micro,Peptron,Public,Asia/Oceania,,,,,$12.6m,Estimate,Yes,No,No,No,0%,$0.0m,$1.4m,$0.0m,$0.0m,$1.4m,,0%,14%,0%,0%,0%,14%,,0%,14%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,,$15.3m,,$0.0m,$2.0m,$0.0m,$0.0m,,$0.0m,$3.7m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$8.5m,$0.0m,$1.1m,$0.0m,$0.0m
1044,Micro,Diffusion Pharmaceuticals,Public,North America,Virginia,Charlottesville,,,$12.6m,Estimate,No,No,No,No,16%,$2.0m,$1.5m,$0.0m,$7.2m,$8.7m,,20%,20%,0%,20%,0%,60%,,20%,20%,0%,20%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.5m,$0.0m,$7.2m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$0.0m,$4.1m,,$15.3m,,$2.7m,$2.0m,$0.0m,$9.7m,,$0.0m,$0.0m,$14.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1045,Micro,ViDAC Pharma,Private,Middle East/Africa,Israel,Jerusalem,Massachusetts,Brookline,$12.6m,Estimate,Yes,No,No,No,49%,$6.1m,$1.5m,$0.0m,$0.0m,$1.5m,,50%,17%,0%,0%,0%,67%,,50%,17%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.1m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.8m,$0.0m,$0.0m,,$15.3m,,$8.5m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.6m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1046,Micro,NeoImmuneTech,Private,Asia/Oceania,,,,,$12.5m,Estimate,Yes,Yes,No,No,15%,$1.9m,$1.4m,$3.5m,$0.0m,$4.9m,,14%,14%,14%,0%,0%,43%,,0%,0%,0%,0%,0%,,14%,14%,14%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$1.4m,$3.5m,$0.0m,$0.0m,$1.0m,$0.8m,$2.0m,$0.0m,,$15.2m,,$2.5m,$1.8m,$4.4m,$0.0m,,$0.0m,$0.0m,$8.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m
1047,Micro,Lantern Pharma,Private,North America,Texas,Dallas,,,$12.5m,Estimate,No,No,No,No,14%,$1.7m,$0.0m,$3.1m,$6.1m,$9.1m,,25%,0%,25%,25%,0%,75%,,25%,0%,25%,0%,0%,,0%,0%,0%,25%,0%,,,,$1.7m,$0.0m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$6.1m,$0.0m,$0.9m,$0.0m,$1.7m,$3.4m,,$15.2m,,$2.4m,$0.0m,$4.3m,$8.5m,,$0.0m,$0.0m,$15.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1048,Micro,BioMed Valley Discoveries,Private,North America,Missouri,Kansas,,,$12.5m,Estimate,Yes,No,No,No,18%,$2.2m,$1.6m,$4.0m,$0.0m,$5.6m,,25%,25%,25%,0%,0%,75%,,25%,25%,0%,0%,0%,,0%,0%,25%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.0m,$0.0m,$0.0m,$1.2m,$0.9m,$2.2m,$0.0m,,$15.2m,,$4.3m,$3.1m,$7.8m,$0.0m,,$0.0m,$0.0m,$15.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1049,Micro,Angiocrine Bioscience,Private,North America,California,La Jolla,,,$12.5m,Estimate,Yes,Yes,Yes,Yes,16%,$2.0m,$1.4m,$0.0m,$0.0m,$1.4m,,14%,14%,0%,0%,0%,29%,,14%,14%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$0.0m,$0.0m,,$15.2m,,$3.4m,$2.5m,$0.0m,$0.0m,,$3.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m
1050,Micro,Nanobiotix,Public,Europe,France,Paris,,,$12.5m,Estimate,No,No,No,No,34%,$4.2m,$0.0m,$3.8m,$0.0m,$3.8m,,33%,0%,17%,0%,17%,67%,,33%,0%,17%,0%,17%,,0%,0%,0%,0%,0%,,,,$4.2m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$2.1m,$0.0m,,$15.1m,,$8.0m,$0.0m,$7.2m,$0.0m,,$0.0m,$0.0m,$15.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1051,Micro,Silenseed,Private,Middle East/Africa,Israel,Modi'in,,,$12.5m,Estimate,No,No,No,No,34%,$4.2m,$0.0m,$3.8m,$0.0m,$3.8m,,50%,0%,25%,0%,0%,75%,,50%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$2.1m,$0.0m,,$15.1m,,$8.0m,$0.0m,$7.2m,$0.0m,,$0.0m,$0.0m,$15.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1052,Micro,Aprea Therapeutics,Private,North America,Massachusetts,Boston,,,$12.5m,Estimate,Yes,No,No,No,34%,$4.2m,$0.0m,$3.8m,$0.0m,$3.8m,,50%,0%,25%,0%,0%,75%,,50%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$2.1m,$0.0m,,$15.1m,,$8.0m,$0.0m,$7.2m,$0.0m,,$0.0m,$0.0m,$15.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1053,Micro,Brickell Biotech,Private,North America,Colorado,Boulder,,,$12.4m,Estimate,Yes,No,No,No,12%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$15.1m,,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,$13.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1054,Micro,Theragnostics,Private,North America,Massachusetts,Boston,,,$12.4m,Estimate,No,No,No,No,52%,$6.4m,$0.0m,$3.9m,$0.0m,$3.9m,,60%,0%,20%,0%,0%,80%,,60%,0%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.4m,$0.0m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$2.2m,$0.0m,,$15.1m,,$9.4m,$0.0m,$5.7m,$0.0m,,$0.0m,$0.0m,$15.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1055,Micro,Immunochina Medical Science,Private,Asia/Oceania,,,,,$12.4m,Estimate,Yes,Yes,Yes,Yes,17%,$2.1m,$3.1m,$3.8m,$0.0m,$6.9m,,17%,33%,17%,0%,0%,67%,,17%,33%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$3.1m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$1.7m,$2.1m,$0.0m,,$15.0m,,$3.5m,$5.1m,$6.4m,$0.0m,,$0.0m,$0.0m,$15.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1056,Micro,Medesis,Private,Europe,France,Montpellier,,,$12.3m,Estimate,No,No,No,No,15%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,13%,0%,0%,0%,0%,13%,,13%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$15.0m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.4m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$4.6m,$0.0m
1057,Micro,Trovagene,Public,North America,California,San Diego,,,$12.3m,Estimate,Yes,No,No,No,18%,$2.2m,$1.6m,$3.9m,$0.0m,$5.5m,,25%,25%,25%,0%,0%,75%,,0%,0%,0%,0%,0%,,25%,25%,25%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.2m,$1.6m,$3.9m,$0.0m,$0.0m,$1.2m,$0.9m,$2.2m,$0.0m,,$15.0m,,$4.2m,$3.1m,$7.7m,$0.0m,,$0.0m,$0.0m,$15.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1058,Micro,Gongwin Biopharm,Public,Asia/Oceania,,,,,$12.3m,Estimate,No,No,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.1m,,0%,14%,14%,0%,14%,43%,,0%,14%,14%,0%,14%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.0m,$0.0m,,$14.9m,,$0.0m,$3.0m,$7.4m,$0.0m,,$4.6m,$0.0m,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1059,Micro,Edinburgh Molecular Imaging,Private,Europe,United Kingdom,Edinburgh,,,$12.3m,Estimate,No,No,No,No,16%,$1.9m,$0.0m,$3.5m,$0.0m,$3.5m,,17%,0%,17%,0%,0%,33%,,17%,0%,17%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$2.0m,$0.0m,,$14.9m,,$2.0m,$0.0m,$3.7m,$0.0m,,$9.2m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1060,Micro,Karus Therapeutics,Private,Europe,United Kingdom,Oxford,,,$12.3m,Estimate,No,No,No,No,55%,$6.8m,$3.3m,$0.0m,$0.0m,$3.3m,,50%,33%,0%,0%,0%,83%,,50%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.8m,$3.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.6m,$1.8m,$0.0m,$0.0m,,$14.9m,,$10.0m,$4.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$14.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1061,Micro,Prana Biotechnology,Public,Asia/Oceania,,,,,$12.3m,Estimate,No,No,No,No,15%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$14.9m,,$3.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$11.3m,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1062,Micro,Mesentech,Private,North America,British Columbia,Vancouver,,,$12.2m,Estimate,No,No,No,No,17%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$14.8m,,$3.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$8.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1063,Micro,2-BBB Medicines,Private,Europe,Netherlands,Leiden,,,$12.2m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.7m,$0.0m,$3.7m,,0%,0%,20%,0%,0%,20%,,0%,0%,0%,0%,0%,,0%,0%,20%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,,$14.8m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$2.0m,$4.3m,$0.0m,$2.0m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1064,Micro,Immunomic Therapeutics,Private,North America,Maryland,Rockville,,,$12.2m,Estimate,No,Yes,Yes,Yes,15%,$1.8m,$0.0m,$3.3m,$0.0m,$3.3m,,20%,0%,20%,0%,0%,40%,,20%,0%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$1.9m,$0.0m,,$14.8m,,$1.9m,$0.0m,$3.5m,$0.0m,,$9.4m,$0.0m,$5.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1065,Micro,Tyme Technologies,Public,North America,New York,New York,,,$12.2m,Estimate,Yes,No,No,No,17%,$2.0m,$0.0m,$3.7m,$0.0m,$3.7m,,25%,0%,25%,0%,0%,50%,,25%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$14.8m,,$5.3m,$0.0m,$9.5m,$0.0m,,$0.0m,$0.0m,$14.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1066,Micro,IGF Oncology,Private,North America,Minnesota,St. Paul,,,$12.2m,Estimate,Yes,No,No,No,17%,$2.0m,$0.0m,$3.7m,$0.0m,$3.7m,,25%,0%,25%,0%,0%,50%,,25%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$14.8m,,$5.3m,$0.0m,$9.5m,$0.0m,,$0.0m,$0.0m,$14.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1067,Micro,CureLab Oncology,Private,North America,Massachusetts,Boston,,,$12.2m,Estimate,No,Yes,Yes,No,17%,$2.0m,$0.0m,$3.7m,$0.0m,$3.7m,,25%,0%,25%,0%,0%,50%,,25%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$14.8m,,$5.3m,$0.0m,$9.5m,$0.0m,,$0.0m,$0.0m,$14.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1068,Micro,Anchiano Therapeutics,Public,Middle East/Africa,,,,,$12.2m,Estimate,No,No,Yes,No,17%,$2.0m,$0.0m,$3.7m,$0.0m,$3.7m,,25%,0%,25%,0%,0%,50%,,25%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$14.8m,,$5.3m,$0.0m,$9.5m,$0.0m,,$0.0m,$0.0m,$14.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1069,Micro,DelMar Pharmaceuticals,Public,North America,British Columbia,Vancouver,,,$12.2m,Estimate,No,No,No,No,30%,$3.7m,$0.0m,$0.0m,$6.6m,$6.6m,,50%,0%,0%,25%,0%,75%,,0%,0%,0%,0%,0%,,50%,0%,0%,25%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.7m,$0.0m,$0.0m,$6.6m,$0.0m,$2.0m,$0.0m,$0.0m,$3.7m,,$14.8m,,$5.3m,$0.0m,$0.0m,$9.5m,,$0.0m,$0.0m,$14.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1070,Micro,Celsius Therapeutics,Private,North America,Massachusetts,Cambridge,,,$12.1m,Estimate,No,Yes,No,No,50%,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,,$14.7m,,$7.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.4m,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m
1071,Micro,Isotope Technologies Garching,Private,Europe,Germany,Dresden,,,$12.1m,Estimate,No,Yes,No,No,17%,$2.1m,$1.5m,$0.0m,$7.4m,$8.9m,,25%,25%,0%,25%,0%,75%,,25%,25%,0%,25%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$0.0m,$7.4m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$0.0m,$4.1m,,$14.7m,,$2.8m,$2.0m,$0.0m,$9.9m,,$0.0m,$0.0m,$14.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1072,Micro,Haisco Pharmaceutical,Public,Asia/Oceania,,,,,$12.1m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$2.8m,$0.0m,$2.8m,,0%,0%,20%,0%,0%,20%,,0%,0%,0%,0%,0%,,0%,0%,20%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,,$14.7m,,$0.0m,$0.0m,$3.5m,$0.0m,,$0.0m,$3.7m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,$0.0m
1073,Micro,Avexxin,Private,Europe,Norway,Trondheim,,,$12.0m,Estimate,No,No,No,No,31%,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$14.6m,,$4.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$2.3m,$5.9m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1074,Micro,Shandong Luoxin Pharma,Public,Asia/Oceania,,,,,$12.0m,Estimate,No,No,No,No,17%,$2.1m,$1.5m,$3.7m,$0.0m,$5.2m,,20%,20%,20%,0%,0%,60%,,0%,20%,0%,0%,0%,,20%,0%,20%,0%,0%,,,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,$1.1m,$0.8m,$2.1m,$0.0m,,$14.6m,,$2.1m,$1.5m,$3.8m,$0.0m,,$0.0m,$0.0m,$7.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.1m,$0.0m,$0.0m,$0.0m,$0.0m
1075,Micro,TheVax Genetics Vaccine Co.,Public,North America,,,,,$12.0m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,33%,0%,0%,33%,,0%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$14.6m,,$0.0m,$0.0m,$3.7m,$0.0m,,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$6.2m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1076,Micro,Temple Therapeutics,Private,Europe,Netherlands,Geleen,,,$12.0m,Estimate,No,No,No,No,12%,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$14.6m,,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.5m,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.7m,$0.0m
1077,Micro,Autotelic,Private,Europe,California,,,,$12.0m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$2.6m,$5.0m,$7.6m,,0%,0%,33%,33%,0%,67%,,0%,0%,0%,0%,0%,,0%,0%,33%,33%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$5.0m,$0.0m,$0.0m,$0.0m,$1.4m,$2.8m,,$14.5m,,$0.0m,$0.0m,$4.9m,$9.6m,,$0.0m,$0.0m,$14.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1078,Micro,Oncotelic,Private,Europe,California,,,,$12.0m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$2.6m,$5.0m,$7.6m,,0%,0%,33%,33%,0%,67%,,0%,0%,0%,0%,0%,,0%,0%,33%,33%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$5.0m,$0.0m,$0.0m,$0.0m,$1.4m,$2.8m,,$14.5m,,$0.0m,$0.0m,$4.9m,$9.6m,,$0.0m,$0.0m,$14.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1079,Micro,Orphagen Pharmaceuticals,Private,North America,California,San Diego,,,$11.9m,Estimate,No,Yes,No,No,28%,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,,$14.5m,,$4.1m,$0.0m,$0.0m,$0.0m,,$3.0m,$0.0m,$4.1m,$4.9m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,$0.0m
1080,Micro,Atreca,Private,North America,California,Redwood City,,,$11.9m,Estimate,No,Yes,No,No,33%,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$14.5m,,$5.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.7m,$2.9m,$0.0m,$3.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1081,Micro,OWC Pharmaceutical Research,Public,Middle East/Africa,,,,,$11.9m,Estimate,No,No,No,No,16%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$14.5m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.1m,$2.8m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1082,Micro,Theranyx,Private,Europe,France,Marseille,,,$11.9m,Estimate,No,Yes,No,No,25%,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,0%,0%,0%,0%,0%,,25%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$14.4m,,$3.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.4m,$3.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1083,Micro,Progenra,Private,North America,Pennsylvania,Malvern,,,$11.9m,Estimate,No,No,No,No,33%,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$14.4m,,$7.4m,$0.0m,$0.0m,$0.0m,,$3.6m,$3.4m,$7.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1084,Micro,Iproteos,Private,Europe,Spain,Barcelona,,,$11.9m,Estimate,Yes,No,No,No,14%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$14.4m,,$2.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$9.5m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1085,Micro,Sirenas Marine Discovery,Private,North America,California,San Diego,,,$11.9m,Estimate,No,Yes,No,No,14%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$14.4m,,$2.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$10.5m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1086,Micro,OHM Oncology,Private,North America,Texas,Austin,,,$11.9m,Estimate,No,No,No,No,100%,$11.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,80%,0%,0%,0%,0%,,20%,0%,0%,0%,0%,,,,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$6.3m,$0.0m,$0.0m,$0.0m,,$14.4m,,$14.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$14.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1087,Micro,SynerGene Therapeutics,Private,North America,Maryland,Potomac,,,$11.9m,Estimate,No,No,Yes,No,18%,$2.1m,$1.5m,$3.8m,$0.0m,$5.3m,,25%,25%,25%,0%,0%,75%,,25%,25%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$2.1m,$0.0m,,$14.4m,,$4.1m,$3.0m,$7.4m,$0.0m,,$0.0m,$0.0m,$14.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1088,Micro,Rgenix,Private,North America,New York,New York,,,$11.9m,Estimate,No,Yes,No,No,54%,$6.4m,$3.1m,$0.0m,$0.0m,$3.1m,,43%,29%,0%,0%,0%,71%,,43%,14%,0%,0%,0%,,0%,14%,0%,0%,0%,,,,$6.4m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,$3.4m,$1.7m,$0.0m,$0.0m,,$14.4m,,$9.7m,$4.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$14.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1089,Micro,Alector,Private,North America,California,South San Francisco,California,Milpitas,$11.8m,Estimate,No,Yes,No,No,16%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$14.4m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$11.2m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1090,Micro,Modern Biosciences,Private,Europe,United Kingdom,London,,,$11.8m,Estimate,No,No,No,No,15%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$14.3m,,$1.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.9m,$10.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m
1091,Micro,Strategia Therapeutics,Private,Asia/Oceania,,,,,$11.8m,Estimate,Yes,Yes,No,No,0%,$0.0m,$2.9m,$3.6m,$0.0m,$6.4m,,0%,40%,20%,0%,0%,60%,,0%,0%,0%,0%,0%,,0%,40%,20%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.9m,$3.6m,$0.0m,$0.0m,$0.0m,$1.6m,$2.0m,$0.0m,,$14.3m,,$0.0m,$6.4m,$7.9m,$0.0m,,$0.0m,$0.0m,$14.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1092,Micro,OncoQR ML,Private,Europe,Austria,Vienna,,,$11.7m,Estimate,No,Yes,No,No,80%,$9.4m,$0.0m,$0.0m,$0.0m,$0.0m,,80%,0%,0%,0%,0%,80%,,60%,0%,0%,0%,0%,,20%,0%,0%,0%,0%,,,,$7.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,,$14.2m,,$14.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$14.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1093,Micro,QBiotics,Private,Asia/Oceania,,,,,$11.6m,Estimate,Yes,No,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,25%,25%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,25%,25%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$14.1m,,$0.0m,$3.1m,$7.6m,$0.0m,,$0.0m,$0.0m,$10.6m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1094,Micro,Yoko Pharma,Private,Asia/Oceania,China,Nanjing,,,$11.6m,Estimate,Yes,Yes,No,No,21%,$2.5m,$1.8m,$0.0m,$0.0m,$1.8m,,20%,20%,0%,0%,0%,40%,,0%,0%,0%,0%,0%,,20%,20%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.5m,$1.8m,$0.0m,$0.0m,$0.0m,$1.3m,$1.0m,$0.0m,$0.0m,,$14.1m,,$3.3m,$2.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.7m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1095,Micro,Integral Molecular,Private,North America,Pennsylvania,Philadelphia,,,$11.6m,Estimate,No,No,No,No,16%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$14.1m,,$2.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.4m,$2.6m,$2.6m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m
1096,Micro,Celleron,Private,Europe,United Kingdom,Oxford,,,$11.6m,Estimate,Yes,No,No,No,19%,$2.2m,$3.2m,$4.0m,$0.0m,$7.2m,,20%,40%,20%,0%,0%,80%,,0%,20%,0%,0%,0%,,20%,20%,20%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$2.2m,$1.6m,$4.0m,$0.0m,$0.0m,$1.2m,$1.8m,$2.2m,$0.0m,,$14.1m,,$3.3m,$4.8m,$6.0m,$0.0m,,$0.0m,$0.0m,$14.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1097,Micro,New Amsterdam Sciences,Private,North America,Arizona,Scottsdale,,,$11.6m,Estimate,No,No,No,No,17%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$14.0m,,$3.0m,$0.0m,$0.0m,$0.0m,,$2.9m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$3.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m
1098,Micro,G&E Herbal Biotechnology,Private,Asia/Oceania,Taiwan,Tainan City,,,$11.5m,Estimate,No,No,No,No,30%,$3.5m,$0.0m,$3.1m,$0.0m,$3.1m,,40%,0%,20%,0%,0%,60%,,40%,0%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.5m,$0.0m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$1.8m,$0.0m,,$14.0m,,$4.0m,$0.0m,$3.6m,$0.0m,,$0.0m,$0.0m,$7.5m,$0.0m,$0.0m,$0.0m,$4.6m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1099,Micro,FLX Bio,Private,North America,California,South San Francisco,,,$11.5m,Estimate,No,Yes,No,No,38%,$4.4m,$3.2m,$4.0m,$0.0m,$7.1m,,40%,40%,20%,0%,0%,100%,,40%,40%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$3.2m,$4.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$1.8m,$2.2m,$0.0m,,$14.0m,,$5.3m,$3.9m,$4.8m,$0.0m,,$0.0m,$0.0m,$14.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1100,Micro,Modra Pharmaceuticals,Private,Europe,Netherlands,Amsterdam,,,$11.5m,Estimate,No,No,No,No,38%,$4.4m,$3.2m,$4.0m,$0.0m,$7.1m,,40%,40%,20%,0%,0%,100%,,40%,40%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$3.2m,$4.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$1.8m,$2.2m,$0.0m,,$14.0m,,$5.3m,$3.9m,$4.8m,$0.0m,,$0.0m,$0.0m,$14.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1101,Micro,Pharma Foods,Public,Asia/Oceania,,,,,$11.5m,Estimate,No,Yes,No,No,17%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$14.0m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.6m,$2.8m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1102,Micro,Kyn Therapeutics,Private,North America,Massachusetts,Boston,,,$11.5m,Estimate,No,Yes,No,No,29%,$3.4m,$1.2m,$0.0m,$0.0m,$1.2m,,33%,17%,0%,0%,0%,50%,,33%,0%,0%,0%,0%,,0%,17%,0%,0%,0%,,,,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$1.8m,$0.7m,$0.0m,$0.0m,,$14.0m,,$3.1m,$1.1m,$0.0m,$0.0m,,$2.1m,$4.2m,$4.2m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1103,Micro,Mission Therapeutics,Private,Europe,United Kingdom,Cambridge,,,$11.5m,Estimate,No,Yes,No,No,33%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$14.0m,,$4.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.5m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m
1104,Micro,ImmuneOnco Biopharma,Private,Asia/Oceania,China,Shanghai,,,$11.5m,Estimate,No,Yes,Yes,Yes,100%,$11.5m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$11.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.1m,$0.0m,$0.0m,$0.0m,,$14.0m,,$14.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$14.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1105,Micro,CellProtect Nordic Pharma,Private,Europe,Sweden,Stockholm,,,$11.5m,Estimate,No,No,No,Yes,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,25%,0%,0%,25%,,0%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$13.9m,,$0.0m,$0.0m,$6.9m,$0.0m,,$0.0m,$0.0m,$6.9m,$0.0m,$0.0m,$3.6m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1106,Micro,DexTech Medical,Public,Europe,Sweden,Uppsala,,,$11.4m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$7.2m,$0.0m,$7.2m,,0%,0%,67%,0%,0%,67%,,0%,0%,67%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$7.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.0m,$0.0m,,$13.9m,,$0.0m,$0.0m,$13.9m,$0.0m,,$0.0m,$0.0m,$13.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1107,Micro,Shenzhen BinDeBio,Private,Asia/Oceania,,,,,$11.4m,Estimate,Yes,Yes,Yes,Yes,0%,$0.0m,$0.0m,$7.2m,$0.0m,$7.2m,,0%,0%,67%,0%,0%,67%,,0%,0%,67%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$7.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.0m,$0.0m,,$13.9m,,$0.0m,$0.0m,$13.9m,$0.0m,,$0.0m,$0.0m,$13.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1108,Micro,Microbiotica,Private,Europe,United Kingdom,Cambridge,,,$11.4m,Estimate,No,No,No,No,17%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$13.8m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$2.4m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m
1109,Micro,Deutsche Biotech Innovativ,Public,Europe,Germany,Frankfurt,,,$11.4m,Estimate,No,Yes,No,No,32%,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$13.8m,,$3.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,$0.0m,$8.6m,$0.0m,$0.0m,$0.0m
1110,Micro,ImaginAb,Private,North America,California,Inglewood,,,$11.3m,Estimate,No,Yes,No,No,36%,$4.1m,$1.5m,$3.7m,$0.0m,$5.2m,,40%,20%,20%,0%,0%,80%,,40%,20%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.8m,$2.1m,$0.0m,,$13.8m,,$5.3m,$1.9m,$4.8m,$0.0m,,$0.0m,$0.0m,$12.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m
1111,Micro,Suzhou NG Biomedicine,Private,Asia/Oceania,,,,,$11.3m,Estimate,No,No,No,No,17%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$13.7m,,$2.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$3.6m,$2.1m,$0.0m,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m
1112,Micro,iTeos Therapeutics,Private,Europe,Belgium,Brussels,,,$11.3m,Estimate,No,Yes,No,No,85%,$9.5m,$1.7m,$0.0m,$0.0m,$1.7m,,80%,20%,0%,0%,0%,100%,,60%,20%,0%,0%,0%,,20%,0%,0%,0%,0%,,,,$7.1m,$1.7m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$5.1m,$1.0m,$0.0m,$0.0m,,$13.7m,,$11.6m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1113,Micro,Neon Therapeutics,Public,North America,Massachusetts,Cambridge,,,$11.3m,Estimate,No,Yes,Yes,Yes,85%,$9.5m,$1.7m,$0.0m,$0.0m,$1.7m,,80%,20%,0%,0%,0%,100%,,60%,20%,0%,0%,0%,,20%,0%,0%,0%,0%,,,,$7.1m,$1.7m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$5.1m,$1.0m,$0.0m,$0.0m,,$13.7m,,$11.6m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1114,Micro,Guangxi Wuzhou Zhongheng,Public,Asia/Oceania,,,,,$11.2m,Estimate,No,No,No,No,18%,$2.0m,$0.0m,$0.0m,$7.2m,$7.2m,,33%,0%,0%,33%,0%,67%,,33%,0%,0%,33%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$7.2m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$4.0m,,$13.6m,,$3.0m,$0.0m,$0.0m,$10.7m,,$0.0m,$0.0m,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1115,Micro,Proteorex Therapeutics,Private,North America,Ontario,Toronto,,,$11.2m,Estimate,No,No,No,No,80%,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,,80%,0%,0%,0%,0%,80%,,80%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,,$13.6m,,$13.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1116,Micro,Johnpro Biotech,Private,Asia/Oceania,Taiwan,Taipei City,,,$11.2m,Estimate,No,No,No,No,80%,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,,80%,0%,0%,0%,0%,80%,,80%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,,$13.6m,,$13.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1117,Micro,SHAL Technologies,Private,North America,California,Livermore,,,$11.2m,Estimate,Yes,No,No,No,80%,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,,80%,0%,0%,0%,0%,80%,,80%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,,$13.6m,,$13.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1118,Micro,IDEAYA Biosciences,Private,North America,California,San Francisco,California,San Diego,$11.2m,Estimate,No,Yes,No,No,80%,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,,80%,0%,0%,0%,0%,80%,,80%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,,$13.6m,,$13.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1119,Micro,Eos Biosciences,Private,North America,California,Los Angeles,,,$11.2m,Estimate,No,No,No,No,80%,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,,80%,0%,0%,0%,0%,80%,,80%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,,$13.6m,,$13.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1120,Micro,TMRC,Public,Middle East/Africa,Tanzania,Dar es Salaam,,,$11.2m,Estimate,Yes,No,No,No,20%,$2.3m,$0.0m,$4.1m,$0.0m,$4.1m,,33%,0%,33%,0%,0%,67%,,0%,0%,0%,0%,0%,,33%,0%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$4.1m,$0.0m,$0.0m,$1.2m,$0.0m,$2.3m,$0.0m,,$13.6m,,$4.8m,$0.0m,$8.7m,$0.0m,,$0.0m,$0.0m,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1121,Micro,Puma Biotechnology,Public,North America,California,Los Angeles,,,$11.2m,Estimate,No,No,No,No,20%,$2.3m,$0.0m,$4.1m,$0.0m,$4.1m,,33%,0%,33%,0%,0%,67%,,0%,0%,0%,0%,0%,,33%,0%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$4.1m,$0.0m,$0.0m,$1.2m,$0.0m,$2.3m,$0.0m,,$13.6m,,$4.8m,$0.0m,$8.7m,$0.0m,,$0.0m,$0.0m,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1122,Micro,Chongqing Lummy Pharmaceutical,Public,North America,California,San Diego,Florida,West Palm Beach,$11.2m,Estimate,No,Yes,No,Yes,20%,$2.3m,$0.0m,$4.1m,$0.0m,$4.1m,,33%,0%,33%,0%,0%,67%,,0%,0%,0%,0%,0%,,33%,0%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$4.1m,$0.0m,$0.0m,$1.2m,$0.0m,$2.3m,$0.0m,,$13.6m,,$4.8m,$0.0m,$8.7m,$0.0m,,$0.0m,$0.0m,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1123,Micro,Intelgen (HK) Limited,Private,North America,Massachusetts,Cambridge,,,$11.2m,Estimate,Yes,No,No,No,20%,$2.3m,$0.0m,$4.1m,$0.0m,$4.1m,,33%,0%,33%,0%,0%,67%,,0%,0%,0%,0%,0%,,33%,0%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$4.1m,$0.0m,$0.0m,$1.2m,$0.0m,$2.3m,$0.0m,,$13.6m,,$4.8m,$0.0m,$8.7m,$0.0m,,$0.0m,$0.0m,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1124,Micro,F1 Oncology,Private,North America,New Mexico,Albuquerque,,,$11.2m,Estimate,No,Yes,Yes,Yes,20%,$2.3m,$0.0m,$4.1m,$0.0m,$4.1m,,33%,0%,33%,0%,0%,67%,,0%,0%,0%,0%,0%,,33%,0%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$4.1m,$0.0m,$0.0m,$1.2m,$0.0m,$2.3m,$0.0m,,$13.6m,,$4.8m,$0.0m,$8.7m,$0.0m,,$0.0m,$0.0m,$13.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1125,Micro,Aptose Biosciences,Public,North America,California,San Diego,Ontario ,Toronto,$11.1m,Estimate,Yes,No,No,No,63%,$7.1m,$1.7m,$0.0m,$0.0m,$1.7m,,60%,20%,0%,0%,0%,80%,,40%,20%,0%,0%,0%,,20%,0%,0%,0%,0%,,,,$4.7m,$1.7m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$1.0m,$0.0m,$0.0m,,$13.5m,,$10.9m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1126,Micro,ImmuNext,Private,North America,New Hampshire,Lebanon,,,$11.1m,Estimate,No,Yes,No,No,17%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$13.4m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.1m,$2.3m,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m
1127,Micro,Innocrin Pharmaceuticals,Private,North America,North Carolina,Durham,,,$11.1m,Estimate,No,No,No,No,42%,$4.6m,$0.0m,$4.2m,$0.0m,$4.2m,,50%,0%,25%,0%,0%,75%,,25%,0%,0%,0%,0%,,25%,0%,25%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$4.2m,$0.0m,$0.0m,$2.4m,$0.0m,$2.3m,$0.0m,,$13.4m,,$7.1m,$0.0m,$6.4m,$0.0m,,$0.0m,$0.0m,$13.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1128,Micro,APCure,Private,Europe,France,Lyon,,,$11.0m,Estimate,No,Yes,No,No,60%,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,,60%,0%,0%,0%,0%,60%,,60%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$13.3m,,$10.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1129,Micro,Longevity Biotech,Private,North America,Pennsylvania,Philadelphia,,,$10.9m,Estimate,No,No,No,No,17%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$13.3m,,$2.3m,$0.0m,$0.0m,$0.0m,,$2.2m,$2.1m,$2.3m,$0.0m,$0.0m,$2.4m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m
1130,Micro,ImmuneOncia Therapeutics,Private,Asia/Oceania,South Korea,Giheung-gu,,,$10.9m,Estimate,No,Yes,No,No,85%,$9.2m,$1.7m,$0.0m,$0.0m,$1.7m,,80%,20%,0%,0%,0%,100%,,80%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.2m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.9m,$0.0m,$0.0m,,$13.2m,,$11.2m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1131,Micro,Theralase,Public,North America,Ontario,Toronto,,,$10.9m,Estimate,No,No,No,No,85%,$9.2m,$1.7m,$0.0m,$0.0m,$1.7m,,80%,20%,0%,0%,0%,100%,,80%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.2m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.9m,$0.0m,$0.0m,,$13.2m,,$11.2m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1132,Micro,ImmunoCellular Therapeutics,Public,North America,California,Westlake Village,,,$10.9m,Estimate,No,Yes,Yes,Yes,85%,$9.2m,$1.7m,$0.0m,$0.0m,$1.7m,,80%,20%,0%,0%,0%,100%,,80%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.2m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.9m,$0.0m,$0.0m,,$13.2m,,$11.2m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1133,Micro,YZY Biopharma,Private,Asia/Oceania,China,Wuhan,,,$10.9m,Estimate,No,Yes,No,No,60%,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,,60%,0%,0%,0%,0%,60%,,60%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$13.2m,,$13.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1134,Micro,BlinkBio,Private,North America,Florida,Jupiter,,,$10.9m,Estimate,No,No,No,No,60%,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,,60%,0%,0%,0%,0%,60%,,60%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$13.2m,,$13.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$13.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1135,Micro,Samus Therapeutics,Private,North America,Massachusetts,Topsfield,,,$10.9m,Estimate,No,No,No,No,19%,$2.1m,$1.5m,$0.0m,$0.0m,$1.5m,,14%,14%,0%,0%,0%,29%,,14%,14%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$0.0m,$0.0m,,$13.2m,,$3.6m,$2.6m,$0.0m,$0.0m,,$0.0m,$5.6m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m
1136,Micro,AdAlta,Public,Asia/Oceania,,,,,$10.9m,Estimate,No,No,No,No,17%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$13.2m,,$2.5m,$0.0m,$0.0m,$0.0m,,$2.4m,$3.5m,$2.5m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m
1137,Micro,National OncoVenture,Private,Asia/Oceania,,,,,$10.9m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.0m,$0.0m,$3.0m,,0%,0%,33%,0%,0%,33%,,0%,0%,0%,0%,0%,,0%,0%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,,$13.2m,,$0.0m,$0.0m,$3.3m,$0.0m,,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1138,Micro,Synergys Biotherapeutics,Private,North America,California,Walnut Creek,,,$10.8m,Estimate,No,Yes,No,No,60%,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,,60%,0%,0%,0%,0%,60%,,60%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,,$13.2m,,$9.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$9.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1139,Micro,Achieve Life Sciences,Public,North America,,,,,$10.8m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.2m,$0.0m,$3.2m,,0%,0%,33%,0%,0%,33%,,0%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,,$13.1m,,$0.0m,$0.0m,$6.1m,$0.0m,,$0.0m,$7.0m,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1140,Micro,Oncurious,Private,Europe,Belgium,Leuven,Belgium,Gent,$10.8m,Estimate,Yes,Yes,No,No,20%,$2.2m,$0.0m,$3.9m,$0.0m,$3.9m,,33%,0%,33%,0%,0%,67%,,33%,0%,0%,0%,0%,,0%,0%,33%,0%,0%,,,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$1.2m,$0.0m,$2.2m,$0.0m,,$13.1m,,$4.7m,$0.0m,$8.4m,$0.0m,,$0.0m,$0.0m,$13.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1141,Micro,Orega Biotech,Private,Europe,France,Montpellier,France,Paris,$10.8m,Estimate,No,Yes,No,No,60%,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,,60%,0%,0%,0%,0%,60%,,60%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,,$13.1m,,$7.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1142,Micro,CleveXel Pharma,Private,Europe,France,Paris,,,$10.8m,Estimate,No,No,No,No,16%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,0%,0%,0%,0%,0%,,20%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$13.1m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$7.1m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m
1143,Micro,Welichem Biotech,Private,North America,British Columbia,Vancouver,,,$10.8m,Estimate,No,No,No,No,19%,$2.1m,$0.0m,$3.7m,$0.0m,$3.7m,,25%,0%,25%,0%,0%,50%,,0%,0%,0%,0%,0%,,25%,0%,25%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$13.1m,,$3.1m,$0.0m,$5.6m,$0.0m,,$0.0m,$0.0m,$8.7m,$0.0m,$0.0m,$0.0m,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1144,Micro,Phosplatin,Private,North America,,,,,$10.7m,Estimate,No,No,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,25%,25%,0%,0%,50%,,0%,25%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$13.0m,,$0.0m,$3.7m,$9.3m,$0.0m,,$0.0m,$0.0m,$13.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1145,Micro,CureTech,Private,Middle East/Africa,,,,,$10.7m,Estimate,Yes,Yes,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,25%,25%,0%,0%,50%,,0%,25%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$13.0m,,$0.0m,$3.7m,$9.3m,$0.0m,,$0.0m,$0.0m,$13.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1146,Micro,CellAct Pharma,Private,Europe,,,,,$10.7m,Estimate,No,No,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,25%,25%,0%,0%,50%,,0%,25%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$13.0m,,$0.0m,$3.7m,$9.3m,$0.0m,,$0.0m,$0.0m,$13.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1147,Micro,Bridge Biotherapeutics,Private,Asia/Oceania,,,,,$10.7m,Estimate,No,Yes,No,No,19%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,0%,0%,0%,0%,0%,,17%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$13.0m,,$3.0m,$0.0m,$0.0m,$0.0m,,$3.9m,$2.3m,$3.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m
1148,Micro,Batu Biologics,Private,North America,California,San Diego,,,$10.7m,Estimate,No,Yes,Yes,Yes,80%,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,,80%,0%,0%,0%,0%,80%,,80%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$0.0m,$0.0m,,$13.0m,,$10.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.3m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1149,Micro,NanoGroup,Public,Europe,Poland,Warsaw,,,$10.7m,Estimate,No,No,No,No,80%,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,,80%,0%,0%,0%,0%,80%,,80%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$0.0m,$0.0m,,$13.0m,,$10.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.3m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1150,Micro,NeoTx Therapeutics,Private,Middle East/Africa,Israel,Rehovot,,,$10.7m,Estimate,No,Yes,No,No,13%,$1.4m,$0.0m,$0.0m,$5.0m,$5.0m,,33%,0%,0%,33%,0%,67%,,0%,0%,0%,0%,0%,,33%,0%,0%,33%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.4m,$0.0m,$0.0m,$5.0m,$0.0m,$0.7m,$0.0m,$0.0m,$2.8m,,$13.0m,,$2.8m,$0.0m,$0.0m,$10.1m,,$0.0m,$0.0m,$13.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1151,Micro,Maxivax,Private,Europe,Switzerland,Geneva,,,$10.7m,Estimate,No,No,No,No,20%,$2.1m,$1.5m,$3.8m,$0.0m,$5.3m,,20%,20%,20%,0%,0%,60%,,20%,20%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$2.1m,$0.0m,,$13.0m,,$3.7m,$2.7m,$6.6m,$0.0m,,$0.0m,$0.0m,$13.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1152,Micro,Nodthera Limited,Private,Europe,United Kingdom,Cambridge,Massachusetts,Boston,$10.7m,Estimate,No,No,No,No,20%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,0%,0%,0%,0%,0%,,20%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$12.9m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.5m,$2.2m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m
1153,Micro,Biodesix,Private,North America,,,,,$10.6m,Estimate,Yes,Yes,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.1m,,0%,25%,25%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,25%,25%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,$0.0m,$0.8m,$2.0m,$0.0m,,$12.9m,,$0.0m,$3.7m,$9.2m,$0.0m,,$0.0m,$0.0m,$12.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1154,Micro,NovoBiotic Pharmaceuticals,Private,North America,Texas,Houston,,,$10.6m,Estimate,No,No,No,No,20%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$12.9m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$9.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1155,Micro,Agilvax,Private,North America,California,Los Angeles,,,$10.6m,Estimate,No,Yes,No,No,20%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$12.9m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$9.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1156,Micro,ImmunGene,Private,North America,California,San Francisco,,,$10.6m,Estimate,Yes,Yes,No,No,63%,$6.7m,$1.6m,$0.0m,$0.0m,$1.6m,,60%,20%,0%,0%,0%,80%,,60%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.6m,$0.9m,$0.0m,$0.0m,,$12.9m,,$10.3m,$2.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$12.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1157,Micro,RiMO Therapeutics,Private,North America,Illinois,Chicago,,,$10.6m,Estimate,No,Yes,No,No,63%,$6.7m,$1.6m,$0.0m,$0.0m,$1.6m,,60%,20%,0%,0%,0%,80%,,60%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.6m,$0.9m,$0.0m,$0.0m,,$12.9m,,$10.3m,$2.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$12.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1158,Micro,ImmunoMet Therapeutics,Private,North America,Texas,Houston,,,$10.6m,Estimate,No,No,No,No,63%,$6.7m,$1.6m,$0.0m,$0.0m,$1.6m,,60%,20%,0%,0%,0%,80%,,60%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.6m,$0.9m,$0.0m,$0.0m,,$12.9m,,$10.3m,$2.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$12.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1159,Micro,Camel-IDS,Private,Europe,Belgium,Brussels,,,$10.6m,Estimate,No,No,No,No,63%,$6.7m,$1.6m,$0.0m,$0.0m,$1.6m,,60%,20%,0%,0%,0%,80%,,60%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.6m,$0.9m,$0.0m,$0.0m,,$12.9m,,$10.3m,$2.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$12.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1160,Micro,Amneal Pharmaceuticals,Public,Europe,,,,,$10.6m,Estimate,No,Yes,No,No,0%,$0.0m,$1.1m,$0.0m,$0.0m,$1.1m,,0%,33%,0%,0%,0%,33%,,0%,0%,0%,0%,0%,,0%,33%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$12.8m,,$0.0m,$1.2m,$0.0m,$0.0m,,$0.0m,$11.6m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1161,Micro,ProMed BioSciences,Private,Asia/Oceania,Hong Kong,Hong Kong,,,$10.5m,Estimate,No,Yes,No,No,40%,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,40%,0%,0%,0%,0%,40%,,20%,0%,0%,0%,0%,,20%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$12.8m,,$6.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1162,Micro,Pascal Biosciences,Public,North America,Washington,Seattle,British Columbia,Vancouver,$10.5m,Estimate,No,Yes,No,No,40%,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,40%,0%,0%,0%,0%,40%,,40%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$12.8m,,$5.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.1m,$2.6m,$0.0m,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1163,Micro,Biothera,Private,North America,,,,,$10.5m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.5m,$7.0m,$10.5m,,0%,0%,50%,50%,0%,100%,,0%,0%,50%,50%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$7.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$3.9m,,$12.7m,,$0.0m,$0.0m,$4.3m,$8.5m,,$0.0m,$0.0m,$12.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1164,Micro,DNAtrix,Private,North America,Texas,Houston,,,$10.4m,Estimate,No,Yes,Yes,No,62%,$6.5m,$0.0m,$3.9m,$0.0m,$3.9m,,75%,0%,25%,0%,0%,100%,,75%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.5m,$0.0m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$2.2m,$0.0m,,$12.7m,,$7.9m,$0.0m,$4.8m,$0.0m,,$0.0m,$0.0m,$12.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1165,Micro,Calidi Biotherapeutics,Private,Europe,Germany,Bernreid,California,San Diego,$10.4m,Estimate,No,Yes,No,Yes,62%,$6.5m,$0.0m,$3.9m,$0.0m,$3.9m,,75%,0%,25%,0%,0%,100%,,75%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.5m,$0.0m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$2.2m,$0.0m,,$12.7m,,$7.9m,$0.0m,$4.8m,$0.0m,,$0.0m,$0.0m,$12.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1166,Micro,BryoLogyx,Private,North America,California,San Francisco,,,$10.4m,Estimate,No,Yes,No,No,40%,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,40%,0%,0%,0%,0%,40%,,40%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$12.6m,,$5.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.4m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1167,Micro,Liomont,Private,North America,,,,,$10.4m,Estimate,No,Yes,No,No,0%,$0.0m,$1.3m,$0.0m,$0.0m,$1.3m,,0%,13%,0%,0%,0%,13%,,0%,0%,0%,0%,0%,,0%,13%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$12.6m,,$0.0m,$1.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.3m,$5.7m,$0.0m,$0.0m,$0.6m,$1.7m,$0.0m,$0.0m,$2.3m,$1.0m,$0.0m,$0.0m,$0.0m,$0.0m
1168,Micro,Synthonics,Private,North America,Virginia,Blacksburg,,,$10.4m,Estimate,No,No,No,No,17%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$12.6m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.0m,$2.2m,$0.0m,$0.0m,$2.3m,$0.0m,$2.2m,$0.0m,$2.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m
1169,Micro,NextCure,Private,North America,Maryland,Beltsville,,,$10.4m,Estimate,No,Yes,No,No,60%,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,,60%,0%,0%,0%,0%,60%,,60%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,,$12.6m,,$9.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$9.3m,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1170,Micro,MultiVir,Private,North America,Massachusetts,Holliston,,,$10.4m,Estimate,No,Yes,Yes,No,21%,$2.2m,$3.1m,$3.9m,$0.0m,$7.0m,,20%,40%,20%,0%,0%,80%,,20%,40%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$3.1m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$1.7m,$2.2m,$0.0m,,$12.6m,,$3.0m,$4.3m,$5.3m,$0.0m,,$0.0m,$0.0m,$12.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1171,Micro,Tactical Therapeutics,Private,North America,New York,New York,,,$10.3m,Estimate,No,No,No,No,20%,$2.0m,$1.5m,$3.7m,$0.0m,$5.1m,,20%,20%,20%,0%,0%,60%,,20%,20%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$2.1m,$0.0m,,$12.6m,,$2.9m,$2.1m,$5.1m,$0.0m,,$0.0m,$0.0m,$10.1m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1172,Micro,Sichuan Huiyang Life Science,Private,Asia/Oceania,,,,,$10.3m,Estimate,No,Yes,No,No,0%,$0.0m,$1.5m,$0.0m,$0.0m,$1.5m,,0%,33%,0%,0%,0%,33%,,0%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,,$12.5m,,$0.0m,$1.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$10.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1173,Micro,Serina Therapeutics,Private,North America,Alabama,Huntsville,,,$10.3m,Estimate,No,No,No,No,18%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$12.5m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.8m,$2.2m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m
1174,Micro,Second Genome,Private,North America,California,South San Francisco,,,$10.3m,Estimate,No,Yes,No,No,37%,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,,$12.5m,,$4.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.9m,$0.0m,$0.0m,$0.0m,$0.0m
1175,Micro,Rich Pharmaceuticals,Public,North America,,,,,$10.3m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$3.8m,$0.0m,$3.8m,,0%,0%,33%,0%,0%,33%,,0%,0%,0%,0%,0%,,0%,0%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,,$12.5m,,$0.0m,$0.0m,$7.4m,$0.0m,,$0.0m,$0.0m,$7.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1176,Micro,Arch Biopartners,Public,North America,Ontario,Toronto,,,$10.3m,Estimate,No,No,No,No,40%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,40%,0%,0%,0%,0%,40%,,40%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$12.4m,,$4.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$2.4m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m
1177,Micro,Prolynx,Private,North America,California,San Francisco,,,$10.3m,Estimate,No,No,No,No,17%,$1.8m,$1.3m,$0.0m,$0.0m,$1.3m,,17%,17%,0%,0%,0%,33%,,17%,17%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.7m,$0.0m,$0.0m,,$12.4m,,$2.9m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$2.1m,$0.0m,$0.0m
1178,Micro,Libbs Farmaceutica,Private,Asia/Oceania,,,,,$10.2m,Estimate,No,Yes,No,No,0%,$0.0m,$1.0m,$0.0m,$0.0m,$1.0m,,0%,20%,0%,0%,0%,20%,,0%,0%,0%,0%,0%,,0%,20%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.5m,$0.0m,$0.0m,,$12.4m,,$0.0m,$1.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m
1179,Micro,Inhibrx,Private,North America,California,La Jolla,,,$10.2m,Estimate,Yes,Yes,No,No,19%,$1.9m,$1.4m,$0.0m,$0.0m,$1.4m,,17%,17%,0%,0%,0%,33%,,17%,0%,0%,0%,0%,,0%,17%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$0.0m,$0.0m,,$12.4m,,$3.5m,$2.6m,$0.0m,$0.0m,,$3.1m,$0.0m,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1180,Micro,Zenith Epigenetics,Private,North America,California,San Francisco,Alberta,Calgary,$10.2m,Estimate,Yes,No,No,No,20%,$2.0m,$1.4m,$3.6m,$0.0m,$5.1m,,20%,20%,20%,0%,0%,60%,,20%,20%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.4m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$2.0m,$0.0m,,$12.4m,,$2.8m,$2.0m,$5.0m,$0.0m,,$0.0m,$0.0m,$9.7m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1181,Micro,Immix Biopharma,Private,North America,Alabama,Birmingham,,,$10.2m,Estimate,No,No,No,No,20%,$2.1m,$0.0m,$3.7m,$0.0m,$3.7m,,33%,0%,33%,0%,0%,67%,,33%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$12.4m,,$4.4m,$0.0m,$8.0m,$0.0m,,$0.0m,$0.0m,$12.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1182,Micro,Biostage,Public,North America,Wisconsin,Madison,,,$10.1m,Estimate,No,No,No,Yes,20%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$12.3m,,$3.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1183,Micro,Antibe Therapeutics,Public,North America,Ontario,Toronto,,,$10.1m,Estimate,No,No,No,No,17%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$12.2m,,$1.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.1m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.4m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m
1184,Micro,Nanovalent,Private,North America,Montana,Bozeman,,,$10.1m,Estimate,Yes,No,No,No,40%,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,40%,0%,0%,0%,0%,40%,,40%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$12.2m,,$8.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1185,Micro,EntreChem,Private,Europe,Spain,Oviedo,,,$10.1m,Estimate,Yes,No,No,No,40%,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,40%,0%,0%,0%,0%,40%,,40%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$12.2m,,$8.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1186,Micro,BiomX,Private,Middle East/Africa,Israel,Ness Ziona,,,$10.1m,Estimate,No,Yes,No,No,40%,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,40%,0%,0%,0%,0%,40%,,40%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$12.2m,,$5.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m
1187,Micro,Guerbet,Public,Europe,,,,,$10.0m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.4m,$0.0m,$3.4m,,0%,0%,33%,0%,0%,33%,,0%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,,$12.2m,,$0.0m,$0.0m,$4.2m,$0.0m,,$0.0m,$1.9m,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m
1188,Micro,Bracco,Private,Europe,,,,,$10.0m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$2.5m,$0.0m,$2.5m,,0%,0%,20%,0%,0%,20%,,0%,0%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,,$12.1m,,$0.0m,$0.0m,$2.3m,$0.0m,,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$1.5m,$0.0m,$6.2m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1189,Micro,GeneScience Pharmaceuticals,Private,Asia/Oceania,China,Changchun,,,$9.9m,Estimate,No,Yes,No,No,42%,$4.2m,$1.5m,$0.0m,$0.0m,$1.5m,,40%,20%,0%,0%,0%,60%,,40%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.9m,$0.0m,$0.0m,,$12.0m,,$5.1m,$1.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.0m,$0.0m,$0.0m,$2.6m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1190,Micro,CohBar,Public,North America,California,Menlo Park,,,$9.9m,Estimate,No,No,No,No,19%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,17%,0%,0%,0%,0%,17%,,17%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$12.0m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.1m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.6m,$0.0m,$0.0m,$0.0m,$0.0m
1191,Micro,SL VAXiGEN,Private,Asia/Oceania,South Korea,Seongnam,,,$9.8m,Estimate,No,No,No,No,21%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$11.9m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1192,Micro,MD Biosciences,Private,Middle East/Africa,Israel,Ness Ziona,Switzerland,Zurich,$9.8m,Estimate,Yes,Yes,No,No,40%,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,40%,0%,0%,0%,0%,40%,,40%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$11.9m,,$6.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.7m,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1193,Micro,LinXis,Private,Europe,Netherlands,Amsterdam,,,$9.8m,Estimate,No,No,No,No,60%,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m,,60%,0%,0%,0%,0%,60%,,60%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,,$11.9m,,$7.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m
1194,Micro,Luzitin,Private,Europe,Portugal,Coimbra,,,$9.8m,Estimate,No,No,No,No,21%,$2.0m,$0.0m,$3.7m,$0.0m,$3.7m,,25%,0%,25%,0%,0%,50%,,25%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$11.9m,,$3.2m,$0.0m,$5.7m,$0.0m,,$0.0m,$0.0m,$8.9m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1195,Micro,Hapten Pharmaceuticals,Private,North America,,,,,$9.8m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.2m,$0.0m,$3.2m,,0%,0%,33%,0%,0%,33%,,0%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,,$11.8m,,$0.0m,$0.0m,$3.8m,$0.0m,,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,$3.3m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1196,Micro,FibroStatin,Private,Europe,Spain,Valencia,,,$9.7m,Estimate,No,No,No,No,20%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$11.8m,,$3.0m,$0.0m,$0.0m,$0.0m,,$2.9m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m
1197,Micro,DiscoveryBioMed,Private,North America,Illinois,Lombard,,,$9.7m,Estimate,No,No,No,No,20%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$11.8m,,$3.0m,$0.0m,$0.0m,$0.0m,,$2.9m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m
1198,Micro,Warp Drive Bio,Private,North America,Massachusetts,Cambridge,,,$9.7m,Estimate,No,No,No,No,40%,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,40%,0%,0%,0%,0%,40%,,40%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$11.8m,,$6.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m
1199,Micro,Oncostellae,Private,Europe,Spain,Santiago de Compostela,,,$9.7m,Estimate,No,No,No,No,20%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$11.8m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$2.4m,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m
1200,Micro,NewBridge Pharmaceuticals,Private,Asia/Oceania,,,,,$9.7m,Estimate,Yes,No,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,20%,20%,0%,20%,60%,,0%,0%,0%,0%,0%,,0%,20%,20%,0%,20%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$11.7m,,$0.0m,$3.4m,$8.4m,$0.0m,,$0.0m,$0.0m,$11.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1201,Micro,NewVac,Private,North America,,,,,$9.7m,Estimate,No,No,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,33%,33%,0%,0%,67%,,0%,0%,0%,0%,0%,,0%,33%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$11.7m,,$0.0m,$3.4m,$8.4m,$0.0m,,$0.0m,$0.0m,$11.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1202,Micro,Esanex,Private,North America,,,,,$9.7m,Estimate,Yes,No,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,33%,33%,0%,0%,67%,,0%,0%,0%,0%,0%,,0%,33%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$11.7m,,$0.0m,$3.4m,$8.4m,$0.0m,,$0.0m,$0.0m,$11.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1203,Micro,Sanochemia Pharmazeutika,Public,Europe,Austria,Burgenland,Austria,Vienna,$9.6m,Estimate,No,No,No,No,46%,$4.4m,$0.0m,$4.0m,$0.0m,$4.0m,,50%,0%,25%,0%,0%,75%,,50%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$4.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$2.2m,$0.0m,,$11.7m,,$5.1m,$0.0m,$4.6m,$0.0m,,$0.0m,$0.0m,$9.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1204,Micro,Huadong Medicine Co.,Public,Asia/Oceania,,,,,$9.6m,Estimate,No,No,No,No,0%,$0.0m,$1.4m,$3.4m,$0.0m,$4.8m,,0%,33%,33%,0%,0%,67%,,0%,33%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$1.9m,$0.0m,,$11.7m,,$0.0m,$1.4m,$3.4m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m
1205,Micro,Therapure Biopharma,Private,North America,,,,,$9.6m,Estimate,No,No,No,No,0%,$0.0m,$1.5m,$0.0m,$0.0m,$1.5m,,0%,17%,0%,0%,0%,17%,,0%,17%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$11.6m,,$0.0m,$2.7m,$0.0m,$0.0m,,$4.7m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m
1206,Micro,Guilin Bajiayi Pharmaceutical,Private,Asia/Oceania,,,,,$9.6m,Estimate,No,Yes,No,No,18%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,14%,0%,0%,0%,0%,14%,,14%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$11.6m,,$2.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.9m,$2.1m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.6m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m
1207,Micro,Kitov,Public,Middle East/Africa,Israel,Tel Aviv,,,$9.6m,Estimate,No,No,No,No,20%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,0%,0%,0%,0%,0%,,20%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$11.6m,,$3.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.6m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1208,Micro,Tusk Therapeutics,Private,Europe,United Kingdom,Stevenage,,,$9.6m,Estimate,No,Yes,No,No,100%,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,75%,0%,0%,0%,0%,,25%,0%,0%,0%,0%,,,,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$5.1m,$0.0m,$0.0m,$0.0m,,$11.6m,,$11.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1209,Micro,H-Immune,Private,Europe,France,Paris,Massachusetts,Cambridge,$9.6m,Estimate,No,Yes,No,No,100%,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,75%,0%,0%,0%,0%,,25%,0%,0%,0%,0%,,,,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$5.1m,$0.0m,$0.0m,$0.0m,,$11.6m,,$11.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1210,Micro,Guangdong Zhongsheng Pharma,Public,Asia/Oceania,China,Dongguan,,,$9.6m,Estimate,No,Yes,No,No,22%,$2.1m,$1.5m,$0.0m,$0.0m,$1.5m,,17%,17%,0%,0%,0%,33%,,17%,17%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$0.0m,$0.0m,,$11.6m,,$2.7m,$1.9m,$0.0m,$0.0m,,$3.2m,$0.0m,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m
1211,Micro,Centaurus Biopharma,Private,Asia/Oceania,,,,,$9.6m,Estimate,Yes,No,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,33%,33%,0%,0%,67%,,0%,33%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$11.6m,,$0.0m,$3.3m,$8.3m,$0.0m,,$0.0m,$0.0m,$11.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1212,Micro,OncoPep,Private,North America,,,,,$9.6m,Estimate,No,Yes,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,33%,33%,0%,0%,67%,,0%,33%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$11.6m,,$0.0m,$3.3m,$8.3m,$0.0m,,$0.0m,$0.0m,$11.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1213,Micro,CerRx,Private,North America,,,,,$9.6m,Estimate,Yes,No,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,33%,33%,0%,0%,67%,,0%,33%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$11.6m,,$0.0m,$3.3m,$8.3m,$0.0m,,$0.0m,$0.0m,$11.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1214,Micro,OncoArendi Therapeutics,Public,Europe,Poland,Warsaw,,,$9.6m,Estimate,No,Yes,No,No,46%,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$11.6m,,$5.0m,$0.0m,$0.0m,$0.0m,,$3.2m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m
1215,Micro,ViroTarg,Private,Asia/Oceania,Australia,Sydney,,,$9.5m,Estimate,Yes,No,No,No,22%,$2.1m,$1.5m,$3.8m,$0.0m,$5.3m,,25%,25%,25%,0%,0%,75%,,25%,25%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$2.1m,$0.0m,,$11.6m,,$3.3m,$2.4m,$5.9m,$0.0m,,$0.0m,$0.0m,$11.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1216,Micro,Madison Vaccines,Private,North America,Montana,Missoula,,,$9.5m,Estimate,No,Yes,Yes,No,22%,$2.1m,$1.5m,$3.8m,$0.0m,$5.3m,,25%,25%,25%,0%,0%,75%,,25%,25%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$2.1m,$0.0m,,$11.6m,,$3.3m,$2.4m,$5.9m,$0.0m,,$0.0m,$0.0m,$11.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1217,Micro,Xeme Biopharma,Private,North America,California,Los Angeles,,,$9.5m,Estimate,Yes,Yes,No,Yes,22%,$2.1m,$1.5m,$3.8m,$0.0m,$5.3m,,25%,25%,25%,0%,0%,75%,,25%,25%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$2.1m,$0.0m,,$11.6m,,$3.3m,$2.4m,$5.9m,$0.0m,,$0.0m,$0.0m,$11.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1218,Micro,Inimmune,Private,North America,California,Sunnyvale,,,$9.5m,Estimate,No,Yes,No,No,20%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$11.6m,,$2.3m,$0.0m,$0.0m,$0.0m,,$4.5m,$0.0m,$2.3m,$2.3m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1219,Micro,Lead Pharma,Private,Europe,Netherlands,Oss,,,$9.5m,Estimate,No,No,No,No,20%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$11.5m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$2.4m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m
1220,Micro,Centus Biotherapeutics,Private,Europe,United Kingdom,Cambridge,,,$9.5m,Estimate,No,Yes,No,No,17%,$1.6m,$1.2m,$0.0m,$5.7m,$6.9m,,25%,25%,0%,25%,0%,75%,,0%,0%,0%,0%,0%,,25%,25%,0%,25%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.6m,$1.2m,$0.0m,$5.7m,$0.0m,$0.9m,$0.7m,$0.0m,$3.2m,,$11.5m,,$2.2m,$1.6m,$0.0m,$7.7m,,$0.0m,$0.0m,$11.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1221,Micro,Syntrix,Private,North America,Washington,Auburn,,,$9.4m,Estimate,Yes,No,No,No,20%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$11.5m,,$2.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.4m,$2.6m,$0.0m,$0.0m,$0.0m,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1222,Micro,Soricimed,Private,North America,New Brunswick,Moncton,,,$9.4m,Estimate,No,No,No,No,47%,$4.4m,$1.6m,$0.0m,$0.0m,$1.6m,,40%,20%,0%,0%,0%,60%,,40%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.9m,$0.0m,$0.0m,,$11.5m,,$8.4m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1223,Micro,Cartesian Therapeutics,Private,North America,Maryland,Gaithersburg,,,$9.4m,Estimate,No,Yes,Yes,Yes,47%,$4.4m,$1.6m,$0.0m,$0.0m,$1.6m,,40%,20%,0%,0%,0%,60%,,40%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.9m,$0.0m,$0.0m,,$11.5m,,$8.4m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1224,Micro,TYG Oncology,Private,Europe,United Kingdom,Nottingham,,,$9.4m,Estimate,No,Yes,No,No,75%,$7.1m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,50%,0%,0%,0%,0%,,25%,0%,0%,0%,0%,,,,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$11.4m,,$11.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1225,Micro,Aadi,Private,North America,Wisconsin,Madison,,,$9.4m,Estimate,No,No,No,No,21%,$2.0m,$0.0m,$3.6m,$0.0m,$3.6m,,20%,0%,20%,0%,0%,40%,,0%,0%,0%,0%,0%,,20%,0%,20%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.0m,$0.0m,$3.6m,$0.0m,$0.0m,$1.1m,$0.0m,$2.0m,$0.0m,,$11.4m,,$2.5m,$0.0m,$4.5m,$0.0m,,$0.0m,$0.0m,$7.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m
1226,Micro,Iconic Therapeutics,Private,North America,California,South San Francisco,,,$9.4m,Estimate,No,No,No,No,40%,$3.8m,$1.4m,$0.0m,$0.0m,$1.4m,,50%,25%,0%,0%,0%,75%,,50%,25%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.8m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.8m,$0.0m,$0.0m,,$11.4m,,$4.5m,$1.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.1m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1227,Micro,TheraMAB,Private,Europe,Germany,Wurzburg,,,$9.3m,Estimate,Yes,Yes,No,No,17%,$1.6m,$1.2m,$0.0m,$0.0m,$1.2m,,25%,25%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,25%,25%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.6m,$1.2m,$0.0m,$0.0m,$0.0m,$0.9m,$0.7m,$0.0m,$0.0m,,$11.3m,,$1.4m,$1.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$6.6m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1228,Micro,Anaeropharma Science,Private,Asia/Oceania,Japan,Nagano,Japan,Tokyo,$9.3m,Estimate,No,Yes,Yes,No,42%,$3.9m,$0.0m,$3.5m,$0.0m,$3.5m,,50%,0%,25%,0%,0%,75%,,50%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$2.0m,$0.0m,,$11.3m,,$4.8m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1229,Micro,AgonOx,Private,North America,Oregon,Portland,,,$9.2m,Estimate,No,Yes,No,No,100%,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,,$11.2m,,$11.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1230,Micro,Tempest Therapeutics,Private,North America,California,San Francisco,,,$9.2m,Estimate,No,Yes,No,No,100%,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,,$11.2m,,$11.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1231,Micro,iOnctura,Private,Europe,Switzerland,Geneva,,,$9.2m,Estimate,No,Yes,No,No,100%,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,,$11.2m,,$11.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1232,Micro,NeRx BioSciences,Private,North America,Indiana,Indianapolis,,,$9.2m,Estimate,No,No,No,No,100%,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,,$11.2m,,$11.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1233,Micro,Novintum BioScience,Private,Europe,United Kingdom,London,,,$9.2m,Estimate,No,No,No,No,100%,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,,$11.2m,,$11.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1234,Micro,ENB Therapeutics,Private,North America,New York,New York,,,$9.2m,Estimate,No,No,No,No,100%,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,,$11.2m,,$11.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1235,Micro,Torque Therapeutics,Private,North America,Massachusetts,Cambridge,,,$9.2m,Estimate,No,Yes,No,Yes,100%,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,,$11.2m,,$11.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1236,Micro,AP Biosciences,Private,Asia/Oceania,Taiwan,Taipei City,,,$9.2m,Estimate,No,Yes,No,No,100%,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,,$11.2m,,$11.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1237,Micro,Storm Therapeutics,Private,Europe,United Kingdom,Cambridge,,,$9.2m,Estimate,No,No,No,No,100%,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,,$11.2m,,$11.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1238,Micro,Tikcro Technologies,Public,Middle East/Africa,Israel,Ness Ziona,,,$9.2m,Estimate,No,Yes,No,No,100%,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,,$11.2m,,$11.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$11.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1239,Micro,Ever Supreme,Private,Asia/Oceania,Taiwan,Taichung City,,,$9.2m,Estimate,No,Yes,Yes,Yes,60%,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,,60%,0%,0%,0%,0%,60%,,60%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,,$11.2m,,$6.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1240,Micro,Tosk,Private,North America,Pennsylvania,Jenkintown,,,$9.2m,Estimate,No,No,No,No,22%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$11.2m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m
1241,Micro,LAM Therapeutics,Private,North America,,,,,$9.1m,Estimate,Yes,No,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.1m,,0%,20%,20%,0%,0%,40%,,0%,20%,20%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.0m,$0.0m,,$11.1m,,$0.0m,$2.2m,$5.5m,$0.0m,,$3.4m,$0.0m,$7.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1242,Micro,Chiva Pharmaceuticals,Private,North America,California,Palo Alto,,,$9.0m,Estimate,No,No,No,No,13%,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,0%,0%,0%,0%,0%,,25%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,$0.0m,,$10.9m,,$1.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$4.1m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1243,Micro,Avixgen,Private,Asia/Oceania,South Korea,Seoul,,,$9.0m,Estimate,No,No,No,No,21%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$10.9m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.3m,$2.3m,$2.2m,$0.0m,$0.0m,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1244,Micro,IGM Biosciences,Private,North America,California,Mountain View,,,$9.0m,Estimate,Yes,Yes,No,No,75%,$6.8m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,$0.0m,,$10.9m,,$8.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.2m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1245,Micro,Isu Abxis,Public,Asia/Oceania,,,,,$9.0m,Estimate,No,Yes,No,No,0%,$0.0m,$1.1m,$0.0m,$0.0m,$1.1m,,0%,33%,0%,0%,0%,33%,,0%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$10.9m,,$0.0m,$1.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$9.4m,$0.0m,$0.0m,$0.0m
1246,Micro,Biozeus,Private,Latin America,,,,,$9.0m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$10.9m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m
1247,Micro,Cold Genesys,Private,North America,California,Santa Ana,,,$8.9m,Estimate,No,Yes,Yes,No,53%,$4.7m,$0.0m,$4.2m,$0.0m,$4.2m,,67%,0%,33%,0%,0%,100%,,33%,0%,0%,0%,0%,,33%,0%,33%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$4.2m,$0.0m,$0.0m,$2.5m,$0.0m,$2.4m,$0.0m,,$10.8m,,$5.7m,$0.0m,$5.1m,$0.0m,,$0.0m,$0.0m,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1248,Micro,Hansoh Pharmaceuticals,Private,Asia/Oceania,,,,,$8.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.1m,$0.0m,$3.1m,,0%,0%,25%,0%,0%,25%,,0%,0%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,,$10.8m,,$0.0m,$0.0m,$3.0m,$0.0m,,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m
1249,Micro,SupremeCure Pharma,Private,Asia/Oceania,Taiwan,Taipei City,,,$8.9m,Estimate,No,No,No,No,75%,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$10.8m,,$10.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1250,Micro,Sapience Therapeutics,Private,North America,New York,Harrison,,,$8.9m,Estimate,Yes,Yes,No,No,75%,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$10.8m,,$10.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1251,Micro,Canqura Oncology,Private,Europe,Sweden,Enkoping,,,$8.9m,Estimate,Yes,No,No,No,75%,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$10.8m,,$10.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1252,Micro,Artios Pharma,Private,Europe,United Kingdom,Cambridge,,,$8.9m,Estimate,No,No,No,No,75%,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$10.8m,,$10.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1253,Micro,Oncotherapy Solutions,Private,Europe,Switzerland,Meyrin,New York,Syracuse,$8.9m,Estimate,No,Yes,No,No,75%,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$10.8m,,$10.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1254,Micro,Minerva Biotechnologies,Private,North America,Massachusetts,Waltham,,,$8.9m,Estimate,No,Yes,Yes,Yes,75%,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$26.5m,,$26.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$26.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1255,Micro,Mirata Biopharma,Private,North America,Texas,Houston,,,$8.9m,Estimate,No,Yes,No,No,75%,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$10.8m,,$10.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1256,Micro,MAA Laboratories,Private,North America,North Carolina,Durham,,,$8.9m,Estimate,No,No,No,No,75%,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$10.8m,,$10.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1257,Micro,Lykera Biomed,Private,Europe,Spain,Barcelona,,,$8.9m,Estimate,No,Yes,No,No,75%,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$10.8m,,$10.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1258,Micro,CiMaas,Private,Europe,Netherlands,Maastricht,,,$8.9m,Estimate,No,Yes,No,Yes,75%,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$10.8m,,$10.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1259,Micro,Gmaxx Biologics,Private,Asia/Oceania,China,Suzhou,,,$8.9m,Estimate,No,No,No,No,20%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$10.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m
1260,Micro,Sentinel Oncology,Private,Europe,United Kingdom,Cambridge,,,$8.9m,Estimate,No,No,No,No,75%,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,50%,0%,0%,0%,0%,,25%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$10.8m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.4m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1261,Micro,Vivace Therapeutics,Private,North America,California,San Mateo,,,$8.8m,Estimate,No,Yes,No,No,75%,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,,$10.7m,,$8.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1262,Micro,Alchemia,Public,Middle East/Africa,Israel,Ness Ziona,,,$8.8m,Estimate,Yes,No,No,No,50%,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$10.7m,,$6.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1263,Micro,Paranta Biosciences,Private,Asia/Oceania,Australia,Melbourne,,,$8.8m,Estimate,No,No,No,No,23%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$10.7m,,$2.5m,$0.0m,$0.0m,$0.0m,,$3.3m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m
1264,Micro,Bluepharma,Private,Europe,Portugal,Coimbra,,,$8.8m,Estimate,No,No,No,No,26%,$2.3m,$0.0m,$4.2m,$0.0m,$4.2m,,33%,0%,33%,0%,0%,67%,,0%,0%,0%,0%,0%,,33%,0%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$4.2m,$0.0m,$0.0m,$1.2m,$0.0m,$2.3m,$0.0m,,$10.6m,,$3.8m,$0.0m,$6.8m,$0.0m,,$0.0m,$0.0m,$10.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1265,Micro,Cellular Dynamics,Private,North America,Minnesota,Waconia,,,$8.7m,Estimate,No,No,No,Yes,20%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$10.6m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.6m,$2.8m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1266,Micro,Xyphos,Private,North America,California,South San Francisco,,,$8.7m,Estimate,No,Yes,Yes,Yes,50%,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$10.6m,,$7.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1267,Micro,SFA Therapeutics,Private,North America,Washington,Seattle,,,$8.7m,Estimate,No,No,No,No,23%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$10.5m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$1.2m,$3.2m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m
1268,Micro,Sun BioPharma,Public,North America,Massachusetts,Watertown,,,$8.6m,Estimate,No,No,No,No,23%,$2.0m,$1.5m,$0.0m,$0.0m,$1.5m,,20%,20%,0%,0%,0%,40%,,20%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$0.0m,$0.0m,,$10.5m,,$3.1m,$2.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m
1269,Micro,Marsala Biotech,Private,North America,,,,,$8.6m,Estimate,No,No,Yes,No,0%,$0.0m,$1.5m,$0.0m,$7.2m,$8.6m,,0%,50%,0%,50%,0%,100%,,0%,50%,0%,50%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$0.0m,$7.2m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$4.0m,,$10.5m,,$0.0m,$1.8m,$0.0m,$8.7m,,$0.0m,$0.0m,$10.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1270,Micro,Biond Biologics,Private,Middle East/Africa,Israel,Nahariya,,,$8.6m,Estimate,No,Yes,No,No,75%,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,,75%,0%,0%,0%,0%,75%,,75%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,,$10.5m,,$7.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.9m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1271,Micro,Kunshan RiboQuark,Private,Asia/Oceania,,,,,$8.6m,Estimate,No,No,No,No,12%,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,$0.0m,,$10.5m,,$0.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.9m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1272,Micro,Blaze Bioscience,Private,North America,Massachusetts,Cambridge,Utah,Salt Lake City,$8.6m,Estimate,No,No,No,No,21%,$1.8m,$1.3m,$0.0m,$0.0m,$1.3m,,20%,20%,0%,0%,0%,40%,,20%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.7m,$0.0m,$0.0m,,$10.5m,,$2.7m,$2.0m,$0.0m,$0.0m,,$0.0m,$2.3m,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m
1273,Micro,Revolution Medicines,Private,North America,California,Redwood City,,,$8.6m,Estimate,No,No,No,No,81%,$6.9m,$1.7m,$0.0m,$0.0m,$1.7m,,75%,25%,0%,0%,0%,100%,,75%,25%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.9m,$0.0m,$0.0m,,$10.4m,,$8.4m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1274,Micro,Therapeutic Solutions,Public,Europe,United Kingdom,London,,,$8.6m,Estimate,No,Yes,No,No,81%,$6.9m,$1.7m,$0.0m,$0.0m,$1.7m,,75%,25%,0%,0%,0%,100%,,75%,25%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.9m,$0.0m,$0.0m,,$10.4m,,$8.4m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1275,Micro,Scandion Oncology,Private,Europe,Denmark,Copenhagen,,,$8.6m,Estimate,No,No,No,No,81%,$6.9m,$1.7m,$0.0m,$0.0m,$1.7m,,75%,25%,0%,0%,0%,100%,,75%,25%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.9m,$0.0m,$0.0m,,$10.4m,,$8.4m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1276,Micro,Escend Pharmaceuticals,Private,North America,California,Menlo Park,,,$8.6m,Estimate,Yes,No,No,No,50%,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$10.4m,,$10.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1277,Micro,Atlanthera,Private,Europe,France,Saint-Herblain,,,$8.6m,Estimate,Yes,No,No,No,50%,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$10.4m,,$10.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1278,Micro,BARcure,Private,Middle East/Africa,Israel,Ness Ziona,,,$8.6m,Estimate,Yes,Yes,No,No,50%,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$10.4m,,$10.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1279,Micro,Ascend Biopharmaceuticals,Private,Asia/Oceania,Australia,Melbourne,,,$8.5m,Estimate,No,No,Yes,No,53%,$4.5m,$0.0m,$4.1m,$0.0m,$4.1m,,67%,0%,33%,0%,0%,100%,,67%,0%,0%,0%,0%,,0%,0%,33%,0%,0%,,,,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.1m,$0.0m,$0.0m,$2.4m,$0.0m,$2.3m,$0.0m,,$94.7m,,$49.8m,$0.0m,$45.0m,$0.0m,,$0.0m,$0.0m,$94.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1280,Micro,Jiangsu Aidea Pharmaceutical,Private,Asia/Oceania,China,Yangzhou,,,$8.5m,Estimate,No,No,No,No,43%,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,,40%,0%,0%,0%,0%,40%,,40%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,,$10.4m,,$4.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1281,Micro,Enterome,Private,Europe,France,Paris,Massachusetts,Cambridge,$8.5m,Estimate,No,Yes,No,No,46%,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,40%,0%,0%,0%,0%,40%,,40%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$10.4m,,$4.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m
1282,Micro,C4 Therapeutics,Private,North America,Texas,Houston,,,$8.5m,Estimate,No,No,No,No,20%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$10.4m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.0m,$2.2m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m
1283,Micro,CyTuVax,Private,Europe,Netherlands,Maastricht,,,$8.5m,Estimate,No,Yes,No,No,23%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$10.3m,,$2.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.9m,$0.0m,$0.0m,$0.0m,$0.0m,$7.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1284,Micro,Shenzhen Cure & Sure Biotech,Private,North America,,,,,$8.5m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,50%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,0%,50%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$10.3m,,$0.0m,$0.0m,$10.3m,$0.0m,,$0.0m,$0.0m,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1285,Micro,NT Pharma,Public,Asia/Oceania,,,,,$8.5m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,50%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,0%,50%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$10.3m,,$0.0m,$0.0m,$10.3m,$0.0m,,$0.0m,$0.0m,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1286,Micro,Pacific Pharmaceuticals,Private,Europe,,,,,$8.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,50%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,0%,50%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$10.3m,,$0.0m,$0.0m,$10.3m,$0.0m,,$0.0m,$0.0m,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1287,Micro,Sopherion Therapeutics,Private,Europe,,,,,$8.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,50%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,0%,50%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$10.3m,,$0.0m,$0.0m,$10.3m,$0.0m,,$0.0m,$0.0m,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1288,Micro,TSD Japan,Private,North America,,,,,$8.5m,Estimate,Yes,Yes,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,50%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,0%,50%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$10.3m,,$0.0m,$0.0m,$10.3m,$0.0m,,$0.0m,$0.0m,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1289,Micro,Cahaba Pharmaceuticals,Private,North America,,,,,$8.5m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,50%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,0%,50%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$10.3m,,$0.0m,$0.0m,$10.3m,$0.0m,,$0.0m,$0.0m,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1290,Micro,VentiRx Pharmaceuticals,Private,North America,,,,,$8.5m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,50%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,0%,50%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$10.3m,,$0.0m,$0.0m,$10.3m,$0.0m,,$0.0m,$0.0m,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1291,Micro,Esperas Pharma,Private,North America,,,,,$8.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,50%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,0%,50%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$10.3m,,$0.0m,$0.0m,$10.3m,$0.0m,,$0.0m,$0.0m,$10.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1292,Micro,Curza,Private,North America,California,San Francisco,,,$8.5m,Estimate,No,No,No,No,25%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$10.3m,,$3.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1293,Micro,Pulmotect,Private,North America,Massachusetts,Cambridge,,,$8.5m,Estimate,No,Yes,No,No,24%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$10.3m,,$2.7m,$0.0m,$0.0m,$0.0m,,$2.6m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1294,Micro,IC-MedTech,Private,North America,,,,,$8.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.1m,$0.0m,$3.1m,,0%,0%,33%,0%,0%,33%,,0%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,,$10.3m,,$0.0m,$0.0m,$3.5m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1295,Micro,Aurum Biosciences,Private,Europe,United Kingdom,Glasgow,,,$8.4m,Estimate,No,No,No,No,20%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$10.2m,,$1.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.6m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1296,Micro,Numerate,Private,North America,California,Santa Monica,,,$8.4m,Estimate,No,No,No,No,20%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$10.2m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m
1297,Micro,Aura Biosciences,Private,North America,Colorado,Aurora,,,$8.4m,Estimate,No,No,No,No,26%,$2.2m,$0.0m,$4.0m,$0.0m,$4.0m,,33%,0%,33%,0%,0%,67%,,0%,0%,33%,0%,0%,,33%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$4.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$2.2m,$0.0m,,$10.1m,,$3.6m,$0.0m,$6.5m,$0.0m,,$0.0m,$0.0m,$10.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1298,Micro,Sermonix Pharmaceuticals,Private,North America,Ohio,Columbus,,,$8.3m,Estimate,No,No,No,No,14%,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,0%,0%,0%,0%,0%,,33%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,$0.0m,,$10.1m,,$1.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.0m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1299,Micro,ACEA Biosciences,Private,North America,,,,,$8.3m,Estimate,Yes,No,No,No,0%,$0.0m,$1.4m,$3.6m,$0.0m,$5.1m,,0%,25%,25%,0%,0%,50%,,0%,25%,25%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.0m,$0.0m,,$10.1m,,$0.0m,$1.9m,$4.8m,$0.0m,,$0.0m,$0.0m,$6.7m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1300,Micro,e-Therapeutics,Public,Europe,United Kingdom,Oxford,United Kingdom,Newcastle,$8.3m,Estimate,No,No,No,No,50%,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$10.1m,,$5.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.4m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1301,Micro,Orphelia Pharma,Private,Europe,France,Paris,France,Lyon,$8.3m,Estimate,Yes,No,No,No,54%,$4.4m,$1.6m,$0.0m,$0.0m,$1.6m,,40%,20%,0%,0%,0%,60%,,40%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.9m,$0.0m,$0.0m,,$10.1m,,$7.4m,$2.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1302,Micro,NMT Pharmaceuticals,Private,Asia/Oceania,Singapore,Singapore,Texas,Webster,$8.3m,Estimate,Yes,No,No,No,54%,$4.4m,$1.6m,$0.0m,$0.0m,$1.6m,,50%,25%,0%,0%,0%,75%,,25%,0%,0%,0%,0%,,25%,25%,0%,0%,0%,,,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,$2.4m,$0.9m,$0.0m,$0.0m,,$10.0m,,$7.4m,$2.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$10.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1303,Micro,Shenzhen Salubris Pharmaceutical,Public,Asia/Oceania,,,,,$8.3m,Estimate,No,No,No,No,19%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$10.0m,,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m
1304,Micro,Lin Bioscience,Private,Asia/Oceania,Taiwan,Taipei City,California,San Diego,$8.2m,Estimate,Yes,No,No,No,50%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$10.0m,,$6.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.7m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1305,Micro,Aposense,Public,Middle East/Africa,Israel,Petach-Tikva,,,$8.2m,Estimate,No,No,No,No,50%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$10.0m,,$6.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.2m,$6.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1306,Micro,Abion,Private,Asia/Oceania,South Korea,Seoul,,,$8.2m,Estimate,No,No,No,No,50%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$10.0m,,$6.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.2m,$6.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1307,Micro,MAX BioPharma,Private,North America,Florida,Jupiter,,,$8.2m,Estimate,No,No,No,No,25%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$9.9m,,$3.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1308,Micro,Hinova Pharmaceuticals,Private,Asia/Oceania,China,Sichuan,,,$8.1m,Estimate,No,No,No,No,53%,$4.3m,$0.0m,$3.9m,$0.0m,$3.9m,,67%,0%,33%,0%,0%,100%,,67%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.3m,$0.0m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$2.2m,$0.0m,,$9.9m,,$5.2m,$0.0m,$4.7m,$0.0m,,$0.0m,$0.0m,$9.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1309,Micro,Avelas Biosciences,Private,North America,California,La Jolla,,,$8.1m,Estimate,No,No,No,No,53%,$4.3m,$0.0m,$3.9m,$0.0m,$3.9m,,67%,0%,33%,0%,0%,100%,,67%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.3m,$0.0m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$2.2m,$0.0m,,$9.9m,,$5.2m,$0.0m,$4.7m,$0.0m,,$0.0m,$0.0m,$9.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1310,Micro,Taiga Biotechnologies,Private,North America,California,San Diego,Japan,Tokyo,$8.1m,Estimate,No,Yes,No,Yes,25%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$9.9m,,$3.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.3m,$3.3m,$0.0m,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1311,Micro,RubrYc Therapeutics,Private,North America,California,San Ramon,,,$8.1m,Estimate,No,Yes,No,No,50%,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$9.8m,,$4.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.9m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1312,Micro,Mannin Research,Private,North America,,,,,$8.1m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$9.8m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.9m,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$2.1m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1313,Micro,Kotobuki Pharmaceutical,Private,Asia/Oceania,,,,,$8.0m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.7m,$0.0m,$3.7m,,0%,0%,17%,0%,17%,33%,,0%,0%,17%,0%,17%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,,$9.8m,,$0.0m,$0.0m,$4.4m,$0.0m,,$0.0m,$0.0m,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1314,Micro,Potenza Therapeutics,Private,North America,Massachusetts,Cambridge,,,$8.0m,Estimate,No,Yes,No,Yes,58%,$4.6m,$3.4m,$0.0m,$0.0m,$3.4m,,50%,50%,0%,0%,0%,100%,,50%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$3.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$1.9m,$0.0m,$0.0m,,$9.7m,,$5.6m,$4.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$9.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1315,Micro,Solural Pharma,Private,Europe,Denmark,Ballerup,,,$7.9m,Estimate,No,No,No,No,26%,$2.1m,$1.5m,$0.0m,$0.0m,$1.5m,,20%,20%,0%,0%,0%,40%,,20%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$0.0m,$0.0m,,$9.6m,,$3.0m,$2.2m,$0.0m,$0.0m,,$0.0m,$2.5m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1316,Micro,Y's Therapeutics,Public,Asia/Oceania,,,,,$7.9m,Estimate,Yes,Yes,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1317,Micro,Oncovir,Private,North America,,,,,$7.9m,Estimate,Yes,Yes,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1318,Micro,Perseus PCI,Private,North America,,,,,$7.9m,Estimate,Yes,Yes,No,Yes,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1319,Micro,Respiratorius,Private,Europe,,,,,$7.9m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1320,Micro,Angimmune,Private,North America,,,,,$7.9m,Estimate,Yes,Yes,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1321,Micro,CAS Lamvac Biotech,Private,Asia/Oceania,,,,,$7.9m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1322,Micro,Fusion Pharma,Private,Europe,,,,,$7.9m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1323,Micro,Lokon Pharma,Private,Europe,,,,,$7.9m,Estimate,No,Yes,Yes,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1324,Micro,Tiltan Pharma,Private,Middle East/Africa,,,,,$7.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1325,Micro,Genus Oncology,Private,North America,,,,,$7.9m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1326,Micro,IRX Therapeutics,Private,North America,,,,,$7.9m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1327,Micro,Privo Technologies,Private,North America,,,,,$7.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1328,Micro,Metromedia Bio-Science,Private,North America,,,,,$7.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1329,Micro,Gliknik,Private,North America,,,,,$7.9m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1330,Micro,BeyondBio,Private,Asia/Oceania,,,,,$7.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1331,Micro,Medinet,Public,Asia/Oceania,,,,,$7.9m,Estimate,No,Yes,No,Yes,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1332,Micro,BioSight,Private,Middle East/Africa,,,,,$7.9m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1333,Micro,Leukos Biotech,Private,Europe,,,,,$7.9m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1334,Micro,SpecificiT Pharma,Private,North America,,,,,$7.9m,Estimate,Yes,Yes,No,Yes,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1335,Micro,Benhealth Biopharmaceutical,Private,Asia/Oceania,,,,,$7.9m,Estimate,No,Yes,Yes,Yes,0%,$0.0m,$0.0m,$3.6m,$0.0m,$3.6m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.6m,,$0.0m,$0.0m,$9.6m,$0.0m,,$0.0m,$0.0m,$9.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1336,Micro,Symphony Evolution,Private,North America,,,,,$7.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.4m,$0.0m,$3.4m,,0%,0%,50%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,0%,50%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,,$9.6m,,$0.0m,$0.0m,$3.5m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1337,Micro,Recce Pharmaceuticals,Public,Asia/Oceania,Australia,Perth,Australia,Sydney,$7.9m,Estimate,No,No,No,No,25%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$9.5m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$2.2m,$2.6m,$0.0m,$0.0m,$0.0m
1338,Micro,GLG Pharma,Private,North America,California,Los Angeles,,,$7.8m,Estimate,Yes,No,No,No,26%,$2.1m,$0.0m,$3.7m,$0.0m,$3.7m,,33%,0%,33%,0%,0%,67%,,33%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$9.5m,,$2.5m,$0.0m,$4.6m,$0.0m,,$0.0m,$0.0m,$7.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1339,Micro,Jin-En International,Private,Asia/Oceania,China,Cangzhou,,,$7.8m,Estimate,No,Yes,No,No,26%,$2.1m,$0.0m,$3.7m,$0.0m,$3.7m,,33%,0%,33%,0%,0%,67%,,33%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$9.5m,,$3.4m,$0.0m,$6.1m,$0.0m,,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1340,Micro,LiPlasome,Private,Europe,Denmark,Hoersholm,,,$7.8m,Estimate,No,No,No,No,26%,$2.1m,$0.0m,$3.7m,$0.0m,$3.7m,,33%,0%,33%,0%,0%,67%,,33%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$9.5m,,$3.4m,$0.0m,$6.1m,$0.0m,,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1341,Micro,Aspyrian Therapeutics,Private,Europe,Belgium,Beerse,,,$7.8m,Estimate,No,Yes,No,No,26%,$2.1m,$0.0m,$3.7m,$0.0m,$3.7m,,33%,0%,33%,0%,0%,67%,,33%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$9.5m,,$3.4m,$0.0m,$6.1m,$0.0m,,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1342,Micro,Neonc Technologies,Private,North America,California,Los Angeles,,,$7.8m,Estimate,No,No,No,No,26%,$2.1m,$0.0m,$3.7m,$0.0m,$3.7m,,33%,0%,33%,0%,0%,67%,,33%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$9.5m,,$3.4m,$0.0m,$6.1m,$0.0m,,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1343,Micro,PharmAust,Public,Asia/Oceania,Australia,Claremont,,,$7.8m,Estimate,No,No,No,No,26%,$2.1m,$0.0m,$3.7m,$0.0m,$3.7m,,33%,0%,33%,0%,0%,67%,,33%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$9.5m,,$3.4m,$0.0m,$6.1m,$0.0m,,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1344,Micro,Shanghai Bioray Laboratory,Private,Asia/Oceania,China,Shanghai,,,$7.8m,Estimate,Yes,Yes,Yes,Yes,26%,$2.1m,$0.0m,$3.7m,$0.0m,$3.7m,,33%,0%,33%,0%,0%,67%,,33%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$9.5m,,$3.4m,$0.0m,$6.1m,$0.0m,,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1345,Micro,CellCentric,Private,Europe,United Kingdom,Cambridge,United Kingdom,Oxford,$7.8m,Estimate,Yes,No,No,No,26%,$2.1m,$0.0m,$3.7m,$0.0m,$3.7m,,33%,0%,33%,0%,0%,67%,,33%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$9.5m,,$3.4m,$0.0m,$6.1m,$0.0m,,$0.0m,$0.0m,$9.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1346,Micro,Kymera Therapeutics,Private,North America,Massachusetts,Cambridge,,,$7.8m,Estimate,No,No,No,No,50%,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,,$9.5m,,$4.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.7m,$2.3m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1347,Micro,Theraclone Sciences,Private,North America,Washington,Seattle,,,$7.8m,Estimate,Yes,Yes,No,No,54%,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$9.5m,,$6.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.8m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1348,Micro,Concentric Analgesics,Private,North America,,,,,$7.8m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$9.4m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$9.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1349,Micro,Octimet Oncology,Private,North America,Washington,Seattle,,,$7.8m,Estimate,No,No,No,No,28%,$2.2m,$1.6m,$4.0m,$0.0m,$5.6m,,33%,33%,33%,0%,0%,100%,,0%,0%,0%,0%,0%,,33%,33%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.2m,$1.6m,$4.0m,$0.0m,$0.0m,$1.2m,$0.9m,$2.2m,$0.0m,,$9.4m,,$2.7m,$1.9m,$4.8m,$0.0m,,$0.0m,$0.0m,$9.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1350,Micro,Pharmaleads,Private,Europe,,,,,$7.7m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$9.4m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$7.6m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1351,Micro,NatureWise Biotech & Medicals,Private,Asia/Oceania,Taiwan,Taipei City,,,$7.7m,Estimate,No,No,No,No,25%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$9.3m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m,$0.0m
1352,Micro,Io Therapeutics,Private,Europe,,,,,$7.6m,Estimate,No,No,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,25%,25%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,25%,25%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$9.3m,,$0.0m,$2.0m,$5.0m,$0.0m,,$0.0m,$2.3m,$7.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1353,Micro,Presage Biosciences,Private,North America,Missouri,St. Louis,,,$7.6m,Estimate,Yes,No,No,No,28%,$2.1m,$3.1m,$0.0m,$0.0m,$3.1m,,20%,40%,0%,0%,0%,60%,,0%,20%,0%,0%,0%,,20%,20%,0%,0%,0%,,,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$2.1m,$1.5m,$0.0m,$0.0m,$0.0m,$1.1m,$1.7m,$0.0m,$0.0m,,$9.2m,,$3.8m,$5.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1354,Micro,Sequoia Sciences,Private,North America,Massachusetts,Boston,,,$7.6m,Estimate,No,No,No,No,27%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$9.2m,,$3.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1355,Micro,Cellestia Biotech,Private,Europe,Switzerland,Basel,Switzerland,Lausanne,$7.6m,Estimate,No,No,No,No,26%,$2.0m,$0.0m,$3.6m,$0.0m,$3.6m,,33%,0%,33%,0%,0%,67%,,33%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.0m,$0.0m,,$9.2m,,$2.5m,$0.0m,$4.5m,$0.0m,,$0.0m,$0.0m,$7.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m
1356,Micro,Legacy Healthcare,Private,Europe,Switzerland,Lausanne,France,Paris,$7.6m,Estimate,No,No,No,No,17%,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,$0.0m,,$9.2m,,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,$7.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1357,Micro,Jnana Therapeutics,Private,North America,Massachusetts,Boston,,,$7.6m,Estimate,No,No,No,No,25%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$9.2m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.2m,$2.3m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1358,Micro,Valerius Biopharma,Private,Europe,Switzerland,Basel,,,$7.6m,Estimate,No,No,No,No,25%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$9.2m,,$2.3m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$2.3m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1359,Micro,Celtic Biotech Iowa,Private,Europe,Iowa,Urbandale,,,$7.5m,Estimate,No,No,No,No,30%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,25%,25%,0%,0%,0%,50%,,25%,25%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$9.2m,,$2.7m,$2.0m,$0.0m,$0.0m,,$0.0m,$1.9m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1360,Micro,Checkmate Pharmaceuticals,Private,North America,Massachusetts,Cambridge,,,$7.5m,Estimate,No,No,No,No,28%,$2.1m,$1.5m,$3.9m,$0.0m,$5.4m,,33%,33%,33%,0%,0%,100%,,33%,33%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$2.2m,$0.0m,,$9.2m,,$2.6m,$1.9m,$4.7m,$0.0m,,$0.0m,$0.0m,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1361,Micro,EnGeneIC,Private,Asia/Oceania,Australia,Sydney,New York,New York,$7.5m,Estimate,No,Yes,No,No,28%,$2.1m,$1.5m,$3.9m,$0.0m,$5.4m,,33%,33%,33%,0%,0%,100%,,33%,33%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$3.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$2.2m,$0.0m,,$9.2m,,$2.6m,$1.9m,$4.7m,$0.0m,,$0.0m,$0.0m,$9.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1362,Micro,Zumutor Biologics,Private,Asia/Oceania,India,Bangalore,Massachusetts,Woburn,$7.5m,Estimate,No,Yes,No,No,25%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$9.1m,,$3.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m
1363,Micro,Quimatryx,Private,Europe,Spain,San Sebastian,,,$7.5m,Estimate,Yes,No,No,No,25%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$9.1m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.9m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1364,Micro,PDX Pharmaceuticals,Private,North America,Oregon,Portland,,,$7.5m,Estimate,No,No,No,No,25%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$9.1m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$2.3m,$0.0m,$0.0m,$1.8m,$0.0m
1365,Micro,Hope Biosciences,Private,North America,Texas,Houston,,,$7.5m,Estimate,No,No,No,No,67%,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,0%,0%,0%,0%,0%,,67%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,,$9.1m,,$9.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$9.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1366,Micro,Ritter Pharmaceuticals,Public,North America,California,Los Angeles,,,$7.5m,Estimate,No,Yes,No,No,23%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$9.1m,,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.5m,$0.0m,$0.0m,$0.0m,$0.0m
1367,Micro,PlumeStars,Private,Europe,Italy,Parma,,,$7.4m,Estimate,Yes,No,No,No,25%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$9.0m,,$4.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1368,Micro,BioClin Therapeutics,Private,Europe,,,,,$7.4m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,33%,0%,0%,33%,,0%,0%,0%,0%,0%,,0%,0%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$9.0m,,$0.0m,$0.0m,$5.2m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1369,Micro,Issar Pharmaceuticals,Private,Asia/Oceania,,,,,$7.4m,Estimate,No,No,No,No,0%,$0.0m,$1.3m,$0.0m,$0.0m,$1.3m,,0%,20%,0%,0%,0%,20%,,0%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$9.0m,,$0.0m,$1.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,$5.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m
1370,Micro,Marino Biotechnology,Private,Asia/Oceania,China,Beijing,,,$7.4m,Estimate,Yes,Yes,Yes,Yes,31%,$2.3m,$5.1m,$0.0m,$0.0m,$5.1m,,25%,75%,0%,0%,0%,100%,,25%,75%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$5.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$2.8m,$0.0m,$0.0m,,$9.0m,,$2.8m,$6.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$9.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1371,Micro,Dauntless Pharmaceuticals,Private,North America,California,San Diego,,,$7.4m,Estimate,No,No,No,No,26%,$1.9m,$1.4m,$0.0m,$0.0m,$1.4m,,17%,17%,0%,0%,0%,33%,,17%,17%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$0.0m,$0.0m,,$8.9m,,$2.5m,$1.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.2m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$1.1m,$0.0m,$0.0m
1372,Micro,Iontas,Private,Europe,United Kingdom,Cambridge,,,$7.3m,Estimate,No,Yes,No,No,25%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$8.9m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.1m,$2.2m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1373,Micro,EpimAb Biotherapeutics,Private,Asia/Oceania,China,Shanghai,,,$7.3m,Estimate,No,Yes,No,No,100%,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,67%,0%,0%,0%,0%,,33%,0%,0%,0%,0%,,,,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,,$8.8m,,$8.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1374,Micro,Glythera,Private,Europe,United Kingdom,Newcastle,,,$7.3m,Estimate,No,Yes,No,No,100%,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,67%,0%,0%,0%,0%,,33%,0%,0%,0%,0%,,,,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,,$8.8m,,$8.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1375,Micro,Atridia,Private,Asia/Oceania,Australia,Sydney,,,$7.2m,Estimate,No,Yes,No,No,32%,$2.3m,$3.4m,$0.0m,$0.0m,$3.4m,,25%,50%,0%,0%,0%,75%,,25%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$3.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$1.9m,$0.0m,$0.0m,,$8.8m,,$2.8m,$4.1m,$0.0m,$0.0m,,$0.0m,$1.9m,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1376,Micro,Fidia,Public,Europe,,,,,$7.2m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.2m,$0.0m,$3.2m,,0%,0%,33%,0%,0%,33%,,0%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,,$8.8m,,$0.0m,$0.0m,$3.6m,$0.0m,,$0.0m,$5.2m,$3.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1377,Micro,ProtoKinetix,Public,North America,Ohio,Marietta,,,$7.2m,Estimate,No,No,No,No,28%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$8.7m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m
1378,Micro,Holy Stone Healthcare,Public,Asia/Oceania,Taiwan,Taipei City,,,$7.2m,Estimate,No,No,No,No,28%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$8.7m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m
1379,Micro,InventisBio,Private,Asia/Oceania,China,Shanghai,,,$7.2m,Estimate,No,Yes,No,No,33%,$2.4m,$3.4m,$0.0m,$0.0m,$3.4m,,25%,50%,0%,0%,0%,75%,,25%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.4m,$3.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$1.9m,$0.0m,$0.0m,,$8.7m,,$2.8m,$4.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1380,Micro,XTL Biopharmaceuticals,Public,Middle East/Africa,,,,,$7.2m,Estimate,No,No,No,No,0%,$0.0m,$0.9m,$0.0m,$0.0m,$0.9m,,0%,20%,0%,0%,0%,20%,,0%,20%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.5m,$0.0m,$0.0m,,$8.7m,,$0.0m,$0.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.9m,$7.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1381,Micro,Arrakis Therapeutics,Private,North America,Massachusetts,Waltham,,,$7.2m,Estimate,No,No,No,No,25%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$8.7m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.1m,$2.2m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m
1382,Micro,Everfront Biotech,Private,Asia/Oceania,,,,,$7.1m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.4m,$0.0m,$3.4m,,0%,0%,33%,0%,0%,33%,,0%,0%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,,$8.7m,,$0.0m,$0.0m,$5.9m,$0.0m,,$0.0m,$2.7m,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1383,Micro,Veana Therapeutics,Private,North America,Oregon,Portland,,,$7.1m,Estimate,Yes,Yes,No,No,30%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,25%,25%,0%,0%,0%,50%,,25%,25%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$0.0m,$0.0m,,$8.7m,,$5.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1384,Micro,Beta Cat Pharmaceuticals,Private,North America,Texas,Houston,,,$7.1m,Estimate,Yes,No,No,No,30%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,25%,25%,0%,0%,0%,50%,,25%,25%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$0.0m,$0.0m,,$8.7m,,$5.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1385,Micro,SYZ Cell Therapy,Private,Asia/Oceania,Hong Kong,Hong Kong,,,$7.1m,Estimate,Yes,Yes,No,Yes,30%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,25%,25%,0%,0%,0%,50%,,25%,25%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$0.0m,$0.0m,,$8.7m,,$5.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1386,Micro,Cleave Biosciences,Private,North America,California,South San Francisco,,,$7.1m,Estimate,Yes,No,No,No,30%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,25%,25%,0%,0%,0%,50%,,25%,25%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$0.0m,$0.0m,,$8.7m,,$5.0m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1387,Micro,Novassay,Private,Europe,Switzerland,Lausanne,,,$7.1m,Estimate,No,No,No,No,25%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$8.7m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$6.4m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1388,Micro,Oshadi Drug Administration,Private,Middle East/Africa,,,,,$7.1m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$7.1m,$0.0m,$7.1m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$7.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.0m,$0.0m,,$8.6m,,$0.0m,$0.0m,$8.6m,$0.0m,,$0.0m,$0.0m,$8.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1389,Micro,AlphaVax,Private,North America,,,,,$7.1m,Estimate,No,Yes,Yes,No,0%,$0.0m,$1.4m,$0.0m,$0.0m,$1.4m,,0%,33%,0%,0%,0%,33%,,0%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,,$8.6m,,$0.0m,$2.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$6.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1390,Micro,SteroTherapeutics,Private,North America,Pennsylvania,Philadelphia,,,$7.1m,Estimate,No,No,No,No,25%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$8.6m,,$3.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.9m,$0.0m,$2.5m,$0.0m,$0.0m
1391,Micro,Gritstone Oncology,Public,North America,California,Emeryville,Massachusetts,Cambridge,$7.0m,Estimate,No,Yes,Yes,Yes,67%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,33%,0%,0%,0%,0%,,33%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,,$8.5m,,$8.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1392,Micro,NewGen Therapeutics,Private,North America,California,Menlo Park,,,$7.0m,Estimate,No,No,No,No,67%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,33%,0%,0%,0%,0%,,33%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,,$8.5m,,$8.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1393,Micro,Refuge Biotech,Private,North America,California,Menlo Park,,,$6.9m,Estimate,No,Yes,Yes,Yes,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1394,Micro,Venn Therapeutics,Private,North America,Florida,Tampa,,,$6.9m,Estimate,No,Yes,Yes,No,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1395,Micro,FogPharma,Private,North America,Massachusetts,Cambridge,,,$6.9m,Estimate,No,No,No,No,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1396,Micro,TILT Biotherapeutics,Private,Europe,Finland,Helsinki,,,$6.9m,Estimate,No,Yes,Yes,No,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1397,Micro,Zelluna,Private,Europe,Norway,Oslo,,,$6.9m,Estimate,No,Yes,No,Yes,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1398,Micro,TargImmune Therapeutics,Private,Europe,Switzerland,Basel,,,$6.9m,Estimate,No,Yes,No,No,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1399,Micro,Oncorus,Private,North America,Massachusetts,Cambridge,,,$6.9m,Estimate,No,Yes,No,No,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1400,Micro,xCella Biosciences,Private,North America,California,Menlo Park,,,$6.9m,Estimate,No,Yes,No,No,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1401,Micro,Qrono,Private,North America,Pennsylvania,Pittsburgh,,,$6.9m,Estimate,No,No,No,No,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1402,Micro,Pinpoint Rx,Private,North America,California,Los Angeles,,,$6.9m,Estimate,No,Yes,No,No,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1403,Micro,Phigenix,Private,North America,Georgia,Atlanta,,,$6.9m,Estimate,No,No,No,No,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1404,Micro,Obsidio Therapeutics,Private,North America,California,Irvine,,,$6.9m,Estimate,No,No,No,No,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1405,Micro,ImmunoBiochem,Private,North America,Ontario,Toronto,,,$6.9m,Estimate,No,Yes,No,No,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1406,Micro,Atrin Pharmaceuticals,Private,North America,Pennsylvania,Doylestown,,,$6.9m,Estimate,No,No,No,No,100%,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$6.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,,$8.4m,,$8.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1407,Micro,Theripion,Private,North America,Washington,Seattle,,,$6.8m,Estimate,No,No,No,No,25%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,25%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$8.2m,,$2.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.0m,$2.1m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1408,Micro,Aoxing Pharmaceutical,Public,Asia/Oceania,,,,,$6.6m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$8.0m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1409,Micro,Taiwan Biotech,Private,Asia/Oceania,Taiwan,Taoyuan,,,$6.6m,Estimate,No,Yes,No,No,36%,$2.4m,$0.0m,$4.3m,$0.0m,$4.3m,,33%,0%,33%,0%,33%,100%,,0%,0%,0%,0%,0%,,33%,0%,33%,0%,33%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$4.3m,$0.0m,$0.0m,$1.2m,$0.0m,$2.4m,$0.0m,,$8.0m,,$2.9m,$0.0m,$5.2m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1410,Micro,Gadeta,Private,Europe,Netherlands,Utrecht,,,$6.6m,Estimate,Yes,Yes,No,Yes,67%,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$8.0m,,$8.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1411,Micro,Siamab Therapeutics,Private,North America,Massachusetts,Newton,,,$6.6m,Estimate,No,Yes,No,No,67%,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$8.0m,,$8.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1412,Micro,Unleash Immuno Oncolytics,Private,North America,Missouri,St. Louis,,,$6.6m,Estimate,No,Yes,No,No,67%,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$8.0m,,$8.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1413,Micro,TheraPten,Private,North America,British Columbia,Kelowna,,,$6.6m,Estimate,Yes,No,No,No,67%,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$8.0m,,$8.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1414,Micro,SapVax,Private,North America,Ohio,Cleveland,New Zealand,Auckland,$6.6m,Estimate,No,Yes,No,No,67%,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$8.0m,,$8.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1415,Micro,Propanc,Public,Asia/Oceania,Australia,Melbourne,,,$6.6m,Estimate,No,No,No,No,67%,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$8.0m,,$8.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1416,Micro,Beijing Doing Biomedical Co.,Private,Asia/Oceania,China,Beijing,,,$6.6m,Estimate,Yes,Yes,Yes,Yes,67%,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$8.0m,,$8.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1417,Micro,iOx Therapeutics,Private,Europe,United Kingdom,Oxford,,,$6.6m,Estimate,No,Yes,No,No,67%,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$8.0m,,$8.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1418,Micro,Centrose,Private,North America,Wisconsin,Madison,,,$6.6m,Estimate,No,Yes,No,No,67%,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$8.0m,,$8.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1419,Micro,NexImmune,Private,North America,Maryland,Gaithersburg,,,$6.6m,Estimate,Yes,Yes,No,Yes,67%,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$8.0m,,$8.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$8.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1420,Micro,Prism Pharma,Private,Asia/Oceania,,,,,$6.6m,Estimate,No,No,No,No,0%,$0.0m,$1.5m,$0.0m,$0.0m,$1.5m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,,$8.0m,,$0.0m,$1.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$6.1m,$0.0m,$0.0m,$0.0m,$0.0m
1421,Micro,Globavir,Private,North America,,,,,$6.5m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$7.9m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$7.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1422,Micro,Beactica,Private,Europe,Sweden,Uppsala,,,$6.4m,Estimate,No,No,No,No,67%,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,33%,0%,0%,0%,0%,,33%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,,$7.8m,,$5.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1423,Micro,Medigen,Private,Asia/Oceania,Taiwan,Taipei City,,,$6.4m,Estimate,No,Yes,No,No,33%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$7.8m,,$3.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1424,Micro,Immunomodulation,Private,North America,Illinois,Northbrook,,,$6.4m,Estimate,No,Yes,No,No,33%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$7.8m,,$3.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1425,Micro,CytoVac,Private,Europe,,,,,$6.4m,Estimate,No,Yes,No,Yes,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,33%,33%,0%,0%,67%,,0%,33%,33%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$7.8m,,$0.0m,$2.2m,$5.5m,$0.0m,,$0.0m,$0.0m,$7.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1426,Micro,CytoVation,Private,Europe,Norway,Bergen,United Kingdom,London,$6.4m,Estimate,No,Yes,No,No,33%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$7.7m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$2.6m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1427,Micro,SQZ Biotech,Private,North America,Massachusetts,Watertown,,,$6.3m,Estimate,No,Yes,No,Yes,67%,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$7.7m,,$5.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m
1428,Micro,Complix,Private,Europe,Belgium,Ghent,Belgium,Diepenbeek,$6.3m,Estimate,No,No,No,No,67%,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$7.7m,,$5.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.1m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1429,Micro,CytImmune Sciences,Private,North America,Maryland,Rockville,,,$6.3m,Estimate,No,Yes,No,No,73%,$4.6m,$1.7m,$0.0m,$0.0m,$1.7m,,67%,33%,0%,0%,0%,100%,,67%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.9m,$0.0m,$0.0m,,$7.6m,,$5.6m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1430,Micro,Netris Pharma,Private,Europe,France,Lyon,,,$6.3m,Estimate,No,Yes,No,No,73%,$4.6m,$1.7m,$0.0m,$0.0m,$1.7m,,67%,33%,0%,0%,0%,100%,,67%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.9m,$0.0m,$0.0m,,$7.6m,,$5.6m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1431,Micro,Lipomedix,Private,Middle East/Africa,Israel,Jerusalem,,,$6.3m,Estimate,No,No,No,No,73%,$4.6m,$1.7m,$0.0m,$0.0m,$1.7m,,67%,33%,0%,0%,0%,100%,,67%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.9m,$0.0m,$0.0m,,$7.6m,,$5.6m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1432,Micro,Cancure,Private,North America,Massachusetts,Boston,,,$6.3m,Estimate,No,Yes,No,Yes,73%,$4.6m,$1.7m,$0.0m,$0.0m,$1.7m,,67%,33%,0%,0%,0%,100%,,67%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.9m,$0.0m,$0.0m,,$7.6m,,$5.6m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1433,Micro,Natco Pharma,Public,Europe,,,,,$6.3m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,33%,0%,0%,0%,33%,,0%,0%,0%,0%,0%,,0%,33%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$7.6m,,$0.0m,$1.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.8m,$3.2m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1434,Micro,BriaCell,Public,North America,British Columbia,Vancouver,California,Berkeley,$6.2m,Estimate,No,Yes,No,Yes,36%,$2.2m,$0.0m,$4.0m,$0.0m,$4.0m,,50%,0%,50%,0%,0%,100%,,50%,0%,0%,0%,0%,,0%,0%,50%,0%,0%,,,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.0m,$0.0m,$0.0m,$1.2m,$0.0m,$2.3m,$0.0m,,$7.6m,,$2.7m,$0.0m,$4.9m,$0.0m,,$0.0m,$0.0m,$7.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1435,Micro,Mironid,Private,Europe,United Kingdom,Chapelhall,,,$6.2m,Estimate,No,No,No,No,33%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$7.6m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1436,Micro,ACF Pharmaceuticals,Private,North America,Texas,Houston,,,$6.2m,Estimate,No,No,No,No,33%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$7.6m,,$3.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1437,Micro,Biotecnol,Private,Europe,Portugal,Oeiras,United Kingdom,London,$6.2m,Estimate,No,Yes,No,No,25%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,0%,0%,0%,0%,0%,,25%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$7.6m,,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$2.1m,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m
1438,Micro,Carrick Therapeutics,Private,Europe,Ireland,Dublin,United Kingdom,Oxford,$6.2m,Estimate,No,No,No,No,36%,$2.2m,$0.0m,$4.0m,$0.0m,$4.0m,,50%,0%,50%,0%,0%,100%,,0%,0%,50%,0%,0%,,50%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$4.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$2.2m,$0.0m,,$7.5m,,$2.7m,$0.0m,$4.9m,$0.0m,,$0.0m,$0.0m,$7.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1439,Micro,biOasis,Public,North America,Connecticut,Guilford,,,$6.2m,Estimate,No,No,No,No,67%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$7.5m,,$5.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.4m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1440,Micro,Sevengenes,Private,North America,Oklahoma,Bartlesville,,,$6.2m,Estimate,No,No,No,No,67%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$7.5m,,$5.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.4m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1441,Micro,Adamed,Private,Europe,Poland,Warsaw,,,$6.2m,Estimate,No,No,No,No,67%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$7.5m,,$5.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.4m,$5.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1442,Micro,Osivax,Private,Europe,France,Lyon,,,$6.2m,Estimate,No,Yes,No,No,25%,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,20%,0%,0%,0%,0%,20%,,20%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,,$7.5m,,$1.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$2.1m,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m
1443,Micro,TherapyX,Private,North America,New York,New York,,,$6.2m,Estimate,No,Yes,No,No,33%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$7.5m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m
1444,Micro,Biomica,Private,Middle East/Africa,Israel,Rehovot,,,$6.2m,Estimate,No,No,No,No,33%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$7.5m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m
1445,Micro,Invenra,Private,North America,Wisconsin,Madison,,,$6.1m,Estimate,No,Yes,No,No,67%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$7.4m,,$4.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1446,Micro,Kronos Bio,Private,North America,Massachusetts,Cambridge,California,San Mateo,$6.1m,Estimate,No,No,No,No,67%,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,67%,0%,0%,0%,0%,67%,,67%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,,$7.4m,,$4.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1447,Micro,Aveta Biomics,Private,North America,Massachusetts,Bedford,,,$6.1m,Estimate,No,No,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.4m,,$2.8m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1448,Micro,EUSA Pharma,Private,Asia/Oceania,,,,,$6.0m,Estimate,No,No,No,No,0%,$0.0m,$1.4m,$3.5m,$0.0m,$4.9m,,0%,33%,33%,0%,0%,67%,,0%,0%,0%,0%,0%,,0%,33%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.4m,$3.5m,$0.0m,$0.0m,$0.0m,$0.8m,$2.0m,$0.0m,,$7.3m,,$0.0m,$2.1m,$5.2m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1449,Micro,Hengrui Therapeutics,Private,North America,,,,,$6.0m,Estimate,No,No,No,No,0%,$0.0m,$1.4m,$3.5m,$0.0m,$4.9m,,0%,33%,33%,0%,0%,67%,,0%,0%,0%,0%,0%,,0%,33%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.4m,$3.5m,$0.0m,$0.0m,$0.0m,$0.8m,$2.0m,$0.0m,,$7.3m,,$0.0m,$2.1m,$5.2m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1450,Micro,Shenzhen BioScien,Private,North America,,,,,$6.0m,Estimate,No,Yes,No,Yes,0%,$0.0m,$1.4m,$3.5m,$0.0m,$4.9m,,0%,33%,33%,0%,0%,67%,,0%,0%,0%,0%,0%,,0%,33%,33%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.4m,$3.5m,$0.0m,$0.0m,$0.0m,$0.8m,$2.0m,$0.0m,,$7.3m,,$0.0m,$2.1m,$5.2m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1451,Micro,EpiDestiny,Private,North America,Ohio,Solon,,,$6.0m,Estimate,No,No,No,No,33%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$7.3m,,$3.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m
1452,Micro,BioMimetix JV,Private,North America,Colorado,Greenwood Village,,,$6.0m,Estimate,No,No,No,No,32%,$1.9m,$1.4m,$0.0m,$0.0m,$1.4m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$0.0m,$0.0m,,$7.3m,,$2.2m,$1.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.8m,$0.0m,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1453,Micro,JenKem Technology,Private,Asia/Oceania,China,Beijing,,,$6.0m,Estimate,No,No,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.3m,,$4.2m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1454,Micro,Cao Pharmaceuticals,Private,North America,Texas,Webster,,,$6.0m,Estimate,Yes,No,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.3m,,$4.2m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1455,Micro,Alethia Biotherapeutics,Private,North America,Quebec,Montreal,,,$6.0m,Estimate,No,Yes,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.3m,,$4.2m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1456,Micro,VM Oncology,Private,North America,California,Fremont,,,$6.0m,Estimate,No,No,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.3m,,$4.2m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1457,Micro,Sensei Biotherapeutics,Private,North America,Maryland,Gaithersburg,,,$6.0m,Estimate,No,Yes,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.3m,,$4.2m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1458,Micro,Orsenix,Private,Europe,Georgia,Atlanta,,,$6.0m,Estimate,Yes,No,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.3m,,$4.2m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1459,Micro,J-Pharma,Private,Asia/Oceania,Japan,Yokohama,,,$6.0m,Estimate,No,No,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.3m,,$4.2m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1460,Micro,IDAC Theranostics,Private,North America,California,Anaheim,,,$6.0m,Estimate,No,Yes,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.3m,,$4.2m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1461,Micro,Keystone Nano,Private,North America,Pennsylvania,State College,,,$6.0m,Estimate,No,No,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.3m,,$4.2m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1462,Micro,BELX Bio-Pharmaceutical,Private,Asia/Oceania,Taiwan,Hsinchu City,,,$6.0m,Estimate,No,No,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.3m,,$4.2m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1463,Micro,Aravive Biologics,Private,North America,Texas,Houston,,,$6.0m,Estimate,Yes,No,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.3m,,$4.2m,$3.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1464,Micro,Nurix,Private,North America,California,San Francisco,,,$6.0m,Estimate,No,No,No,No,33%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$7.3m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1465,Micro,Tilos Therapeutics,Private,North America,Massachusetts,Lexington,,,$6.0m,Estimate,No,Yes,No,No,33%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$7.3m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1466,Micro,Jiangxi Qingfeng Pharmaceutical,Private,Asia/Oceania,China,Ganzhou,,,$6.0m,Estimate,No,No,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,0%,0%,0%,0%,0%,,33%,33%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.2m,,$4.2m,$3.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1467,Micro,OncoVent,Private,North America,Alberta,Edmonton,,,$6.0m,Estimate,No,Yes,No,No,37%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,0%,0%,0%,0%,0%,,33%,33%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$7.2m,,$4.2m,$3.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$7.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1468,Micro,Skyhawk Therapeutics,Private,North America,Massachusetts,Waltham,,,$5.9m,Estimate,No,No,No,No,33%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$7.2m,,$3.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.5m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1469,Micro,Avergen,Private,Europe,Germany,Martinsried,,,$5.9m,Estimate,No,No,No,No,33%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$7.2m,,$3.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$3.5m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1470,Micro,Vividion Therapeutics,Private,North America,California,San Diego,,,$5.9m,Estimate,No,No,No,No,33%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$7.1m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.3m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1471,Micro,Actuate Therapeutics,Private,North America,Texas,Fort Worth,,,$5.9m,Estimate,No,No,No,No,33%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$7.1m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.3m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1472,Micro,ANI Pharmaceuticals,Public,North America,Minnesota,Baudette,,,$5.8m,Estimate,No,Yes,Yes,No,36%,$2.1m,$0.0m,$3.8m,$0.0m,$3.8m,,50%,0%,50%,0%,0%,100%,,50%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$7.1m,,$2.5m,$0.0m,$4.6m,$0.0m,,$0.0m,$0.0m,$7.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1473,Micro,Tioma Therapeutics,Private,North America,Missouri,St. Louis,,,$5.8m,Estimate,No,Yes,No,No,36%,$2.1m,$0.0m,$3.8m,$0.0m,$3.8m,,50%,0%,50%,0%,0%,100%,,50%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$7.1m,,$2.5m,$0.0m,$4.6m,$0.0m,,$0.0m,$0.0m,$7.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1474,Micro,TP Therapeutics,Private,North America,California,San Diego,,,$5.8m,Estimate,Yes,No,No,No,36%,$2.1m,$0.0m,$3.8m,$0.0m,$3.8m,,50%,0%,50%,0%,0%,100%,,50%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$3.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$2.1m,$0.0m,,$7.1m,,$2.5m,$0.0m,$4.6m,$0.0m,,$0.0m,$0.0m,$7.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1475,Micro,Guangzhou Double Bioproducts,Private,North America,,,,,$5.8m,Estimate,No,No,Yes,No,0%,$0.0m,$1.0m,$0.0m,$4.8m,$5.8m,,0%,50%,0%,50%,0%,100%,,0%,0%,0%,0%,0%,,0%,50%,0%,50%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.6m,$0.0m,$2.7m,,$7.1m,,$0.0m,$1.2m,$0.0m,$5.9m,,$0.0m,$0.0m,$7.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1476,Micro,Akston Biosciences,Private,North America,Massachusetts,Beverly,,,$5.8m,Estimate,No,No,No,No,33%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$7.0m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m
1477,Micro,Efranat,Private,Middle East/Africa,,,,,$5.8m,Estimate,No,Yes,No,No,0%,$0.0m,$1.5m,$0.0m,$0.0m,$1.5m,,0%,33%,0%,0%,0%,33%,,0%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$7.0m,,$0.0m,$3.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1478,Micro,HiFiBiO Therapeutics,Private,North America,Massachusetts,Cambridge,France,Paris,$5.8m,Estimate,No,No,No,No,33%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$7.0m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m
1479,Micro,SynDevRx,Private,North America,Massachusetts,Cambridge,,,$5.7m,Estimate,No,No,No,No,37%,$2.1m,$1.5m,$0.0m,$0.0m,$1.5m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.9m,$0.0m,$0.0m,,$7.0m,,$2.7m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m
1480,Micro,SatRx,Private,Europe,,,,,$5.6m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$2.7m,$0.0m,$2.7m,,0%,0%,50%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,0%,50%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.5m,$0.0m,,$6.8m,,$0.0m,$0.0m,$2.4m,$0.0m,,$0.0m,$0.0m,$2.4m,$4.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1481,Micro,Precision Biosciences,Private,North America,North Carolina,Durham,,,$5.6m,Estimate,Yes,Yes,Yes,Yes,33%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,0%,0%,0%,0%,0%,,33%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$6.8m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$2.1m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1482,Micro,Dexcel Pharma,Private,Middle East/Africa,Israel,Or Akiva,,,$5.6m,Estimate,No,No,No,No,33%,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$6.7m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.2m,$2.3m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1483,Micro,Cyclopharma,Private,Europe,,,,,$5.5m,Estimate,No,No,No,No,0%,$0.0m,$2.6m,$0.0m,$0.0m,$2.6m,,0%,50%,0%,0%,0%,50%,,0%,25%,0%,0%,0%,,0%,25%,0%,0%,0%,,,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m,$1.5m,$0.0m,$0.0m,,$6.7m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$1.5m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1484,Micro,Innovative Targeting Solutions,Private,North America,British Columbia,Vancouver,,,$5.5m,Estimate,No,Yes,No,No,33%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$6.7m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.2m,$2.2m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1485,Micro,DanPET,Private,Europe,Sweden,Malmo,,,$5.5m,Estimate,No,No,No,No,33%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$6.7m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.4m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1486,Micro,Camino Pharma,Private,North America,California,San Diego,,,$5.5m,Estimate,No,No,No,No,33%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$6.7m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$4.4m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1487,Micro,Glycostem Therapeutics,Private,Europe,Netherlands,Oss,,,$5.5m,Estimate,Yes,Yes,Yes,Yes,44%,$2.4m,$1.7m,$0.0m,$0.0m,$1.7m,,33%,33%,0%,0%,0%,67%,,0%,33%,0%,0%,0%,,33%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$1.0m,$0.0m,$0.0m,,$6.7m,,$3.9m,$2.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1488,Micro,Aurealis Pharma,Private,Europe,Switzerland,Basel,,,$5.4m,Estimate,No,No,No,No,33%,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$6.6m,,$2.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.2m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1489,Micro,Opthea,Public,Asia/Oceania,Australia,South Yarra,,,$5.4m,Estimate,No,No,No,No,31%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$6.5m,,$1.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.9m,$0.0m,$4.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1490,Micro,Shanghai Acebright,Private,Asia/Oceania,China,Shanghai,,,$5.3m,Estimate,No,No,No,No,0%,$0.0m,$1.4m,$0.0m,$0.0m,$1.4m,,0%,33%,0%,0%,0%,33%,,0%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,,$6.5m,,$0.0m,$2.0m,$0.0m,$0.0m,,$2.2m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1491,Micro,TRIGR Therapeutics,Private,North America,California,Irvine,,,$5.3m,Estimate,No,Yes,No,No,100%,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,,$6.5m,,$6.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1492,Micro,Bioquark,Private,North America,Pennsylvania,Philadelphia,,,$5.3m,Estimate,No,No,No,No,45%,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$6.5m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.9m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1493,Micro,Suzhou NeuPharma Co.,Private,Asia/Oceania,,,,,$5.2m,Estimate,No,No,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,50%,50%,0%,0%,100%,,0%,50%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$6.4m,,$0.0m,$1.8m,$4.5m,$0.0m,,$0.0m,$0.0m,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1494,Micro,Istari Oncology,Private,North America,,,,,$5.2m,Estimate,No,Yes,Yes,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,50%,50%,0%,0%,100%,,0%,50%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$6.4m,,$0.0m,$1.8m,$4.5m,$0.0m,,$0.0m,$0.0m,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1495,Micro,Dekk-Tec,Private,North America,,,,,$5.2m,Estimate,No,No,No,No,0%,$0.0m,$1.5m,$3.7m,$0.0m,$5.2m,,0%,50%,50%,0%,0%,100%,,0%,50%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$2.1m,$0.0m,,$6.4m,,$0.0m,$1.8m,$4.5m,$0.0m,,$0.0m,$0.0m,$6.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1496,Micro,Oncolix,Public,North America,Texas,Houston,,,$5.1m,Estimate,No,No,No,No,44%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$6.2m,,$3.6m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1497,Micro,DrugCendR,Private,North America,California,La Jolla,,,$5.1m,Estimate,No,No,No,No,44%,$2.2m,$1.6m,$0.0m,$0.0m,$1.6m,,33%,33%,0%,0%,0%,67%,,33%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$6.2m,,$3.6m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1498,Micro,Shanghai JinManTe Biotechnology,Private,Asia/Oceania,China,Shanghai,,,$5.1m,Estimate,No,Yes,No,No,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,33%,0%,0%,0%,33%,,0%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$6.2m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1499,Micro,Therapeia,Private,Asia/Oceania,,,,,$5.1m,Estimate,No,No,No,No,0%,$0.0m,$1.5m,$3.6m,$0.0m,$5.1m,,0%,50%,50%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,50%,50%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.5m,$3.6m,$0.0m,$0.0m,$0.0m,$0.8m,$2.0m,$0.0m,,$6.2m,,$0.0m,$1.8m,$4.4m,$0.0m,,$0.0m,$0.0m,$6.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1500,Micro,Aranda Pharma,Private,Europe,Finland,Kuopio,,,$5.1m,Estimate,No,No,No,No,33%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$6.1m,,$2.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1501,Micro,Pin Therapeutics,Private,North America,California,South San Francisco,,,$5.1m,Estimate,No,No,No,No,33%,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,33%,0%,0%,0%,0%,33%,,33%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,$0.0m,,$6.1m,,$2.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1502,Micro,Shenzhen MingSight Relin,Private,North America,,,,,$5.0m,Estimate,Yes,No,No,No,0%,$0.0m,$1.1m,$0.0m,$0.0m,$1.1m,,0%,25%,0%,0%,0%,25%,,0%,25%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$6.1m,,$0.0m,$1.3m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.3m,$3.4m,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1503,Micro,Tarrex Biopharma,Private,Asia/Oceania,China,Xiamen,California,San Diego,$5.0m,Estimate,No,No,No,No,100%,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,50%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,,$6.0m,,$6.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1504,Micro,StemSynergy Therapeutics,Private,North America,Florida,Miami,Tennessee,Franklin,$5.0m,Estimate,No,No,No,No,100%,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,50%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,,$6.0m,,$6.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1505,Micro,NeoPhore,Private,Europe,United Kingdom,Cambridge,,,$5.0m,Estimate,No,Yes,No,No,100%,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,50%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,,$6.0m,,$6.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1506,Micro,Celtic Pharma,Private,North America,New York,New York,Bermuda,Hamilton,$5.0m,Estimate,No,No,No,No,100%,$5.0m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,50%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,,$6.0m,,$6.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$6.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1507,Micro,Amorsa Therapeutics,Private,North America,,,,,$4.8m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$5.9m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1508,Micro,NanoProteagen,Private,North America,Massachusetts,Boston,,,$4.8m,Estimate,Yes,No,No,No,50%,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$5.8m,,$5.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1509,Micro,Epigenetix,Private,Europe,United Kingdom,Cambridge,,,$4.8m,Estimate,Yes,Yes,No,No,50%,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$5.8m,,$5.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1510,Micro,Cartherics,Private,Asia/Oceania,Australia,Clayton,,,$4.8m,Estimate,No,Yes,Yes,Yes,50%,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$5.8m,,$5.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1511,Micro,Rgene Corporation,Private,North America,California,San Francisco,,,$4.8m,Estimate,Yes,No,No,No,50%,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$5.8m,,$5.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1512,Micro,Race Oncology,Public,Asia/Oceania,Australia,Melbourne,,,$4.8m,Estimate,Yes,No,No,No,50%,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$5.8m,,$5.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1513,Micro,Felicitex,Private,North America,Massachusetts,Natick,,,$4.8m,Estimate,No,No,No,No,50%,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$5.8m,,$5.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1514,Micro,Alissa Pharma,Private,North America,New York,New York,,,$4.8m,Estimate,No,Yes,No,No,50%,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$5.8m,,$5.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1515,Micro,Sunshine Biopharma,Public,North America,Quebec,Pointe-Claire,,,$4.8m,Estimate,No,No,No,No,50%,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$5.8m,,$5.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1516,Micro,MAB Discovery,Private,Europe,Germany,Neuried,,,$4.8m,Estimate,No,No,No,No,50%,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$5.8m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1517,Micro,Ayala Pharmaceuticals,Private,North America,Delaware,Wilmington,Israel ,Rehovot,$4.8m,Estimate,Yes,No,No,No,44%,$2.1m,$1.5m,$0.0m,$0.0m,$1.5m,,33%,33%,0%,0%,0%,67%,,0%,0%,0%,0%,0%,,33%,33%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$1.5m,$0.0m,$0.0m,$0.0m,$1.1m,$0.8m,$0.0m,$0.0m,,$5.8m,,$3.4m,$2.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1518,Micro,Zhuhai MAB Biological Technology,Private,Asia/Oceania,China,Zhuhai,,,$4.7m,Estimate,Yes,Yes,No,No,28%,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,$0.0m,,$5.7m,,$0.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.9m,$4.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1519,Micro,Ultimovacs,Private,Europe,,,,,$4.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.3m,$3.4m,$0.0m,$4.7m,,0%,50%,50%,0%,0%,100%,,0%,0%,50%,0%,0%,,0%,50%,0%,0%,0%,,,,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$1.9m,$0.0m,,$5.7m,,$0.0m,$1.6m,$4.1m,$0.0m,,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1520,Micro,Suzhou Kintor Pharmaceuticals,Private,Asia/Oceania,,,,,$4.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.3m,$3.4m,$0.0m,$4.7m,,0%,50%,50%,0%,0%,100%,,0%,0%,50%,0%,0%,,0%,50%,0%,0%,0%,,,,$0.0m,$0.0m,$3.4m,$0.0m,$0.0m,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$1.9m,$0.0m,,$5.7m,,$0.0m,$1.6m,$4.1m,$0.0m,,$0.0m,$0.0m,$5.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1521,Micro,Tianjin Hemay Pharmaceutical Co.,Private,Asia/Oceania,,,,,$4.6m,Estimate,No,No,No,No,0%,$0.0m,$3.2m,$0.0m,$0.0m,$3.2m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,,$5.6m,,$0.0m,$3.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.7m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m
1522,Micro,PEP-Therapy,Private,Europe,France,Paris,,,$4.6m,Estimate,No,No,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1523,Micro,Accurexa,Public,North America,Delaware,Newark,,,$4.6m,Estimate,No,No,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1524,Micro,Proteros biostructures,Private,Europe,Germany,Martinsried,Massachusetts,Cambridge,$4.6m,Estimate,No,No,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1525,Micro,Horizon Discovery,Public,Europe,United Kingdom,Cambridge,Colorado,Lafayette,$4.6m,Estimate,No,Yes,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1526,Micro,Western Oncolytics,Private,North America,Pennsylvania,Pittsburgh,,,$4.6m,Estimate,No,Yes,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1527,Micro,Barricade Therapeutics,Private,North America,Texas,Fort Worth,,,$4.6m,Estimate,No,No,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1528,Micro,Oncoinvent,Private,Europe,Norway,Oslo,,,$4.6m,Estimate,No,Yes,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1529,Micro,EpiAxis Therapeutics,Private,Asia/Oceania,Australia,Canberra,,,$4.6m,Estimate,No,No,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1530,Micro,Oxford Vacmedix,Private,Europe,United Kingdom,Oxford,,,$4.6m,Estimate,No,Yes,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1531,Micro,Oncology Research,Private,Asia/Oceania,Japan,Kawasaki,United Kingdom,Edinburgh,$4.6m,Estimate,No,No,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1532,Micro,Olema Pharmaceuticals,Private,North America,California,San Francisco,,,$4.6m,Estimate,No,No,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1533,Micro,METABOSTEM,Private,Europe,Spain,Barcelona,,,$4.6m,Estimate,No,Yes,No,Yes,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1534,Micro,Quentis Therapeutics,Private,North America,New York,New York,,,$4.6m,Estimate,No,Yes,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1535,Micro,Amal Therapeutics,Private,Europe,Switzerland,Geneva,,,$4.6m,Estimate,No,Yes,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1536,Micro,SunRock Biopharma,Private,Europe,Spain,Santiago de Compostela,,,$4.6m,Estimate,Yes,Yes,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1537,Micro,Grid Therapeutics,Private,North America,North Carolina,Durham,,,$4.6m,Estimate,No,Yes,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1538,Micro,Glactone Pharma,Private,Europe,Sweden,Helsingborg,,,$4.6m,Estimate,No,Yes,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1539,Micro,AdoRx Therapeutics,Private,Europe,United Kingdom,Edinburgh,,,$4.6m,Estimate,No,Yes,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1540,Micro,Dracen Pharmaceuticals,Private,North America,New York,New York,,,$4.6m,Estimate,No,No,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1541,Micro,Rainforest Pharmacal,Private,North America,Texas,San Antonio,,,$4.6m,Estimate,No,No,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1542,Micro,Nkarta Therapeutics,Private,North America,California,South San Francisco,,,$4.6m,Estimate,No,Yes,No,Yes,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1543,Micro,Takis,Private,Europe,Italy,Rome,,,$4.6m,Estimate,No,Yes,No,No,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1544,Micro,Gaia BioMedicine,Private,Asia/Oceania,Japan,Fukuoka,,,$4.6m,Estimate,No,No,No,Yes,100%,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.6m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,,$5.6m,,$5.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1545,Micro,MiNA Therapeutics,Private,Europe,,,,,$4.6m,Estimate,No,Yes,No,No,0%,$0.0m,$1.5m,$0.0m,$0.0m,$1.5m,,0%,33%,0%,0%,0%,33%,,0%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,,$5.6m,,$0.0m,$2.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m
1546,Micro,DiverDrugs,Private,Europe,,,,,$4.6m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$5.5m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1547,Micro,JINIS Biopharmaceuticals,Private,Asia/Oceania,,,,,$4.6m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,33%,0%,0%,0%,33%,,0%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$5.5m,,$0.0m,$1.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$2.0m,$0.0m,$0.0m,$0.0m
1548,Micro,Immune Cell Therapy,Private,North America,,,,,$4.5m,Estimate,Yes,Yes,Yes,Yes,0%,$0.0m,$3.3m,$0.0m,$0.0m,$3.3m,,0%,67%,0%,0%,0%,67%,,0%,67%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$3.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,,$5.5m,,$0.0m,$5.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1549,Micro,iX Biopharma,Public,Asia/Oceania,,,,,$4.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$5.4m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$5.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1550,Micro,Vacthera BioTech,Private,Europe,Austria,Vienna,,,$4.4m,Estimate,No,Yes,No,No,50%,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$5.3m,,$2.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1551,Micro,Mavupharma,Private,North America,Washington,Kirkland,,,$4.4m,Estimate,No,No,No,No,50%,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$5.3m,,$2.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1552,Micro,Setlance,Private,Europe,Italy,Siena,,,$4.4m,Estimate,No,No,No,No,50%,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$5.3m,,$2.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1553,Micro,Flash Therapeutics,Private,Europe,France,Toulouse,,,$4.4m,Estimate,No,No,Yes,No,50%,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$5.3m,,$2.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1554,Micro,Thyas,Private,Asia/Oceania,Japan,Kyoto,,,$4.4m,Estimate,No,No,No,Yes,50%,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$5.3m,,$2.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1555,Micro,Noigel,Private,North America,New York,New York,,,$4.4m,Estimate,No,No,No,No,50%,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$5.3m,,$2.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1556,Micro,Kleo Pharmaceuticals,Private,North America,Connecticut,New Haven,,,$4.4m,Estimate,No,Yes,No,No,50%,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.2m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$5.3m,,$2.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1557,Micro,Guangzhou BeBetter Medicine,Private,Asia/Oceania,China,Guangzhou,,,$4.4m,Estimate,Yes,No,No,No,44%,$1.9m,$1.4m,$0.0m,$0.0m,$1.4m,,33%,33%,0%,0%,0%,67%,,33%,0%,0%,0%,0%,,0%,33%,0%,0%,0%,,,,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$1.0m,$0.8m,$0.0m,$0.0m,,$5.3m,,$3.1m,$2.2m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1558,Micro,Piramal Imaging,Public,Europe,,,,,$4.3m,Estimate,No,Yes,No,No,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,33%,0%,0%,0%,33%,,0%,0%,0%,0%,0%,,0%,33%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$59.0m,,$0.0m,$18.3m,$0.0m,$0.0m,,$0.0m,$40.7m,$18.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1559,Micro,Geistlich,Private,Europe,United Kingdom,Manchester,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1560,Micro,Redwood Bioscience,Public,North America,California,Emeryville,,,$4.3m,Estimate,Yes,Yes,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1561,Micro,CorMedix,Public,North America,New Jersey,Berkeley Heights,,,$4.3m,Estimate,Yes,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1562,Micro,Enceladus Pharmaceuticals,Private,Europe,Netherlands,Naarden,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1563,Micro,Genenta Science,Private,Europe,Italy,Milan,New York,New York,$4.3m,Estimate,No,Yes,Yes,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1564,Micro,Advanomics,Private,North America,Quebec,Montreal,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1565,Micro,Nexoligo,Private,Asia/Oceania,Unknown,Unknown,Unknown,Unknown,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1566,Micro,Pi Therapeutics,Private,Middle East/Africa,Israel,Ness Ziona,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1567,Micro,OncoTab,Private,North America,North Carolina,Charlotte,,,$4.3m,Estimate,No,Yes,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1568,Micro,Synovo,Public,Europe,Germany,Tubingen,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1569,Micro,Cyclosam Therapeutics,Private,North America,Texas,Angleton,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1570,Micro,Sagetis Biotech,Private,Europe,Spain,Barcelona,,,$4.3m,Estimate,No,No,Yes,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1571,Micro,Orum Therapeutics,Private,Asia/Oceania,South Korea,Daejeon,,,$4.3m,Estimate,No,Yes,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1572,Micro,Rigenerand,Private,Europe,Italy,Medolla,,,$4.3m,Estimate,No,Yes,Yes,Yes,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1573,Micro,Biogazelle,Private,Europe,Belgium,Gent,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1574,Micro,Kyras Therapeutics,Private,North America,New York,New York,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1575,Micro,AMI Onco Theranostics,Private,North America,New York,Buffalo,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1576,Micro,Treat U,Private,Europe,Portugal,Coimbra,,,$4.3m,Estimate,Yes,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1577,Micro,PanTher Therapeutics,Private,North America,Massachusetts,Cambridge,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1578,Micro,Onco-Therapies,Private,North America,California,Pasadena,,,$4.3m,Estimate,No,Yes,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1579,Micro,OncoTherics,Private,Europe,United Kingdom,Leicestershire,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1580,Micro,Haim Bio,Private,Asia/Oceania,South Korea,Seoul,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1581,Micro,Cyto-Sen,Private,North America,Florida,Orlando,,,$4.3m,Estimate,Yes,Yes,No,Yes,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1582,Micro,Oncorena,Private,Europe,Sweden,Goteborg,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1583,Micro,Avenzoar Pharmaceuticals,Private,North America,California,Encinitas,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1584,Micro,Lynkcell,Private,North America,Wyoming,Sheridan,,,$4.3m,Estimate,No,Yes,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1585,Micro,Kalos Therapeutics,Private,North America,Arizona,Phoenix,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1586,Micro,Fortis Therapeutics,Private,North America,California,La Jolla,,,$4.3m,Estimate,No,Yes,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1587,Micro,SciTech Development,Private,North America,Michigan,Grosse Pointe Farms,,,$4.3m,Estimate,Yes,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1588,Micro,Cureport,Private,North America,Massachusetts,Worcester,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1589,Micro,Ningbo Shengjian Biomedical,Private,Asia/Oceania,China,Ningbo,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1590,Micro,BioEclipse Therapeutics,Private,North America,California,San Francisco,,,$4.3m,Estimate,No,Yes,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1591,Micro,Cancer Therapeutics,Private,Asia/Oceania,Australia,Melbourne,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1592,Micro,Carisma Therapeutics,Private,North America,Pennsylvania,Philadelphia,,,$4.3m,Estimate,No,Yes,Yes,Yes,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1593,Micro,ITUS Corporation,Public,North America,California,San Jose,,,$4.3m,Estimate,No,Yes,Yes,Yes,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1594,Micro,Leaf Vertical,Private,North America,Florida,Orlando,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1595,Micro,BioTheryX,Private,North America,New York,New York,California,San Diego,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1596,Micro,Biopep Solutions,Private,North America,British Columbia,Richmond,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1597,Micro,Vescor,Private,North America,New York,New York,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1598,Micro,Chuan An Biotechnology,Private,Asia/Oceania,Taiwan,Kaohsiung City,,,$4.3m,Estimate,No,Yes,No,Yes,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1599,Micro,APIM Therapeutics,Private,Europe,Norway,Trondheim,,,$4.3m,Estimate,Yes,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1600,Micro,Somantix,Private,Europe,Netherlands,Utrecht,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1601,Micro,Codiak Biosciences,Private,North America,Massachusetts,Cambridge,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1602,Micro,Hangzhou Converd,Private,Asia/Oceania,China,Hangzhou,,,$4.3m,Estimate,No,Yes,No,Yes,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1603,Micro,Mantis Therapeutics,Private,Europe,Germany,Leiden,,,$4.3m,Estimate,No,Yes,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1604,Micro,Mediphage Bioceuticals,Private,North America,Ontario,Toronto,,,$4.3m,Estimate,No,No,Yes,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1605,Micro,Antikor Biopharma,Private,Europe,United Kingdom,Stevenage,,,$4.3m,Estimate,No,Yes,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1606,Micro,UbiQ,Private,Europe,Netherlands,Amsterdam,,,$4.3m,Estimate,Yes,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1607,Micro,Sartar Therapeutics,Private,Europe,Finland,Helsinki,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1608,Micro,Affichem,Private,Europe,France,Toulouse,,,$4.3m,Estimate,Yes,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1609,Micro,Tactiva Therapeutics,Private,North America,New York,Buffalo,,,$4.3m,Estimate,No,Yes,Yes,Yes,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1610,Micro,Nova Laboratories,Private,Europe,United Kingdom,Leicestershire,,,$4.3m,Estimate,Yes,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$5.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$5.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1611,Micro,Dalriada Therapeutics,Private,North America,Ontario,Mississauga,,,$4.3m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$2.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1612,Micro,Vycellix,Private,North America,Florida,Miami,,,$4.2m,Estimate,No,Yes,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$2.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1613,Micro,Siwa Therapeutics,Private,North America,Illinois,Chicago,,,$4.2m,Estimate,No,No,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$2.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1614,Micro,ImmuSmol,Private,Europe,France,Pessac,,,$4.2m,Estimate,No,Yes,No,No,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.2m,,$2.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1615,Micro,Feldan Therapeutics,Private,North America,Quebec,Quebec City,,,$4.2m,Estimate,No,Yes,No,Yes,50%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,50%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$5.1m,,$2.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1616,Micro,ViciniVax,Private,Europe,,,,,$4.1m,Estimate,No,Yes,No,No,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,33%,0%,0%,0%,33%,,0%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$5.0m,,$0.0m,$1.9m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$1.6m,$1.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1617,Micro,XTuit Pharmaceuticals,Private,North America,Massachusetts,Waltham,,,$4.0m,Estimate,No,No,No,No,50%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$4.9m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m
1618,Micro,Plasticell,Private,Europe,United Kingdom,Stevenage,,,$4.0m,Estimate,No,No,No,Yes,50%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$4.9m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m
1619,Micro,GammaDelta Therapeutics,Private,Europe,United Kingdom,London,,,$4.0m,Estimate,No,Yes,No,Yes,50%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$4.9m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1620,Micro,Cyteir Therapeutics,Private,North America,Massachusetts,Lexington,,,$4.0m,Estimate,No,No,No,No,50%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$4.9m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1621,Micro,Elstar Therapeutics,Private,North America,Massachusetts,Cambridge,,,$4.0m,Estimate,No,Yes,No,No,50%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$4.9m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1622,Micro,Immunscape,Private,Europe,Sweden,Vasastan,,,$4.0m,Estimate,No,Yes,No,No,50%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$4.9m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1623,Micro,GNT Biotech & Medicals,Private,Asia/Oceania,Taiwan,Taipei City,,,$4.0m,Estimate,No,No,No,No,50%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$4.9m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1624,Micro,Modularix,Private,Europe,Sweden,Stockholm,,,$4.0m,Estimate,No,No,No,No,50%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$4.9m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1625,Micro,Pepromene Bio,Private,North America,California,Irvine,,,$4.0m,Estimate,No,Yes,Yes,Yes,50%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$4.9m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1626,Micro,Shenzhen Longrui,Private,Asia/Oceania,,,,,$4.0m,Estimate,No,Yes,No,No,0%,$0.0m,$1.1m,$0.0m,$0.0m,$1.1m,,0%,50%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,50%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$4.9m,,$0.0m,$1.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1627,Micro,7 Hills Pharma,Private,North America,Texas,Houston,,,$4.0m,Estimate,No,Yes,No,No,50%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$4.9m,,$2.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m
1628,Micro,Cancer Targeted Technology,Private,North America,Washington,Woodinville,,,$4.0m,Estimate,No,No,No,No,58%,$2.3m,$1.7m,$0.0m,$0.0m,$1.7m,,50%,50%,0%,0%,0%,100%,,50%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$4.8m,,$2.8m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1629,Micro,3-V Biosciences,Private,North America,California,Menlo Park,,,$4.0m,Estimate,No,No,No,No,58%,$2.3m,$1.7m,$0.0m,$0.0m,$1.7m,,50%,50%,0%,0%,0%,100%,,50%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$4.8m,,$2.8m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1630,Micro,Oric Pharmaceuticals,Private,North America,California,South San Francisco,,,$4.0m,Estimate,No,No,No,No,58%,$2.3m,$1.7m,$0.0m,$0.0m,$1.7m,,50%,50%,0%,0%,0%,100%,,50%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$4.8m,,$2.8m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1631,Micro,Meryx,Private,North America,North Carolina,Chapel Hill,,,$4.0m,Estimate,No,No,No,No,58%,$2.3m,$1.7m,$0.0m,$0.0m,$1.7m,,50%,50%,0%,0%,0%,100%,,50%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$4.8m,,$2.8m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1632,Micro,Minomic,Private,Asia/Oceania,Australia,Sydney,,,$4.0m,Estimate,No,Yes,No,No,58%,$2.3m,$1.7m,$0.0m,$0.0m,$1.7m,,50%,50%,0%,0%,0%,100%,,50%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$4.8m,,$2.8m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1633,Micro,PDC*line Pharma,Private,Europe,France,La Tronche,Belgium,Lliege,$4.0m,Estimate,No,Yes,No,Yes,58%,$2.3m,$1.7m,$0.0m,$0.0m,$1.7m,,50%,50%,0%,0%,0%,100%,,50%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$4.8m,,$2.8m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1634,Micro,StemGen,Private,Europe,Italy,Milan,,,$4.0m,Estimate,No,No,No,No,58%,$2.3m,$1.7m,$0.0m,$0.0m,$1.7m,,50%,50%,0%,0%,0%,100%,,50%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$4.8m,,$2.8m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1635,Micro,Suzhou Stainwei Biotech,Private,Asia/Oceania,China,Suzhou,,,$4.0m,Estimate,No,Yes,No,No,58%,$2.3m,$1.7m,$0.0m,$0.0m,$1.7m,,50%,50%,0%,0%,0%,100%,,50%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$4.8m,,$2.8m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1636,Micro,WntResearch,Public,Europe,Sweden,Malmo,,,$4.0m,Estimate,No,No,No,No,58%,$2.3m,$1.7m,$0.0m,$0.0m,$1.7m,,50%,50%,0%,0%,0%,100%,,50%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$4.8m,,$2.8m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1637,Micro,CicloMed,Private,North America,Missouri,Kansas City,,,$4.0m,Estimate,No,No,No,No,58%,$2.3m,$1.7m,$0.0m,$0.0m,$1.7m,,50%,50%,0%,0%,0%,100%,,50%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$4.8m,,$2.8m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1638,Micro,Accendatech,Private,Asia/Oceania,China,Tianjin,,,$4.0m,Estimate,No,No,No,No,58%,$2.3m,$1.7m,$0.0m,$0.0m,$1.7m,,50%,50%,0%,0%,0%,100%,,50%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$4.8m,,$2.8m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1639,Micro,Morphogenesis,Private,North America,Florida,Tampa,,,$4.0m,Estimate,Yes,Yes,Yes,Yes,58%,$2.3m,$1.7m,$0.0m,$0.0m,$1.7m,,50%,50%,0%,0%,0%,100%,,50%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.9m,$0.0m,$0.0m,,$4.8m,,$2.8m,$2.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1640,Micro,MegaPro Biomedical,Private,Asia/Oceania,,,,,$4.0m,Estimate,No,No,No,No,0%,$0.0m,$1.4m,$0.0m,$0.0m,$1.4m,,0%,33%,0%,0%,0%,33%,,0%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,,$4.8m,,$0.0m,$1.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$3.0m,$0.0m,$0.0m,$0.0m
1641,Micro,Open Therapeutics,Private,North America,Ohio,Cincinnati,,,$3.9m,Estimate,No,No,No,No,50%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$4.8m,,$2.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.4m,$0.0m,$2.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1642,Micro,Viracta Therapeutics,Private,Europe,,,,,$3.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,100%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,0%,100%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$4.8m,,$0.0m,$0.0m,$4.8m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1643,Micro,OncBioMune Mexico,Public,North America,,,,,$3.9m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,100%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,0%,100%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$4.8m,,$0.0m,$0.0m,$4.8m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1644,Micro,Annias Immunotherapeutics,Private,North America,,,,,$3.9m,Estimate,No,Yes,No,Yes,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,100%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,0%,100%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$4.8m,,$0.0m,$0.0m,$4.8m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1645,Micro,Binjiang Pharma,Private,Asia/Oceania,,,,,$3.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,100%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,0%,100%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$4.8m,,$0.0m,$0.0m,$4.8m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1646,Micro,Elion Oncology,Private,Europe,,,,,$3.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,100%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,0%,100%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$4.8m,,$0.0m,$0.0m,$4.8m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1647,Micro,Alpha Biopharma,Private,Europe,,,,,$3.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,100%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,0%,100%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$4.8m,,$0.0m,$0.0m,$4.8m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1648,Micro,Isofol Medical,Public,Europe,,,,,$3.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,100%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,0%,100%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$4.8m,,$0.0m,$0.0m,$4.8m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1649,Micro,MTG Biotherapeutics,Private,Asia/Oceania,,,,,$3.9m,Estimate,No,Yes,Yes,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,100%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,0%,100%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$4.8m,,$0.0m,$0.0m,$4.8m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1650,Micro,Jiangsu Ambition Medical,Private,Europe,,,,,$3.9m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.9m,$0.0m,$3.9m,,0%,0%,100%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,0%,100%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.9m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m,,$4.8m,,$0.0m,$0.0m,$4.8m,$0.0m,,$0.0m,$0.0m,$4.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1651,Micro,Technomark Life Sciences,Private,Europe,United Kingdom,London,Pennsylvania,Wayne,$3.9m,Estimate,No,No,No,No,16%,$0.6m,$0.0m,$0.0m,$0.0m,$0.0m,,25%,0%,0%,0%,0%,25%,,0%,0%,0%,0%,0%,,25%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.3m,$0.0m,$0.0m,$0.0m,,$4.8m,,$1.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.2m,$0.0m
1652,Micro,Euclises,Private,North America,Missouri,St. Louis,,,$3.9m,Estimate,No,No,No,No,50%,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.0m,$0.0m,$0.0m,$0.0m,,$4.7m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$2.3m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1653,Micro,Verlyx Pharma,Private,North America,,,,,$3.6m,Estimate,No,No,No,No,0%,$0.0m,$1.5m,$0.0m,$0.0m,$1.5m,,0%,33%,0%,0%,0%,33%,,0%,33%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$4.3m,,$0.0m,$2.7m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,$0.0m
1654,Micro,Nymox,Public,North America,,,,,$3.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,50%,0%,0%,50%,,0%,0%,50%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1655,Micro,Axelar,Private,Europe,,,,,$3.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1656,Micro,Telormedix,Private,Europe,,,,,$3.5m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1657,Micro,KeChow Pharma,Private,Asia/Oceania,,,,,$3.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1658,Micro,Momotaro-Gene,Private,Asia/Oceania,,,,,$3.5m,Estimate,No,Yes,Yes,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1659,Micro,Curasight,Private,Europe,,,,,$3.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1660,Micro,Komipharm,Public,Asia/Oceania,,,,,$3.5m,Estimate,Yes,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1661,Micro,RhoVac,Private,Europe,,,,,$3.5m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1662,Micro,ValiSeek,Private,Europe,,,,,$3.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1663,Micro,LIPAC Oncology,Private,North America,,,,,$3.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1664,Micro,Replimune,Public,Europe,,,,,$3.5m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1665,Micro,Lumicell,Private,North America,,,,,$3.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1666,Micro,Nanjing Mese Pharmaceutical,Private,Asia/Oceania,,,,,$3.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1667,Micro,Intensity Therapeutics,Private,North America,,,,,$3.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1668,Micro,Epitopoietic Research,Private,Europe,,,,,$3.5m,Estimate,No,Yes,No,Yes,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1669,Micro,Genprex,Public,North America,,,,,$3.5m,Estimate,No,No,Yes,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1670,Micro,Beijing Biohealthcare,Private,Asia/Oceania,,,,,$3.5m,Estimate,No,Yes,Yes,Yes,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1671,Micro,Jiangsu Aosaikang Pharmaceutical,Private,Asia/Oceania,,,,,$3.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1672,Micro,Hamlet Pharma,Public,Europe,,,,,$3.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1673,Micro,Cancer Vaccines,Private,Europe,,,,,$3.5m,Estimate,No,No,No,Yes,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1674,Micro,Lunamed,Private,Europe,,,,,$3.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1675,Micro,Curadis,Private,Europe,,,,,$3.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$3.5m,$0.0m,$3.5m,,0%,0%,100%,0%,0%,100%,,0%,0%,100%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.0m,$0.0m,,$4.3m,,$0.0m,$0.0m,$4.3m,$0.0m,,$0.0m,$0.0m,$4.3m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1676,Micro,QUE Oncology,Private,Asia/Oceania,Australia,Queens,Georgia,Atlanta,$3.5m,Estimate,No,No,No,No,67%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$4.2m,,$2.5m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1677,Micro,Aminex Therapeutics,Private,North America,,,,,$3.4m,Estimate,No,No,No,No,0%,$0.0m,$3.4m,$0.0m,$0.0m,$3.4m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$3.4m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,,$4.1m,,$0.0m,$4.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$4.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1678,Micro,Zhejiang Conba Pharmaceutical,Public,Asia/Oceania,China,Hangzhou,,,$3.3m,Estimate,No,No,No,No,64%,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,50%,0%,0%,0%,0%,50%,,50%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.1m,$0.0m,$0.0m,$0.0m,,$4.0m,,$1.9m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1679,Micro,Ambicion,Public,Asia/Oceania,,,,,$3.2m,Estimate,No,Yes,No,Yes,0%,$0.0m,$1.3m,$0.0m,$0.0m,$1.3m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.3m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.8m,$0.0m,$0.0m,,$3.9m,,$0.0m,$1.8m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.8m,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1680,Micro,VCN Biosciences,Private,Europe,,,,,$2.8m,Estimate,No,No,No,No,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$3.5m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1681,Micro,PersImmune,Private,North America,,,,,$2.8m,Estimate,Yes,Yes,Yes,Yes,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$3.5m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1682,Micro,Phebra,Private,Asia/Oceania,,,,,$2.8m,Estimate,Yes,No,No,No,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$3.5m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1683,Micro,Novita Pharmaceuticals,Private,North America,,,,,$2.8m,Estimate,No,No,No,No,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$3.5m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1684,Micro,Tara Immuno-Oncology,Private,North America,,,,,$2.8m,Estimate,No,Yes,Yes,No,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$3.5m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1685,Micro,Minneamrita Therapeutics,Private,North America,,,,,$2.8m,Estimate,No,No,No,No,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$3.5m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1686,Micro,JW Therapeutics,Private,Asia/Oceania,,,,,$2.8m,Estimate,Yes,Yes,Yes,Yes,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$3.5m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1687,Micro,Impact Therapeutics,Private,Asia/Oceania,,,,,$2.8m,Estimate,No,No,No,No,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$3.5m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1688,Micro,Full Hope Biomedical,Private,Asia/Oceania,,,,,$2.8m,Estimate,No,Yes,No,Yes,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$3.5m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1689,Micro,StemMed,Private,North America,,,,,$2.8m,Estimate,No,No,No,No,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$3.5m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1690,Micro,Shanghai Theorion Pharmaceutical,Private,Asia/Oceania,China,Shanghai,,,$2.8m,Estimate,No,No,No,No,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$3.5m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1691,Micro,Amphivena Therapeutics,Private,North America,,,,,$2.8m,Estimate,Yes,Yes,No,No,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$3.5m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1692,Micro,amcure,Private,Europe,,,,,$2.8m,Estimate,No,No,No,No,0%,$0.0m,$1.6m,$0.0m,$0.0m,$1.6m,,0%,50%,0%,0%,0%,50%,,0%,50%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.6m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$3.5m,,$0.0m,$3.5m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.5m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1693,Micro,Zhejiang Teruisi Biopharma,Private,Asia/Oceania,China,Huzhou,,,$2.7m,Estimate,No,Yes,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1694,Micro,Rain Therapeutics,Private,North America,California,Newark,,,$2.7m,Estimate,No,No,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1695,Micro,Argon Pharma,Private,Europe,Spain,Barcelona,,,$2.7m,Estimate,No,No,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1696,Micro,Exotech Bio,Private,North America,California,San Francisco,,,$2.7m,Estimate,No,No,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1697,Micro,Bach BioSciences,Private,North America,Massachusetts,North Andorver,,,$2.7m,Estimate,No,Yes,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1698,Micro,Pangaea Biotech,Private,Europe,Spain,Barcelona,,,$2.7m,Estimate,No,No,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1699,Micro,HanX Biopharmaceuticals,Private,Asia/Oceania,China,,,,$2.7m,Estimate,No,No,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1700,Micro,Belina Pharma,Private,Europe,Sweden,Helsingborg,Sweden,Danderyd,$2.7m,Estimate,No,No,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1701,Micro,ViaMune,Private,North America,Georgia,Athens,,,$2.7m,Estimate,No,Yes,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1702,Micro,Vaxeal,Private,Europe,Switzerland,Vevey,France,Paris,$2.7m,Estimate,No,Yes,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1703,Micro,Galaxy Biotech,Private,North America,California,Sunnyvale,,,$2.7m,Estimate,No,No,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1704,Micro,Apo-T,Private,Europe,Netherlands,Oss,,,$2.7m,Estimate,No,No,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1705,Micro,Y Biologics,Private,Asia/Oceania,South Korea,Daejeon,,,$2.7m,Estimate,No,Yes,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1706,Micro,INmune Bio,Private,North America,California,La Jolla,,,$2.7m,Estimate,No,Yes,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1707,Micro,Elpis Biopharmaceuticals,Private,North America,Massachusetts,Lexington,,,$2.7m,Estimate,No,Yes,Yes,Yes,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1708,Micro,Vedantra Pharmaceuticals,Private,North America,Massachusetts,Cambridge,,,$2.7m,Estimate,No,Yes,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1709,Micro,Bionetix,Private,North America,Quebec,Ste-Anne-de-Bellevue,,,$2.7m,Estimate,No,No,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1710,Micro,CNS Pharmaceuticals,Private,North America,Texas,Houston,,,$2.7m,Estimate,No,No,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1711,Micro,TheraBiologics,Private,North America,California,Arcadia,,,$2.7m,Estimate,No,No,No,Yes,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1712,Micro,ModiQuest Therapeutics,Private,Europe,Netherlands,Oss,,,$2.7m,Estimate,No,Yes,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1713,Micro,STC Biologics,Private,North America,Massachusetts,Newton,,,$2.7m,Estimate,No,Yes,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1714,Micro,Navigo Proteins,Private,Europe,Germany,Halle,,,$2.7m,Estimate,No,No,No,No,100%,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,100%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$2.7m,$0.0m,$0.0m,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,,$3.2m,,$3.2m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$3.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1715,Micro,Maverick Therapeutics,Private,North America,California,Brisbane,,,$2.3m,Estimate,No,Yes,No,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1716,Micro,Jiangsu Kanion Pharmaceutical,Public,Asia/Oceania,China,Lianyungang,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1717,Micro,Provecs Medical,Private,Europe,Germany,Hamburg,,,$2.3m,Estimate,No,Yes,Yes,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1718,Micro,Abilita Bio,Private,North America,California,San Diego,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1719,Micro,Parabon NanoLabs,Private,North America,Virginia,Reston,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1720,Micro,Meridian Lab,Private,North America,North Carolina,Charlotte,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1721,Micro,Noile-Immune Biotech,Private,Asia/Oceania,Japan,Tokyo,,,$2.3m,Estimate,No,Yes,Yes,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1722,Micro,Affinita Biotech,Private,North America,California,South San Francisco,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1723,Micro,Bantam Pharmaceutical,Private,North America,New York,New York,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1724,Micro,Cullinan Oncology,Private,North America,Massachusetts,Cambridge,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1725,Micro,Circle Pharma,Private,North America,California,South San Francisco,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1726,Micro,Bliss Biopharmaceutical,Private,Asia/Oceania,China,Hangzhou,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1727,Micro,Shanghai Haiyan Pharmaceutical,Private,Asia/Oceania,China,Shanghai,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1728,Micro,Vaxiion,Private,North America,California,San Diego,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1729,Micro,TransCode Therapeutics,Private,North America,Massachusetts,Boston,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1730,Micro,Trojantec,Private,Europe,Cyprus,Nicosia,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1731,Micro,Angiex,Private,North America,Massachusetts,Cambridge,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1732,Micro,Primmune Therapeutics,Private,North America,California,San Diego,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1733,Micro,Promega,Private,North America,Wisconsin,Madison,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1734,Micro,Janpix,Private,North America,Ontario,Mississauga,Massachusetts,Cambridge,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1735,Micro,Navire Pharma,Private,North America,California,Palo Alto,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1736,Micro,Shenzhen SiBiono GeneTech Co.,Private,Asia/Oceania,China,Shenzhen,,,$2.3m,Estimate,No,No,Yes,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1737,Micro,Quadriga BioSciences,Private,North America,California,Los Altos,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1738,Micro,PepVax,Private,North America,Maryland,Bethesda,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1739,Micro,OncoSelect Therapeutics,Private,North America,California,San Francisco,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1740,Micro,Repare Therapeutics,Private,North America,Quebec,St-Laurent,Massachusetts,Cambridge,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1741,Micro,Phoenix Molecular Designs,Private,North America,British Columbia,Richmond,British Columbia,Vancouver,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1742,Micro,Photolitec,Private,North America,New York,Buffalo,New York,Buffalo,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1743,Micro,Ribon Therapeutics,Private,North America,Massachusetts,Lexington,Massachusetts,Cambridge,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1744,Micro,Actavalon,Private,North America,California,San Diego,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1745,Micro,PMV Pharma,Private,North America,New Jersey,Cranbury,Massachusetts,Lexington,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1746,Micro,CanImGuide Therapeutics,Private,Europe,Sweden,Lund,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1747,Micro,Orca Therapeutics,Private,Europe,Netherlands,Amsterdam,Netherlands,Nijmegen,$2.3m,Estimate,No,No,Yes,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1748,Micro,Bioarchitech,Private,Europe,United Kingdom,Oxford,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1749,Micro,OnKure,Private,North America,Colorado,Boulder,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1750,Micro,C-TRI,Private,Asia/Oceania,India,New Delhi,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1751,Micro,Essa Pharma,Public,North America,British Columbia,Vancouver,Texas,Houston,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1752,Micro,NED Biosystems,Private,North America,Massachusetts,Cambridge,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1753,Micro,Peptomyc,Private,Europe,Spain,Barcelona,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1754,Micro,MEKanistic Therapeutics,Private,North America,Michigan,Ann Arbor,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1755,Micro,Ectin Research,Private,Europe,Sweden,Molndal,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1756,Micro,EnzymeBioSystems,Public,North America,Nevada,Las Vegas,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1757,Micro,Advanced Imaging Projects,Private,North America,Florida,Dorsal,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1758,Micro,miRecule,Private,North America,Maryland,Gaithersburg,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1759,Micro,WindMIL Therapeutics,Private,North America,Maryland,Baltimore,,,$2.3m,Estimate,No,Yes,No,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1760,Micro,MonTa Biosciences,Private,Europe,Denmark,Lyngby,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1761,Micro,Jin Yang Pharm,Public,Asia/Oceania,South Korea,Seoul,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1762,Micro,For-Robin,Private,North America,New York,Buffalo,New York,Williamsville,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1763,Micro,IRAD Oncology,Private,North America,California,San Diego,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1764,Micro,IDP Pharma,Private,Europe,Spain,Barcelona,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1765,Micro,RIFT Biotherapeutics,Private,North America,California,San Diego,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1766,Micro,DotBio,Private,Asia/Oceania,Singapore,Singapore,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1767,Micro,ImCheck Therapeutics,Private,Europe,France,Marseille,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1768,Micro,Modulate Therapeutics,Private,North America,West Virginia,Morgantown,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1769,Micro,Hercules Pharmaceuticals,Private,Europe,Netherlands,Breukelen,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1770,Micro,StarWise Therapeutics,Private,North America,Wisconsin,Madison,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1771,Micro,HepaRx,Private,Middle East/Africa,Israel,Ness Ziona,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1772,Micro,Xinjiang Huashidan Pharma,Private,Asia/Oceania,China,Urumqi,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1773,Micro,GeneSegues Therapeutics,Private,North America,Minnesota,Minnetonka,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1774,Micro,Palleon Pharmaceuticals,Private,North America,Massachusetts,Waltham,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1775,Micro,GeneaMed,Private,Europe,Poland,Lodz,,,$2.3m,Estimate,Yes,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1776,Micro,Ennovabio,Private,Asia/Oceania,China,Shanghai,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1777,Micro,FTG Bio,Private,North America,New Jersey,Hackensack,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1778,Micro,Cells for Cells,Private,Latin America,Chile,Santiago,,,$2.3m,Estimate,No,No,No,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1779,Micro,Ecrins Therapeutics,Private,Europe,France,La Tronche,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1780,Micro,Zhejiang Bossan,Private,Asia/Oceania,China,Zheijiang,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1781,Micro,Prana Therapeutics,Public,North America,Florida,Gainesville,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1782,Micro,Enlyton,Private,North America,Texas,Austin,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1783,Micro,Rigvir Group,Private,Europe,Latvia,Riga,,,$2.3m,Estimate,No,Yes,Yes,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1784,Micro,Dongguan Daxin Biotechnology,Private,Asia/Oceania,China,Guangdong,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1785,Micro,Sitka Biopharma,Private,North America,British Columbia,Vancouver,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1786,Micro,Cybrexa Therapeutics,Private,North America,Connecticut,New Haven,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1787,Micro,TargaGenix,Private,North America,New York,Stony Brook,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1788,Micro,CyTIX,Private,Asia/Oceania,Japan,Tokyo,,,$2.3m,Estimate,No,Yes,No,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1789,Micro,Pepscan Therapeutics,Private,Europe,Netherlands,Lelystad,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1790,Micro,Curtana Pharmaceuticals,Private,North America,Texas,Austin,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$101.0m,,$101.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$101.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1791,Micro,CharlestonPharma,Private,North America,South Carolina,Charleston,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1792,Micro,Macrophage Pharma,Private,Europe,United Kingdom,Berkshire,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1793,Micro,Cho Pharma,Private,Asia/Oceania,Taiwan,Taipei,,,$2.3m,Estimate,Yes,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1794,Micro,Carina Biotech,Private,Asia/Oceania,Australia,Adelaide,,,$2.3m,Estimate,No,Yes,Yes,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1795,Micro,Gan & Lee,Private,Asia/Oceania,China,Beijing,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1796,Micro,Avalon GloboCare,Public,North America,New Jersey,Freehold,,,$2.3m,Estimate,No,Yes,Yes,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1797,Micro,ImmPACT-Bio,Private,Middle East/Africa,Israel,Ness Ziona,,,$2.3m,Estimate,No,Yes,Yes,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1798,Micro,Soteria Cell Therapeutics,Private,North America,California,San Francisco,,,$2.3m,Estimate,No,Yes,Yes,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1799,Micro,Affigen,Private,North America,Missouri,St Louis,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1800,Micro,Torskal Nanosciences,Private,Europe,France,Saint-Denis,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1801,Micro,Swalife Biotech,Private,Europe,Ireland,Cork,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1802,Micro,Saksin Lifesciences,Private,Asia/Oceania,India,Chennai,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1803,Micro,Onchilles Therapeutics,Private,North America,California,San Diego,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1804,Micro,Oblique Therapeutics,Private,Europe,Sweden,Stockholm,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1805,Micro,Foghorn Therapeutics,Private,North America,Massachusetts,Cambridge,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1806,Micro,Argonaut Therapeutics,Private,Europe,United Kingdom,Oxford,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1807,Micro,Accent Therapeutics,Private,North America,Massachusetts,Lexington,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1808,Micro,StemTek Therapeutics,Private,Europe,Spain,Bizkaia,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1809,Micro,Evoq Therapeutics,Private,North America,Michigan,Ann Arbor,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1810,Micro,CHIME BioTherapeutics,Private,North America,California,San Diego,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1811,Micro,Valo Therapeutics,Private,Europe,Finland,Helsinki,United Kingdom,Oxford,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1812,Micro,Pionyr Immunotherapeutics,Private,North America,California,South San Francisco,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1813,Micro,Cancelex,Private,Asia/Oceania,Hong Kong,Hong Kong,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1814,Micro,CureMeta,Private,North America,Massachusetts,Boston,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1815,Micro,Reveris Therapeutics,Private,North America,North Carolina,Chapel Hill,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1816,Micro,Lava Therapeutics,Private,Europe,Netherlands,North Brabant,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1817,Micro,PrimeVax,Private,North America,California,Orange,,,$2.3m,Estimate,No,Yes,No,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1818,Micro,Qualigen,Private,North America,California,Carlsbad,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1819,Micro,Thermosome,Private,Europe,Germany,Martinsried,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1820,Micro,SumiQ Therapeutics,Private,Europe,Netherlands,Amsterdam,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1821,Micro,Stimunity,Private,Europe,France,Paris,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1822,Micro,Obsidian Therapeutics,Private,North America,Massachusetts,Cambridge,,,$2.3m,Estimate,No,No,Yes,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1823,Micro,MediSix Therapeutics,Private,Asia/Oceania,Singapore,Singapore,,,$2.3m,Estimate,No,Yes,Yes,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1824,Micro,Incysus,Private,North America,New York,New York,Alabama,Birmingham,$2.3m,Estimate,No,Yes,No,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1825,Micro,Elthera,Private,Europe,Switzerland,Schlieren,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1826,Micro,Cedilla Therapeutics,Private,North America,Massachusetts,Cambridge,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1827,Micro,Axis Therapeutics,Private,Asia/Oceania,Hong Kong,Hong Kong,,,$2.3m,Estimate,No,Yes,No,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1828,Micro,Akriveia Therapeutics,Private,North America,Massachusetts,Cambridge,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1829,Micro,Achilles Therapeutics,Private,Europe,United Kingdom,Stevenage,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1830,Micro,MetaStat,Public,North America,Massachusetts,Boston,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1831,Micro,Cleara Biotech,Private,Europe,Netherlands,Utrecht,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1832,Micro,RadImmune Therapeutics,Private,North America,California,Menlo Park,Massachusetts,Cambridge,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1833,Micro,Portage Glasgow Limited,Public,Europe,United Kingdom,Glasgow,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1834,Micro,Novelogics Biotechnology,Private,North America,British Columbia,Vancouver,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1835,Micro,Epigen Therapeutics,Private,Europe,Italy,Pordenone,Italy,Siena,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1836,Micro,Elpiscience,Private,Asia/Oceania,China,Shanghai,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1837,Micro,Immune-Onc Therapeutics,Private,North America,California,Palo Alto,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1838,Micro,Dragonfly Therapeutics,Private,North America,Maine,Bangor,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1839,Micro,Optera Therapeutics,Private,North America,California,San Francisco,,,$2.3m,Estimate,No,No,No,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1840,Micro,Meditope Biosciences,Private,North America,California,Pasadena,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1841,Micro,ADCendo,Private,Europe,Denmark,Copenhagen,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1842,Micro,Oncoxx,Private,Europe,Italy,Chieti,Italy,L'Aquila,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1843,Micro,Living Pharma,Private,North America,Maryland,Baltimore,,,$2.3m,Estimate,No,Yes,Yes,Yes,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1844,Micro,Dragonboat Biopharmaceutical,Private,Asia/Oceania,China,Shanghai,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1845,Micro,Tizona Therapeutics,Private,North America,California,South San Francisco,,,$2.3m,Estimate,No,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1846,Micro,Suzhou Galaxy Biopharma,Private,Asia/Oceania,China,Taichang,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1847,Micro,Jing Medicine Technology,Private,Asia/Oceania,China,Shanghai,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1848,Micro,Russian Pharmaceutical Technolog,Private,Europe,Russia,St Petersburg,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1849,Micro,Akanocure Pharmaceuticals,Private,North America,Indiana,West Lafayette,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1850,Micro,Adagene,Private,Asia/Oceania,China,Suzhou,,,$2.3m,Estimate,Yes,Yes,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1851,Micro,Third Coast Therapeutics,Private,North America,Illinois,Evanston,,,$2.3m,Estimate,No,No,No,No,100%,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,100%,0%,0%,0%,0%,100%,,100%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$2.3m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,,$2.8m,,$2.8m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1852,Micro,Tragara Pharmaceuticals,Private,Asia/Oceania,,,,,$2.1m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,50%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,50%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$2.6m,,$0.0m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1853,Micro,Andarix,Private,Europe,,,,,$2.1m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,50%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,50%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$2.6m,,$0.0m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1854,Micro,Wuxi Fortune Pharmaceutical,Private,Europe,,,,,$2.1m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,50%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,50%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$2.6m,,$0.0m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1855,Micro,Ascelia Pharma,Private,Europe,,,,,$2.1m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,50%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,50%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$2.6m,,$0.0m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1856,Micro,F-Star Alpha,Private,Europe,,,,,$2.1m,Estimate,No,Yes,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,50%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,50%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$2.6m,,$0.0m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1857,Micro,Placon Therapeutics,Private,North America,,,,,$2.1m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,50%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,50%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$2.6m,,$0.0m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1858,Micro,iPharma,Private,Europe,,,,,$2.1m,Estimate,Yes,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,50%,0%,0%,0%,50%,,0%,0%,0%,0%,0%,,0%,50%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.7m,$0.0m,$0.0m,,$2.6m,,$0.0m,$2.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.6m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1859,Micro,Iroko Pharmaceuticals,Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1860,Micro,Genyous Biomed,Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1861,Micro,CellSight Technologies,Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1862,Micro,Cleveland BioLabs,Public,North America,New York,Buffalo,,,$1.7m,Estimate,No,Yes,No,No,237%,$4.0m,$39.6m,$3.6m,$0.0m,$43.2m,,12%,18%,6%,0%,0%,35%,,12%,18%,6%,0%,0%,,0%,0%,0%,0%,0%,,,,$4.0m,$39.6m,$3.6m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$2.1m,$22.2m,$2.0m,$0.0m,,$2.1m,,$0.1m,$0.6m,$0.1m,$0.0m,,$0.0m,$0.1m,$0.7m,$0.1m,$0.0m,$0.0m,$0.0m,$0.1m,$0.0m,$0.1m,$0.0m,$0.4m,$0.6m,$0.0m,$0.0m,$0.0m
1863,Micro,Vigeo Therapeutics,Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1864,Micro,TTC Oncology,Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1865,Micro,EirGenix,Private,Asia/Oceania,,,,,$1.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1866,Micro,Erimos,Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1867,Micro,Taivex Therapeutics,Private,Asia/Oceania,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1868,Micro,Bexion,Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1869,Micro,Salspera,Private,North America,,,,,$1.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1870,Micro,Shandong New Age Pharmaceutical,Private,Asia/Oceania,,,,,$1.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1871,Micro,Pinzelife,Private,Asia/Oceania,,,,,$1.7m,Estimate,Yes,Yes,Yes,Yes,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1872,Micro,PIN Pharma,Private,North America,,,,,$1.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1873,Micro,Pellficure Pharmaceuticals,Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1874,Micro,Vanquish Oncology,Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1875,Micro,OrienGene Biotechnology,Private,Asia/Oceania,,,,,$1.7m,Estimate,No,Yes,Yes,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1876,Micro,OncoNano Medicine,Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1877,Micro,Oblato,Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1878,Micro,XSpray,Private,Europe,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1879,Micro,NH TherAguix,Private,Europe,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1880,Micro,Medvax Technologies,Private,North America,,,,,$1.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1881,Micro,Kangpu Biopharmaceuticals,Private,Asia/Oceania,,,,,$1.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1882,Micro,Taizhou Hanzhong Biomedical,Private,Asia/Oceania,,,,,$1.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1883,Micro,Immunovo,Private,Europe,,,,,$1.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1884,Micro,Shanghai Houchao Biotechnology,Private,Asia/Oceania,China,Shanghai,,,$1.7m,Estimate,No,Yes,Yes,Yes,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1885,Micro,"Fusion Pharmaceuticals, Canada",Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1886,Micro,Rapamycin Holdings,Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1887,Micro,Zhejiang DTRM Biopharma,Private,Asia/Oceania,,,,,$1.7m,Estimate,Yes,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1888,Micro,Alden Cancer Therapy II,Private,Europe,,,,,$1.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1889,Micro,Beijing Sinotau Pharmaceuticals,Private,Asia/Oceania,,,,,$1.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1890,Micro,BiOncotech Therapeutics,Private,Europe,,,,,$1.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1891,Micro,Birdie Biopharmaceuticals,Private,Asia/Oceania,,,,,$1.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1892,Micro,Anke Biotechnology,Public,Asia/Oceania,,,,,$1.7m,Estimate,No,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1893,Micro,Andes Biotechnologies,Private,Latin America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1894,Micro,ALX Oncology,Private,North America,,,,,$1.7m,Estimate,Yes,Yes,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1895,Micro,Five Eleven Pharma,Private,North America,,,,,$1.7m,Estimate,No,No,No,No,0%,$0.0m,$1.7m,$0.0m,$0.0m,$1.7m,,0%,100%,0%,0%,0%,100%,,0%,100%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$1.7m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.9m,$0.0m,$0.0m,,$2.1m,,$0.0m,$2.1m,$0.0m,$0.0m,,$0.0m,$0.0m,$2.1m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1896,Micro,Lay Line Genomics,Private,Europe,,,,,$1.5m,Estimate,No,Yes,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.9m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.9m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1897,Micro,SEDOR Pharmaceuticals,Private,North America,,,,,$1.5m,Estimate,No,No,No,No,0%,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,0%,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,0%,0%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$1.8m,,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.8m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1898,Micro,Churchill Pharmaceuticals,Private,North America,,,,,$1.2m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,100%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,100%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$1.4m,,$0.0m,$1.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1899,Micro,Zucero Therapeutics,Private,Asia/Oceania,,,,,$1.2m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,100%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,100%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$1.4m,,$0.0m,$1.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1900,Micro,MorEx Development Partners,Private,Europe,,,,,$1.2m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,100%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,100%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$1.4m,,$0.0m,$1.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1901,Micro,Valor Biotherapeutics,Private,North America,,,,,$1.2m,Estimate,Yes,Yes,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,100%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,100%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$1.4m,,$0.0m,$1.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1902,Micro,Beijing Sailin Tai Pharma,Private,Asia/Oceania,,,,,$1.2m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,100%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,100%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$1.4m,,$0.0m,$1.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
1903,Micro,Omnitura Therapeutics,Private,North America,,,,,$1.2m,Estimate,No,No,No,No,0%,$0.0m,$1.2m,$0.0m,$0.0m,$1.2m,,0%,100%,0%,0%,0%,100%,,0%,0%,0%,0%,0%,,0%,100%,0%,0%,0%,,,,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,,$0.0m,$1.2m,$0.0m,$0.0m,$0.0m,$0.0m,$0.6m,$0.0m,$0.0m,,$1.4m,,$0.0m,$1.4m,$0.0m,$0.0m,,$0.0m,$0.0m,$1.4m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m,$0.0m
